Flow diversion in the treatment of intracranial aneurysms
Detection of meningitis in infants
Diagnostic errors in cerebrovascular pathology
Endarterectomy, stenting, or medical treatment for symptomatic carotid near-occlusion

Official Journal ASNR • ASFNR • ASHNR • ASPNR • ASSR
Indications for Use:
The FRED™ X System is indicated for use in the internal carotid artery from the petrous segment to the terminus for the endovascular treatment of adult patients (22 years of age or older) with wide-necked (neck width ≥ 4 mm or dome-to-neck ratio < 2) saccular or fusiform intracranial aneurysms arising from a parent vessel with a diameter ≥ 2.0 mm and ≤ 5.0 mm.

Rx Only:
Federal (United States) law restricts this device to sale by or on the order of a physician.

Introducing FRED™ X

The FRED™ X Flow Diverter features the same precise placement and immediate opening of the FRED™ Device, now with X Technology. X Technology is a covalently bonded, nanoscale surface treatment, designed to:

» Reduce material thrombogenicity

» Maintain natural vessel healing response

» Improve device deliverability and resheathing

The only FDA PMA approved portfolio with a 0.021” delivery system for smaller device sizes, and no distal lead wire.

* Data is derived from in vivo and ex vivo testing and may not be representative of clinical performance.


For more information, contact your local MicroVention sales representative or visit our website. www.microvention.com

Indications for Use: The FRED X System is indicated for use in the internal carotid artery from the petrous segment to the terminus for the endovascular treatment of adult patients (22 years of age or older) with wide-necked (neck width ≥ 4 mm or dome-to-neck ratio < 2) saccular or fusiform intracranial aneurysms arising from a parent vessel with a diameter ≥ 2.0 mm and ≤ 5.0 mm.

Rx Only: Federal (United States) law restricts this device to sale by or on the order of a physician.

MICROVENTION, FRED and HEADWAY are registered trademarks of MicroVention, Inc. in the United States and other jurisdictions. Styfinox X is a trademark of MicroVention, Inc. © 2022 MicroVention, Inc. MM1222 US 02/22
INDICATIONS FOR USE:
The WEB Aneurysm Embolization System is intended for the endovascular embolization of ruptured and unruptured intracranial aneurysms and other neurovascular abnormalities such as arteriovenous fistulae (AVF). The WEB Aneurysm Embolization System is also intended for vascular occlusion of blood vessels within the neurovascular system to permanently obstruct blood flow to an aneurysm or other vascular malformation.

POTENTIAL COMPLICATIONS:
Potential complications include but are not limited to the following: hematoma at the site of entry, aneurysm rupture, emboli, vessel perforation, parent artery occlusion, hemorrhage, ischemia, vasospasm, clot formation, device migration or misplacement, premature or difficult device detachment, non-detachment, incomplete aneurysm filling, revascularization, post-embolization syndrome, and neurological deficits including stroke and death. For complete indications, potential complications, warnings, precautions, and instructions, see instructions for use (IFU provided with the device).

VIA 21, 27, 33 - The VIA Microcatheter is intended for the introduction of interventional devices (such as the WEB device/stents/flow diverters) and infusion of diagnostic agents (such as contrast media) into the neuro, peripheral, and coronary vasculature.

VIA 17, 17 Preshaped - The VIA Microcatheter is intended for the introduction of interventional devices (such as the WEB device/stents/flow diverters) and infusion of diagnostic agents (such as contrast media) into the neuro, peripheral, and coronary vasculature.

The VIA Microcatheter is contraindicated for use with liquid embolic materials, such as n-butyl 2-cyanoacrylate or ethylene vinyl alcohol & DMSO (dimethyl sulfoxide).

The device should only be used by physicians who have undergone training in all aspects of the WEB Aneurysm Embolization System procedure as prescribed by the manufacturer.

RX Only: Federal law restricts this device to sale by or on the order of a physician.

For healthcare professional intended use only.

WEB™ and VIA™ are registered trademarks of Sequent Medical, Inc. in the United States.

©2021 MicroVention, Inc. MM1184 WW 11/2021
What does seeing better with MultiHance® mean?¹-⁴*

MultiHance® demonstrated significantly improved visualization and contrast enhancement of CNS lesions when compared with Gadavist® at 0.1 mmol/kg.¹†

- The 0.1 mmol/kg dose of MultiHance demonstrated consistently better lesion visualization for all readers compared to all tested MR contrast agents.¹-⁴

- 3 blinded independent readers reported superiority for MultiHance in significantly (P=.0001) more patients for all evaluated end points. The opinions of the 3 readers were identical for 61.9%–73.5% of the patients, resulting in values of 0.414–0.629 for inter-reader agreement.

Contraindications

MultiHance is contraindicated in patients with known allergic or hypersensitivity reactions to gadolinium-based contrast agents.

Warnings and Precautions

Nephrogenic Systemic Fibrosis: NSF has occurred in patients with impaired elimination of GBCAs. Higher than recommended dosing or repeated dosing appears to increase risk.

Hypersensitivity Reactions: Anaphylactic and anaphylactoid reactions have been reported, involving cardiovascular, respiratory, and/or cutaneous manifestations. Some patients experienced circulatory collapse and died. In most cases, initial symptoms occurred within minutes of MultiHance administration and resolved with prompt emergency treatment. Consider the risk for hypersensitivity reactions, especially in patients with a history of hypersensitivity reactions or a history of asthma or other allergic disorders.

Gadolinium Retention: Gadolinium is retained for months or years in several organs. The highest concentrations have been identified in the bone, followed by brain, skin, kidney, liver, and spleen. At equivalent doses, retention varies among the linear agents. Retention is lowest and similar among the macrocyclic GBCAs. Consequences of gadolinium retention in the brain have not been established, but they have been established in the skin and other organs in patients with impaired renal function. Minimize repetitive GBCA imaging studies, particularly closely spaced studies when possible.

Acute Renal Failure: In patients with renal insufficiency, acute renal failure requiring dialysis or worsening renal function have occurred with the use of GBCAs. The risk of renal failure may increase with increasing dose of the contrast agent. Screen all patients for renal dysfunction by obtaining a history and/or laboratory tests. 

Extravasation and Injection Site Reactions: Extravasation of MultiHance may lead to injection site reactions, characterized by local pain or burning sensation, swelling, blistering, and necrosis. Exercise caution to avoid local extravasation during intravenous administration of MultiHance.

Cardiac Arrhythmias: Cardiac arrhythmias have been observed in patients receiving MultiHance in clinical trials. Assess patients for underlying conditions...
MultiHance® (gadobenate dimeglumine) injection, 529 mg/mL is a gadolinium-based contrast agent indicated for intravenous use in:

- Magnetic resonance angiography (MRA) to evaluate adults with known or suspected renal or aorto-ilio-femoral occlusive vascular disease.
- Magnetic resonance imaging (MRI) of the central nervous system (CNS) in adults and pediatric patients (including term neonates) to visualize lesions with abnormal blood brain barrier or abnormal vascularity of the brain, spine, and associated tissues or to evaluate adults with known or suspected renal or aorto-ilio-femoral occlusive vascular disease.
- For patients at highest risk for NSF, do not exceed the recommended dose.
- Screen patients for acute kidney injury and other conditions that may reduce renal function. For patients at risk for chronically reduced renal function (e.g. age > 60 years, hypertension or diabetes), estimate the glomerular filtration rate (GFR) through laboratory testing. Minimize repetitive GBCA imaging studies, particularly closely spaced studies of kidneys with persistent abnormal findings.

**ADVERSE REACTIONS**
The most commonly reported adverse reactions are nausea (1.3%) and headache (1.2%).

**USE IN SPECIFIC POPULATIONS**

**Pregnancy:** GBCAs cross the human placenta and result in fetal exposure and gadolinium retention. Use only if imaging is essential during pregnancy and cannot be delayed.

**Lactation:** There is no information on the effects of the drug on the breastfed infant or the effects of the drug on milk production. However, limited literature reports that breastfeeding after MultiHance administration to the mother would result in the infant receiving an oral dose of 0.001%–0.04% of the maternal dose.

**Pediatric Use:** MultiHance is approved for intravenous use for MRI of the CNS to visualize lesions with abnormal blood brain barrier or abnormal vascularity of the brain, spine, and associated tissues in pediatric patients from birth, including term neonates, to less than 17 years of age. Adverse reactions in pediatric patients were similar to those reported in adults. No dose adjustment according to age is necessary in pediatric patients two years of age and older. For pediatric patients, less than 2 years of age, the recommended dosage range is 0.1 to 0.2 mL/kg. The safety of MultiHance has not been established in preterm neonates.

Please see full Prescribing Information and Patient Medication Guide for additional important safety information for regarding MultiHance (gadobenate dimeglumine) injection, 529 mg/mL at https://www.braccoimaging.com/us-en/products/magnetic-resonance-imaging/multihance

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

MultiHance is manufactured for Bracco Diagnostics Inc. by BIPSO GmbH – 78224 Singen (Germany) and by Patheon Italia S.p.A., Ferentino, Italy. MultiHance is a registered trademark of Bracco International B.V. MultiHance Multipack is a trademark of Bracco International B.V. All other trademarks and registered trademarks are the property of their respective owners.

**References:**

Bracco Diagnostics Inc.
259 Prospect Plains Road, Building H
Monroe Township, NJ 08831 USA
Phone: 609-514-2200
Toll Free: 1-877-272-2269 (U.S. only)
Fax: 609-514-2446
© 2022 Bracco Diagnostics Inc. All Rights Reserved. US-MH-2100019 02/22
**Multicenter double-blind randomized intraindividual crossover study design of 123 patients with known or suspected brain disease to compare gadobutrol versus gadobenate dimeglumine (the MERIT Study).**

**Objectives:** To compare the contrast MR images in the absence of companion non-contrast MR images. The following adverse reactions have been identified during post approval use of MultiHance in MRI of the CNS, 217 pediatric subjects received MultiHance vs. 11 subjects who received placebo. Prolongations including QTc. The average changes in QTc values compared with placebo were minimal.

**Adverse Reactions**

**Warnings and Precautions (5.1)**

- **Hypersensitivity Reactions:** Anaphylactic and anaphylactoid reactions have been reported after GBCA administration. These reactions have occurred in patients with a history of previous reactions to GBCA. A single intravenous dose of 0.1 mmol/kg of MultiHance was administered to patients. MultiHance has been shown to be dialyzable. Clinical consequences of overdosage with MultiHance have not been reported. Treatments that have been used include the usual supportive measures such as intravenous fluid administration, antihistamines, and corticosteroids. If further treatment is required, consultation with a Poison Control Center is recommended.

**References:**


AJNR urges American Society of Neuroradiology members to reduce their environmental footprint by voluntarily suspending their print subscription.

The savings in paper, printing, transportation, and postage directly fund new electronic enhancements and expanded content.

The digital edition of AJNR presents the print version in its entirety, along with extra features including:

- Publication Preview
- Case Collection
- Podcasts
- The AJNR News Digest
- The AJNR Blog

It also reaches subscribers much faster than print. An electronic table of contents will be sent directly to your mailbox to notify you as soon as it publishes. Readers can search, reference, and bookmark current and archived content 24 hours a day on www.ajnr.org.

ASNR members who wish to opt out of print can do so by using the AJNR Go Green link on the AJNR Website (http://www.ajnr.org/content/subscriber-help-and-services). Just type your name in the email form to stop print and spare our ecosystem.
EDITOR-IN-CHIEF
Jeffrey S. Ross, MD
Professor of Radiology, Department of Radiology, Mayo Clinic College of Medicine, Phoenix, AZ

SENIOR EDITORS
Harry J. Cloft, MD, PhD
Professor of Radiology and Neurosurgery, Department of Radiology, Mayo Clinic College of Medicine, Rochester, MN
Christopher G. Filippi, MD
Professor and Alice Ettinger-Jack R. Dreyfuss Chair of Radiology, Tufts University School of Medicine, Radiologist-in-Chief
Tufts University Medical Center, Boston, MA
Thierry A.G.M. Huisman, MD, PD, FICIS, FCR
Radiologist-in-Chief and Chair of Radiology, Texas Children's Hospital, Professor of Radiology, Pediatrics, Neurosurgery, and OB/GYN, Baylor College of Medicine, Houston, TX
Yvonne W. Lui, MD
Associate Professor of Radiology, Chief of Neuroradiology, New York University School of Medicine, New York, NY
C.D. Phillips, MD, FACR
Professor of Radiology, Weill Cornell Medical College, Director of Head and Neck Imaging, New York-Presbyterian Hospital, New York, NY
Lubdha M. Shah, MD, MS
Professor of Radiology and Director of Spine Imaging, University of Utah Department of Radiology and Imaging Sciences, Salt Lake City, UT

STATISTICAL SENIOR EDITOR
Bryan A. Comstock, MS
Senior Biostatistician, Department of Biostatistics, University of Washington, Seattle, WA

ARTIFICIAL INTELLIGENCE DEPUTY EDITOR
Peter D. Chang, MD
Assistant Professor-in-Residence, Departments of Radiological Sciences, Computer Sciences, and Pathology, Director, Center for Artificial Intelligence in Diagnostic Imaging (CAIDI), University of California, Irvine, Irvine, CA

EDITORIAL BOARD
Ashley H. Aiken, Atlanta, GA
Matthew D. Alexander, Salt Lake City, UT
Lea M. Alhillal, Phoenix, AZ
Jason W. Allen, Atlanta, GA
Mohammed A. Almekhlaï, Calgary, Alberta, Canada
Niranjana Balu, Seattle, WA
Matthew J. Barkovich, San Francisco, CA
Joachim Berkefeld, Frankfurt, Germany
Karen Buch, Boston, MA
Judah Burns, New York, NY
Danielle Byrne, Dublin, Ireland
Federico Cagnazzo, Montpellier, France
Gloria C. Chang, New York, NY
Daniel Chow, Irvine, CA
Kars C.J. Compagne, Rotterdam, The Netherlands
Yonghong Ding, Rochester, MN
Birgit Ertl-Wagner, Toronto, Ontario, Canada
Aaron Field, Madison, WI
Nils D. Forkert, Calgary, Alberta, Canada
Frank Gaillard, Melbourne, Australia
Joseph J. Gewemte, Ann Arbor, Michigan
Brent Griffith, Detroit, MI
Michael J. Hoch, Philadelphia, PA
Joseph M. Hoxworth, Phoenix, AZ
Raymond Y. Huang, Boston, MA
Susie Y. Huang, Boston, MA
Ferdinand K. Hui, Honolulu, HI
Christof Karmonik, Houston, TX
Gregor Kasprian, Vienna, Austria
Timothy J. Kaufmann, Rochester, MN
Hillary R. Kelly, Boston, MA
Toshibumi Kinoshita, Akita, Japan
Ioannis Koktzoglou, Evanston, IL
Stephen F. Krall, Houston, TX
Luke Ledbetter, Los Angeles, CA
Franklin A. Marden, Chicago, IL
Markus A. Möhlenbruch, Heidelberg, Germany
Mahmoud Mossa-Basha, Morrisville, NC
Renato Hoffmann Nunes, Sao Paulo, Brazil
Sam Payabvash, New Haven, CT
Johannes A.R. Pfaff, Salzburg, Austria
Elke I. Pichowiak, Bern, Switzerland
Laurent Pierot, Reims, France
Alexander R. Podgorsak, Chicago, IL
Eytan Raz, New York, NY
Jeff Rudie, San Diego, CA
Paul M. Ruggieri, Cleveland, OH
Fatih Seker, Heidelberg, Germany
Maksim Shapiro, New York, NY
Timothy Shepherd, New York, NY
Mark S. Shirotshi, Los Angeles, CA
Neetu Soni, Rochester, NY

SPECIAL CONSULTANTS TO THE EDITOR
AJNR Blog Editor
Neil Lall, Denver, CO
Case of the Month Editor
Nicholas Stence, Aurora, CO
Case of the Week Editors
Matylda Machnowska, Toronto, Ontario, Canada
Anvita Pauranik, Calgary, Alberta, Canada
Vinil Shah, San Francisco, CA
Classic Case Editor
Sandy Cheng-Yu Chen, Taipei, Taiwan
Health Care and Socioeconomics Editor
Pina C. Sannella, New York, NY
Physics Editor
Greg Zaharchuk, Stanford, CA
Podcast Editor
Kevin Hiatt, Winston-Salem, NC
Twitter Editor
Jacob Omsby, Albuquerque, NM

Official Journal:
American Society of Neuroradiology
American Society of Functional Neuroradiology
American Society of Head and Neck Radiology
American Society of Pediatric Neuroradiology
American Society of Spine Radiology

Ashok Srivivasan, Ann Arbor, MI
Jason F. Talbott, San Francisco, CA
Andranik Tomasian, Los Angeles, CA
Fabrizio Truji, Milan, Italy
Arastoo Yassough, Philadelphia, PA
Richard Watts, New Haven, CT
Elysa Widjava, Toronto, Ontario, Canada
Ronald Wolf, Philadelphia, Pennsylvania
Shuang Xia, Tianjin, China
Leonard Yeo, Singapore
Woong Yoon, Gangwon, South Korea
David M. Yousem, Evergreen, CO
Carlos Zamora, Chapel Hill, NC
Chengcheng Zhu, Seattle, WA

EDITORIAL FELLOW
Alexandre Bouet, Toronto, Ontario, Canada
1311 Comparison of 30-Day Outcomes after Carotid Artery Stenting in Patients with Near-Occlusion and Severe Stenosis: A Propensity Score Matching Analysis  C. Štěchovský, et al.


1333 Duct-like Recess in the Infundibular Portion of Third Ventricle Cranioopharyngiomas: An MRI Sign Identifying the Papillary Type  J.M. Pascual, et al.


1350 Diagnostic Accuracy of MRI for Detection of Meningitis in Infants  S.F. Kralik, et al.

1356 MR Imaging Characteristics and ADC Histogram Metrics for Differentiating Molecular Subgroups of Pediatric Low-Grade Gliomas  S. Shrot, et al.

1363 Noninvasive Follow-up Imaging of Ruptured Pediatric Brain AVMS Using Arterial Spin-Labeling  J.F. Hak, et al.


1375 35 YEARS AGO IN AJNR

ONLINE FEATURES

WHITE PAPER

E19 Amyloid-Related Imaging Abnormalities with Emerging Alzheimer Disease Therapeutics: Detection and Reporting Recommendations for Clinical Practice  P.M. Cogswell, et al.

LETTERS


E38 Reply  R. Li, et al.

BOOK REVIEWS  R.M. Quencer, Section Editor

Please visit www.ajnrblog.org to read and comment on Book Reviews.
Explore the New ASNR Career Center

Your Premier Resource for Professional Development

- Access to jobs in the National Healthcare Career Network
- Confidential resume posting
- One-time free resume review
- Professional online profile
- Saved jobs capability

Start here: careers.asnr.org
In Planning for Brain Metastases Treatment, Imaging may be the Missing Link in Cost Containment

When faced with a patient presenting with metastatic brain cancer, determining whether to use up-front stereotactic radiosurgery (SRS) vs. first treating with whole brain radiotherapy (WBRT) is a significant clinical decision.

**WBRT: The whole story on cognitive impairment**

While whole brain radiotherapy (WBRT) has been the main treatment option for many years, experts agree that it often results in cognitive deterioration and a negative impact on quality of life. This mental decline has a devastating impact on patients and their families and adds ongoing costs for the healthcare systems managing these symptoms.

Using WBRT instead of SRS in some patients is estimated to decrease the total costs of brain metastasis management, though with increased toxicity.

**SRS: Fewer side effects but greater risk of missed tumors**

The cost of upfront SRS is the greatest contributor to cost of brain metastasis management. SRS is often more expensive than WBRT. What’s more, multiple applications of SRS can increase the cost of treatment greatly.

Stereotactic radiosurgery (SRS) has far fewer side effects, but upfront use of SRS is expensive and can carry the risk of missed tumors, requiring repeat procedures such as salvage SRS.

Number of lesions and lesion size are key factors to be considered when determining the treatment plan for these patients. It follows that increased diagnostic information and accuracy could be beneficial in directing the proper therapy and improving overall long-term patient outcomes and containing costs. Getting the diagnosis right the first time is crucial to ensure proper treatment begins quickly, and high cost/high stakes procedures such as SRS need precise surgical planning.

**What does optimal visualization mean for outcomes and cost?**

For surgical planning with SRS, radiologists need the best visualization achievable to accurately count the number and size of the lesions. These metrics are the key predictors of the need for SRS, WBRT, or a combination of both.

By selecting the ideal contrast agent and equipment protocols, neuroradiologists can identify the proximate numbers of metastases for upfront treatment and reduced salvage treatment occurrences.

**The role of radiology**

As medical care for oncology patients continues to evolve, it will be increasingly important to assess the cost of various interventions given the often-limited life expectancy of cancer patients, the rising costs of cancer therapy, and the increasing prevalence of cancer in an aging population.

Through seeing all the tumors and tumor borders as clearly as technology allows, radiology can play a part in ensuring that proper treatment can begin quickly, while containing costs through optimized patient care. Efforts to carefully manage treatment approaches require improvements in protocol design, contrast administration in imaging, and utilizing multimodal imaging approaches.

In this era of precision medicine, radiology departments’ contribution to this improved standard of care will have significant short and long-term implications by reducing cost of care, providing a more proximate diagnosis, and ensuring optimal patient outcomes.

Join us April 29-May 3, 2023, to present the best scientific research in neuroradiology.

ASNR is looking for abstract submissions on the topics of Adult Brain, Spine, Head and Neck, Pediatrics, Functional/Advanced Imaging, Interventional, Health Policy, and AI/Informatics.

**ABSTRACT SUBMISSION DEADLINE**
Tuesday, November 1, 2022 (11:59 PM ET)
Submit online at https://bit.ly/3PsTO19
Acceptance notifications will be sent on or before January 17, 2023, upon conclusion of peer review.

**ABSTRACT SUBMISSION CATEGORIES**
Scientific Oral Presentation: *in person* presenter attendance required
Electronic Scientific Poster: *in person OR virtual* presenter attendance required
Electronic Excerpta Poster: *in person OR virtual* presenter attendance required
Electronic Educational Exhibit: *in person OR virtual* presenter attendance required

**ABSTRACT SUBMISSION INFORMATION AND CRITERIA**
• By submitting an abstract, you agree that the presenting author will register for the meeting at their own expense. Oral abstract presenters must register and attend in-person. ePosters/ Educational Exhibits presenters may register for the virtual or in-person meeting format.
• ASNR requires disclosure from all persons in control of content, including all authors on abstracts. When added to an abstract, all co-authors on your submission will be notified to log-in and complete their own disclosure form. Once all co-authors have submitted disclosure, you will be able to finalize your submission. You will not be able to finalize your submission until all authors and co-authors have completed their disclosure forms. If any disclosures cannot be submitted by the deadline, remove authors with missing disclosures and submit the abstract. Authors may be added after submission if disclosure is completed. Email education@asnr.org to add authors after the submission deadline.
• Maximum length, not including spaces, title, authors, or image: 2,500 characters (combined from all text fields).
• The submission site allows uploading of a single JPG file with each submission. Only one graphic file may be submitted with each abstract. This single JPG can contain multiple images, graphics, and tables.
• At least one reference is required, and up to five references may be included. References should be formatted according to AJNR author instructions.
• **DO NOT SUBMIT DUPLICATE ABSTRACTS IN MULTIPLE CATEGORIES OR SUBMISSION TYPES.**
• Changes can be made to submitted abstracts until the deadline.
• ASNR encourages presenters to submit manuscripts based on their work to the American Journal of Neuroradiology or Neurographics before considering other journals.
• Available ASNR awards include the David M. Yousem Research Fellow Award, Cornelius Dyke Memorial Award, Outstanding Presentation Awards, and Educational Exhibit Awards.

Questions? Contact the ASNR Education Department at education@asnr.org.
Title: Midtown East. Looking out at the East River in New York City, on the left across the river in the borough of Queens, are two of the red-and-white striped stacks of the Ravensport generating station, a.k.a. Big Allis, for the Allis-Chalmers industrial machinery corporation. One of its units was the world’s first 100-million kilowatt generator in the world in 1965. On the right is the Ed Koch Queensboro Bridge. In between are Roosevelt Island and the Roosevelt Island tram, the latter providing the only direct passage to/from Manhattan besides by boat, though the bridge used to have a vehicular elevator down to the island from 1934–1955. Currently a residential area, it was the site of several hospitals serving incarcerated, indigent, psychiatric, long-term, and smallpox patients. Coler Specialty Hospital remains active. This image is dedicated to the memory of my father Richard S. Hauben, MD, who completed a rotating internship and internal medicine residency on Roosevelt Island a very long time ago.

Manfred Hauben, MD, MPH, Pfizer Inc and NYU Langone Health, New York City
Multimodality Imaging in Primary Progressive Aphasia

M. Roytman, G.C. Chiang, M.L. Gordon, and A.M. Franceschi

ABSTRACT

SUMMARY: Primary progressive aphasia is a clinically and neuropathologically heterogeneous group of progressive neurodegenerative disorders, characterized by language-predominant impairment and commonly associated with atrophy of the dominant language hemisphere. While this clinical entity has been recognized dating back to the 19th century, important advances have been made in defining our current understanding of primary progressive aphasia, with 3 recognized subtypes to date: logopenic variant, semantic variant, and nonfluent/agrammatic variant. Given the ongoing progress in our understanding of the neurobiology and genomics of these rare neurodegenerative conditions, accurate imaging diagnoses are of the utmost importance and carry implications for future therapeutic triaging. This review covers the diverse spectrum of primary progressive aphasia and its multimodal imaging features, including structural, functional, and molecular neuroimaging findings; it also highlights currently recognized diagnostic criteria, clinical presentations, histopathologic biomarkers, and treatment options of these 3 primary progressive aphasia subtypes.

ABBREVIATIONS: AD = Alzheimer disease; ASL = arterial spin-labeling; FTLD = frontotemporal lobar degeneration; lvPPA = logopenic variant PPA; nfvPPA = nonfluent/agrammatic variant PPA; PPA = primary progressive aphasia; 3R = 3-repeat; 4R = 4-repeat; svPPA = semantic variant PPA; TDP-43 = transactive-response DNA-binding protein 43; TSPO = translocator protein 18 kDa

Neurodegenerative disorders encompass an assortment of clinically and histopathologically diverse conditions, typically slowly progressive and associated with gradual neurologic dysfunction. While precise mechanisms leading to their development continue to be elucidated, these disorders can be broadly grouped into categories based on similar histopathology, including tauopathies (eg, some cases of frontotemporal lobar degeneration [FTLD], corticobasal degeneration, progressive supranuclear palsy), transactive-response DNA-binding protein 43 (TDP-43) accumulation (eg, other cases of FTLD, amyotrophic lateral sclerosis), β-amyloid accumulation (eg, Alzheimer disease [AD]), and α-synucleinopathies (eg, Parkinson disease, dementia with Lewy bodies, multiple system atrophy), noting mixed pathologies in some cases. Primary progressive aphasia (PPA), clinically characterized by language-predominant impairment, has been histopathologically linked to both underlying FTLD (eg, semantic variant PPA [svPPA] and nonfluent/agrammatic variant PPA [nfvPPA]) and AD-type pathology (eg, logopenic variant PPA [lvpPPA]) (Fig 1). The microtubule-associated protein τ, encoded by the MAPT gene, has been shown to pathologically aggregate when in an abnormal hyperphosphorylated form (p-τ) and result in extracellular neurofibrillary tangles that contribute to neurodegeneration. Tauopathies are characterized by the predominance of abnormally deposited alternatively spliced τ isoforms (eg, 3-repeat [3R] versus 4-repeat [4R]-tauopathies), which may be seen in some cases of PPA. Deposits of TDP-43, a cellular protein encoded by the TARDBP gene and with 4 described subtypes (A, B, C, D), is an additional frequently identified pathologic substrate seen in cases of PPA. While trends have been reported between these histopathologic entities and PPA subtypes (lvpPPA: AD pathology; svPPA: TDP-43; nfvPPA: 4R-τ), no absolute association exists and inconsistencies regarding the frequency of molecular alterations for each variant have been described across studies, likely related to varied diagnostic approaches.

While a progressive neurodegenerative disorder characterized by language-predominant impairment has been a recognized entity dating back to the 19th century, inconsistencies regarding its...
Table 1: Inclusion and exclusion criteria for PPA diagnosis

<table>
<thead>
<tr>
<th>Criteria</th>
<th>Inclusion</th>
</tr>
</thead>
<tbody>
<tr>
<td>Most prominent clinical feature is language difficulty</td>
<td>Aphasias should be the most prominent deficits at symptom onset and for the initial phases of the disease</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Exclusion</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pattern of deficits is better accounted for by other nondegenerative nervous system or medical disorders</td>
</tr>
<tr>
<td>Prominent initial episodic memory, visual memory, and visuoperceptual impairments</td>
</tr>
<tr>
<td>Prominent initial behavioral disturbance</td>
</tr>
</tbody>
</table>

--------------------------------------------------

Terminology and nomenclature exist in the literature. In an effort to improve diagnostic uniformity and the reliability of research results, Gorno-Tempini et al. published a 2011 framework for PPA diagnosis and classification using a 2-step process. Initially, patients must meet the criteria of Mesulam for the overarching diagnosis of PPA, requiring a language-predominant deficit in the absence of significant episodic memory, behavioral, or visuo-spatial disturbances, and are subsequently subdivided into the clinical variant that best corresponds to their specific language disturbance. Inclusion and exclusion criteria for the diagnosis of PPA, as well as the specific diagnostic criteria for each PPA subtype, are outlined in Tables 1 and 2. In addition to clinical features, a PPA diagnosis can be further supported by pathology (eg, FTLD- versus AD-type pathology) if such pathologic or genetic data are available as well as imaging if a typical pattern of atrophy and/or hypometabolism is identified. Therefore, an accurate diagnosis of PPA requires a multidisciplinary approach, inclusive of clinical, pathologic, and radiologic evaluation. Early in the disease course, some patients may be referred to as “PPA unclassifiable,” with further elucidation of their specific subtype as the disease progresses. While most patients do not have abnormalities on a general neurologic examination at diagnosis, features such as parkinsonism, apraxia, and upper motor neuron involvement have been reported as PPA progresses.

Advances in the understanding of PPA, particularly the recognition of variant-specific patterns of atrophy and/or hypometabolism, have reinforced the role of structural, functional, and molecular neuroimaging in supporting the diagnosis, when clinically suspected. This review highlights available imaging modalities in the identification of PPA as well as characteristic variant-specific features with which neuroradiologists should be familiar to aid in a prompt and accurate diagnosis.

Logopenic Variant PPA

LvPPA is the most recently described of the 3 PPA variants, first reported in 2004 by Gorno-Tempini et al. Clinically characterized by word-finding difficulties and lapses in conversation, lvPPA has been reported to exhibit histopathologic findings and biomarkers that overlap with AD pathology (eg, β-amyloid [Aβ] and neurofibrillary tangles) and, therefore, is considered a clinical variant of AD.

Classically, patients with lvPPA present with word-finding difficulties and lapses in conversation, giving rise to its "logopenic" name (Greek, "lack of words"). Early in the disease, patients exhibit "tip-of-the-tongue" pauses with pauses in word retrieval as well as anomia. Spelling or speech-sounding errors are also frequently described, and patients may struggle to understand complex sentences or retain verbal information. The diagnostic feature that distinguishes lvPPA from svPPA and nfvPPA is an early and disproportionate difficulty in repeating heard phrases and sentences, corresponding to an impairment of phonologic or verbal working memory. While language is the dominant issue, extralinguistic difficulties related to memory, praxis, and visuospatial awareness have been reported. Patients often exhibit generalized anxiety, irritability, and dependence on their primary caregivers, behavioral features that may also occur with typical AD or other AD variants.

As a whole, PPA is a rare entity with an estimated prevalence of 3–7 cases per 100,000, often occurring in late middle life (mean age of disease onset, 62.34 years) with an average delay between first symptoms and diagnosis of 3.21 years in 1 study. Given the novelty of lvPPA as a clinical entity, its precise prevalence is not definitively known. However, a 2016 retrospective analysis of a cohort from a tertiary center (n = 97) in patients with language deficits and CSF biomarkers from the French AD databank, performed to better understand PPA demographics, revealed lvPPA as the most common variant of PPA (51%, 49/97) with a slight female predominance (57%, 28:21, female/male). Within this group, lvPPA was more frequently associated with an AD CSF profile (85%) than nfvPPA (35%) or svPPA (20%), contributing to the present day notion of lvPPA as a clinical variant of AD.
In a study investigating CSF fluid biomarkers (including Aβ 42, τ, p-τ) in 13 patients with lvPPA, 62% (8 of 13) demonstrated a profile indicative of AD pathology (lvPPA+), while 38% (5 of 13) had a non-AD profile (lvPPA−). Subsequent analyses demonstrated that those in the lvPPA+ group exhibited more advanced imaging findings compared with those in the lvPPA− group, including more extensive hypometabolism and larger regions of involvement throughout the inferior parietal and superior and middle temporal cortices. Such heterogeneity of pathologies identified in this study may reflect a “locomotor aphasia complex,” with at least 2 existing lvPPA subvariants.15

PPA may be inherited in an autosomal dominant manner, most commonly associated with mutations in the progranulin (GRN) gene on chromosome 17. While the presence of a GRN mutation does not necessarily lead to PPA, a language disorder often emerges in many patients with this mutation. The clinical symptoms of this language disorder can vary widely, with heterogeneity even among family members with the same GRN mutation. However, among patients with nonamyloid PPA with GRN mutations, lvPPA was found to be the most frequent linguistic variant.16 In 1 study, 42% of patients with lvPPA were found to carry the apolipoprotein E e4 allele, known to confer an increased risk of sporadic AD and in keeping with our understanding of lvPPA as a clinical variant of AD, compared with 26% of patients with svPPA and 20% of patients with nfvPPA.17 Other predisposing gene variants or mutations found to be associated with lvPPA include TREM2, TOMM40, APP, PSEN1 and PSEN2, and MAPT.18

While the aforementioned evidence supports underlying AD pathology in most patients with lvPPA, not all cases of lvPPA are attributed to AD pathology. In 1 postmortem analysis of 99 patients with lvPPA, 76% had primary AD pathology, while FTLD-TAR DNA-binding protein (FTLD-TDP) and FTLD-τ pathologies were identified in 14% and 5% of patients, respectively.17

To date, no pharmacologic options have been shown to improve or protect against declining function in lvPPA. However, supportive care measures such as speech-language therapy have demonstrated efficacy in improving communication.19 Given that underlying AD pathology is associated with most lvPPA cases, use of emerging anti-amyloid therapies in lvPPA may be investigated.

### Structural Imaging

The presence of specific regional patterns of atrophy or metabolic impairment is the key neuroimaging diagnostic feature for each of the 3 PPA variants (Table 2). Structural imaging, including CT and MR imaging, can be used to identify these classic patterns of focal atrophy. Included in the 2011 Gorno-Tempi Diagnostic Criteria, MR imaging can be used to identify asymmetric, classically left-sided widening of the Sylvian fissure, indicative of the posterior per-Sylvian and temporoparietal atrophy seen in lvPPA. The posterior aspect of the left superior temporal gyrus, corresponding to the expected Wernicke area, is typically involved. This finding, particularly when progressive over multiple examinations and in conjunction with a clinical history of progressive word-finding difficulty, should raise the possibility of underlying lvPPA (Fig 2). Notably,

### Table 2: Diagnostic criteria for PPA variants

<table>
<thead>
<tr>
<th>Clinical diagnosis</th>
<th>lvPPA</th>
<th>svPPA</th>
<th>nfvPPA</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Impaired single-word retrieval in spontaneous speech and naming AND</td>
<td>1. Impaired confrontation naming</td>
<td>1. Agrammatism in language production AND/OR</td>
<td></td>
</tr>
<tr>
<td>2. Impaired repetition of sentences and phrases</td>
<td>2. Impaired single-word comprehension AND</td>
<td>2. Effortful, halting speech with inconsistent speech sound errors and distortions (apraxia of speech)</td>
<td></td>
</tr>
<tr>
<td>At least 3 of the following: 1. Speech (phonologic) errors in spontaneous speech and naming</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2. Spared single-word comprehension and object knowledge</td>
<td>2. Surface dyslexia or dysgraphia</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4. Absence of frank agrammatism</td>
<td>4. Spared speech production (grammar and motor speech)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Imaging-supported diagnosis</td>
<td>Predominant left-posterior periosylvian or temporoparietal atrophy and/or hypoperfusion or hypometabolism</td>
<td>Predominant anterior temporal lobe atrophy and/or hypoperfusion or hypometabolism</td>
<td>Predominant left posterior frontoinsular atrophy and/or hypoperfusion or hypometabolism</td>
</tr>
<tr>
<td>Pathology-supported diagnosis (or presence of known pathogenic mutation)</td>
<td>AD</td>
<td>TDP-43</td>
<td>4R-τ</td>
</tr>
</tbody>
</table>

*Histopathologic evidence of a specific neurodegenerative pathology (eg, FTLD-τ, FTLD-TDP, AD, other), particularly if most characteristic pathology.
while most patients are left-hemispheric language dominant, involvement of the right hemisphere has been reported and hypothesized to occur in left-handed individuals or those with a history of developmental learning disabilities (eg, dyslexia).20

The preferred structural imaging technique for the diagnosis of PPA is MR imaging, due to its superior soft-tissue resolution and ability to precisely localize anatomic atrophy. Advanced MR imaging techniques, such as voxel-based morphometry analysis and DTI, may be used to demonstrate focal GM atrophy primarily in the left lateral temporal and inferior parietal lobes (including the left angular and supramarginal gyri) and left precuneus and left posterior cingulate gyrus. Advanced cortical volumetric software such as the FDA-approved NeuroQuant (https://www.cortechs.ai/products/neuroquant-ct/) and Icometrix (https://www.icometrix.com/) are increasingly being used in routine clinical assessment of various neurodegenerative disorders. In a study investigating the utility of MR imaging in differentiating PPA variants, MR imaging demonstrated a high specificity for the characteristic atrophy patterns of lvPPA (95%) and nfvPPA (91%), noting a low sensitivity for both (43% for lvPPA; 21% for nfvPPA).22 Therefore, while the presence of left posterior peri-Sylvian or temporoparietal region atrophy is highly suggestive of lvPPA, its absence does not exclude the diagnosis. In a prospective study investigating 130 patients with neurodegenerative aphasia, of whom 52 had lvPPA, GM loss was identified in patients with lvPPA, more commonly on the left and greatest in the posterior temporal lobe extending to the frontal and parietal regions.23 Fractional anisotropy and mean diffusivity analyses within this cohort revealed left-greater-than-right bilateral WM involvement, greatest in the posterior left temporal WM and extending into the anterior temporal, frontal, parietal, and occipital WM, as well as involving the bilateral superior and inferior longitudinal fasciculi and inferior occipitofrontal fasciculus. The posterior superior temporal and inferior parietal cortices have been shown to play a role in phonologic loop functions.21 Therefore, involvement of these regions and WM tracts in the superior and inferior longitudinal fasciculi likely account for the poor repetition, naming, and comprehension seen in patients with lvPPA.23,24

Atrophy may also be identified anteriorly with involvement of the hippocampi, among other structures, with the overall extent and pattern of atrophy varying widely among individual patients. Most important, the presence of progressive atrophy with time supports the diagnosis of PPA, a critical observation worthy of mention when interpreting such structural imaging examinations.

Functional Imaging. fMRI, which can be performed with task-based paradigms or in a resting state, uses blood oxygen level-dependent contrast to identify areas of brain activation on the basis of oxygen extraction.25 While fMRI is not in routine clinical use for the diagnosis of PPA and limited literature exists regarding its specific findings in lvPPA, fMRI has been reported to demonstrate functional changes in patients with svPPA (formerly referred to as semantic dementia).26 to be discussed later in this review. Such advanced imaging techniques could be useful in

FIG 2. Coronal T1-weighted MR imaging (A), axial T1-weighted MR imaging (B), and sagittal T1-weighted MR imaging (C) in a right-handed individual with impaired repetition of phrases demonstrate asymmetric widening of the left Sylvian fissure with left posterior peri-Sylvian and temporoparietal atrophy (white arrows, A–C), suspicious for lvPPA.

FIG 3. Voxel-level imaging findings in lvPPA and dementia of the Alzheimer type (DAT) compared with controls. 3D renderings show regions of reduced FDG metabolism and GM volume in lvPPA compared with controls and in DAT compared with controls. Note, lvPPA demonstrates hypometabolism and focal atrophy primarily in the left lateral temporal and inferior parietal lobes (including the left angular and supramarginal gyri) and left precuneus and left posterior cingulate gyrus. Adapted with permission from Madhavan et al.84 R indicates right; L, left.
identifying aberrant and compensatory language network changes and may prove useful in guiding future therapeutic trials.\textsuperscript{11}

Cerebral perfusion, which has been linked to cognition and neuronal activity, can be measured with MR imaging using the noncontrast arterial spin-labeling (ASL) technique.\textsuperscript{27} While limited data exist regarding use of ASL for lvPPA specifically, ASL has been shown to identify hypoperfusion patterns in other dementia subtypes before symptom onset and also correspond to disease-specific regions of hypometabolism identified on [18F] FDG-PET. However, limitations of the ASL technique for clinical use include its low SNR on conventional 1.5T field strength MR imaging, with 3T field strength MR imaging preferred for use in the ASL technique, as well as technical issues with quantification. Further studies assessing the potential role of ASL for patients with lvPPA as well as its performance compared with [18F] FDG-PET are warranted.

\textbf{Molecular Imaging} Molecular imaging allows in vivo identification and quantification of cerebral metabolism, abnormal deposition of \(\beta\)-amyloid and \(\tau\), and the presence of brain inflammation, important neuroimaging biomarkers that may improve early diagnosis and assist in assessing neurodegenerative disease progression.\textsuperscript{27-29} Currently available molecular imaging modalities include SPECT and PET, with a number of investigational radiotracers on the horizon.\textsuperscript{30} Advantages of PET imaging include superior spatial and contrast resolution compared with SPECT, though it is a more expensive examination and less widely available. Limitations include attenuation correction and motion artifacts, which may cause inaccurate anatomic coregistration. Molecular neuroimaging has been shown to be useful in the diagnosis of PPA.\textsuperscript{31-33}

\([^{18}\text{F}]\) FDG-PET assesses cerebral glucose metabolism, which is abnormally reduced in neurodegeneration due to synaptic dysfunction and neuronal loss.\textsuperscript{2} The characteristic pattern of hypometabolism in lvPPA includes asymmetric involvement of the left posterior peri-Sylvian and left lateral temporoparietal regions, mirroring previously described regions of atrophy, specifically involving the left inferior parietal lobule and left posterior superior and middle temporal gyri, including the expected Wernicke area (Broadman area 22) (Figs 3 and 4). SPECT, which demonstrates regional hypoperfusion similar to the metabolic alterations on \([^{18}\text{F}]\) FDG-PET is infrequently used in clinical practice due to technical disadvantages and poorer accuracy.\textsuperscript{29}

Amyloid PET is a valuable examination for the diagnosis of AD and other neurodegenerative disorders demonstrating \(A\beta\) pathology.\textsuperscript{16} In a meta-analysis of 1251 patients from 36 dementia centers, \(A\beta\)-positivity was identified in 86% of patients with lvPPA with evidence of AD pathology identified in 76% of those who

\textbf{FIG 4.} \([^{18}\text{F}]\) FDG-PET cortical surface maps demonstrate an abnormal FDG distribution pattern with moderate-to-severe hypometabolism in the left, lateral temporoparietal lobes including in the left precuneus and posterior cingulate gyrus (A), with corresponding disproportionate cortical atrophy in the left lateral temporoparietal region visualized on brain CT (B), findings are further supported by a semiquantitative FDG-PET analysis using \(z\) scores calculated in comparison with age-matched cognitively healthy controls, demonstrating markedly decreased values in the left parietal and left lateral temporal regions, including in the precuneus and posterior cingulate gyrus (B).

\textbf{FIG 5.} \([^{18}\text{F}]\) florbetaben PET axial gray-scale (A), axial color map fused to a T1-weighted MR image (B), and left lateral 3D stereotactic surface projection (C) demonstrate focal areas of increased cortical \(\beta\)-amyloid deposition in the left temporal lobe (arrows).
underwent a postmortem examination (Fig 5). Aβ-positivity was also seen in a minority of those with nfvPPA (20%) and svPPA (16%); however, Aβ-positivity was thought to represent a concomitant age-related process in these patients rather than being attributable to their PPA syndrome. In another study, 88% (46 of 52 patients) meeting the criteria for lvPPA demonstrated Aβ-positivity, with low Aβ-positivity rates in patients not meeting criteria for lvPPA (10%, 13 of 130 patients). 

In a study evaluating amyloid metabolism in PPA, 100% (4/4) of patients with lvPPA demonstrated elevated cortical Pittsburgh compound B uptake versus 16% (1/6) of patients with nfvPPA and 20% (1/5) of those with svPPA. Thus, amyloid PET imaging can be useful in distinguishing lvPPA from nfvPPA and svPPA, noting that comorbid age-related Aβ pathology may occur in each of these entities and an amyloid PET scan with positive findings does not equate to a diagnosis of lvPPA.

In addition to β-amyloid plaques, neurofibrillary tangles are a hallmark pathologic finding in AD. τ-targeting PET tracers have been used for molecular imaging in PPA, most commonly [18F] flortaucipir (AV-1451), an FDA-approved, first-generation τ PET ligand. In a study investigating use of [18F] AV-1451 in PPA, patients with lvPPA exhibited striking uptake throughout the neocortex, most notably in the left temporoparietal region, compared with controls and subjects with other PPA variants, confirming the use of this radiotracer in distinguishing PPA subtypes. In a case series of patients with typical amnestic AD and atypical variants (posterior cortical atrophy, lvPPA, and corticobasal syndrome), all patients demonstrated region-specific distribution of [18F] AV-1451, indicating that τ PET can serve as a key biomarker linking molecular AD neuropathologic conditions with clinically significant neurodegenerative syndromes.

The use of PET tracers that target the translocator protein 18 kDa (TSPO) have also been explored in PPA, with the goal of characterizing the role of microglial activation and associated neuroinflammation in the pathogenesis of PPA. TSPO, originally named the peripheral benzodiazepine receptor, is an 18-kDa outer mitochondrial membrane protein, which has been found in disease-relevant areas across a broad spectrum of neurodegenerative diseases. Histopathologic studies have demonstrated asymmetric distribution of activated microglia in PPA, including high microglial densities in the superior temporal and inferior frontal gyri of the language-dominant hemisphere, consistent with postmortem and/or in vivo atrophy distribution. Patterns of microglial activation revealed variation favoring areas of increased atrophy in regions associated with language function, demonstrating concordance among patterns of microglial activation, atrophy, and clinical PPA phenotype. These findings support the potential use of TSPO PET in the evaluation of PPA subtypes.

Semantic Variant PPA

svPPA, previously referred to as “semantic dementia” in case reports throughout the 20th century, is a heterogeneous clinical syndrome characterized by progressive loss of knowledge about words and objects, including a fluent dysphasia with severe anomia, reduced vocabulary, and prominent impairment of single-word comprehension, which progresses to a stage of virtually complete dissolution of the semantic components of language. The criteria for the clinical diagnosis of svPPA are detailed in Table 2. Notably, a right temporal lobe–predominant variant of svPPA featuring impaired facial recognition (ie, prosopagnosia) and changes in affect and social behavior, in addition to semantic memory impairment, has also been described.

svPPA is currently recognized within the clinical spectrum of FTLD (Fig 1), with underlying histopathology most often attributable to TDP-43 type C, characterized by long dystrophic neurites and identified in >80% of patients with svPPA. Some cases have been associated with other histopathologic findings, including FTLD-TDP types A and B, FTLD-τ (particularly 3R-τ [Pick bodies] and 4R globular glial tauopathy), as well as AD pathology. SvPPA is almost always sporadic, rather than familial, and is the least heritable compared with other FTLD syndromes, with only 2%–4% of cases demonstrating an autosomal dominant pattern and suspected family history identified in 2%–17% of patients. Genetic disorders linked to familial FTLD-TDP include those associated with mutations in the GRN gene (FTLD-TDP type A), expansions in the chromosome 9 open reading frame 72 (C9orf72) gene (FTLD-TDP types A or B), and mutations in the valosin-containing protein (VCP) gene (FTLD-type D). In the absence of a strong family history of svPPA, an underlying genetic abnormality is considered unlikely.

The precise prevalence of svPPA is not definitively known because diagnosis requires extensive clinical expertise and available data has largely been derived from tertiary care research center referrals, likely not representative of the general population. However, the 2016 retrospective analysis from the French AD databank identified 26% (25 of 97) of PPA cases with CSF biomarkers to be svPPA, with a mean age of disease onset at 59.5 years and an average delay of 4.5 years between first symptom and diagnosis, a male predominance (68%; 8:17, female/male), and underlying AD pathology in only 20% of cases. The estimated svPPA prevalence based on the French AD databank cohort was 0.8 per 100,000 individuals, increasing with patient age. With regard to FTLD, its overall prevalence varies widely across studies, ranging from 2 to 31 per 100,000 individuals with an estimated true point prevalence of 15 to 22 per 100,000 and an incidence of 2.7 to 4.1 per 100,000 in those younger than 70 years of age. One series assessing 353 consecutive patients with FTLD identified 18.7% as having svPPA. An epidemiologic study investigating FTLD syndromes in 2 UK counties with a population of 1.69 million yielded an estimated svPPA prevalence of 1.2 per 100,000.

No disease-modifying medications are currently available for the treatment of svPPA. A variety of psychotropic medications have been used to manage associated behavioral symptoms, though evidence of efficacy from randomized clinical trials is lacking. Speech-language therapy has been shown to slow progression of anomia and may even offer a protective benefit to lexical items not yet lost, noting that treatment is suspected to be most beneficial at early stages of disease, supporting the advantage of an early diagnosis. A double-blind, sham-controlled, randomized clinical trial of transcranial direct current stimulation in patients with svPPA is ongoing.
with corresponding marked hypometabolism (involvement of the contralateral cortex). Similarly, a longitudinal investigation mapping the progression of GM atrophy in patients with svPPA identified marked cortical thinning in the left temporal lobe, particularly at the temporal pole; entorhinal cortex; and parahippocampal, fusiform, and inferior temporal gyri, extending to the medial portion of the temporal lobes with involvement of the amygdala and parahippocampal gyri, as well as the left temporal pole, middle temporal gyrus, and caudate nucleus. Surface-based analysis of patients with svPPA identified marked cortical thinning in the left temporal lobe, particularly at the temporal pole; entorhinal cortex; and parahippocampal, fusiform, and inferior temporal gyri, with similar-yet-less extensive involvement of the contralateral cortex. Similarly, a longitudinal investigation mapping the progression of GM atrophy in predominantly left-versus-predominantly right temporal lobe variants of svPPA identified significant progression of GM atrophy in both the affected and contralateral temporal regions. Voxel-based morphometry has also identified asymmetric regional reduction in the temporal, periventricular, and callosal WM in patients with svPPA.

DTI has been used to study structural connectivity changes on the whole-brain level in patients with svPPA, with reports of reduced fractional anisotropy and increased diffusivity in the anterior temporal lobe extending dorsally and posteriorly into the ventral frontal regions. Tractography has similarly been implemented in svPPA, identifying disruptions of structural connectivity related to GM atrophy, most severely affecting the WM tracts connecting the temporal regions with the frontal, parietal, and occipital regions (ie, uncinate fasciculus, arcuate fasciculus, superior longitudinal fasciculus, and inferior longitudinal fasciculus).

Functional Imaging. Task-based fMRI studies have reported that patients with svPPA compared with healthy controls demonstrate decreased activation in the mid-fusiform and superior temporal gyri; increased activation in the intraparietal sulcus, inferior frontal gyrus, and left superior temporal gyrus/sulcus; and a lack of activation in the anterior temporal lobe. Similarly, resting-state fMRI studies in patients with svPPA have demonstrated reduced functional connectivity in the language and executive networks, with extensive disruptions between the anterior temporal lobe and a broad range of brain regions across the temporal, frontal, parietal, and occipital lobes. Magnetoencephalographic imaging has also been implemented to investigate whole-brain resting-state functional connectivity, identifying significant hyposynchrony of α and β frequencies within the left temporoparietal junction in patients with svPPA.

Regarding ASL MR imaging, a study investigating the prognostic value of regional CBF as measured by ASL MR imaging in patients with svPPA reported that ASL MR imaging may be sensitive to functional changes not identified on structural MR imaging, potentially serving as a prognostic biomarker marker of disease progression. Further studies assessing the potential role of ASL in patients with svPPA as well as its performance compared with [18F] FDG-PET are warranted.

Molecular Imaging. [18F] FDG-PET and SPECT can be performed to demonstrate characteristic asymmetric hypometabolism/hypoperfusion predominantly affecting the anterior temporal regions, most
commonly involving the left temporal pole (Figs 8 and 9). While svPPA is often associated with TDP-43 pathology, no available PET radioligand for TDP-43 exists to date. Given the presence of AD pathology in some cases of svPPA, reported in up to 20% of cases within the 2016 French AD databank retrospective cohort, amyloid PET may result in an amyloid-positive examination in a minority of svPPA patients.

While τ pathology is infrequently reported in patients with svPPA, studies with radioligands that demonstrate an affinity for τ, including [18F] THK-5351 and flortaucipir ([18F] AV-1451), have demonstrated asymmetric retention in the temporal lobes in a pattern consistent with the expected distribution of TDP-43 pathology, hypothesized to reflect off-target binding to monoamine oxidase as a consequence of inflammation in the affected regions. A study investigating the novel τ PET tracer [18F] PI-2620, which has a low affinity for monoamine oxidase, demonstrated slightly elevated uptake involving the anterior and lateral temporal lobes in 1 of 2 subjects with svPPA, without elevated uptake in the other subject [Fig 10]. There are no studies to date of PET ligands with an for inflammatory biomarkers (eg, monoamine oxidase B, TSPO/peripheral benzodiazepine receptor, or cyclooxygenase) in svPPA.

Nonfluent/Agrammatic PPA

nvPPA, previously referred to as “progressive nonfluent aphasia” in a series by Grossman et al and “PPA with agrammatism” by Mesulam, is the most diverse of the 3 PPA subtypes. Classically, patients present with a progressive language-predominant disturbance characterized by agrammatism in language production and apraxia of speech, with abnormally short (ie, telegraphic) phrases that tend to lack function words. Patients with nvPPA have reduced verb production and diminished complexity in terms of grammar use, as well as difficulty with complex coordination of muscle groups involved in articulation of speech sounds (ie, apraxia of speech) and distortion of prosody (ie, rhythm, stress, and intonation of speech). The rate of word production in patients with nvPPA has been reported to be less than one-third of the rate in healthy adults. Single-word
comprehension is notably preserved, though patients with nfvPPA may experience difficulty understanding sentences with complex syntax, such as those with relative clauses (eg, “he met a man who knew his brother”) or those with passive voice (eg, “the snake was bitten by the mongoose”).62,64 Complete criteria for a clinical diagnosis of nfvPPA, as defined by Gorno-Tempini et al,6 are described in Table 2.

Although typically considered a tauopathy, nfvPPA is the most heterogeneous of the PPAs, with a variety of other associated underlying pathologies. While 4R-τ is the most commonly reported underlying pathology, 1 postmortem series identified 23% of patients with nfvPPA exhibiting 3Ra-τ pathology (Pick bodies) and a minority with underlying TDP-43 or AD-type pathology.65 Patients with apraxia of speech and parkinsonism are more often associated with having a tauopathy than TDP-43 pathology.5,66 Similar to its pathologic heterogeneity, the clinical spectrum of nfvPPA has been described as the most diverse of the PPA subtypes, with a number of variant nfvPPA subsyndromes reported.11

NfvPPA is also the most heritable of the PPAs, with approximately 30% of patients reporting a positive family history.67 Mutations in all of the major genes associated with FTLD (eg, GRN, MAPT, C9orf72) have been identified in nfvPPA. Therefore, genetic screening should be considered in patients with a relevant family history.11 Additional detailed phenotyping of the genetic forms of nfvPPA will be required to improve on the continuously evolving understanding of PPA variants within the spectrum of FTLD.

The precise prevalence of nfvPPA is not definitively known because diagnosis requires extensive clinical expertise and available data have largely been derived from tertiary care research center referrals, likely not representative of the general population. However, the 2016 retrospective analysis from the French AD databank identified 24% (23 of 97) of PPA cases with available CSF biomarkers as nfvPPA, with a mean age of disease onset at 60.9 years, an average delay of 2.3 years between first symptom and diagnosis, slight male predominance (52%; 11:12, female/male), and underlying AD pathology in 35% of cases.14 In 2 series of 353 patients with FTLD, 24.6% of cases were identified as nfvPPA.41 An epidemiologic study investigating FTLD syndromes in 2 UK counties with a population of 1.69 million yielded an estimated nfvPPA prevalence of 1.5 per 100,000.42

No pharmacologic option exists to improve or protect against declining function for patients with nfvPPA. However, speech-language treatment has demonstrated efficacy and structured oral reading has been proposed as a treatment method for apraxia of speech in nfvPPA.68 Additionally, transcranial direct current stimulation over the left posterior peri-Sylvian region and the Broca area has also been investigated as a potential treatment technique for nfvPPA.69 Supportive care remains the mainstay of PPA treatment, noting that patients with nfvPPA may experience dysphagia and should consult with a dietician or speech therapist for consideration of assisted feeding.11 Early detection of deficits, particularly physical, is critical to optimize outcomes related to changes in functional status. Support groups can also be extremely helpful, both for patients and their caregivers. Patients with nfvPPA who experience limited verbal output but with preserved comprehension may also benefit from alternative forms of communication devices.

**Structural Imaging.** The most common imaging feature associated with nfvPPA is regional atrophy predominantly involving the inferior frontal, opercular, and insular regions of the dominant hemisphere (Broadmann area 44/45; Broca area), most commonly on
the left, with associated widening of the left Sylvian fissure (Fig 11). Notably, the left inferior frontal gyrus and pars opercularis and triangularis of the left frontal operculum are considered the syndrome-specific epicenters of disease in nfvPPA (Fig 12).\textsuperscript{70,71} Similar to other PPA variants, while the presence of left, posterior, frontoinsular atrophy is highly suggestive of nfvPPA, its absence does not exclude the diagnosis. A wide variety of nfvPPA imaging patterns has been reported, ranging from no specific pattern of atrophy to left-hemispheric, left-frontotemporal, bifrontal, or even generalized patterns of atrophy, with imaging inconsistencies largely attributable to the clinical and histopathologic heterogeneity of nfvPPA syndromes.\textsuperscript{72} Given the progressive nature of all PPA subtypes, comparison with prior imaging and serial examinations may reveal subtle region-specific progressive atrophy and should be pursued in the appropriate clinical setting.

DTI techniques have demonstrated involvement of the dorsal language pathway of long-range WM fibers connecting the frontal, subcortical, and parietal areas, a unique finding in nfvPPA that has not been described in other PPA subtypes,\textsuperscript{73,74} as well as WM damage in the dorsal pathway (superior longitudinal fasciculus).\textsuperscript{64} GM atrophy has also been described in the premotor regions, the supplementary motor area, and striatum.\textsuperscript{10,70} Syntactic processing deficits in patients with nfvPPA have been associated with structural and functional abnormalities involving the posterior part of the inferior frontal gyrus.\textsuperscript{75} Although most cases affect the left hemisphere, right-hemispheric involvement has also been reported, hypothesized to occur in left-handed individuals or those with a history of developmental learning disabilities, such as dyslexia.\textsuperscript{76}

Longitudinal progression of atrophy in nfvPPA has been reported to involve the posterior frontal regions, supplementary motor area, insula, striatum, inferior parietal regions, and underlying WM.\textsuperscript{70} Furthermore, atrophy typically progresses from the frontal operculum to the supplementary motor complex through the frontal aslant tract, which plays a role in the initiation and execution of movements, particularly articulation, and ultimately to the basal ganglia and supramarginal gyrus.\textsuperscript{73} The loss of integrity of the frontal aslant tract in nfvPPA is associated with distortion errors made by patients in spontaneous speech, as well as verbal fluency task performance. Therefore, nfvPPA is an example of a network disorder involving the circuit of regions and connections involved in speech production.\textsuperscript{77}

Functional Imaging. A resting-state fMRI study demonstrated decreased functional connectivity between the left inferior frontal gyrus and posterior middle temporal gyrus in nfvPPA, even in patients without advanced atrophy.\textsuperscript{78} Such results suggest the possibility of fMRI serving as a useful imaging technique for the early detection of PPA, particularly nfvPPA, which may ultimately improve patient outcomes as disease-modifying therapies emerge in the clinical setting.

There are limited data regarding the use of ASL for nfvPPA specifically. Further studies assessing the potential role of ASL for patients with nfvPPA as well as its performance compared with [\textsuperscript{18F}]FDG-PET are needed.

Molecular Imaging. [\textsuperscript{18F}]FDG-PET and SPECT can be performed to demonstrate characteristic asymmetric hypometabolism-hypoperfusion predominantly affecting the left posterior frontal and peri-insular regions, including the left frontal operculum (Fig 13). Specifically, metabolic reduction in the left posterior frontoinsular region, including the inferior frontal gyrus, insula, and premotor and supplementary motor areas, is necessary to make an imaging-supported diagnosis of nfvPPA.\textsuperscript{6}

Regarding the cortical amyloid burden in nfvPPA, a study investigating [\textsuperscript{11C}]-Pittsburgh compound B in PPA subtypes demonstrated increased binding in only a few subjects with nfvPPA, in an uptake pattern similar to that of AD, including elevated tracer binding throughout the neocortex and striatum.\textsuperscript{79} A recent study investigating patients with PPA with discordant amyloid status (eg, nfvPPA with AD pathology) found that most cases exhibited FTLD-\(\tau\) as the primary pathologic diagnosis with AD as an incidental age-related contribution.\textsuperscript{80} Specifically, 24 of 28 patients (86%) with svPPA and 28 of 31 patients (90%) with nfvPPA had negative amyloid PET findings, whereas 25 of 26 patients (96%) with logopenic PPA had scans with positive findings. The
amyloid-positive svPPA and nfvPPA cases with available postmortem data (2 of 4 and 2 of 3, respectively) all had a primary FTLD and secondary AD pathology diagnoses. Therefore, some patients with nfvPPA may have a PET examination positive for amyloid, and the presence of amyloid-positivity is not pathognomonic for any 1 PPA variant.

\(\tau\)-targeting PET tracers have been used in nfvPPA, most commonly \(^{[18F]}\)flortaucipir (AV-1451), a first-generation \(\tau\) PET ligand, which exhibits increased uptake in the left-greater-than-right frontal operculum and left middle and inferior frontal gyri (Fig 14).\(^{19}\) nfvPPA has also been shown to demonstrate less robust-but-focal uptake in the frontal WM and subcortical structures (Fig 15), regions known to be functionally impaired in nfvPPA, suggesting disease-specific binding to FTLD-4R \(\tau\).\(^{81}\) In nfvPPA, AV-1451 has been used to study \(\tau\) propagation in the left-hemispheric syntactic network, which comprises anterior frontal and posterior temporal nodes connected by the left arcuate fasciculus, with deposition greatest in the 2 nodes of the

**FIG 13.** \(^{[18F]}\)FDG-PET cortical surface maps demonstrate an abnormal FDG distribution pattern with severe left-greater-than-right hypometabolism, most pronounced in the dorsal frontal lobes and left peri-insular region (A), with corresponding disproportionate cortical atrophy particularly pronounced in the left insular region visualized on brain MR views (B), findings further supported by semiquantitative FDG-PET analysis using z scores calculated in comparison with age-matched cognitively healthy controls, demonstrating markedly decreased values in the left > right peri-insular region, including in the pars opercularis and pars triangularis of the left inferior frontal gyrus, corresponding to the expected Broca area (B).

**FIG 14.** \(^{[18F]}\)flortaucipir in nfvPPA. A, On voxelwise comparison with healthy controls, agPPA demonstrates increased uptake in the left-greater-than-right frontal operculum; middle and inferior frontal gyri; and left superior frontal gyrus (pFWE < .05). B, The W score frequency map demonstrates elevated W scores above 1.65 in the bilateral middle frontal gyri and frontal operculum in approximately two-thirds of patients scanned, with voxels above 1.65 in 8 of 11 patients in peak areas. C, ROI analyses reveals group differences in those with in nfvPPA compared with controls in the bilateral pars opercularis (left, \(P = .0001\); right, \(P = .0018\)), pars triangularis (left, \(P = .0016\); right, \(P = .0029\)), precentral gyrus (left, \(P = .003\); right, \(P = .0112\)), and superior frontal gyrus (left, \(P = .03\); right, \(P = .045\)). Adapted with permission from Tsai et al.\(^{81}\)
syntactic network. The left arcuate fasciculus also demonstrated decreased fractional anisotropy in nfvPPA, particularly near the anterior node, suggesting propagation from node to connected node in human brain networks in the setting of neurodegenerative diseases, including PPA.

TSPO-targeting tracers have been explored in PPA, with the goal of characterizing the role of microglial activation and associated neuroinflammation in the pathogenesis of PPA. One study identified significantly increased mean [11C] PK-11195 binding in FTLD (n = 5, including 4 patients with nfvPPA and 1 patient with behavioral-variant frontotemporal dementia) in regions such as the left dorsolateral prefrontal cortex, right hippocampus, and parahippocampus.

CONCLUSIONS
PPA is a unique and complex spectrum of neurodegenerative disorders that requires a multidisciplinary approach to diagnosis, relying on the aggregate findings of clinical presentation, histopathologic biomarkers, and imaging features. A number of structural, functional, and molecular imaging modalities can support an accurate diagnosis, and neuroradiologists should be familiar with the classic imaging features of each PPA subtype, because prompt and accurate diagnosis may allow improved outcomes and intervention, particularly as disease-modifying therapies enter clinical practice.

Disclosure forms provided by the authors are available with the full text and PDF of this article at www.ajnr.org.
56. Bevan-Jones WR, Cope TE, Simon Jones P, et al. AV-1451 binding in vivo mirrors the expected distribution of TDP-43 pathology in the
semantic variant of primary progressive aphasia. J Neurol Neurosurg Psychiatry 2018;89:1032–37 CrossRef Medline


Flow Diversion in the Treatment of Intracranial Aneurysms: A Pragmatic Randomized Care Trial


ABSTRACT

BACKGROUND AND PURPOSE: Flow diversion is a recent endovascular treatment for intracranial aneurysms. We compared the safety and efficacy of flow diversion with the alternative standard management options.

MATERIALS AND METHODS: A parallel group, prerandomized, controlled, open-label pragmatic trial was conducted in 3 Canadian centers. The trial included all patients considered for flow diversion. A Web-based platform 11 randomly allocated patients to flow diversion or 1 of 4 alternative standard management options (coiling with/without stent placement, parent vessel occlusion, surgical clipping, or observation) as prespecified by clinical judgment. Patients ineligible for alternative standard management options were treated with flow diversion in a registry. The primary safety outcome was death or dependency (mRS > 2) at 3 months. The composite primary efficacy outcome included the core lab–determined angiographic presence of a residual aneurysm, aneurysm rupture, progressive mass effect during follow-up, or death or dependency (mRS > 2) at 3–12 months.

RESULTS: Between May 2011 and November 2020, three hundred twenty-three patients were recruited: Two hundred seventy-eight patients (86%) had treatment randomly allocated (139 to flow diversion and 139 to alternative standard management options), and 45 (14%) received flow diversion in the registry. Patients in the randomized trial frequently had unruptured (83%), large (52% ≥10 mm) carotid (64%) aneurysms. Death or dependency at 3 months occurred in 16/138 patients who underwent flow diversion and 12/137 patients receiving alternative standard management options (relative risk, 1.33; 95% CI, 0.65–2.69; P = .439). A poor primary efficacy outcome was found in 30.9% (43/139) with flow diversion and 45.6% (62/136) of patients receiving alternative standard management options, with an absolute risk difference of 14.7% (95% CI, 3.3%–26.0%; relative risk, 0.68; 95% CI, 0.50–0.92; P = .014).

CONCLUSIONS: For patients with mostly unruptured, large, anterior circulation (carotid) aneurysms, flow diversion was more effective than the alternative standard management option in terms of angiographic outcome.

ABBREVIATIONS: ASMO = alternative standard management option; DSMC = Data Safety and Monitoring Committee; FD = flow diversion; FIAT = Flow Diversion in Intracranial Aneurysm Treatment; PVO = parent vessel occlusion; RCT = randomized controlled trial

Flow diversion (FD) is an innovative treatment of intracranial aneurysms.1–3 Flow diverters are low-porosity, braided endovascular stent devices designed to normalize flow in a vessel with an aneurysm and occlude the aneurysm by thrombosis of the sac.4 FD can often accomplish what other interventions cannot, such as reconstructing a cerebral vessel having a giant aneurysm and occluding the aneurysm while preserving normal parent and branching vessels.5 Yet FD has also been associated with unexpected delayed complications, such as aneurysm ruptures, parenchymal hematomas at a distance from the aneurysm, and strokes from stent thrombosis.6,7 First approved in 2011 in the United States for the treatment of unruptured, large and giant aneurysms of the proximal segments of the carotid artery,7 clinical usage has since expanded to aneurysms of all sizes, locations, and presentations. More than 22 systematic reviews of case series have shown aneurysm occlusion rates exceeding 75%, with treatment-related morbidity and mortality
in the range of 2%–10%. The role that FD should play in clinical practice still remains unclear because opinions and practices vary widely and randomized comparisons with standard management options are few. Two randomized trials were published in 2018; both restricted inclusion to large or complex anterior circulation aneurysms treatable by only 1 specific comparator intervention. One comparison of FD with stent-assisted coiling in 144 patients raised safety concerns but showed increased rates of complete angiographic occlusions with FD. Another trial in 80 patients showed FD to be safer but less effective than surgical bypass and parent vessel occlusion (PVO). The Flow Diversion in Intracranial Aneurysm Treatment (FIAT) trial was launched in 2011 to introduce to endovascular practice a promising-but-unvalidated innovation for patients with difficult intracranial aneurysms. FIAT was pragmatic, all-inclusive, and proposed a 1:1 randomized allocation for the treatment by FD or alternative standard management options (ASMOs) (defined as any other prespecified alternative management option), along with a registry of patients treated with FD considered ineligible for ASMO. The main hypothesis of the trial was that treatment with FD would increase the percentage of patients with a good outcome by 15%, a composite that included occlusion or near-occlusion of the aneurysm combined with an independent clinical outcome (mRS < 3) at 3–12 months. The aim of this article was to present the final results of the FIAT randomized trial.

**MATERIALS AND METHODS**

FIAT was an investigator-led, pragmatic, multicenter, randomized controlled care trial integrated into clinical practice. FIAT compared a policy of using either FD (any flow diverter device with or without coiling) or ASMO to manage patients with difficult intracranial aneurysms. The ASMO was selected according to clinical judgment at the time of enrollment but before randomized allocation. Patients deemed ineligible for other management alternatives were included in a parallel FD registry. There were 3 participating Canadian centers (Montreal, Edmonton, Ottawa). All sites received institutional review board approval. The protocol was published, and the trial was registered at ClinicalTrials.gov No. NCT01349582. The trial was temporarily interrupted in June 2014 for safety concerns, mainly driven by registry results, but the Data Safety and Monitoring Committee (DSMC) recommended trial continuation because treatment-related morbidity between randomized groups was similar.

**Patients**

All patients with an aneurysm for which FD was considered a promising treatment were eligible to participate. Exclusion criteria were few: 1) severe allergy, intolerance, or bleeding disorder that precluded dual antiplatelet agents; 2) absolute contraindication to endovascular treatment or anesthesia; and 3) inability to provide consent. All patients or designees signed an informed consent form to participate in the study.

**Randomization and Masking**

Concealment of randomized allocation was assured through a Web-based platform. Treating physicians first had to choose, for each patient, 1 of 4 alternatives to permit computer-generated randomized allocation (1, coiling [with or without high-porosity stent placement], 2, PVO, 3, surgical clipping, and 4, conservative management). Patients ineligible for ASMO were treated with FD in a registry. The randomized allocation was stratified according to comparator intervention and center. In February 2015, the protocol was modified to allow the use of prerandomization. With prerandomization, treatment allocation (and that the planned treatment was randomly allocated) is revealed to the patient at the time of consent. Patients who disagreed with the allocated management were still offered study participation.

Patients, interventionalists, and outcome assessors were not masked to treatment assignment, which was deemed unfeasible.

**Interventions**

There were no selection criteria for centers. Standard local procedures were followed. Any flow-diverting devices implanted in the parent vessel were permitted, but intra-aneurysmal flow diverters (such as the Woven EndoBridge [WEB; Microvention]) were excluded. Antiplatelet and anticoagulation regimens and testing for platelet inhibition were according to routine practice at each site. Case report forms were simple, and data were collected parsimoniously, to facilitate completion by normal care personnel.

**Hypotheses, Outcomes, and Number of Patients**

The safety of FD was defined in terms of the mRS scale at 3 months for all patients in the randomized controlled trial (RCT) or registry who received FD at any time: Two hundred patients could suffice to show that if the observed number of patients with mRS > 2 is 10%, the 95% CI of the percentage is from 7.0% to 14.9%. The randomized trial was powered (80%) to show a 15% increase (from 75% to 90%, α error = .05; 224 patients plus losses and crossovers, for a total of 250 patients) in the percentage of patients reaching the composite primary efficacy outcome, including complete or near-complete (residual neck) angiographic occlusion of the aneurysm (3–12 months) and an independent functional outcome (mRS < 3). Clinical outcome was determined by clinicians not blinded to the treatment allocation according to a simplified, standardized mRS questionnaire. The target number of patients was reached in July 2020 (n = 250), and a blinded report was sent to the DSMC. The DSMC recommended trial continuation to account for crossovers and patients lost to follow-up. The steering committee decided to stop inclusions on December 1, 2020, when 278 patients had been recruited to the RCT (a 24% increase over the initial estimate of 224, to account for 10% dilution of effect because of prerandomization). Data entry was locked on June 1, 2021, without knowledge of outcome results.

The primary safety outcome was death or dependency (mRS > 2) at 3 months. The primary efficacy outcome was a composite of clinical and angiographic results observed at least 3–12 months after treatment. One primary poor efficacy outcome was allocated per patient; when a patient had >1 outcome, the following hierarchical order was used to classify each patient: death > mRS 3–5 (from any cause, including aneurysm rupture or progressing mass effect with the mRS assessment being made at the time of follow-up imaging) > aneurysm rupture during follow-up > retreatment during follow-up > initial treatment failure > residual aneurysm at
imaging follow-up (12 months) as adjudicated by an independent core lab according to a previously validated classification system.\textsuperscript{20,21} This system includes 3 ordinal categories (complete occlusion, residual neck, residual aneurysm). The residual aneurysm category was used to adjudicate treatment failure for primary outcome analyses, and the complete occlusion category was used for exploratory analyses. The presence of various endovascular or surgical devices on imaging precluded blinding of core lab assessors.

Secondary outcomes included the individual components of the composite primary outcome as well as the mRS score at discharge and 3 and 12 months posttreatment; success in occluding the aneurysm at the end of the procedure (when appropriate); perioperative complications (ischemic strokes and intracranial hemorrhages within 1 month of the intervention); angiographic results at 12 months; length of hospital stay (number of days); discharge disposition (home, other hospital, rehabilitation facility, death); any new stroke, neurologic symptom, or sign during follow-up; and retreatment of the index aneurysm at any time.

### Analyses and Statistics
Blinded data were examined at prespecified intervals by an independent DSMC, composed of an interventional neuroradiologist, a statistician, and an ethicist, but no statistical tests were performed. Three subgroups of patients were analyzed as registered: ASMO (randomly allocated), FD (randomly allocated), and registry. According to protocol, the safety analyses included all patients who were allocated to or received FD at any time. Primary analyses are intent-to-treat. The primary safety outcome was adjudicated when the mRS was $>2$ within 3 months of the intervention, regardless of the cause. Failure to reach the primary efficacy end point was adjudicated per patient. Primary safety and efficacy outcomes are described using percentages and 95% confidence intervals. The impact of missing data on the conclusions was studied using sensitivity analyses in which missing data were replaced by either a good or a bad outcome. The risk difference and relative risks were estimated using a generalized estimating equation with a binomial distribution and a log- or identity-link function. The 95% confidence intervals are reported. The groups were not different with respect to risk factors for poor outcomes, and no adjustments for residual confounding factors were made.

The analyses of interactions between prespecified subgroups of interest and treatment were made by adding subgroup variables and interaction in the generalized estimating equation models. Treatment and aneurysm subgroups were examined as prespecified in 2010, regardless of the results of tests for interactions. Subgroup results according to aneurysm size ($<10$ mm or $\geq10$ mm), location (the proximal carotid artery, including the cavernous-to-superior hypophyseal segment [the initial FDA-approved FD indications], other anterior circulation, and posterior circulation aneurysms), and according to selected ASMOS before stratified randomized allocation\textsuperscript{14} are reported. Per-protocol exploratory analyses were defined in 2 ways: “As-attempted” analyses included patients in whom FD or ASMO was attempted (regardless of randomized allocation), and “as-treated” analyses included only patients in whom FD or ASMO was actually performed at the time of the initial treatment. We also explored what results would have been if complete occlusion (rather than the combination of complete and near-complete occlusion) had been used as the criterion for a good angiographic end point, to comply with a recent FDA definition and to permit comparisons with published case series and meta-analyses. The number of adverse events within the ASMO and FD groups was compared using the $\chi^2$ test with exact $P$ values. Analyses were performed using SAS software, Version 9.4 (SAS Institute) and SPSS, Version 26 (IBM) with a significance level of 5%. There was no correction of $P$ values to account for the multiplicity of exploratory analyses.

### Roles of the Sponsor and Funding Source
The trial was sponsored by the Centre Hospitalier de l’Université de Montréal. The sponsor had no part in study design, conduct, or reporting, and no access to the data. There was no funding source for this study.

### RESULTS
The number of patients who were registered or randomly assigned received the intended treatment and were analyzed for the safety and efficacy outcomes are shown in the trial profile (Fig 1). Of 323
recruited patients between May 2011 and November 2020, two hundred seventy-eight patients (86%) were randomly allocated to receive FD (n = 139) or ASMO (n = 139), and 45 (14%) received FD in the registry because they were deemed ineligible for standard options.

Patients and aneurysms compared in the randomized trial are described in Table 1. The characteristics of registry patients are described in the Online Supplemental Data. Registry patients more frequently had fusiform aneurysms with undefined necks (22/45 or 49%) than patients included in the RCT (43/278 or 16%). Randomized groups were similar. More than 80% of patients had unruptured aneurysms. Aneurysms were ≥10 mm in 52% and symptomatic in 46% of patients. The ASMO selected before randomization was coiling (with or without stent placement) in 199 patients (72%), PVO in 45 (16%), surgical clipping in 11 (4%), and observation in 23 patients (8%). The specific comparator intervention of patients actually randomized to ASMO is detailed in Fig 1.

Details of the interventions actually carried out are provided in the Online Supplemental Data. High-porosity stents were used in 36/87 patients (41%) treated by coiling ± stent placement in the ASMO group. PVO was performed using endovascular means without surgical bypass in all patients treated by PVO.

Ten patients randomly allocated to FD initially received ASMO, while 14 patients allocated to ASMO initially received FD (Fig 1 and Online Supplemental Data).

The safety of FD, predefined by protocol as mRS > 2 at 3 months in any patient treated with FD at any time (n = 209), is detailed in the Online Supplemental Data.

The primary safety outcome, death or dependency at 3 months from any cause, occurred in 16 of 138 (11.5%); 95% CI, 6.9%–18.3%) patients randomly allocated to FD and in 12 of 137 (8.6%; 95% CI, 4.7%–14.9%) patients allocated to ASMO (relative risk, 1.33; 95% CI, 0.65–2.69; P = 0.439) (Fig 1; details in the Online Supplemental Data). The most frequent causes of death or dependency at 3 months were thromboembolic (n = 14; ASMO = 7/FD = 7), followed by hemorrhagic complications (n = 7; ASMO = 3/FD = 4) and progressive mass effect from giant aneurysms (n = 7; ASMO = 2/FD = 5).

The composite primary efficacy outcome was available for 275 of 278 patients in the RCT (98.9%). A poor primary efficacy outcome was found in 30.9% (43/139; 95% CI, 23.5%–39.4%) of patients with FD and 45.6% (62/136; 95% CI, 37.1%–54.3%) with ASMO, an absolute risk difference of 14.7%, (95% CI, 3.3%–26.0%) (relative risk, 0.68; 95% CI, 0.50–0.92; P = 0.014). Details of each component of the primary outcome are provided in Table 2. Attributing a good or a bad outcome when data were missing did not significantly modify the results. The primary outcome for per-protocol analyses is detailed in the Online Supplemental Data. As-attempted and as-treated analyses yielded similar results compared with intent-to-treat analyses, with patients undergoing FD having better primary efficacy outcomes than those undergoing ASMO (P < .001 for both).

The mean time of follow-up mRS recorded for the primary efficacy outcome was at 12.7 (SD, 7.4) months for ASMO and 12.2 (SD, 8.0) months for FD. The mean time of angiographic follow-up included in the primary efficacy outcome measure was 11.0 (SD, 5.3) months for patients randomly allocated to ASMO and 11.6 (SD, 5.7) months for patients randomly allocated to FD.

Prespecified subgroups of interest are shown in Fig 2, even though none of the interaction tests were significant. On the basis of this description, we observed that patients preselected for coiling with or without stent placement (n = 199) who were randomly allocated to FD had better outcomes, as did patients preselected for conservative treatment who randomly underwent

Table 1: Patient and aneurysm characteristics for the randomized groups

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Randomization</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>ASMO (n = 139)</td>
</tr>
<tr>
<td>Age (mean) (SD)</td>
<td>57 (12)</td>
</tr>
<tr>
<td>Female (No.) (%)</td>
<td>108 (77.7%)</td>
</tr>
<tr>
<td>Presentation (No.) (%)</td>
<td></td>
</tr>
<tr>
<td>Asymptomatic</td>
<td>72 (51.8%)</td>
</tr>
<tr>
<td>Mass effect</td>
<td>41 (29.5%)</td>
</tr>
<tr>
<td>SAH</td>
<td>26 (18.7%)</td>
</tr>
<tr>
<td>Aneurysm size (mm)</td>
<td></td>
</tr>
<tr>
<td>Mean (SD)</td>
<td>13 (9)</td>
</tr>
<tr>
<td>Median (range)</td>
<td>10 (2–51)</td>
</tr>
<tr>
<td>0–9 (No.) (%)</td>
<td>66 (47.5%)</td>
</tr>
<tr>
<td>10–25 (No.) (%)</td>
<td>59 (42.4%)</td>
</tr>
<tr>
<td>&gt;25 (No.) (%)</td>
<td>14 (10.1%)</td>
</tr>
<tr>
<td>Aneurysm neck (mm)</td>
<td></td>
</tr>
<tr>
<td>Mean (SD)</td>
<td>5 (3)</td>
</tr>
<tr>
<td>Median (min–max)</td>
<td>5 (2–15)</td>
</tr>
<tr>
<td>Undefined (No.) (%)</td>
<td>22 (15.8%)</td>
</tr>
<tr>
<td>Location (No.) (%)</td>
<td></td>
</tr>
<tr>
<td>Anterior circulation</td>
<td>108 (77.7%)</td>
</tr>
<tr>
<td>Proximal carotid</td>
<td>71 (51.1%)</td>
</tr>
<tr>
<td>Extraficial</td>
<td>14 (10.1%)</td>
</tr>
<tr>
<td>Ophthalmic</td>
<td>57 (41.0%)</td>
</tr>
<tr>
<td>Other carotid</td>
<td>20 (14.4%)</td>
</tr>
<tr>
<td>Other anterior</td>
<td>17 (12.2%)</td>
</tr>
<tr>
<td>Posterior circulation</td>
<td>31 (22.3%)</td>
</tr>
</tbody>
</table>

Note: —min indicates minimum; max. maximum.

Table 2: Primary efficacy outcome

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Randomization</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>ASMO (n = 139) (No.)</td>
</tr>
<tr>
<td>Poor outcome</td>
<td>62 (44.6%)a</td>
</tr>
<tr>
<td>Clinical</td>
<td>13 (9.4%)</td>
</tr>
<tr>
<td>mRS ≥2b</td>
<td>13 (9.4%)</td>
</tr>
<tr>
<td>Aneurysm rupture</td>
<td>0</td>
</tr>
<tr>
<td>Angiographic</td>
<td>49 (35.3%)</td>
</tr>
<tr>
<td>Retreatment</td>
<td>7 (5.0%)</td>
</tr>
<tr>
<td>Immediate failurec</td>
<td>8 (5.8%)</td>
</tr>
<tr>
<td>Good outcome</td>
<td>74 (53.2%)</td>
</tr>
<tr>
<td>Angiographic complete</td>
<td>74 (53.2%)</td>
</tr>
<tr>
<td>Occlusion</td>
<td>60 (43.2%)</td>
</tr>
<tr>
<td>Residual neck</td>
<td>14 (10.1%)</td>
</tr>
<tr>
<td>Not available</td>
<td>3 (2.2%)</td>
</tr>
</tbody>
</table>

a It is 45.6% (62/136) when adjusting for missing data.

b Comprises 14 deaths (ASMO = 9/FD = 5).

c Immediate treatment failures are treatments that were attempted but failed, with no further angiographic follow-up.

FD \( (n = 23) \). The comparison of FD with PVO \( (n = 45) \) appeared to favor PVO, but it was inconclusive. Predefined subgroup analyses according to rupture status, size, and location showed better outcomes for unruptured, anterior circulation, and large \( (\geq 10 \text{ mm}) \) aneurysms, while results were similar for <10-mm aneurysms and inconclusive for ruptured and posterior circulation aneurysms (Fig 2).

The primary efficacy outcome, modified to restrict the definition of a good angiographic outcome to complete occlusions, also showed the superiority of FD \( (P = .006) \) for all patients and for the same subgroups (Online Supplemental Data).

Secondary outcomes (successful intervention, perioperative complications, days of hospitalization, discharge disposition, mRS at discharge, and retreatment of the index aneurysm during follow-up) were similar in both groups (Online Supplemental Data). Details of angiographic results are also provided in the Online Supplemental Data.

Serious adverse events occurred in 28 patients with FD and 27 with ASMO. The distribution of serious and nonserious adverse events was not different between groups \( (P = .10) \). The only differences between groups were a nonsignificantly larger number of delayed \( (\geq 1 \text{ month}) \) serious events that occurred after FD \( (9 \text{ versus } 3 \text{ events}) \). Nonserious adverse events were more frequent with FD \( (22 \text{ versus } 9) \). Details are provided in the Online Supplemental Data. Details of poor clinical outcome at any time point are given for all patients in the Online Supplemental Data. The mRS scores for all patients in the RCT at 3 months and at the time of the primary efficacy outcome are detailed in the Online Supplemental Data.

**DISCUSSION**

FIAT is the first pragmatic trial showing improved efficacy outcomes with FD compared with other common management options. FIAT is also unique in showing that an endovascular innovation can be assessed in a randomized trial at the same time that it is introduced in clinical practice. This change is an important breakthrough, for neurovascular devices have so far been approved on the basis of industry-led single-arm case series of ~100 patients selected for regulatory approval purposes. This is problematic, for clinical usage typically expands beyond the initial regulatory indications without reliable evidence that the innovation improves patient outcomes.

FIAT successfully addressed the multiple challenges that confront trials that assess the safe introduction of promising-but-potentially risky surgical innovations. One challenge is the diversity of patients, aneurysms, and clinical presentations. Before the availability of FD, these patients were treated using various ASMOs selected according to clinical presentation, individual patient anatomy, aneurysm location and morphology, local practice patterns, and individual preferences. The goal of treatment also varies, from relief of symptoms of
mass effect to the prevention of life-threatening aneurysm ruptures in asymptomatic individuals. An explanatory attitude, looking for a signal that the innovation can work, fearing to lose that signal due to the noise associated with heterogeneity, might have called for multiple trials, each comparing FD in homogeneous patients eligible for only a single alternative treatment. However, this approach would not have addressed our main concern, which is whether FD actually improves patient outcomes in routine practice.26

FIAT is also the prototype care trial.13 The guiding principle of the design is that patients are better protected when promising-but-unproven innovations are offered within a carefully controlled research context. This principle means that each item of the trial protocol must be reviewed to best protect the medical interest of participants.13,22 Care trials are as inclusive as possible; protocols are flexible and allow the use of the treatment the patient would have otherwise received. The comparator intervention was prespecified before stratified randomized allocation, allowing valid comparisons within subgroups.

Care trials are fully integrated into clinical practice, and involve no extra risks, tests, visits, or cost compared with routine care. Although this design allowed us to conduct the trial without the support of industry or research agencies, the lack of funding discouraged many centers from participating. The data were collected by normal care personnel at the time of routine clinical follow-up visits. The main drawback of the approach, when rigorously applied, is that blinding becomes almost impossible. To mitigate that problem, we used a standardized, simplified mRS questionnaire18 and dichotomized results for a more difficult end point, allowing valid comparisons within subgroups.

The primary end point of the trial was a composite that attempted to capture in 1 judgment the comparative value of treatment in terms of safety and efficacy. This outcome combined clinical results (an independent functional score [mRS <3], which is the scale most frequently used in stroke trials) and the absence of clinical events signaling treatment failure during follow-up (such as aneurysm rupture, progressive mass effect, or retreatment of the index aneurysm). To account for the relatively short follow-up compared with lifetime protection against ruptures, which is the goal of treatment in many patients, the primary outcome included an angiographic result: complete or near-complete occlusion of the aneurysm. Angiographic outcomes are routinely used in practice to judge the success of therapy.28 They are also the most common primary outcome of aneurysm trials.20,28–33 Residual aneurysm was used to judge treatment failure because this category has been shown to be repeatable and its clinical significance is more constant across various raters, imaging modalities, and treatments.20,21 The exploratory analyses we performed showed that using complete or near-complete occlusion as the angiographic outcome did not change the conclusions.

The overall morbidity and mortality of patients treated in FIAT are relatively high compared with these outcomes in other endovascular trials.34–36 However, those comparisons are not valid because aneurysms considered for FD in FIAT were typically larger, more frequently had symptoms of mass effect, and many were difficult to treat by any and all methods. The primary safety outcome for all patients who received FD (26/209 or 12%; Online Supplemental Data) was at the upper limit of our initial estimate (10%) but similar that in to another randomized trial that compared FD with stent-assisted coiling.11 In the Parent Artery Reconstruction for Large or Giant Cerebral Aneurysms Using a Tubridge Flow Diverter (PARAT) trial, the rates of death or stroke related to target vessels at 1-year follow-up were 14% and 17% in the stent-assisted coiling and FD groups, respectively.12 Delayed complications, such as aneurysm ruptures, parenchymal hematomas at a distance from the aneurysm, and strokes from stent thrombosis were infrequent (10/209 or 4.8% of all patients having undergone FD in FIAT; Online Supplemental Data), but they remain a concern if FD is to be widely used.

The trial was all-inclusive, but not all patients with aneurysms were considered for FD, and results may not apply to all patients. To examine how study results could apply in clinical decision-making, one must examine prespecified subgroups of patients, even if the interaction tests were not statistically significant. The interaction test examines the potential influence of a variable on a single relative treatment effect, an implausible assumption in this trial comparing FD with as widely different options as conservative management and PVO. Nevertheless, subgroup results should always be interpreted with caution.

Examining the prespecified subgroups defined according to the comparator ASMO showed that FD was more effective than coiling with or without stent placement, but comparisons with PVO or surgical clipping were too few to draw firm conclusions.

Because of the pragmatic nature of the trial, conservative management was a potential prespecified ASMO (actually selected in 23 or 8% of patients in the RCT). This design choice may seem to unfairly favor FD. However, the alternative, to exclude these patients from the RCT, would have deprived the trial of the capacity to show this important advance provided by FD, ie, the ability to treat patients who otherwise could not be treated.

For prespecified aneurysm characteristics, FD was shown to be superior in the treatment of large, unruptured intradural carotid aneurysms (>10 mm), confirming the results of a previous trial.11 For the initially approved regulatory indications for the use of FD (proximal carotid aneurysms), results were neutral, for they pull in opposite directions. Many large or giant extracranial carotid aneurysms were treated with PVO, a treatment subgroup that was superior to FD (but not significantly) (Fig 2). Another trial showed FD to be less effective (but safer) than surgical occlusion and bypass in the treatment of complex anterior circulation aneurysms.12 Surgical bypass was not used in FIAT, even in combination with PVO, and the RCT included only those patients with a circle of Willis that allowed safe carotid occlusion without bypass. PVO remains a good option for these selected patients.37

Posterior circulation aneurysms have been shown in observational studies to have worse outcomes after FD than anterior circulation aneurysms, but FIAT randomized results show that ASMOs did not perform better for these difficult lesions (Fig 2).25

There are a priori concerns with the use of antiplatelet regimens that come with the use of FD in patients with SAH from a recently ruptured aneurysm.38 Too few patients with SAH were included in FIAT for conclusions to be drawn about FD use in these patients.

For the most frequently encountered small (<10 mm), unruptured, asymptomatic, intradural aneurysms, the primary efficacy
outcome was similar for patients treated with FD or ASMO. Only by looking at the rate of complete occlusion in exploratory analyses can a signal possibly favoring FD be detected (Online Supplemental Data). FIAT results are in accordance with performance goals for FD of small and medium aneurysms that have recently been proposed (morbidity/mortality in 7.8% of patients [4.8%–11.4%]).19 Subgroup safety data for coding with or without stent placement (3% vs 5%; 95% CI, 0.6%–8.5%) and for the corresponding stratified patients with FD (5% vs 95% CI, 1.6%–11.4%) were comparable in FIAT, but a larger RCT would be needed for the ongoing concern of delayed complications with FD related to antiplatelet regimens and delayed stent thrombosis. Some believe that a 5%–8% risk may already be too high to justify the preventive treatment of small unruptured aneurysms.9 The pertinent question regarding small asymptomatic aneurysms is whether they should even be treated at all.80 A pragmatic RCT has recently been launched to address this question.91

There are limitations to this study: Only 3 Canadian centers participated, limiting the generalizability of results. The recruitment period had to be increased to nearly 10 years, during which the indications for FD are likely to have changed. FIAT is the largest RCT on FD so far, but the number of patients remains small. On final analysis, safety results include the possibility of harm or benefit compared with other management options. Prerandomization resulted in 24 crossovers (8.6%) that dilute the contrast between groups. An aneurysm for which FD is considered a promising treatment is a vague definition that may be differently interpreted from one clinician to another and that may also change with time and experience. Clinical outcome assessment and core lab adjudications could not be masked to treatment allocation. Trial results were mainly driven by angiographic results, and the hard clinical outcome (death or dependency) accounted for a relatively small number of poor outcomes in both groups (13 versus 10 patients, including 9 versus 5 deaths). Potential bias from lack of blinding of mRS clinical assessors should not have significantly affected the results. The 12-month follow-up period was relatively short; too short to evaluate the effects of treatment on aneurysm rupture. In addition, this follow-up may not have given enough time for some FD-treated aneurysms to become occluded or for some recurrences after coiling to become apparent.82

CONCLUSIONS

For patients with mostly unruptured, large, anterior circulation (carotid) aneurysms, FD was more effective than ASMO in terms of angiographic outcome. More randomized trials are needed to assess safety.

Disclosure forms provided by the authors are available with the full text and PDF of this article at www.ajnr.org.

REFERENCES


ORIGINAL RESEARCH
ADULT BRAIN

3D Enhancement Color Maps in the Characterization of Intracranial Atherosclerotic Plaques

S. Sanchez, A. Raghuram, R. Fakih, L. Wendt, G. Bathla, M. Hickerson, S. Ortega-Gutierrez, E. Leira, and E.A. Samaniego

ABSTRACT

BACKGROUND AND PURPOSE: High-resolution MR imaging allows the identification of culprit symptomatic plaques after the administration of gadolinium. Current high-resolution MR imaging methods are limited by 2D multiplanar views and manual sampling of ROIs. We analyzed a new 3D method to objectively quantify gadolinium plaque enhancement.

MATERIALS AND METHODS: Patients with stroke due to intracranial atherosclerotic disease underwent 7T high-resolution MR imaging. 3D segmentations of the plaque and its parent vessel were generated. Signal intensity probes were automatically extended from the lumen into the plaque and the vessel wall to generate 3D enhancement color maps. Plaque gadolinium (Gd) uptake was quantified from 3D color maps as gadolinium uptake = \( \frac{\text{Plaque } T1 + \text{Gd} - \text{Plaque } T1/\text{SD Plaque } T1} \). Additional metrics of enhancement such as enhancement ratio, variance, and plaque-versus-parent vessel enhancement were also calculated. Conventional 2D measures of enhancement were collected for comparison.

RESULTS: Thirty-six culprit and 44 nonculprit plaques from 36 patients were analyzed. Culprit plaques had higher gadolinium uptake than nonculprit plaques (\( P < .001 \)). Gadolinium uptake was the most accurate metric for identifying culprit plaques (OR, 3.9; 95% CI 2.1–8.3). Gadolinium uptake was more sensitive (86% versus 70%) and specific (71% versus 68%) in identifying culprit plaques than conventional 2D measurements. A multivariate model, including gadolinium uptake and plaque burden, identified culprit plaques with an 83% sensitivity and 86% specificity.

CONCLUSIONS: The new 3D color map method of plaque-enhancement analysis is more accurate for identifying culprit plaques than conventional 2D methods. This new method generates a new set of metrics that could potentially be used to assess disease progression.

ABBREVIATIONS: Gd = gadolinium; HR = high-resolution; ICAD = intracranial atherosclerotic disease; IPH = intraplaque hemorrhage; PB = plaque burden; RI = remodeling index; SI = signal intensity

Intracranial atherosclerotic disease (ICAD) can account for 10% of TIs and 30%–50% of ischemic strokes. The main criterion for diagnosing and monitoring ICAD relies on luminal stenosis. More accurate methods of detecting the presence of atherosclerotic plaques and monitoring disease progression are needed. There is growing evidence that high-resolution MR imaging (HR-MR imaging) can be used to better characterize atherosclerotic plaques than current luminal imaging modalities. HR-MR imaging can be used to determine plaque burden (PB) and the remodeling index (RI) and detect plaque enhancement after the administration of gadolinium (Gd) contrast. Two meta-analyses of symptomatic ICAD have shown that plaque enhancement has the strongest association with the presence of culprit symptomatic plaques.

Different biologic processes lead to plaque enhancement, including neovascularization, inflammation, and endothelial dysfunction. The analysis of atherosclerotic carotid plaques has shown a correlation between these histopathologic changes and plaque enhancement. Plaque enhancement is highly suggestive of an “active” plaque that might be symptomatic. Moreover, strong plaque enhancement suggests greater neovascularization and increased
endothelial permeability. Hence, the exact quantification of plaque enhancement could potentially provide an insight into the biology of intracranial atherosclerosis, by detecting changes such as wall thickening and hemorrhage. Accurately quantifying plaque enhancement also has the potential of identifying ICAD mimics such as venous plexus contamination and thrombus recanalization, among others.

Current analyses of plaque enhancement are based on 2D imaging sampling and manual determination of ROIs. This approach is limited by sampling errors and the plane of view chosen to draw the ROIs. We describe a new 3D method of plaque sampling that captures the entire plaque and parent artery. This method generates hundreds of data points to determine the level of plaque enhancement, overcoming the limitation of restricting the analysis to a specific plane of view that might not represent the enhancement of the entire plaque. We hypothesize that this new method of 3D plaque enhancement color mapping will lead to better identification of symptomatic atherosclerotic plaques.

MATERIALS AND METHODS

Image Acquisition

After approval from the institutional review board (University of Iowa) and obtaining informed consent, patients with stroke attributable to ICAD underwent 7T MR imaging. The ICAD stroke etiology was adjudicated on the basis of Trial of Org 10172 in Acute Stroke Treatment (TOAST) and ASCOD (A, atherosclerosis; S, small-vessel disease; C, cardiac pathology; O, other causes; and D, dissection) criteria. Patients were excluded if they had any contraindication to 7T MR imaging, were medically unstable, or had a glomerular filtration rate of <60 mL/min per 1.73 m². Images were obtained between August 2018 and July 2021.

HR-MR imaging was acquired with a MR950 7T scanner (GE Healthcare) using an 8-channel head coil. 3D T1-weighted FSE (Cube; GE Healthcare) images were acquired both before and 5 minutes after the administration of Gd. Technical parameters for acquisition are described in the Online Supplemental Data. Images were analyzed in at least 3 planes to identify the presence of atherosclerotic plaques using the PACS. Plaque presence was defined as wall thickening of a vessel segment compared with the proximal and/or normal vessel segment. A senior investigator analyzed the following arterial segments in each subject to identify the presence of plaques: supraclinoid internal carotid arteries, MCAs, anterior cerebral arteries, V4 segments of the vertebral arteries, basilar artery, and posterior cerebral arteries. The specific stroke mechanism due to ICAD was also adjudicated by the senior investigator on the basis of previously described criteria. The Warfarin-Aspirin Symptomatic Intracranial Disease (WASID)-based degree of stenosis, RI, and the area degree of stenosis were manually calculated in several planes, as previously described. PB was calculated with the following formula: [(Area of the Vessel Wall at Maximal Stenosis – Area of the Lumen at Maximal Stenosis/Area of the Vessel Wall at Maximal Stenosis) × 100].

Plaque Characterization

Plaques were detected by a senior investigator, and culprit status was adjudicated by 2 investigators with extensive experience in the analysis of plaques using HR-MR imaging. If there was disagreement, the senior investigator adjudicated the culprit status. Generally, a culprit plaque was defined as a lesion in the ipsilateral vascular territory of an area of infarction accompanied by clinical symptoms. If >1 plaque was present in the same vascular territory, the most stenotic lesion was selected for analysis. Areas of cerebral infarction related to the presence of culprit plaques were identified in DWI. Other plaques in the same vascular territory of culprit plaques were excluded from the analysis. Plaques located in other vascular territories were considered asymptomatic or nonculprit. Disagreements were resolved by consensus and after reviewing additional images and clinical data. The morphologic characteristics and enhancement patterns of culprit plaques were compared with those of nonculprit plaques. Additionally, the presence of intraplaque hemorrhage (IPH) was assessed by 2 investigators (S.S. and E.A.S.) by identifying T1 hyperintensity within the plaque.

3D Plaque Analysis

We modified a previously described semiautomated method of analyzing Gd enhancement in the wall of brain aneurysms to study plaques and their parent arteries. Luminal segmentations in the vascular territory of the plaque were created manually using 3D Slicer (http://www.slicer.org) on T1 and T1 + Gd images. The diseased arterial segment containing the plaque was segmented at the plaque and extended approximately 5 mm beyond the plaque boundaries so that the plaque and the contiguous parent artery were included. Segmentations were performed by 2 investigators with at least 1 year of experience (S.S. and A.R.). In case of disagreement, the senior investigator adjudicated the proper parent vessel and plaque boundaries.

Signal intensity (SI) probes were orthogonally extended from the lumen into the plaque and arterial wall (Fig 1). The high spatial resolution of 7T imaging made it possible to accurately estimate the arterial wall and plaque thickness. For parent vessel analysis, SI probes were extended 0.5 mm into the arterial wall of the parent vessel, which is the average wall thickness used in our analysis and has been reported by others in ex vivo samples. For plaque analysis, the length of the probe was customized on the basis of detailed measurements of plaque thickness obtained on 7T MR images (Fig 2). SI color maps were generated through an automated process using image-processing tools and custom scripts in Matlab 2020b (MathWorks). The SI of the plaque and arterial wall was mapped from T1 and T1 + Gd images separately (Fig 3). The SI of the genu of the corpus callosum was used to obtain a normalized mean enhancement ratio. In addition, conventional 2D CR was calculated for comparison.

3D Analysis of Plaque Enhancement

The highest SI of each probe on the T1 and T1 + Gd images was obtained for the analysis. The mean (μ) SI and SD of each plaque and parent artery were calculated. These values were then divided by the SI of the corpus callosum to obtain a normalized ratio that could be used to compare among subjects. We studied the following enhancement metrics:

1) Mean enhancement ratio = mean SI on T1 + Gd images normalized to the corpus callosum. This is the standard measurement of contrast enhancement.
2) Plaque enhancement variance = \( \sigma^2 \) of the SI values measured by the probes on T1 + Gd images. This measurement was used to analyze the dispersion of enhancement within the plaque.

3) Gd-uptake, which measured the amount of Gd absorbed by the plaque compared with T1, using the following equation:

\[
\text{Gd Uptake} = \frac{\mu_{\text{PlaqueT1+Gd}} - \mu_{\text{VesselT1+Gd}}}{\sigma_{\text{PlaqueT1}}}.
\]

Previous studies have shown that culprit plaques had higher SDs in T1 images compared with nonculprit plaques. To account for this baseline variation, we decided to include SD as a normalization factor in our analysis.

4) Plaque versus arterial enhancement, which measured the difference in the mean enhancement of the plaque compared with the parent artery.

\[
\text{Plaque vs Arterial Enhancement} = \frac{\mu_{\text{PlaqueT1+Gd}} - \mu_{\text{VesselT1+Gd}}}{\sigma_{\text{VesselT1+Gd}}}.
\]

Because we analyzed plaques in different arteries, the SD of the arterial SI was used for normalization and to perform standardized comparisons of plaques in different territories.

**Statistical Analysis**

Various statistical analyses were conducted using SPSS Statistics 27.0 (IBM). Interrater reliability in the identification of culprit plaques was calculated with a Cohen \( k \) coefficient. Categoric variables are presented as frequency and percentage, and continuous variables are described as mean (SD). Shapiro-Wilk tests were used to evaluate normality for variables of interest within our sample, with \( P \) values of <.05 considered non-normally distributed variables. A Student \( t \) test was used to compare the means between normally distributed variables, and a Mann-Whitney \( U \) test was used to compare the distributions between non-normally distributed variables. \( \chi^2 \) tests were used to compare categoric variables. Univariate logistic regressions were performed to analyze relevant demographic, morphologic, and SI variables. An \( \alpha \) threshold of .05 was used to assess significance for all hypothesis tests.

The multivariate model in this analysis was constructed through an Akaike information criterion–based forward selection procedure. All variables of interest in the data set were initially
considered candidates for the multivariate model. The variable that reduced the Akaike information criterion of the model the most when added was included in the model. Other variables were included in the model only if they had a correlation of <0.5 with each variable that was already added to the model. Once there were no remaining variables that reduced the Akaike information criterion value of the multivariate model or had correlations of <0.5 with each variable present in the multivariate model, the algorithm was terminated, and the resulting model was selected.

Receiver operator characteristic metrics, including sensitivity and specificity, were calculated for each variable of interest (including the predictions output from the multivariable model) at its optimal threshold value, as determined by the Youden J statistic. Area under the curve values for each variable were also computed.

RESULTS

Patients and Plaque Characteristics

Thirty-six patients with a total of 80 plaques were included in the analysis. Approximately 47.2% were men, and the mean age was 59 (SD, 12) years. The mean NIHSS score at admission was 2.5 (SD, 3). Additional demographics are described in the Online Supplemental Data. Areas of cerebral infarction with DWI findings are reported...
in the Online Supplemental Data. The agreement in the identification of culprit plaques was high (κ = 0.8). Culprit plaques had a higher degree of stenosis, PB, and RI than nonculprit plaques. In addition, culprit plaques more frequently had a concentric morphology than nonculprit plaques (Table 1).

**3D Enhancement Characterization**

A mean of 125 (SD, 79) probes per plaque were generated. Culprit plaques had a higher mean enhancement ratio than nonculprit plaques (μ = 0.80 [SD, 0.30] versus 0.61 [SD, 0.17]; P = .004). This enhancement was more heterogeneous in culprit plaques than in nonculprit plaques (SD2 = 0.33 [SD, 0.13] versus 0.26 [SD, 0.08]; P = .041). Culprit plaques with IPH were also more heterogeneous in T1 than culprit plaques without IPH (SD2Plaque T1 = 0.20 ± 0.03 versus 0.15 ± 0.04; P = .03). Culprit plaques took up significantly more Gd than nonculprit plaques (2.01 [SD, 0.91] versus 1.06 [SD, 0.76]; P < .001) (Fig 3).

In univariate logistic regressions, several metrics were used to identify culprit plaques (Table 2). We used the following variables to generate a multivariate logistic regression model of culprit plaque identification: PB (OR, 3.7; 95% CI, 1.6–10; P = .004); Gd-uptake (OR, 2.3; 95% CI, 1.1–5.3; P = .033); and stenosis (OR, 1.3; 95% CI, 0.7–2.7; P = .4). The combined receiver operating characteristic analysis of this model had a sensitivity of 83% and a specificity of 86% (area under the curve = 0.87).

The conventional 2D method to quantify plaque enhancement with a CRstalk of ≥0.56 had a sensitivity of 70% and a specificity of 68% in detecting culprit plaques (area under the curve = 0.68). In contrast, a Gd-uptake threshold of ≥1.23 had a sensitivity of 86% and a specificity of 71% (area under the curve = 0.81) in detecting culprit plaques with the new 3D method (On-line Supplemental Data).

**Parent Arteries of Culprit and Nonculprit Plaques**

A mean of 858 (SD, 564) probes per arterial segment were generated. There was no statistical difference of enhancement between parent arteries of culprit and nonculprit plaques (μ = 0.59 [SD, 0.20] versus 0.62 [SD, 0.14]; P = .62).

**Discussion**

Identifying symptomatic plaques will improve the diagnosis of ICAD as a stroke etiology and may guide targeted endovascular interventions such as angioplasty and stent placement. In this report, we describe a new method to quantify plaque enhancement, which generates 3D enhancement maps from hundreds of data points. Several enhancement metrics generated through this method enable detailed analysis of plaque and its parent artery enhancement. This new method was more accurate in detecting and quantifying plaque enhancement than the conventional 2D multiplanar method.

Gd uptake was the most accurate enhancement metric in detecting culprit plaques (OR, 3.9; 95% CI, 2.1–8.3). This metric quantifies the difference of enhancement between T1 and T1 + Gd images. It is similar to the “enhancement ratio,” which has been shown in other studies to be an independent identifier of stroke in patients with ICAD.22 One key difference is that Gd uptake accounts for the inherent heterogeneity of enhancement on T1 images. This metric analyzes plaques individually. Other metrics such as mean plaque enhancement ratio, plaque versus arterial enhancement, and plaque enhancement variance were also significant in detecting culprit plaques. This last parameter was also described by Shi et al20 as a strong identifier of culprit plaques. The signal dispersion detected in the analysis of histograms in their study was confirmed in our study. This heterogeneity in the distribution of enhancement can be seen in the 3D color maps of the plaque and parent vessel (Figs 1 and 3). Subtle color differences along the diseased arterial segment reflect different enhancement patterns, which ultimately suggest different biologic processes and stages of disease progression.6 IPH is a strong identifier of culprit plaques.16,20 The new method of plaque-enhancement analysis captured an increased SI dispersion in T1 due to IPH. Detailed quantification of plaque enhancement has the potential of identifying IPH and, in some instances, even determining the response to medical therapy.23

3D methods of vessel analysis have been used previously to visualize morphologic features such as vessel caliber and angulation.14 The analysis of vessel wall geometries has been shown to influence the effectiveness of endovascular interventions.21 Volumetric 3D maps of ICAD provide a more detailed characterization of PB, RI, and subtle differences in plaque morphology within different vascular territories. Qiao et al14 showed that posterior circulation arteries have a greater capacity for positive remodeling than anterior circulation arteries. Their 3D volumetric map made it possible to quantify the wall thickness and lumen area of the entire vessel segment. Similarly, our 3D analysis provides an objective survey of enhancement of the target arterial segment. Although our analysis

---

**Table 2: Univariate and multivariate logistic regression**

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Univariate Logistic Regression</th>
<th>Multivariate Analysis</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>ORa 95% CI P Value</td>
<td>ORb 95% CI P Value</td>
</tr>
<tr>
<td>Mean enhancement ratio plaque</td>
<td>2.3 1.4–4.1 .002</td>
<td></td>
</tr>
<tr>
<td>Plaque enhancement variance</td>
<td>1.9 1.2–3.2 .013</td>
<td></td>
</tr>
<tr>
<td>Plaque vs vessel enhancement</td>
<td>7.4 3.2–22 &lt;.001b</td>
<td></td>
</tr>
<tr>
<td>Locationb</td>
<td>1.5 0.6–4 .4</td>
<td></td>
</tr>
<tr>
<td>Morphology</td>
<td>10.1 3.7–30 &lt;.001c</td>
<td></td>
</tr>
<tr>
<td>Area of stenosis</td>
<td>4 2.3–8 &lt;.001c</td>
<td></td>
</tr>
<tr>
<td>Stenosis</td>
<td>2.4 1.5–4.3 .001c</td>
<td>1.3 0.7–2.7 .4</td>
</tr>
<tr>
<td>Gd uptake</td>
<td>3.9 2.1–8.3 &lt;.001c</td>
<td>2.3 1.3–5.3 .033c</td>
</tr>
<tr>
<td>PB</td>
<td>6.1 3–14.9 &lt;.001c</td>
<td>3.7 1.6–10 .004c</td>
</tr>
</tbody>
</table>

a One SD increase in each variable.
b Anterior-versus-posterior circulation.
c P < .05.

**DISCUSSION**

Identifying symptomatic plaques will improve the diagnosis of ICAD as a stroke etiology and may guide targeted endovascular interventions such as angioplasty and stent placement.21 In this
is not focused on plaque geometry, it has the potential to generate vessel wall metrics that are not limited to plaque enhancement. Quantifying enhancement through 3D analysis allows easier identification of potential culprit plaques.

Identifying symptomatic plaques through HR-MR imaging could lead to the diagnosis of stroke etiology. Fakhih et al reported that an analysis of a cryptogenic stroke cohort showed that approximately 73% of patients had an underlying atherosclerotic plaque that most likely was the cause of the stroke. A recent review showed that more than half of patients without significant luminal stenosis might have a culprit intracranial plaque identified on HR-MR imaging. Generating 3D enhancement color maps for detailed analysis of vessel segments could increase the detection of atherosclerotic changes in patients with cryptogenic stroke. In this study, we found that objectively quantifying Gd uptake combined with PB achieved a sensitivity of 83% and specificity of 86% in detecting culprit plaques. Moreover, when the new 3D method was compared with previous work that used 2D measurements of enhancement, it proved to be more sensitive and specific.

This was an exploratory pilot study testing a new method to quantify plaque enhancement; therefore, it has several limitations. First, a total of 80 plaques were analyzed, which is standard for 7T MR imaging studies. However, a larger study would be optimal for defining better thresholds of culprit plaque detection. Generating precise segmentations can be time-consuming and requires several quality checkpoints. Each plaque and vessel segmentation requires approximately 60 minutes. Future studies should focus on accurate automated segmentation to reduce the processing time. In some cases, our registration pipeline did not coregister T1 and T1 + Gd sequences well due to image distortion. T1 and T1 + Gd images were segmented individually, increasing the overall analysis time to limit this artifact. Processing time could be shortened if one segmentation is performed in coregistered T1 and T1 + Gd reconstructions. Co-registration may be better implemented using 3T HR-MR imaging, which has fewer challenges for image registration than 7T HR-MR imaging. Once segmentation processing has been completed, generating 3D color maps is automatic and the quantification of plaque enhancement is highly reliable (Fig 1). A second limitation is that although the software was engineered for plaque-enhancement quantification, other metrics such as PB, RI, and area of stenosis were obtained manually from source images.

CONCLUSIONS
Detecting and quantifying plaque enhancement through 3D color maps are promising for characterizing ICAD. This new method is more accurate than current methods that rely on 2D multiplanar analysis.

Disclosure forms provided by the authors are available with the full text and PDF of this article at www.ajnr.org.

REFERENCES
22. Shi Z, Zhao M, Li J, et al. Association of hypertension with both occurrence and outcome of symptomatic patients with mild


Detection of Early Ischemic Changes with Virtual Noncontrast Dual-Energy CT in Acute Ischemic Stroke: A Noninferiority Analysis


ABSTRACT

BACKGROUND AND PURPOSE: Dual-energy virtual NCCT has the potential to replace conventional NCCT to detect early ischemic changes in acute ischemic stroke. In this study, we evaluated whether virtual NCCT is noninferior compared with standard linearly blended NCCT, a surrogate of conventional NCCT, regarding the detection of early ischemic changes with ASPECTS.

MATERIALS AND METHODS: Adult patients who presented with suspected acute ischemic stroke and who underwent dual-energy NCCT and CTA and brain MR imaging within 48 hours were included. Standard linearly blended images were reconstructed to match a conventional NCCT. Virtual NCCT images were reconstructed from CTA. ASPECTS was evaluated on conventional NCCT, virtual NCCT, and DWI, which served as the reference standard. Agreement between CT assessments and the reference standard was evaluated with the Lin concordance correlation coefficient. Noninferiority was assessed with bootstrapped estimates of the differences in ASPECTS between conventional and virtual NCCT with 95% CIs.

RESULTS: Of the 193 included patients, 100 patients (52%) had ischemia on DWI. Compared with the reference standard, the ASPECTS concordance correlation coefficient for conventional and virtual NCCT was 0.23 (95% CI, 0.15–0.32) and 0.44 (95% CI, 0.33–0.53), respectively. The difference in the concordance correlation coefficient between virtual and conventional NCCT was 0.20 (95% CI, 0.01–0.39) and did not cross the prespecified noninferiority margin of –0.10.

CONCLUSIONS: Dual-energy virtual NCCT is noninferior compared with conventional NCCT for the detection of early ischemic changes with ASPECTS.

ABBREVIATION: CCC = concordance correlation coefficient

CT of the head is the most commonly used technique in the evaluation of stroke. Initial NCCT is the first-line study in the evaluation of suspected stroke to exclude intracranial hemorrhage or an alternative explanation for the patient’s symptoms. While early ischemic changes can be detected with NCCT, sensitivity is limited relative to DWI, which remains the reference standard for the detection of cerebral ischemia. However, MR imaging has limited availability. Early ischemic changes can be evaluated with ASPECTS on CT and are prognostic for functional outcome after IV thrombolysis and endovascular thrombectomy. ASPECTS is used for thrombectomy decision-making, because the large thrombectomy trials excluded patients with a low ASPECTS.

Dual-energy CT enables acquisition of CT images at 2 different tube voltages instead of one and has several applications in neurointervention and neuroradiology. For instance, iodine contrast can be separated from blood components in patients with large-vessel occlusion who underwent endovascular thrombectomy. Similarly, it is also possible to subtract iodine maps from the CTA images, resulting in virtual NCCT images.

It is unknown whether virtual NCCT is noninferior to conventional NCCT for the detection of early ischemic changes. If virtual NCCT is noninferior compared with conventional NCCT, then the latter may be omitted from the stroke imaging protocol, reducing the radiation exposure to the patient. We performed a noninferiority analysis comparing virtual NCCT with standard linearly blended NCCT, a surrogate of conventional NCCT, for the detection of early ischemic changes.

Received January 21, 2022; accepted after revision June 17.

From the Departments of Radiology (F.K., F.v.O., G.Z., D.N.W., L.M., J.J.H., M.W.) and Medicine (V.Y.D., D.B.B.), Stanford University, Stanford, California; and Departments of Radiology (F.K., J.W.D., F.v.O., H.W.A.M.d.J., B.K.V.) and Neurology (F.K., L.J.K.), University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.

This research has been made possible by the Dutch Heart Foundation, the Netherlands Organisation for Scientific Research, and the Domain Applied and Engineering Sciences, as part of their joint strategic research program “Earlier Recognition of Cardiovascular Diseases” (grant No. 14732).

Please address correspondence to Frans Kauw, MD, Department of Radiology, Room Q.O.I.4.46, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX Utrecht, the Netherlands; e-mail: f.kauw-3@umcutrecht.nl

Indicates open access to non-subscribers at www.ajnr.org

http://dx.doi.org/10.3174/ajnr.A7600


1259
detection of early ischemic changes with ASPECTS in patients with acute ischemic stroke.

**MATERIALS AND METHODS**

**Patient Selection**

Adult (18 years of age or older) patients who presented with suspected acute ischemic stroke and who underwent dual-energy CT (Somatom Force; Siemens) between February 2018 and February 2019 were selected for this study. The inclusion criteria were the availability of dual-energy NCCT and CTA scans and brain MR imaging within 48 hours after CT. Imaging was routinely performed as part of our standard-of-care stroke protocol. This study was approved by the Stanford University Institutional Review Board and complied with the Health Insurance Portability and Accountability Act. The need for informed consent was waived.

**Image Acquisition and Preparation**

NCCT and CTA were acquired helically using tube voltages of 80 and 140 kV (peak) with a tin filter and tube currents of 640 and 320 mAs, respectively. The images were acquired in dual-energy mode. The conventional NCCT was a standard linearly blended reconstruction to match a conventional 120-kVp NCCT. The virtual NCCT was reconstructed from CTA. The dual-energy data sets were routinely postprocessed using available dedicated software (syngo; Siemens) that was provided by the vendor to reconstruct virtual NCCT images. Section thicknesses of conventional and virtual NCCT were 3 mm.

DWI parameters were the following: TR = 6000 ms, TE = 78.2 ms, b-values = 0 and 1000, flip angle = 90°, and section thickness = 5 mm.

**Interobserver Study**

CT data were saved and presented in a random order to 2 experienced neuroradiologists (M.W. and J.W.D.) in the form of videos with fixed window settings (window width = 50 HU and window level = 40 HU). The reviewers evaluated the presence of early ischemic changes (yes or no) and rated ASPECTS, which is a prognostic score and allows quantification of the extensiveness of ante-ischemic changes (yes or no) and rated ASPECTS, which is a prognostic score and allows quantification of the extensiveness of ante-ischemic changes (yes or no). The level of agreement was interpreted on the basis of the following intervals for $k$: poor, $<0.20$; fair, $0.21–0.40$; moderate, $0.41–0.60$; good, $0.61–0.80$; and very good, $0.81–1.00$. Confidence intervals for $k$ statistics were based on 5000 bootstrap resamples.

Measures of sensitivity and specificity were calculated for virtual and conventional NCCT. We used a global test to compare the sensitivity and specificity.13 For feasibility, we concluded that the maximum study size was 200 patients. Our a priori power calculation determined that this would provide 77% power to show noninferiority, given a noninferiority margin of −0.10. Concordance between adjudicated CT assessments and the MR imaging criterion standard was quantified using the Lin concordance correlation coefficient (CCC),14,15 which is also a measure of accuracy against the criterion standard. Bootstrapped estimates were obtained of the differences between virtual and conventional NCCT with 2-sided 95% CIs. Noninferiority of virtual NCCT to conventional NCCT was prespecified as the lower boundary greater than −0.10 for the 95% CI of their difference in the CCC. In case the 95% CI of the difference in the CCC was greater than 0, superiority could be inferred.

All analyses were performed in the R statistical computing framework, Version 4.0 (http://www.r-project.org/), and the CCC was estimated using the epiR R package.

**RESULTS**

Imaging assessment was not possible in 3 of the 196 included patients. As a result, 193 patients remained for the final analysis (Table 1). In 100 patients (52%), ischemia was detected with MR imaging in different ASPECTS regions.

Some differences were observed between the observations of reviewers 1 and 2 (Fig 1). Interobserver agreement regarding the presence of early ischemic changes was moderate for conventional (weighted $k = 0.42$; 95% CI, 0.27–0.56) and virtual NCCT (weighted $k = 0.48$; 95% CI, 0.36–0.60) (Fig 2). Interobserver agreement regarding ASPECTS was fair for conventional NCCT (weighted $k = 0.38$; 95% CI, 0.23–0.54) and virtual NCCT (weighted $k = 0.27$; 95% CI, 0.14–0.4).

The sensitivity of virtual and conventional NCCT for the detection of early ischemic changes was 0.37 (95% CI, 0.28–0.47) and 0.27 (95% CI, 0.19–0.37), respectively ($P = .078$). Specificity was...
0.91 (95% CI, 0.83–0.96) and 0.94 (95% CI, 0.86–0.98), respectively (Table 2). The global test finding was not significant ($P = .111$).

The forest plots (Fig 2) for the CCC showed overlapping intervals for early ischemic changes and nonoverlapping 95% CIs for ASPECTS. The difference in the CCC between virtual and conventional NCCT was 0.201 (95% CI, 0.014–0.389) regarding ASPECTS and 0.077 (95% CI, −0.041–0.191) regarding early ischemic changes. Neither 95% CI for the difference in the CCC crossed the prespecified noninferiority margin of 0.10, thereby establishing noninferiority of virtual NCCT compared with conventional NCCT with respect to both ASPECTS and early ischemic changes. Furthermore, virtual NCCT was demonstrated to be superior to conventional NCCT with respect to ASPECTS. Sample acquisitions of conventional NCCT, virtual NCCT, and DWI MR imaging are shown in Fig 3.

**DISCUSSION**

This study shows that detection of early ischemic changes with dual-energy virtual NCCT in patients with suspected stroke is...
nonsuperior compared with standard linearly blended NCCT. Furthermore, virtual NCCT was demonstrated to be superior to conventional NCCT with respect to ASPECTS.

To the best of our knowledge, no studies have evaluated early ischemic changes on virtual NCCT images reconstructed from CTA. Studies in fields other than neuroradiology have shown contradictory results, and the reliability of the virtual NCCT maps seems to be influenced by the clinical indication. Excluding intracranial hemorrhage is an important application of NCCT in the acute stroke setting and can also be done with dual-energy virtual NCCT images. Dual-energy CT can also be used to distinguish intracranial hemorrhage and extravasation of iodine contrast after endovascular treatment of stroke. In addition, 1 study showed high sensitivity and specificity for detecting the hyperdense artery sign on dual-energy virtual NCCT. Previous studies showed that the detection of the ischemic core with dual-energy virtual NCCT images derived from NCCT was superior compared with conventional NCCT. It is difficult to compare these studies with our study because the reconstructions were acquired from different CT images (NCCT versus CTA). However, all studies indicated that dual-energy virtual NCCT has the potential to replace conventional NCCT with respect to the detection of early ischemic changes.

The observed interobserver variability with regard to the detection of early ischemic changes and ASPECTS was moderate and fair, respectively, and similar for virtual NCCT and conventional NCCT in this study. ASPECTS is known to have relatively poor intraobserver and interobserver agreement, as was the case in this study. Recently, this finding was supported by a study that demonstrated a relatively poor interobserver agreement in a large group of 100 readers. The agreement, based on the CCC, between the dual-energy virtual NCCT assessments and MR imaging assessments regarding the presence of early ischemic changes was slightly better than the agreement between conventional NCCT assessments and MR imaging assessments. With regard to ASPECTS, the CCC showed fair agreement between both CT modalities and MR imaging, which is in line with findings in a previous study.

The applications of dual-energy CT are becoming increasingly apparent. If dual-energy virtual NCCT of the brain can replace conventional NCCT, this would result in less radiation exposure for the patient. Whether dual-energy virtual NCCT saves time in the acute stroke work-up needs to be elucidated because dual-energy reconstructions also take time. Automated dual-energy reconstructions do not add extra time to the imaging protocol, unless manual processing is required. The disadvantages of replacing conventional NCCT with virtual NCCT include the necessity of acquiring CTA, turning on the dual-energy mode, and the requirements of added storage and bandwidth. Besides replacing conventional NCCT, future applications of virtual NCCT may include improvement of the conventional NCCT in case of severe movement artifacts and reduction of the radiation dose in a nonacute setting.

Most dual-energy CT scanners, using a dual source with a dual detector or a monosource with rapid kilovolt (peak) switching, require that the dual-energy setting be switched on beforehand to acquire dual-energy data. Other detector-based spectral CT scanners have a single source and a single dual-layered detector that is always switched on. In the acute stroke imaging work-up, NCCT needs to be acquired first to exclude intracranial hemorrhage. Because the dual-energy virtual NCCT images need to be reconstructed from the CTA, which is often only performed if an NCCT has ruled out an intracranial hemorrhage, it is difficult to omit the conventional NCCT in clinical practice. On the other hand, even in patients who have intracranial hemorrhage, CTA is often performed to look for cerebral aneurysms, cerebral arteriovenous malformations, or other vascular malformations as the cause of the bleed. Taken together, the role of dual-energy virtual NCCT seems dependent on the indication and on whether CTA is performed regardless of the findings on NCCT.

Several strengths can be noted in this study. To prevent observer bias, the observers who assessed the CT were blinded to clinical information and MR images; vice versa, the observer who assessed the MR images was blinded to the CT images. Another strength was the power calculation, which helped to achieve a reliable noninferiority analysis.
A limitation of this study was the potential risk of selection bias because patients were selected who underwent dual-energy CT and diffusion-weighted MR imaging. However, besides the imaging criteria, we used wide inclusion criteria (adult patients with a suspicion of acute ischemic stroke). Nevertheless, the results of this study need to be validated, preferably in a large prospective study. Due to missing data, extensive patient characteristics were not reported in this study. Although we did not use conventional single-source NCCT in this study, standard linearly blended images closely resemble conventional NCCT.31 Another limitation is the time interval between the acquired CT scan and the DWI. Although the time window was within 48 hours, this theoretically could have resulted in larger or additional infarcts on MR imaging compared with CT. This possibility may also partially explain the fair agreement between CT and MR imaging in this study. In addition, MR imaging is more sensitive for detecting ischemia; therefore, ASPECTS may differ between CT and MR imaging assessments, which are acquired simultaneously because small infarcts may be visible on MR imaging but not on CT. In this study, the dual-energy CT scanner and the software of 1 vendor were used, limiting the ability to generalize these findings. Future studies should include a broader range of CT vendors and software to increase generalizability.

CONCLUSIONS
Dual-energy virtual NCCT is noninferior compared with NCCT for the detection of early ischemic changes with ASPECTS.

Disclosure forms provided by the authors are available with the full text and PDF of this article at www.ajnr.org.

REFERENCES
medium after mechanical revascularisation in acute ischaemic stroke. *Eur Radiol* 2014;24:834–40 CrossRef Medline
Optimizing the Definition of Ischemic Core in CT Perfusion: Influence of Infarct Growth and Tissue-Specific Thresholds


ABSTRACT

BACKGROUND AND PURPOSE: CTP allows estimating ischemic core in patients with acute stroke. However, these estimations have limited accuracy compared with MR imaging. We studied the effect of applying WM- and GM-specific thresholds and analyzed the infarct growth from baseline imaging to reperfusion.

MATERIALS AND METHODS: This was a single-center cohort of consecutive patients (n = 113) with witnessed strokes due to proximal carotid territory occlusions with baseline CT perfusion, complete reperfusion, and follow-up DWI. We segmented GM and WM, coregistered CTP with DWI, and compared the accuracy of the different predictions for each voxel on DWI through receiver operating characteristic analysis. We assessed the yield of different relative CBF thresholds to predict the final infarct volume and an estimated infarct growth–corrected volume (subtracting the infarct growth from baseline imaging to complete reperfusion) for a single relative CBF threshold and GM- and WM-specific thresholds.

RESULTS: The fixed threshold underestimated lesions in GM and overestimated them in WM. Double GM- and WM-specific thresholds of relative CBF were superior to fixed thresholds in predicting infarcted voxels. The closest estimations of the infarct on DWI were based on a relative CBF of 25% for a single threshold, 35% for GM, and 20% for WM, and they decreased when correcting for infarct growth: 25% for a single threshold, 25% for GM, and 15% for WM. The combination of 25% for GM and 15% for WM yielded the best prediction.

CONCLUSIONS: GM- and WM-specific thresholds result in different estimations of ischemic core in CTP and increase the global accuracy. More restrictive thresholds better estimate the actual extent of the infarcted tissue.

ABBREVIATIONS: ICC = intraclass correlation coefficient; IG = infarct growth; IQR = interquartile range; rCBF = relative CBF

CTP is a widely available technique that allows measuring hypoperfused brain tissue and estimating ischemic core in patients with acute stroke. The ischemic core is often defined by CBF thresholds. However, despite their clinical usefulness, the most often used CBF-based definitions of ischemic core may not be accurate for research purposes. They often overestimate the true infarct (example in the Online Supplemental Data) and have limited accuracy compared with MR imaging. In addition, differences in the neurochemical response to ischemia in GM and WM lead to a varied vulnerability to ischemia. Applying homogeneous CBF thresholds in the whole brain may result in under- or overestimating the lesion in brain areas with different susceptibility to ischemia. Also, ischemic core volumes estimated by CTP, especially those affecting WM, are often smaller than in follow-up MR imaging. This overestimation, applied to routine clinical practice, could lead to not offering reperfusion treatment to patients who could benefit from it. These findings can be explained by the delay between baseline imaging and the follow-up imaging used to measure final infarct volume. The baseline-to-follow-up imaging delay may be a source of error because stroke is a dynamic process that results in progressive brain damage, mainly if successful reperfusion is not achieved. In addition,
cerebral ischemia is a dynamic process, and it is difficult to accurately establish the evolution of the infarction. Some studies have assumed both linear\textsuperscript{11} and logarithmic\textsuperscript{12} infarct growth (IG), but it is currently under discussion.\textsuperscript{13}

All these factors highlight the need for further research to improve tissue-outcome predictions in patients with stroke.\textsuperscript{14} Here, we studied the best thresholds for defining ischemic core using global- versus GM- and WM-specific CBF thresholds and accounting for IG in a cohort of patients with baseline CTP, complete reperfusion, and follow-up MR imaging.

**MATERIALS AND METHODS**

**Study Population**

The study population ($n = 101$, Online Supplemental Data) was part of a prospectively collected clinical registry of patients with acute ischemic stroke admitted in to a Comprehensive Stroke Center between March 2010 and December 2017. We included all consecutive patients with proximal occlusions in the carotid territory with a pretreatment whole-brain CTP <6 hours from symptom onset to neuroimaging, complete endovascular reperfusion defined as modified TICI 3, and a follow-up MR imaging. Proximal arterial occlusions included those located at the terminal intracranial carotid artery, the M1–M2 segments of the MCA, and the A1 segment of the anterior cerebral artery. There were no vascular re-occlusions in our cohort. We prospectively collected baseline characteristics, demographics, clinical course, and reperfusion therapy–related variables.

**Standard Protocol Approvals, Registrations, and Patient Consent**

The local Ethics Committee at Hospital Clinic approved the study (registration code, HCB/2018/0680).

**Neuroimaging**

The imaging protocol included a baseline multimodal whole-brain CT scan (total acquisition time, 83 seconds), which included NCCT (140 kV, 127 mAs, FOV = 225 mm, matrix = $512 \times 512$, section thickness = 5 mm); CTA (120 kV, 663 mAs, FOV = 261 mm, matrix = $512 \times 512$, section thickness = 0.6 mm); and CTP (80 kV [peak], 250 mAs, 1.5-second rotation, FOV = 18 mm, matrix = $512 \times 512$, and forty-nine 2-mm-thickness slices). Patients were scanned within a median (interquartile range [IQR]) of 129 minutes (72–211 minutes) from stroke onset using a Somatom Definition Flash 128-section dual-source multidetector scanner (Siemens), with a 98-mm z-coverage and 26 time points acquired each 1.5 seconds and 4 last time points each 5 seconds (total acquisition time, 59 seconds). Fifty milliliters of nonionic iodinated contrast were administered intravenously at 5 mL/s using a power injector, followed by a saline flush of 20 mL at an injection rate of 2 mL/s. To ensure complete filling of the collateral circulation, we acquired CTA after the CTP.

The ASPECTS was assessed on the baseline NCCT. CTP maps were calculated by the commercial software MiStar (Apollo Medical Imaging Technology) using a model-free singular-value decomposition algorithm with a delay and dispersion correction. The software automatically performs motion correction and selects an arterial input function from an unaffected artery (usually the anterior cerebral artery) and a venous output function from a large draining vein (the sagittal sinus). The software generates CBF, CBV, MTT, and delay time maps. Of note, the delay-corrected deconvolution method produces delay time maps rather than the more extensively used time-to-maximum maps.\textsuperscript{15} A threshold of 3 seconds on the delay time maps was used to define the hyperperfusion,\textsuperscript{9} and “ischemic core” was defined within the hypoperfused area with a series of relative CBF thresholds as a percentage of the mean perfusion values from the entire unaffected, contralateral hemisphere.\textsuperscript{16} The final vessel patency was graded on DSA at the end of mechanical thrombectomy according to the modified TICI classification.\textsuperscript{17} The follow-up MR imaging (total acquisition time, 24 minutes and 18 seconds) was performed on a 1.5T Magneton Aera unit (Siemens) at a median of 43 hours (IQR, 22–69 hours) after the CTP.

DWI lesion volumes were calculated using Amira software (Visage Imaging) through a semiautomated thresholding method to identify ROIs with a signal intensity exceeding the values in the contralateral hemisphere by $>3$ SDs.\textsuperscript{18} T1WI\textsubscript{s} were transferred into stereotaxic space using the diffeomorphic anatomical registration through exponentiated Lie algebra (DARTEL) normalization algorithm in Statistical Parametric Mapping (SPM12; http://www.fil.ion.ucl.ac.uk/spm/), and the resulting GM and WM probabilistic maps obtained in the native space were used to obtain GM and WM segmentations (Fig 1). T1WI, DWI, GM, WM, and lesion masks were coregistered to the baseline CTP for posterior analysis. Moreover, due to the clinical practice nature of our MR imaging protocol, DWI could not be corrected for distortions before applying the normalization.

The increase in infarct volume was calculated by subtracting the baseline CTP ischemic core from the final infarct volume measured on DWI. We calculated a theoretic IG-corrected volume for CTP-based estimations by subtracting the IG from baseline imaging to complete reperfusion. Assuming a linear IG, we estimated the infarct progression rate by dividing the nonviable tissue volume by the time delay to imaging.\textsuperscript{19} Finally, the estimated IG was calculated by multiplying the estimated infarct progression rate by the time from baseline imaging to complete reperfusion (Online Supplemental Data).

**Statistical Analysis and Outcome Measures**

We assessed the yield of different relative CBF (rCBF) thresholds to predict the following: 1) infarcted voxels in coregistered DWI through receiver operating characteristic analysis, and 2) final DWI lesion volume (net difference of the estimation and intraclass correlation coefficient [ICC]). We used the ICC (2-way...
mixed model, absolute agreement for single measures) to study the association between the 2 repeat measurements of ischemic core (acute CTP and follow-up DWI) because the ICC measure reflects both the degree of correlation and agreement between measurements of continuous data. Reliability was considered good when the ICC was $0.80$. When 2 different thresholds had similar performances according to the ICC and volume prediction, we chose the threshold that caused the least overestimation of the lesion compared with DWI. All these analyses were performed for the entire brain parenchyma and GM and WM separately. The theoretic IG correction was applied only in volume difference and ICC analyses. Continuous variables were reported as mean (SD) or median (IQR) as appropriate, and categoric variables, as proportions. Differences in proportions were studied with the $\chi^2$ or Fisher exact test. All analyses were performed using SPSS, Version 26.0 (IBM), and the level of significance was set at $P < .05$, 2-sided.

Data Availability
The data sets generated and analyzed during the current study are available from the corresponding author on reasonable request.

RESULTS
From 113 patients with full data available, we excluded 12 patients due to inaccurate WM and GM segmentation or poor CTP/MR imaging coregistration (see the flow diagram in the Online Supplemental Data). The main characteristics of the final cohort of 101 patients are summarized in the Online Supplemental Data.

Whole-Brain versus GM- and WM-Specific Thresholds
In the analysis of the final volume, the best single threshold was rCBF 25%. The best thresholds were different for GM (rCBF 35%) and WM (rCBF 20%). Furthermore, estimates in GM were more constant with less variations when changing the thresholds (Fig 2). A double GM- and WM-specific threshold of rCBF 45% and 30% was superior to a fixed threshold (rCBF 35%) in predicting infarcted voxels (Youden index, 0.32 versus 0.30). The fixed threshold underestimated lesions in GM and overestimated them in WM. The different thresholds between the volume prediction and the individual voxel prediction could be partially explained by the IG from CTP to MR imaging, which cannot be controlled in the voxel-based study (Fig 3). Subgroup analysis of patients with rapid (<60 minutes after CTP acquisition) complete endovascular reperfusion showed no differences in the results compared with the whole cohort.

Accounting for IG
By means of standard rCBF 30% thresholds, the median time from CTP to complete reperfusion was 95 minutes (IQR, 80–122 minutes), and the median IG was 5.2 mL (IQR, 1.5–10.8 mL). Considering the estimated IG velocity and the time to complete reperfusion, we calculated the theoretic ischemic core in CTP for each case. The closest estimations of this IG-corrected core were based on the rCBF 20% threshold (Figs 4A, -B). The effect of accounting for IG occurred both on WM- and GM-specific thresholds. For GM, the best IG-corrected core was based on the rCBF 25% threshold, while for WM, it was the rCBF 15% threshold (Fig 4C). The combination of 25% for GM and 15% for WM yielded the most accurate representation of IG-corrected ischemic core.

Spatial Distribution Analysis
According to the results obtained by applying the standard rCBF 30% threshold, most false-positives (predicted infarcted tissue in the
CTP without an ischemic lesion in DWI) were limited to the subcortical WM, while true-positives (predicted infarcted tissue in CTP with an ischemic lesion in DWI) were more common in the GM of the basal ganglia (Fig 5A). However, by means of a dual GM-WM threshold based on the best performing values in the previous analysis (rCBF 20% for WM and 35% for GM; Fig 5B), the number of false-positives in the subcortical WM was notably lower.

**DISCUSSION**

Establishing the extent of the ischemic core in the onset of an acute stroke is critical when considering reperfusion therapy. Although in routine clinical practice, an NCCT is sufficient to decide on treatment in patients with <6 hours from symptom onset, CTP-based definitions have often been used due to the availability of the technique and the fair correlations between the initial ischemic area predicted on CBF or CBV maps and the final lesion on DWI. However, some reports have challenged the value of CTP-based definitions. Core overestimation in WM has been highlighted as a focus of future effort to improve CTP accuracy. Here, we addressed 2 physiologically relevant simple issues that can be easily implemented in clinical practice. Advanced computing methods may further help in defining critically hypoperfused areas that predict the irreversible injury of the tissue, but the methodology described here may be enough to avoid overestimations of infarct volumes and undertreating patients who may benefit from reperfusion.

In agreement with previous studies, we found that GM showed more vulnerability to ischemia than WM, so applying a common, more traditional threshold for both tissues resulted in overestimating the infarcted area in WM while underestimating the ischemia effects on GM. In that same way, a specific threshold of rCBF 35% in GM and 25% in WM was better correlated with the final infarct on DWI. The greater stability of the GM estimations may be because perfusion is more constant in this tissue or because the final infarct volumes are smaller. The higher estimations of optimal thresholds in the prediction of the fate of individual voxels (a double GM-WM threshold of CBF 45% and 30%) could be due to the limitations of the latter analysis, favoring less specific thresholds. In accordance with this issue, establishing stricter thresholds in the voxel-based study is related to a greater error when coregistering. However, using a postprocessing program based on density differences between GM and WM entails less inherent error than in previous studies, which were based on probabilistic maps. Nevertheless, these results reflect the physiologic aspects of greater ischemia susceptibility on GM compared with WM, which is especially remarkable when optimal reperfusion is achieved and can be neutralized using tissue-specific CTP thresholds.

The reperfusion grade could be a crucial factor confounding the correct estimation of the final ischemic area due to variable IG from baseline to follow-up imaging. Although the rCBF 30% threshold was originally derived using a contemporaneous CTP-
DWI model, in which the potential effect of reperfusion is less relevant, CTP is especially useful to predict the final infarct with a good correlation between ischemic cores estimated by rCBF 30% and DWI findings when no reperfusion therapies are administered. On the other hand, fixed rCBF thresholds may overestimate final infarct volume in the case of recanalization, and the overestimation is more relevant when the time from symptom onset to neuroimaging is shorter. It is unclear whether these findings are secondary to the actual reversibility of CBF and CBV lesions after reperfusion or only due to technical limitations. When complete reperfusion occurs, mainly when the time to reperfusion is short as it is in our cohort, it is common for the ischemic lesion to be mostly limited to GM. Collaterality, although not specifically analyzed in this study, also plays an important role in brain tissue viability and IG rate. For example, the hypoperfusion intensity ratio in a biomarker based on CTP reflects the presence of collaterals and the eligibility of patients for reperfusion treatment in the acute phase. Using more specific CTP thresholds could be especially beneficial for avoiding overestimating infarct size in patients with good collaterals. Our study based on patients with a complete and short time to reperfusion showed a substantial overestimation of the final infarct on WM using a fixed threshold. Applying variable GM-WM thresholds offered a more precise estimation of the final ischemic core, with rCBF thresholds of 25% for GM and rCBF 15% for WM yielding the closest estimate of the IG-corrected core.

IG is also directly related to the time taken to complete the treatment. Theoretically, the penumbra region would become entirely ischemic core if there is no reperfusion, which is not expected to vary its volume time-wise. Ischemic core, however, is likely to expand with time each second the CBF is impaired. It is unclear whether the IG rate threshold varies according to the symptom-onset time to reperfusion, but it could change on the basis of the time from imaging to recanalization. Considering that the GM is less resistant to ischemia, a greater IG is expected at lower thresholds than in WM, as shown in our analysis. However, the IG correction is an approximation to a complex phenomenon, and results derived from it should be interpreted with caution.

The quality of the metrics used in the study (IG, volume differences, and so forth) rely on a good coregistration of the CTP and MR imaging techniques. Due to the inherent changes in tissue viability and, therefore, imaging quality and contrast, the coregistration (and segmentation) methodologies used in acute ischemic stroke studies are subject to technical errors. On the other hand, there is no established model of rapid tissue segmentation in routine clinical practice. In this work, as a proof of concept, we have used a more time-consuming postprocessing methodology (the DARTEL toolbox) to normalize coregistered T1WIs to obtain improved GW-WM segmentation compared with those obtained with NCCT. This segmentation, although better than that of NCCT, is not free of potential inaccuracies because the Montreal Neurological Institute templates are derived from much younger, healthier brains. Moreover, due to the clinical practice nature of our MR imaging protocol, DWIs could not be corrected for distortions before applying the normalization. Nevertheless, following the proof-of-concept nature of this work, we included only patients with final optimal CTP-MR imaging coregistration and WM-GM segmentation. If our approach is replicated in other cohorts and proved useful, future effort should focus on developing a system to improve CTP tissue segmentation fast enough to be used in clinical practice, for example, an atlas-based approach to obtain a rapid WM-GM segmentation in the CTP native space. CTP methods for the definition of ischemic core are an approximation to a dynamic and complex process. CTP acquisition parameters and postprocessing are a source of variability in the values obtained from perfusion maps. The CTP analysis was performed with the commercial software MIStar; therefore, our results may not be generalizable to other methodologies, and further studies with other available commercial software are warranted to confirm these results.

This study has some limitations, mainly related to its retrospective, observational design and the modest population size due to the strict inclusion criteria. However, it accurately represents the actual population and the decision-making issues tested in real-life clinical situations. In addition, its results tally with those obtained in previous studies and current knowledge about the effects of ischemia on the human brain. Also, only patients with complete recanalization were studied, so the generalizability of these results to other clinical contexts has to be analyzed in follow-up studies. An external validation would also reinforce these results. Establishing different thresholds in GM and WM based on their susceptibility to ischemia could enhance the precision of CTP to determine whether it is salvageable tissue, thus helping make therapeutic decisions. However, there is no established model of rapid segmentation in routine clinical practice, so future effort should focus on developing a system to improve CTP accuracy using these pathophysiologic principles adapted to daily practice.

CONCLUSIONS

GM- and WM-specific thresholds result in different thresholds for predicting infarcted tissue in CTP and increase the accuracy of the estimations regarding the tissue fate and total infarct volume of each voxel. IG from baseline to follow-up imaging can substantially alter the predictive value of different CTP-based definitions of ischemic core. Compared with the often-used threshold of rCBF 30%, more restrictive thresholds such as rCBF 20%, mainly referring to WM, may better estimate the actual extent of the infarcted tissue.

ACKNOWLEDGMENTS

The authors thank the staff and participants of Hospital Clinic for their relevant contributions. This work was partially developed at the Centro Esther Koplowitz, Barcelona, Centres de Recerca de Catalunya Programme/Generalitat de Catalunya.

Disclosure forms provided by the authors are available with the full text and PDF of this article at www.ajnr.org.

REFERENCES

Diagnostic Errors in Cerebrovascular Pathology: Retrospective Analysis of a Neuroradiology Database at a Large Tertiary Academic Medical Center

G. Biddle, R. Assadsangabi, K. Broadhead, L. Hacein-Bey, and V. Ivanovic

ABSTRACT

BACKGROUND AND PURPOSE: Diagnostic errors affect 2%–8% of neuroradiology studies, resulting in significant potential morbidity and mortality. This retrospective analysis of a large database at a single tertiary academic institution focuses on diagnostic misses in cerebrovascular pathology and suggests error-reduction strategies.

MATERIALS AND METHODS: CT and MR imaging reports from a consecutive database spanning 2015–2020 were searched for errors of attending physicians in cerebrovascular pathology. Data were collected on missed findings, study types, and interpretation settings. Errors were categorized as ischemic, arterial, venous, hemorrhagic, and “other.”

RESULTS: A total of 245,762 CT and MR imaging neuroradiology examinations were interpreted during the study period. Vascular diagnostic errors were present in 165 reports, with a mean of 49.6 (SD, 23.3) studies on the shifts when an error was made, compared with 34.9 (SD, 19.2) on shifts without detected errors (P < .0001). Seventy percent of examinations occurred in the hospital setting; 93.3% of errors were perceptual; 6.7% were interpretive; and 93.9% (n = 155) were clinically significant (RADPEER 2B or 3B). The distribution of errors was arterial and ischemic each with 33.3%, hemorrhagic with 21.8%, and venous with 7.5%. Most errors involved brain MR imaging (30.3%) followed by head CTA (27.9%) and noncontrast head CT (26.1%). The most common misses were acute/subacute infarcts (25.1%), followed by aneurysms (13.7%) and subdural hematomas (9.7%).

CONCLUSIONS: Most cerebrovascular diagnostic errors were perceptual and clinically significant, occurred in the emergency/inpatient setting, and were associated with higher-volume shifts. Diagnostic errors could be minimized by adjusting search patterns to ensure vigilance on the sites of the frequently missed pathologies.

ABBREVIATIONS: ACA = anterior cerebral artery; PCA = posterior cerebral artery; QA = quality assurance
and to offer potential strategies to decrease error rates, particularly by identifying common blind spots.

MATERIALS AND METHODS

Institutional review board approval was obtained for this retrospective study with a waiver of informed consent. The neuroradiology quality assurance (QA) database of diagnostic errors made by attending neuroradiologists at our institution was searched from January 2015 through March 2020 (63 months). The database was searched for vascular diagnostic errors by the 16 current and recently employed full-time diagnostic neuroradiologists (see below for details regarding the QA process). Vascular diagnostic errors were categorized as follows: ischemic (acute/subacute infarcts, chronic infarcts, multiple infarcts, hypoxic-ischemic encephalopathy), hemorrhagic (subdural, epidural, subarachnoid, contusion, intraventricular, retrocaval, quantitative expanding hemorrhage), arterial (aneurysm, large-vessel occlusion, significant stenosis [>70% narrowing], dissection, AVM-AVF, vasospasm, subclavian steal), venous (abnormalities of the dural sinuses, cortical veins, or deep veins), and other (overcalls, posterior reversible encephalopathy syndrome). A broad definition of large-vessel occlusions was used including the intracranial ICA, M1, and M2 of the MCA, anterior cerebral artery (ACA), intracranial vertebral artery, basilar artery, and proximal posterior cerebral artery (PCA).19

The primary radiologic peer-review method used in the United States is the American College of Radiology RADPEER (https://www.acr.org/Clinical-Resources/RADPEER) scoring system.20 Revised most recently in 2016, RADPEER uses a 3-point scoring scale (1, concur with interpretation; 2, discrepancy in interpretation not ordinarily expected to be made; and 3, discrepancy in an interpretation that should be made most of the time) with the option to designate a discrepancy as likely to be clinically insignificant (option A) or likely to be clinically significant (option B).21 Clinically significant errors are defined in this article as findings that were erroneously characterized or not observed that affected the patient’s treatment or follow-up if the findings had been accurately reported. Thus, we collected data on the following variables associated with the studies: clinically significant errors (RADPEER 2B, 3B) determined at the time of the peer-review process, interpretation setting (inpatient/emergency versus outpatient), mean number of CT and MR imaging scans read during the shift when the diagnostic error was made, study type, error type (perceptual, interpretive), and mean patient age.

The mean volume of interpreted studies per shift was extracted electronically from the department of radiology database, limiting the search to the shifts that were staffed by a neuroradiologist and MR imaging/CT examinations in neuroradiology. The total volume and mean number of interpreted neuroradiology studies during the 2015–2020 study period were collected. A shift was defined as daily output of interpreted CT or MR imaging studies by an attending neuroradiologist. Shifts with ≤10 interpreted studies per day were excluded as outliers, as many of those likely pertain to reports generated on days off, administrative or other, in order to catch up with overflow work from the day before. The mean volume of interpreted studies per shift for studies containing a vascular diagnostic error was compared with the mean number of interpreted studies per shift for studies that did not have a documented error, using the Welch t test.

Neuroradiology Division and the QA Process

Our neuroradiology QA database includes only CT and MR imaging examinations that are collected from several sources. As part of the QA process, each radiologist in our department is required to evaluate 3 random (software-generated) studies on the days they are assigned to the clinical service and assign a RADPEER score (1, 2A, 2B, 3A, or 3B) to each reviewed study. RADPEER scores 2 and 3 are flagged for further review. Also, in an effort to capture as many diagnostic errors as possible, all added neuroradiology reports (approximately 1000 addenda per year) are reviewed. Most reports are added for technical reasons (ie, documentation of contrast or radiation dose, comparison with outside studies not available at the time of the original interpretation) and, therefore, automatically eliminated from the review process. Reports that contain potential diagnostic errors are flagged for further review. Most (approximately 90%) flagged cases are screened through 2 mechanisms: reviews of random, and added studies. In addition, reports that are submitted by clinicians or radiologists because of disagreement with the original interpretation are flagged for further review. All flagged studies are either reviewed by 2 attending neuroradiologists, or, during our quarterly QA conference, assigned a consensus RADPEER score and entered in our QA database. Study findings are correlated against histologic findings or clinical follow-up, when available. Our neuroradiology division does not currently support subspecialized rotations such as vascular, head and neck, skull base, brain, or pediatric subdivisions, but rather functions as a general neuroradiology practice wherein every subspecialist reads all types of studies. All neuroradiologists included in this study are attending radiologists, full-time employees, and have similar yearly productivity relative value unit rates per full-time employee effort.

RESULTS

During the study period, a total of 245,762 CT and MR imaging studies were interpreted by our neuroradiology section, with a mean volume of 35.2 interpreted studies per shift. Vascular errors made up 25.8% of documented errors in this data set, with a total of 175 errors seen in 165 studies that contained a vascular diagnostic error, with a mean of 49.6 (SD, 23.3) interpreted CT and MR imaging studies on shifts when errors were made, totaling 158 shifts. Shifts in which no errors were documented had a mean volume of 34.9 (SD, 19.2) interpreted CT and MR imaging studies per shift. The results suggest a highly significant difference between the mean volume of interpreted studies per shift for the 2 groups. The results suggest a highly significant difference (t 162 = 7.9, P < .0001), with studies containing an error interpreted during higher-volume shifts.

The mean patient age in this study was 54.9 (SD, 23.8) years; 96 patients (58.2%) were men and 69 (41.8%) were women. Of the 165 studies with an error, 116 (70%) involved patients in the hospital setting (emergency department or inpatient), while the remaining occurred in the ambulatory setting. Table 1 shows the breakdown of errors relative to the examination type, with MR
Table 1: Diagnostic error versus imaging technique

<table>
<thead>
<tr>
<th>Study</th>
<th>Total Examinations (n = 165)</th>
<th>Percentage (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>MR imaging brain</td>
<td>50</td>
<td>30.3%</td>
</tr>
<tr>
<td>CTA head</td>
<td>46</td>
<td>27.9%</td>
</tr>
<tr>
<td>Noncontrast head CT</td>
<td>43</td>
<td>26.1%</td>
</tr>
<tr>
<td>CTA neck</td>
<td>7</td>
<td>4.2%</td>
</tr>
<tr>
<td>MRA brain</td>
<td>5</td>
<td>3.0%</td>
</tr>
<tr>
<td>CT neck</td>
<td>4</td>
<td>2.4%</td>
</tr>
<tr>
<td>CT cervical spine</td>
<td>4</td>
<td>2.4%</td>
</tr>
<tr>
<td>MR imaging cervical spine</td>
<td>2</td>
<td>1.2%</td>
</tr>
<tr>
<td>MRA neck</td>
<td>1</td>
<td>0.6%</td>
</tr>
<tr>
<td>MR imaging lumbar spine</td>
<td>1</td>
<td>0.6%</td>
</tr>
<tr>
<td>MR imaging total spine</td>
<td>1</td>
<td>0.6%</td>
</tr>
<tr>
<td>CT sinus</td>
<td>1</td>
<td>0.6%</td>
</tr>
</tbody>
</table>

Table 2: Error type based on pathology

<table>
<thead>
<tr>
<th>Pathology</th>
<th>Total Errors (n = 175)</th>
<th>Percentage (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acute/subacute infarct</td>
<td>44</td>
<td>25.1%</td>
</tr>
<tr>
<td>Aneurysm</td>
<td>24</td>
<td>13.7%</td>
</tr>
<tr>
<td>Subdural hematoma</td>
<td>17</td>
<td>9.7%</td>
</tr>
<tr>
<td>Significant arterial stenosis</td>
<td>11</td>
<td>6.3%</td>
</tr>
<tr>
<td>Dural sinus occlusion</td>
<td>11</td>
<td>6.3%</td>
</tr>
<tr>
<td>Epidural hematoma</td>
<td>8</td>
<td>4.6%</td>
</tr>
<tr>
<td>Large-vessel occlusion</td>
<td>8</td>
<td>4.6%</td>
</tr>
<tr>
<td>Overcall</td>
<td>7</td>
<td>4.0%</td>
</tr>
<tr>
<td>Arterial dissection</td>
<td>7</td>
<td>4.0%</td>
</tr>
<tr>
<td>Hypoxic-ischemic encephalopathy</td>
<td>7</td>
<td>4.0%</td>
</tr>
<tr>
<td>Chronic infarct</td>
<td>5</td>
<td>2.9%</td>
</tr>
<tr>
<td>AVM-AVF</td>
<td>5</td>
<td>2.9%</td>
</tr>
<tr>
<td>Subarachnoid hemorrhage</td>
<td>5</td>
<td>2.9%</td>
</tr>
<tr>
<td>Hemorrhagic contusion</td>
<td>3</td>
<td>1.7%</td>
</tr>
<tr>
<td>Embolic infarct</td>
<td>2</td>
<td>1.1%</td>
</tr>
<tr>
<td>Intraventricular hemorrhage</td>
<td>2</td>
<td>1.1%</td>
</tr>
<tr>
<td>Retroclival bleed</td>
<td>2</td>
<td>1.1%</td>
</tr>
<tr>
<td>Vasospasm</td>
<td>2</td>
<td>1.1%</td>
</tr>
<tr>
<td>Subclavian steal</td>
<td>1</td>
<td>0.6%</td>
</tr>
<tr>
<td>Sinus pericranii</td>
<td>1</td>
<td>0.6%</td>
</tr>
<tr>
<td>Deep neck vein occlusion</td>
<td>1</td>
<td>0.6%</td>
</tr>
<tr>
<td>Growing hemorrhage</td>
<td>1</td>
<td>0.6%</td>
</tr>
<tr>
<td>PRES</td>
<td>1</td>
<td>0.6%</td>
</tr>
</tbody>
</table>

Note: PRES indicates posterior reversible encephalopathy syndrome.

imaging of the brain being the most common with 30.3% (n = 50), followed by CTA of the head (27.9%, n = 46) and noncontrast head CT (26.1%, n = 43). The remaining study types for which an error was detected had ≤7 cases each. Errors were considered perceptual in 154 (93.3%) and interpretive in the remaining 11 (6.7%) cases. Clinically significant errors were found in 155 (93.9%) cases (RADPEER score of 2B or 3B). All non-clinically significant errors were found to be perceptual.

The total distribution of errors in this study is given in Table 2. Figure 1 shows that ischemic and arterial errors were equally prevalent with 58 errors each (33.3%), followed by hemorrhage (21.8%, n = 38) and venous abnormalities (7.5%, n = 13). Eight errors categorized as “other” (4.6%) included a single case of a posterior reversible encephalopathy syndrome as well as 7 overcalls consisting of 2 aneurysms, a pseudoaneurysm, a carotid injury, a vertebral artery occlusion, an epidural bleed, and a penumbra called an infarct. The breakdown of 58 missed ischemic injuries included 44 that were acute/subacute, 7 attributed to hypoxic-ischemic encephalopathy, 5 chronic ischemic insults, as well as 2 multiple, thought to be embolic. Figure 2 demonstrates the specific locations of acute infarcts, with MCA territory being the most common, followed by thalamic and cerebellar territories. The average size of infarct errors was: MCA (1.6 cm; range, 0.5–3.5 cm); cerebellar (2.0 cm; range, 0.4–3.9 cm); thalamic (1.4 cm; range, 0.6–2.4 cm), while the less frequently seen errors involved the ACA at 2.6 cm (range, 0.7–4.5 cm), brainstem at 0.8 cm (range 0.4–1.1 cm), and embolic at 0.6 cm (range, 0.4–0.8 cm).

Figure 3 shows that of 58 cases of arterial pathology, 24 were attributed to cerebral aneurysms; 11, to significant stenoses; 8, to large-vessel occlusion (5 located at the M2 segment, as well as 1 each in the M1, PCA, and basilar artery, respectively); 7, to arterial dissection; 5, to AVM/AVF; 2, to vasospasm, and 1, to subclavian steal. With the exception of a 5.3-cm abdominal aortic aneurysm that was not discussed on MR imaging of the lumbar spine, the average size of aneurysms was 0.5 cm (range, 0.2–0.7 cm). Table 3 shows the location of missed aneurysms: 14 of the 25 aneurysmal errors (56.0%) involved the ICA, with 5 in the cavernous segment, 4 in the clinoid and supraclinoid segments, 3 in the terminus, and 2 par-apophathalamic aneurysms. There were 4 MCA aneurysms as well as 2 aneurysms seen in the ACA and posterior communicating artery, while the abdominal aorta and PCA had 1 aneurysm. Figure 4 demonstrates the location of the combined 27 cases of significant stenosis, large-vessel occlusion, and arterial dissection, with the ICA and MCA, specifically the distal M2 segment, being the most common. Of the 8 large-vessel occlusions, 5 were of the M2 segment of the MCA, with single cases involving the M1 segment of the MCA, the PCA, and the basilar artery respectively.

The most common missed hemorrhagic lesions were subdural hematomas (n = 17), followed by epidural hematomas (n = 8) and subarachnoid hemorrhage (n = 5). We found ≤3 errors of the following conditions: hemorrhagic contusion (n = 3), intraventricular hemorrhage (n = 2), retroclival bleed (n = 2), and expanding parenchymal hemorrhage (n = 1) using a standard 3-orthogonal-plane measurement and comparison per routine interpretation determined at the time of the RADPEER process (Fig 5). The average size of hemorrhagic lesions included 0.5 cm for subdural hematoma (range, 0.3–1.0 cm), 0.4 cm for epidural hematomas (range, 0.3–0.5 cm), 0.6 cm for contusions (range, 0.2–0.9 cm), and 0.3 cm for retroclival bleed (range, 0.2–0.4 cm). The growing hemorrhage on the follow-up CT 12 hours later increased to a volume of 10.9 mL from an initial 5.7 mL, which was not reported. The most common error involving the venous system was dural sinus occlusion, which was seen in 11 cases; the remaining 2 cases were sinus pericranii and a deep neck vein thrombosis.

The imaging technique with errors was further categorized for the top 3 most common pathologies. For the 44 acute/subacute ischemic strokes, 21 were on MR imaging of the brain, 12 were on CTA of the head, and 11 were on noncontrast head CT. Of the 24 aneurysms (seen on 23 examinations; 1 CTA study contained bilateral missed aneurysms), 14 were on CTA of the head, 5 were on MR imaging of the brain, 3 were on MRA of the brain, and 1 abdominal aortic aneurysm was seen on MR imaging of...
involved acute/subacute ischemic injuries, cerebral aneurysms, subdural hematomas, and significant arterial stenosis. Every year in the United States, >215,000 deaths are thought to result from medical errors, third in prevalence only after cancer and heart disease,22 for which the impact of radiologic diagnostic errors is considered major.5,23 The current standard used to define errors in radiology interpretation is a discrepancy in interpretation that differs substantially from the consensus of peers, for which the current evaluation mechanism in the United States is the aforementioned RADPEER process.20,21 In that sense, a criterion standard is lacking; objective reference standards such as postmortem-proved or surgically confirmed diagnoses are, indeed, very uncommonly available.24

Because most cerebrovascular conditions have a poor natural history, particularly severe consequences can be expected to result from an erroneous or delayed diagnosis.25 Therefore, diagnostic errors in this organ system have relatively heightened relevance in comparison with other, more forgiving anatomic areas and disease processes.26,27 For instance, the reported prognosis of untreated acute ischemic stroke from large-vessel occlusion is consistent with high rates (up to 64%) of severe functional dependence or death (measured by the 90-day mRS, with scores of >2); for non-large-vessel occlusion strokes, the reported average expected rates of functional dependence or death are around 24%.19,28 Our study contained 44 missed, acute/subacute ischemic injuries.

The natural history of intracranial aneurysms suggests annual rupture rates around 1.1%–1.3%.29,30 Although the prevalence of intracranial aneurysms worldwide may be far larger than previously thought, possibly ranging between 5% and 8%,31,32 hemorrhagic rates may be high in certain populations with specific risk factors.33-35 A cumulative hemorrhagic rate of 10.5% at 10 years has been estimated for previously unruptured aneurysms,30 and the 10-year mortality rate for ruptured, untreated aneurysms was reported at around 76%.36 Our study contained 24 missed aneurysms.

Subdural and epidural hematomas can have devastating morbidity and mortality if not recognized and acted on in a timely manner.37 Subdural hematomas may often be treated conservatively on the basis of objective criteria such as the Glasgow Coma Scale score, the width of the hematoma, or the amount of midline shift.38,39 A study by Ryan et al40 published in 2012 in the *Journal of Trauma and Acute Care Surgery* explored mortality and functional outcomes

---

**DISCUSSION**

In this series, most cerebrovascular diagnostic errors were perceptual and clinically significant and occurred in the emergency/inpatient setting and were associated with higher-volume shifts. Although uncommon, cerebrovascular diagnostic errors had a significant clinical impact on most patients because 54.8% of errors involved acute/subacute ischemic injuries, cerebral aneurysms, subdural hematomas, and significant arterial stenosis. Every year in the United States, >215,000 deaths are thought to result from medical errors, third in prevalence only after cancer and heart disease,22 for which the impact of radiologic diagnostic errors is considered major.5,23 The current standard used to define errors in radiology interpretation is a discrepancy in interpretation that differs substantially from the consensus of peers, for which the current evaluation mechanism in the United States is the aforementioned RADPEER process.20,21 In that sense, a criterion standard is lacking; objective reference standards such as postmortem-proved or surgically confirmed diagnoses are, indeed, very uncommonly available.24

Because most cerebrovascular conditions have a poor natural history, particularly severe consequences can be expected to result from an erroneous or delayed diagnosis.25 Therefore, diagnostic errors in this organ system have relatively heightened relevance in comparison with other, more forgiving anatomic areas and disease processes.26,27 For instance, the reported prognosis of untreated acute ischemic stroke from large-vessel occlusion is consistent with high rates (up to 64%) of severe functional dependence or death (measured by the 90-day mRS, with scores of >2); for non-large-vessel occlusion strokes, the reported average expected rates of functional dependence or death are around 24%.19,28 Our study contained 44 missed, acute/subacute ischemic injuries.

The natural history of intracranial aneurysms suggests annual rupture rates around 1.1%–1.3%.29,30 Although the prevalence of intracranial aneurysms worldwide may be far larger than previously thought, possibly ranging between 5% and 8%,31,32 hemorrhagic rates may be high in certain populations with specific risk factors.33-35 A cumulative hemorrhagic rate of 10.5% at 10 years has been estimated for previously unruptured aneurysms,30 and the 10-year mortality rate for ruptured, untreated aneurysms was reported at around 76%.36 Our study contained 24 missed aneurysms.

Subdural and epidural hematomas can have devastating morbidity and mortality if not recognized and acted on in a timely manner.37 Subdural hematomas may often be treated conservatively on the basis of objective criteria such as the Glasgow Coma Scale score, the width of the hematoma, or the amount of midline shift.38,39 A study by Ryan et al40 published in 2012 in the *Journal of Trauma and Acute Care Surgery* explored mortality and functional outcomes

---

**FIG 1.** Categories of errors.

**FIG 2.** Errors in acute/subacute infarct location.
Although relatively benign compared with other causes of stroke, possibly due to the younger age of patients, the natural history of cervical artery dissection includes neurologic injury and severe hemodynamic compromise. Recurrent TIA, stroke, or death may be seen in up to 15% within 2 weeks following intimal injury, and recurrence of dissection is seen in roughly 1–8% of patients. Our study contained 7 cases of missed dissections.

The mean number of interpreted studies per shift was a factor that reached statistical significance, because more errors were made on busier shifts, showing a higher propensity for diagnostic errors with higher-volume reads, as suggested by the literature. Potential avenues toward error reduction indeed include reporting template adjustments to include areas affected by frequent mistakes, both by radiologists and interpreting neuroradiology section reads a large number of studies (>240,000 encounters annually), are linked to some coronavirus disease (known or cryptic), trauma, and infection, though rare occurrences have recently been shown to be linked to some coronavirus disease 2019 (COVID-19) vaccines. Although relatively benign compared with other causes of stroke, possibly due to the younger age of patients, the natural history of cervical artery dissection includes neurologic injury and severe hemodynamic compromise. Recurrent TIA, stroke, or death may be seen in up to 15% within 2 weeks following intimal injury, and recurrence of dissection is seen in roughly 1–8% of patients. Our study contained 7 cases of missed dissections.

The mean number of interpreted studies per shift was a factor that reached statistical significance, because more errors were made on busier shifts, showing a higher propensity for diagnostic errors with higher-volume reads, as suggested by the literature. Potential avenues toward error reduction indeed include reporting template adjustments to include areas affected by frequent mistakes, both by radiologists and interpreting neuroradiology section reads a large number of studies (>240,000

![FIG 3. Errors in overall vascular pathology.](image)

### Table 3: Location of missed aneurysm

<table>
<thead>
<tr>
<th>Aneurysm Location</th>
<th>Total (n=24)</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>ICA, cavernous</td>
<td>5</td>
<td>20.8%</td>
</tr>
<tr>
<td>MCA</td>
<td>4</td>
<td>16.7%</td>
</tr>
<tr>
<td>ICA, clinoid</td>
<td>4</td>
<td>16.7%</td>
</tr>
<tr>
<td>ICA, terminus</td>
<td>3</td>
<td>12.50%</td>
</tr>
<tr>
<td>ICA, paraphthalamic</td>
<td>2</td>
<td>8.3%</td>
</tr>
<tr>
<td>AcomA</td>
<td>2</td>
<td>8.3%</td>
</tr>
<tr>
<td>PcomA</td>
<td>2</td>
<td>8.3%</td>
</tr>
<tr>
<td>Abdominal aorta</td>
<td>1</td>
<td>4.2%</td>
</tr>
<tr>
<td>PCA</td>
<td>1</td>
<td>4.2%</td>
</tr>
</tbody>
</table>

Note: AcomA indicates anterior communicating artery; PcomA, posterior communicating artery.

in adult patients at a Level 1 Trauma Center. That study demonstrated that inpatient mortality was 16% (15% for surgical patients, 17% for the nonsurgical group), lower than that in previous studies from the 1970s to 2000s, which reported 22%–57% mortality rates. The authors credited the widespread and liberal use of CT, which allows detecting patients with less severe hematomas, and recent advances in surgical techniques as the main reasons for improved outcomes. Our study contained 17 missed subdural hematomas. Epidural hematomas may have better prognoses compared with subdural hemorrhage with prompt surgical evacuation, with a 17% reported mortality; however, that figure rises to 65% if surgery is performed >2 hours from the onset of coma. Our study contained 8 missed epidural hematomas.

The prognosis of large intracranial artery stenotic disease was evaluated in multiple trials, which have found an annual risk of death around 11.2% and an annual risk of stroke of 12.5%–17.1%. Our study contained 11 missed large-artery stenoses.

Cerebral venous thrombosis, which encompasses both dural sinus and cortical vein thrombosis, accounts for 0.5% of all strokes. Common predisposing factors are hypercoagulable disorders (known or cryptic), trauma, and infection, though rare occurrences have recently been shown to be linked to some coronavirus disease 2019 (COVID-19) vaccines. Although relatively benign compared with other causes of stroke, possibly due to the younger age of patients, the natural history of cervical artery dissection includes neurologic injury and severe hemodynamic compromise. Recurrent TIA, stroke, or death may be seen in up to 15% within 2 weeks following intimal injury, and recurrence of dissection is seen in roughly 1–8% of patients. Our study contained 7 cases of missed dissections.

The mean number of interpreted studies per shift was a factor that reached statistical significance, because more errors were made on busier shifts, showing a higher propensity for diagnostic errors with higher-volume reads, as suggested by the literature. Potential avenues toward error reduction indeed include reporting template adjustments to include areas affected by frequent mistakes, both by radiologists and interpreting neuroradiology section reads a large number of studies (>240,000

![FIG 3. Errors in overall vascular pathology.](image)

### Table 3: Location of missed aneurysm

<table>
<thead>
<tr>
<th>Aneurysm Location</th>
<th>Total (n=24)</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>ICA, cavernous</td>
<td>5</td>
<td>20.8%</td>
</tr>
<tr>
<td>MCA</td>
<td>4</td>
<td>16.7%</td>
</tr>
<tr>
<td>ICA, clinoid</td>
<td>4</td>
<td>16.7%</td>
</tr>
<tr>
<td>ICA, terminus</td>
<td>3</td>
<td>12.50%</td>
</tr>
<tr>
<td>ICA, paraphthalamic</td>
<td>2</td>
<td>8.3%</td>
</tr>
<tr>
<td>AcomA</td>
<td>2</td>
<td>8.3%</td>
</tr>
<tr>
<td>PcomA</td>
<td>2</td>
<td>8.3%</td>
</tr>
<tr>
<td>Abdominal aorta</td>
<td>1</td>
<td>4.2%</td>
</tr>
<tr>
<td>PCA</td>
<td>1</td>
<td>4.2%</td>
</tr>
</tbody>
</table>

Note: AcomA indicates anterior communicating artery; PcomA, posterior communicating artery.

in adult patients at a Level 1 Trauma Center. That study demonstrated that inpatient mortality was 16% (15% for surgical patients, 17% for the nonsurgical group), lower than that in previous studies from the 1970s to 2000s, which reported 22%–57% mortality rates. The authors credited the widespread and liberal use of CT, which allows detecting patients with less severe hematomas, and recent advances in surgical techniques as the main reasons for improved outcomes. Our study contained 17 missed subdural hematomas. Epidural hematomas may have better prognoses compared with subdural hemorrhage with prompt surgical evacuation, with a 17% reported mortality; however, that figure rises to 65% if surgery is performed >2 hours from the onset of coma. Our study contained 8 missed epidural hematomas.

The prognosis of large intracranial artery stenotic disease was evaluated in multiple trials, which have found an annual risk of death around 11.2% and an annual risk of stroke of 12.5%–17.1%. Our study contained 11 missed large-artery stenoses.

Cerebral venous thrombosis, which encompasses both dural sinus and cortical vein thrombosis, accounts for 0.5% of all strokes. Common predisposing factors are hypercoagulable disorders (known or cryptic), trauma, and infection, though rare occurrences have recently been shown to be linked to some coronavirus disease 2019 (COVID-19) vaccines. Although relatively benign compared with other causes of stroke, possibly due to the younger age of patients, the natural history of cervical artery dissection includes neurologic injury and severe hemodynamic compromise. Recurrent TIA, stroke, or death may be seen in up to 15% within 2 weeks following intimal injury, and recurrence of dissection is seen in roughly 1–8% of patients. Our study contained 7 cases of missed dissections.
studies in this article), so a second reading cannot be reasonably used widely; however, we used the double-reading method in collecting cases for our QA database and when assessing addended reports, which has proved efficient in uncovering a large number of diagnostic errors that could then be further analyzed. Our robust quality-improvement program methods used to identify errors uncovered approximately 10% of our total errors (internal data), and any strategy aimed at reducing errors based on the findings in our sample of discovered errors is expected to be applicable to our studies. Although our QA methods may be biased toward detecting clinically significant errors, we believe that such methodology does the following: 1) serves to collect as many cases as feasible in a random manner, 2) allows root-cause analysis, and 3) provides an opportunity for the design of interventional strategies aimed at reducing diagnostic errors.

A direct comparison of our neurovascular error rates with those of other practices is not possible because no relevant literature exists that discusses vascular error rates. Why our perceptual error rates are at the high end of the spectrum of published literature is currently being evaluated, with possible factors including technical issues in vascular imaging, volumes of interpreted examinations per shift, significant underappreciation of neuroradiology error rates in the literature, and, possibly, our unique methodology of collecting cases for the QA database. Error identification and implementation of corrective systems significantly impact patient care and medicolegal exposure. We are also actively investigating other variables that may show potential correlations with diagnostic errors. For example, there is evidence that high participation rates at multidisciplinary tumor boards is strongly correlated with low attending errors.55 These data may offer additional guidance on future interventions toward error reduction.

CONCLUSIONS
Most vascular errors noted in our series were perceptual and clinically significant, occurring in the emergency/inpatient setting and associated with higher-volume shifts. Acute/subacute ischemia, aneurysms, and subdural hematomas represent more than half of all errors. Hopefully, errors in vascular neuroradiology could be minimized if search patterns were altered to include hypervigilance of the sites most frequently affected by disease.

ACKNOWLEDGMENT
We would like to acknowledge Michelle Wilkins for data mining and data analysis support.

Disclosure forms provided by the authors are available with the full text and PDF of this article at www.ajnr.org.

REFERENCES
2. Balogh EP, Miller BT, Ball JR, eds; Committee on Diagnostic Error in Health Care, Board on Health Care Services, Institute of Medicine, and National Academies of Sciences, Engineering, and Medicine.
Larger Posterior Revascularization Associated with Reduction of Choroidal Anastomosis in Moyamoya Disease: A Quantitative Angiographic Analysis

ABSTRACT

BACKGROUND AND PURPOSE: Choroidal anastomosis, a hemorrhage-prone periventricular collateral manifestation in Moyamoya disease, outflows to the cortex posterior to the central sulcus. The objective of the present study was to test whether the angiographic extent of revascularization posterior to the central sulcus contributes to the postoperative reduction of choroidal anastomosis.

MATERIALS AND METHODS: This retrospective cohort study included choroidal anastomosis-positive hemispheres before direct bypass surgery. The postoperative reduction of choroidal anastomosis was determined by a consensus of 2 raters according to the previous research. An imaging software automatically traced the angiographic revascularization area, which was subsequently divided into anterior and posterior parts by an anatomic line corresponding to the central sulcus. Each area was quantitatively measured as a percentage relative to the whole supratentorial area.

RESULTS: Postoperative reduction of choroidal anastomosis was achieved in 68 (85.0%) of the 80 included hemispheres. The revascularization area posterior to the central sulcus was significantly larger in the hemispheres with reduction than in those with no reduction (mean, 15.2% [SD, 7.1%] versus 4.2% [SD, 3.4%]; P < .001), whereas no significant difference was observed in the revascularization area anterior to the central sulcus. Multivariate analysis revealed that the revascularization area posterior to the central sulcus was the only significant factor associated with reduction (OR, 1.57; 95% CI, 1.21–2.03, for every 1% increase).

CONCLUSIONS: The results suggest that a larger revascularization posterior to the central sulcus is associated with postoperative reduction of choroidal anastomosis regardless of the extent of anterior revascularization. It might facilitate optimal selection of the revascularization site for preventing hemorrhage.

ABBREVIATIONS: CS = central sulcus; PCA = posterior cerebral artery; STA = superficial temporal artery

Choroidal anastomosis is one of the abnormal periventricular collaterals in Moyamoya disease.1–5 The collateral is characterized by a connection between the choroidal and medullary arteries, which outflows to the cortex via retrograde flow in the medullary artery (Fig 1).2,3,6 Choroidal anastomosis is commonly observed in hemorrhagic Moyamoya disease7–9 and is associated with an extremely high risk of bleeding,4,5,10 After bypass surgery, the normalized direction of flow in the medullary artery can induce angiographic reduction of choroidal anastomosis.6,11 This change might explain the effectiveness of direct bypass in preventing bleeding.12–14 However, only a few studies have focused on the factors contributing to this change.15 A recent study revealed that choroidal anastomosis outflows to the cortex posterior to the central sulcus (CS).16 We hypothesized that a larger angiographic extent of revascularization posterior to the CS is associated with the reduction of choroidal anastomosis. Testing this hypothesis might help to determine the optimal revascularization site for preventing hemorrhage.

MATERIALS AND METHODS

The present retrospective cohort study was approved by Kyoto University Hospital institutional ethics committee (R1600). The Strengthening the Reporting of Observational Studies in Epidemiology was followed. All participants gave opt-out
consent in accordance with the ethical standards of the institutional and national research committees.

**Patients and Setting**
The present study included patients who had been diagnosed with Moyamoya disease according to the guidelines, who had presented with ischemic and hemorrhagic symptoms, who had undergone superficial temporal artery (STA)-MCA anastomosis at our hospital in the past 5 years, and who had been deemed positive for choroidal anastomosis before the operation.

Our original surgical procedures for STA-MCA anastomosis have been described in detail elsewhere. The addition of encephalomyosynangiosis was considered in pediatric patients.

**Assessment of Choroidal Anastomosis**
Patients routinely underwent MR imaging and conventional angiography before and after the operation. Postoperative angiographies were acquired at 3–6 months after completion of bilateral operations.

Two raters (T.F. and A.M.), blinded to other clinical information to avoid biases, viewed conventional angiograms and the sliding-thin-slab MIP coronal MRA to grade the development of choroidal anastomosis by hemisphere. The presence or absence of the anastomosis was determined by a consensus of 2 raters. The determinants for the presence of choroidal anastomosis were defined in the previous studies. In brief, choroidal anastomosis is defined as an anastomosis between the choroidal artery, either anterior or posterior, and the medial end of the medullary artery. The positive angiographic indicator of choroidal anastomosis is dilation and extension of the choroidal artery beyond the level of the lateral ventricle. This indicator corresponded to that of grade 2 choroidal anastomosis defined by Fujimura et al.

According to previous research, reduction of choroidal anastomosis was defined as no apparent anastomosis on a postoperative image, which corresponded to grade 0 or 1 defined by Fujimura et al. Reduction was recorded as a dichotomous variable (yes/no). The study population partly overlapped with that of our previous study. Recording of this variable had been completed for all hemispheres before the measurement of the revascularization area, to avoid making arbitrary decisions on the reduction of choroidal anastomosis.

**Measurement of Revascularization Area**
According to the method of Bang et al., we quantitatively measured the revascularization area relative to the whole supratentorial area on the lateral views of postoperative external carotid angiography. To ensure objectivity, we used imaging software (ImageJ, Version 1.52a; National Institutes of Health), which facilitated binary image conversion and automatic tracing of the revascularization area (Fig 2). The threshold for binary image conversion was set as the “default.” An unsubtracted angiographic image was also imported into the software for measuring the supratentorial area and determining the CS. We adopted the Rhoton method to determine the location of the CS. In brief, the extended line of the CS was approximated to the line connecting the midportion of the zygomatic arch and the point located...
2 cm behind the midpoint between the nasion and inion. The accuracy of this topographic method has been confirmed in several studies.21,22 The extended line of the CS divided the revascularization area into 2 areas, those anterior and posterior to the CS, and each pixel area was measured. Anterior and posterior revascularization areas were calculated as a percentage relative to the whole supratentorial area through setting each revascularization pixel area and whole supratentorial pixel area as the numerator and denominator, respectively (Fig 2). Revascularization areas were regarded as a continuous variable.

**Other Variables**

We measured 7 other variables as potential confounders: age at the operation, sex, symptom at onset, Suzuki stage,23 the presence or absence of posterior cerebral artery (PCA) involvement,24 the addition of encephalomyosynangiosis,25 and the preoperative hemodynamic state assessed with SPECT.26 According to Takahashi et al,26 the hemodynamic state in the MCA territory was classified into 1 of the following 3 stages: stage 0, normal baseline with normal acetazolamide-challenged CBF; stage 1, normal baseline with reduced acetazolamide-challenged CBF; and stage 2, reduced baseline with reduced acetazolamide-challenged CBF. We also assessed the hemodynamic status in the posterior half of the MCA territory because this area might be more closely associated with choroidal anastomosis. A commercially available software (NEURO FLEXER; https://neuro-flexer.software.informer.com/) with the functions of NEUROSTAT (http://128.95.65.28/~Download/) developed by Ogura et al27 was used to set the ROIs. The latest version of this software can automatically set ROIs including the anterior cerebral artery, MCA, anterior MCA, posterior MCA, PCA, basal ganglia, thalamus, pons, vermis, and cerebellar hemisphere. The hemodynamic status in the posterior MCA territory was classified into 1 of the 3 stages in the same manner as described above. All variables were recorded separately by hemisphere.

**Statistical Analysis**

The sample size was determined by the number of cases treated during the study period. All statistical analyses were performed for single hemispheres. For comparison of baseline characteristics (univariate analysis), the t test, Wilcoxon rank-sum test, \( \chi^2 \) test, or Fisher exact test was used as appropriate. To identify independent factors associated with the reduction of choroidal anastomosis, we used a multiple logistic regression analysis. Variables with a \( P \) value \(< .1 \) in univariate analyses were incorporated into the multiple logistic regression analysis. \( P \) values \(< .05 \) were considered significant. Neither loss to follow-up nor missing data occurred. All analyses were performed using JMP software (Version 15; SAS Institute).

**RESULTS**

Of a total of 121 patients (184 hemispheres) who underwent STA-MCA anastomosis in the study period, 88 hemispheres were identified as positive for choroidal anastomosis with preoperative MR imaging and conventional angiography. Postoperative angiography was not performed in 8 hemispheres for the following reasons: allergic reaction to the contrast medium occurring after the first angiography (3 hemispheres) and patients not providing informed consent for the second angiography (5 hemispheres). The remaining 80 hemispheres were included in the analysis (Fig 3). Baseline characteristics of the 80 hemispheres, including 43 left and 37 right hemispheres, are summarized in Table 1.

![Flow chart for patient inclusion.](image)

**Table 1: Baseline variables**

<table>
<thead>
<tr>
<th>Total</th>
<th>Reduction of Choroidal Anastomosis</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Yes</td>
</tr>
<tr>
<td>No. of hemispheres</td>
<td>80</td>
</tr>
<tr>
<td>Revascularization area (mean) [%]*</td>
<td></td>
</tr>
<tr>
<td>Posterior to CS</td>
<td>13.6 (SD, 7.7)</td>
</tr>
<tr>
<td>Anterior to CS</td>
<td>12.6 (SD, 7.0)</td>
</tr>
<tr>
<td>Median age (yr) (IQR)</td>
<td>12 (8–36)</td>
</tr>
<tr>
<td>Female (%)</td>
<td>47 (58.8)</td>
</tr>
<tr>
<td>Hemorrhagic presentation (%)</td>
<td>17 (21.3)</td>
</tr>
<tr>
<td>Median Suzuki stage (IQR)</td>
<td>3 (3–3)</td>
</tr>
<tr>
<td>PCA involvement (%)</td>
<td>10 (12.5)</td>
</tr>
<tr>
<td>SPECT stage 2</td>
<td></td>
</tr>
<tr>
<td>MCA territory (%)</td>
<td>37 (46.3)</td>
</tr>
<tr>
<td>Posterior MCA territory (%)</td>
<td>27 (33.8)</td>
</tr>
<tr>
<td>Addition of EMS (%)</td>
<td>21 (26.3)</td>
</tr>
</tbody>
</table>

*EMS indicates encephalomyosynangiosis; IQR, interquartile range; NA, not applicable.

*Percentage relative to whole supratentorial area.
Reduction of choroidal anastomosis after the operation was confirmed in 68 (85.0%) of the 80 hemispheres with postoperative conventional and MR angiographies. Conventional and MR angiographies were performed an average of 148.7 and 129.3 days after ipsilateral surgery, respectively.

**Revascularization Area and Choroidal Anastomosis Reduction**

The relationship between each revascularization area and reduction of choroidal anastomosis is shown in Table 1 and Fig 4. The revascularization area posterior to the CS was significantly larger in the hemispheres exhibiting reduction than in those exhibiting no reduction (mean, 15.2% [SD, 7.1%] versus 4.2% [SD, 3.4%]; P < .001), whereas no significant difference was observed in the revascularization area anterior to the CS (P = .74). The cutoff value of the revascularization area posterior to the CS for predicting reduction was 10.7% according to the analysis of the receiver operating characteristic curve (Fig 4, dotted line). All 52 hemispheres in which the area exceeded 10.7% showed reduction, whereas only 16 of the 28 hemispheres (57.1%) with the area below 10.7% showed reduction.

Figure 5 shows a representative case in which choroidal anastomosis responsible for hemorrhage has been markedly reduced after bypass surgery. The revascularization area posterior to the CS was relatively large (16.1%), whereas that anterior to the CS was small (3.4%).

**Factors Associated with Choroidal Anastomosis Reduction**

In the univariate analysis, the revascularization area posterior to the CS was the only significant factor associated with reduction of choroidal anastomosis (Table 1). Although the proportion of the hemisphere with stage 2 hemodynamic compromise in the posterior MCA territory was larger in the reduction group than in the no-reduction group (36.8% versus 16.7%), the difference was not statistically significant (P = .17). Three variables with a P value < .1 (the revascularization area posterior to the CS, sex, and hemorrhagic presentation) were incorporated in the multiple logistic regression analysis, revealing that the revascularization area posterior to the CS remained statistically significant (OR, 1.57; 95% CI, 1.21–2.03, for every 1% increase; Table 2).

We performed a sensitivity analysis in which we incorporated SPECT stage 2 in the posterior MCA territory in the multivariate analysis together with the above 3 variables. This analysis also revealed that the revascularization area posterior to the CS remained statistically significant (Online Supplemental Data).

**Outcome**

No subsequent intracranial hemorrhage associated with choroidal anastomosis occurred after the operation in the study population. However, there was a patient in whom de novo bleeding from the remaining choroidal anastomosis occurred 13 years after the operation (Fig 6). In this case, the revascularization area anterior to the CS was relatively large (12.3%), but that posterior to the CS was very small (1.5%). This patient’s data were not included in the statistical analyses because the patient did not fulfill the inclusion criteria in terms of the operation date.

---

**FIG 4.** Comparison of each revascularization area between hemispheres exhibiting reduction of choroidal anastomosis and those exhibiting no reduction. The dotted line indicates the cutoff value (10.7%).

**FIG 5.** Case 1 [a 9-year-old girl]. A, CT at onset shows intraventricular hemorrhage. B, Preoperative left internal carotid angiography shows choroidal anastomosis [dotted circle], which corresponds to the hemorrhage site. C, Quantitative measurement of the revascularization area in the left hemisphere. The revascularization areas anterior and posterior to the CS are 3.4% and 16.1%, respectively. The dotted line indicates the CS. D, Postoperative left internal carotid angiography shows reduction of choroidal anastomosis.
We performed a supplemental analysis to identify factors associated with the overall revascularization area (the area comprising both anterior and posterior revascularization areas). As shown in the Online Supplemental Data, female sex ($P = .02$), PCA involvement ($P < .001$), and SPECT stage 2 in the MCA territory ($P < .001$) were univariate factors positively associated with the overall revascularization area.

**DISCUSSION**

There were 3 major observations from our study: First, 85% of the patients had reduction of choroidal anastomosis after bypass surgery. Second, the revascularization area posterior to the CS was significantly associated with the reduction, whereas that anterior to the CS was not. Third, a posterior revascularization area of $<10.7\%$ increased the risk of choroidal anastomosis persistence.

The reduction rate of choroidal anastomosis in our series seems comparable with that in the literature (62%–70%). The angiographic analysis of the trial has also revealed that choroidal anastomosis, which is most likely to be distributed posteriorly, is responsible for posterior hemorrhage. PCA involvement is another significant factor associated with posterior hemorrhage. All these findings, together with ours, suggest the significance of the revascularization site for preventing hemorrhage.

The periventricular vascular morphology typical of Moyamoya disease might explain the reduction of choroidal anastomosis depending on the revascularization site. Periventricular anastomosis is a term defining anastomotic collaterals between the perforating or choroidal artery and the medullary artery in the periventricular area. It is classified into 3 types: lenticulostriate, thalamic, and choroidal anastomosis. Choroidal anastomosis outflows to the cortex posterior to the CS, whereas lenticulostriate anastomosis outflows anterior to the CS. Because a revascularization overlapping the outflow is more likely to normalize the medullary artery flow and promote successful reduction of the anastomosis, a larger revascularization area posterior to the CS might increase the probability of the reduction of choroidal anastomosis.

We identified, however, some hemispheres exhibiting reduction of choroidal anastomosis despite relatively small posterior revascularization. This finding might be explained by 2 possible reasons: First, some of the choroidal anastomoses might outflow exactly into the CS; in such cases, the revascularization could overlap the outflow even with a limited revascularization area posterior to the CS. Second, augmentation of CBF in the cortex posterior to the CS, which could not be assessed with angiography alone, might account for the reduction of choroidal anastomosis.

### Table 2: Multiple adjusted ORs for reduction of choroidal anastomosis

<table>
<thead>
<tr>
<th></th>
<th>Crude (95% CI)</th>
<th>Multivariate Adjustment (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Revascularization area posterior to CSa</td>
<td>1.53 (1.20–1.95)</td>
<td>1.57 (1.21–2.03)</td>
</tr>
<tr>
<td>Female</td>
<td>3.44 (0.94–12.59)</td>
<td>3.96 (0.66–23.86)</td>
</tr>
<tr>
<td>Hemorrhagic presentation</td>
<td>0.3 (0.08–11.1)</td>
<td>0.97 (0.16–6.07)</td>
</tr>
</tbody>
</table>

*a Every 1% increase.

**FIG 6.** Case 2. The patient had initially manifested seizure at 43 years of age and had undergone direct bypass. A, Quantitative measurement of the revascularization area in the left hemisphere. The revascularization areas anterior and posterior to the CS were 12.3% and 1.5%, respectively. The dotted line indicates the CS. B, Postoperative left ICA shows persistence of choroidal anastomosis (dotted circle). C, CT obtained at the onset of de novo intracranial hemorrhage, which occurred 13 years after the operation.
Our results do not conflict with various excellent modifications of direct bypass, most of which target the frontal lobe. Targeting the frontal lobe, including the motor cortex, seems a reasonable approach for ischemic Moyamoya disease. However, our results suggest that hemorrhagic Moyamoya disease requires a different strategy in terms of the revascularization site, especially for those with both choroidal anastomosis and mild hemodynamic failure. According to a recent study, a substantial number of patients with hemorrhagic Moyamoya disease have only mild hemodynamic failure. Given that the overall width of revascularization depends on the preoperative hemodynamic status as suggested in our Online Supplemental Data, bypass directly targeting the outflow might be reasonable for those with mild hemodynamic failure.

Our results suggest that severe hemodynamic compromise in the posterior half of the MCA territory, which might partly lead to a larger posterior revascularization area, is not a direct factor for reducing choroidal anastomosis. This finding is supported by the previous report, in which development of choroidal anastomosis showed no relation to the hemodynamic stage. Reduction of choroidal anastomosis might depend more directly on the surgical procedure, including selection of the recipient artery, than on the hemodynamic status in the parietal lobe. This speculation, however, should be validated in further studies.

The present study has several limitations. First, the study excluded 8 hemispheres in which postoperative angiography was not performed. The possible selection bias caused by this exclusion seems minimal, however, because exclusions should occur randomly according to the reasons for not performing postoperative angiography. Second, the present results were obtained at a single institution, and this might limit generalization, especially to indirect bypass. Third, it remains unknown whether reduction of periventricular anastomosis, including choroidal anastomosis, is associated with subsequent bleeding. Answering this question might require long-term follow-up, considering late-onset hemorrhage shown in Fig 6. Further prospective studies are required.

CONCLUSIONS
The present results support our hypothesis that a larger angiographic extent of revascularization posterior to the CS is associated with postoperative reduction of choroidal anastomosis. A small revascularization in this area might result in persistence of choroidal anastomosis regardless of the revascularization extent anterior to the CS. The present study might facilitate optimization of a direct bypass strategy focusing on hemorrhage prevention through selection of the revascularization site. Further studies are required.

ACKNOWLEDGMENT
We are grateful to Ms Mayu Masuko and Dr Makiko Haragi for providing the beautiful illustration (Fig 1).

Disclosure forms provided by the authors are available with the full text and PDF of this article at www.ajnr.org.

REFERENCES


Correlation of Call Burden and Sleep Deprivation with Physician Burnout, Driving Crashes, and Medical Errors among US Neurointerventionalists


ABSTRACT

BACKGROUND AND PURPOSE: High call frequency can lead to inadequate sleep, fatigue, and burnout, resulting in detrimental effects on physicians and patients. We aimed to assess the correlation between the frequency and burden of neurointerventional surgery calls and sleep deprivation with physician burnout, physical and driving safety, and fatigue-related medical errors.

MATERIALS AND METHODS: We sent an online questionnaire to the members of the 2 neurointerventional surgery societies comprising 50 questions and spanning 3 main topics: 1) overnight/weekend call burden, 2) sleeping patterns, and 3) Copenhagen Burnout Inventory.

RESULTS: One hundred sixty-four surveys were completed. Most (54%) neurointerventional surgeons reported burnout. Call burden of ≥1 every 3 days and being in practice >10 years were independent predictors of burnout. Thirty-nine percent reported falling asleep at the wheel, 23% reported a motor vehicle crash/near-crash, and 34% reported medical errors they considered related to call/work fatigue. On multivariate logistic regression, high call burden (called-in ≥3 times/week) was an independent predictor of sleeping at the wheel and motor vehicle crashes. Reporting <4 hours of uninterrupted sleep was an independent predictor of motor vehicle crashes and medical errors. Most neurointerventional surgeons recommended a maximum call frequency of once every 3 days.

CONCLUSIONS: Call frequency and burden, number of years in practice, and sleep deprivation are associated with burnout of neurointerventional surgeons, sleeping at the wheel, motor vehicle crashes, and fatigue-related medical errors. These findings contribute to the increasing literature on physician burnout and may guide future societal recommendations related to call burden in neurointerventional surgery.

ABBREVIATIONS: CBI = Copenhagen Burnout Inventory; NIS = neurointerventional surgeons; RVU = Relative Value Unit; SNIS = Society of Neurointerventional Surgery; SVIN = Society of Vascular and Interventional Neurology

P hysician burnout is a major health care concern and is very common among health care workers compared with the general population.1 More than 45% of US physicians reported at least 1 symptom of burnout with a prevalence approaching 50%.3,3 Work-related burnout has been defined as a combination of emotional exhaustion, depersonalization, and job dissatisfaction.4 Physicians experiencing burnout syndrome feel emotional exhaustion with a loss of enthusiasm for work, depersonalization and cynicism, and a low sense of personal accomplishment.5,6 Burnout is associated with alcohol and substance abuse, broken relationships, early retirement, and suicidal ideation in cross-sectional studies.7-10 Not only does burnout correlate with adverse personal effects, but it is also associated with professionalism, quality of patient care, and increased medical errors.11,12 Variable rates of physician burnout are noted among different subspecialties but range from approximately 40% to 75% in certain specialties such as emergency medicine. Nearly 60% of radiologists and neurologists as well as 50% of neurosurgeons have reported burnout.13 Neurointerventional surgeons (NIS) may be at high risk for burnout given the call frequency, overnight calls, the relatively high proportion of urgent/emergent cases, and, in particular, the
considerable increase since 2015 in the number of acute stroke thrombectomy cases, frequently occurring outside regular hours. NIS often commute emergently from home with interrupted sleep, raising their risk of sleeping at the wheel, being involved in motor vehicle crashes, and committing fatigue-related medical errors. Work-related interruption of sleep has been strongly correlated with physician burnout.14,15

The American College of Graduate Medical Education has recently increased its focus on promoting well-being and avoiding burnout in trainees by increasing education on wellness, exercise, healthy diet, sleeping habits, and work-life balance, in addition to setting limits on weekly and individual shift work hours. However, attending physicians are not subject to these guidelines on call frequency or work hours. Our study aimed to establish more accurate and robust rates of burnout among NIS by using the Copenhagen Burnout Inventory (CBI) survey and to specifically assess the association of call frequency and coverage to rates of burnout, inadequate sleep, daytime fatigue, medical errors, and vehicular crashes/near-crashes. Finally, we polled the NIS community for recommendations on optimum call frequency, organization, and compensation.

MATERIALS AND METHODS

The study protocol was reviewed by Northwestern University, Feinberg School of Medicine institutional review board, which exempted the study as a nonhuman subject design. The study survey was designed by 5 experienced NIS and 1 sleep medicine physician. The study used a 3-part survey (a detailed 3-part questionnaire that can be found in the Online Supplemental Data) and was designed to be completed in 5 minutes. The survey was initially developed in the REDCap electronic data capture tool (https://catalyst.harvard.edu/redcap/) and distributed via e-mail to the Society of Neurointerventional Surgery (SNIS) and Society of Vascular and Interventional Neurology (SVIN) boards as a single-click link to be distributed to their membership. In addition, it was then posted to SNIS members using the society’s “SNIS Connect” platform, and the remainder was sent by direct e-mail. A reminder e-mail was sent 10–15 days later during the period of the study, which extended from March 1 to May 31, 2018. Because responses were anonymous, REDCap recorded the Internet Protocol addresses of respondents to avoid duplicates.

Part 1, Overnight and weekend call: 15 questions that surveyed the existing frequency and model of call, including backup call, number of hospitals covered, following-day adjustment in response to being late on call, division of weeknight and weekend calls, call-compensation systems, and their recommendations on optimal call frequency, model, and compensation.

Part 2, Sleep: surveyed the association of work and call coverage with sleep, daytime fatigue, history of previous call-related motor vehicle crashes/near-crashes, history of previous work-related errors, and the existing prevalence of sleep disorders. We categorized sleeping hours into 3 categories: <4 hours, 4–6 hours, and 6–8 hours.

Part 3, Burnout: CBI used 3 domains: personal burnout (6 questions), work-related burnout (7 questions), and patient-related burnout (6 questions).

There were 5 possible answers to each question, and those answers were converted to a scoring system from 0 to 100 and subcategorized as follows: always, 100; often, 75; sometimes, 50; seldom, 25; and never/almost never, 0. A mean score of ≥50 points in any domain was positive for burnout.16,17 We also collected the demographics of survey respondents, including age, sex, years of practice, practice setting, and location.

Statistical Analysis

All analysis was conducted using SPSS (Version 24.0; IBM) and R statistical and computing software (http://www.r-project.org/). Descriptive statistics were reported in percentages, means, medians, and range. Factors affecting our dependent variables (burnout, motor vehicle crashes/near-crashes, sleeping at the wheel, and fatigue-related medical errors) were evaluated in a univariate analysis using the Fisher exact and χ² tests. Multivariate logistic regression analysis was performed to evaluate independent predictors of those dependent variables. A P value <.05 was considered statistically significant. The Cronbach α coefficient testing was used to assess the reliability of the CBI Likert scale, with values ≥.9 considered excellent, .7 to <.9 good, .6 to <.7 acceptable, .5 to <.6 poor, and <.5 unacceptable.

RESULTS

Sample and Demographics

Based on a previously published study in 2019, the number of US NIS in 2 of the largest neurointerventional societies in the United States, SNIS and SVIN, was 898 and 496, respectively with many of those physician-surgeons having dual membership in >1 society. The study estimated the total number of US NIS at that time to be approximately 1200 physicians. After sending surveys to the members of SNIS and SVIN, we had 164 respondents, most of whom were between 40 and 49 years of age (50%), with approximately 20% of respondents between 30 and 39 years, 20% between 50 and 59 years, and 10% between 60 and 69 years of age. Only 1 respondent was older than 69 years of age, and 2 respondents were younger than 30 years of age. Seventy-eight percent of respondents had been in practice for >5 years, with approximately 18% practicing for >20 years. Most respondents practiced in large urban cities with populations of >500,000, with only 11.5% of respondents practicing in small or rural cities. There was a homogeneous distribution among respondents in terms of their practice settings with 41.5% in academic, 33.5% in community, and only 11.5% in private practice, and 25% in a mixed practice. The male/female ratio among respondents was approximately 9:1.

Call Burden

Regarding call frequency, 48% of respondents were on call more than once every 3 days; 32%, once every 3 days; 15%, once every 4 days; 4%, once every 5 days; and only 1%, less than once every 5 days. Most respondents (59%) use a one week at a time call coverage model, whereas 28% had fixed weekdays with a rotating weekend, and 13% used miscellaneous arrangements including a night float, sole operator call, or alternating calls on a biweekly or monthly basis. When it came to being “called-in” during nights and weekends, 33% of respondents reported an average ≥4 times during a week of calls; 26%, 3 times; 29%, twice; and 12%, once,
resulting in approximately 60% of respondents being called-in ≥3 times during weekends and after-hours. Nearly all (98%) respondents had no built-in mechanism for taking the next day off if they were called-in or worked past midnight, and 86% responded “never or rarely” to how often they rescheduled next-day patients under these circumstances. A third (35%) of respondents covered >1 hospital when on-call, but only 6% were responsible for >3 hospitals. Only 34% of respondents reported having >1 person on call (eg, backup or call tree), while 48% of respondents who covered call at >1 hospital did not have a built-in system for a backup call person. When asked what would constitute optimal call frequency, most NIS respondents once every 3–4 days (39% once every 4 days and 37% once every 3 days) with only 7% suggesting a call frequency greater than every 3 days.

Increased call-in frequency ≥3 times a week was significantly associated with falling asleep at the wheel (47.9% versus 26.5%, \(P = .006\)), and in multivariate logistic regression, it was an independent predictor of falling asleep at the wheel (OR, 3.36; 95% CI, 1.51–7.86; \(P = .004\)). Even though increased call-in frequency showed a trend only toward motor vehicle crashes/near-crashes in univariate analysis (28.1% versus 16.2%, \(P = .09\)), when controlling for other variables in a multivariate logistic regression analysis, increased call-in frequency was an independent predictor of motor vehicle crashes/near-crashes (OR, 3.07; 95% CI, 1.17–8.80; \(P = .03\)).

### Call Compensation

When looking at different compensation models, 84% of respondents were salary-based versus only 8% reporting a compensation model that was purely based on Relative Value Units (RVUs) or 9% with alternative compensation models. Greater than half of respondents received bonuses based on RVUs alone (18%) or RVUs combined with other productivity factors (35%), but only 8% of respondents had their RVUs in after-hours multiplied by a factor because most (92%) had fixed RVUs regardless of the day and time of the week. Only half of respondents (51%) received extra compensation for overnight/weekend calls, with 22% having call compensation built into their base salary and the rest having a certain number of calls included in their baseline salary. Only 61 physicians (37%) responded to the question about the number of calls included in the baseline salary, and the mean/median and mode of answers were 10 calls per month, with a range between 1 and 31. When we looked at the monetary value for weekend call compensation, 50% of respondents were compensated at $1000–$2000, 30% were compensated <$1000, and 20% were compensated at >$2000. Call compensation was overall slightly greater on the weekends, with 21% being compensated <$10000 and 28% compensated >$2000.

### Physician Burnout

Table 1 demonstrates the mean, SD, median, and range of the CBI scales. The results showed good-to-excellent internal consistency with a Cronbach \(\alpha\) coefficient of ≥ 0.8. The Cronbach \(\alpha\) was .91 for personal burnout, .79 for work-related burnout, and .91 for patient-related burnout. More than half of respondents (54%) reported burnout in at least 1 of the domains: 12.2% in a single domain, 28.7% in 2 domains, and 13.4% in all domains. The highest burnout perceived was in the personal burnout domain with almost half of respondents (48.8%) reporting burnout in this domain and a nearly equivalent number (44.5%) of respondents reporting work-related burnout, but only 16.5% perceived patient-related burnout (for which the cutoff point of CBI scale score was 50 points).

The Online Supplemental Data demonstrate a univariate correlation of potential independent factors for burnout. There was a trend toward increased burnout in respondents who covered calls a week at a time compared with using a split weekday/weekend model (60.4% versus 43.5%; \(P = .07\)) after removing other less common models. There was a trend toward increased burnout with decreased sleep (61.4% versus 48.9%, \(P = .12\), for <4 hours of uninterrupted sleep and 75% versus 51.4%, \(P = .06\), for <6 total hours of sleep), but this did not reach statistical significance. Even though call frequency did not correlate with burnout in univariate analysis, a call frequency of ≥3 times a week was an independent predictor of burnout (OR, 3.24; 95% CI, 1.22–9.19; \(P = .02\)) when accounting for various factors in a multivariate logistic regression model (Online Supplemental Data). NIS with >10 years of practice showed a trend toward an increased likelihood of experiencing burnout (59.3% versus 47.9%, \(P = .16\)), and practicing for >10 years was an independent predictor of burnout in multivariate logistic regression analysis (OR, 2.78; 95% CI, 1.11–7.69; \(P = .03\)). However, physicians reporting burnout did not have a statistically increased risk of motor vehicle crashes/near-crashes (28.1% versus 17.3%, \(P = .14\)), sleeping at the wheel (39.3% versus 38.7%, \(P = .99\)), and/or reporting fatigue-related medical errors (31.5% versus 37.3%; \(P = .51\)).

### Sleep and Fatigue

The total and uninterrupted hours of sleep while on call and not on call are demonstrated in Table 2. Regarding on-call days and total sleep hours, 65% slept between 4 and 6 hours versus 23% who had 6–8 hours of sleep, but there was also less uninterrupted sleep, with 43% reporting <4 hours and only 10% achieving 6–8 hours. When off-call, no respondent slept <4 hours, and 89% reported 6–8 hours of sleep per day, most of which was uninterrupted (80%). When asked to rate the quality of sleep during a call night, only 9% of respondents thought it was average/same as a noncall night, 57% believed they had fair sleep quality, and 34% reported poor sleep quality. Sleep disorders were identified in 16% of respondents, with 9% reporting sleep apnea. Sleep deprivation and call-/work-related fatigue resulted in 39% falling asleep at the wheel at least once, 23% experiencing motor vehicle crashes/near-crashes, and 34% reporting medical errors. Most (75%) respondents related that they needed a daytime nap due to call-related...
fatigue, yet only 42% would have the ability/chance to sleep during work hours.

The Online Supplemental Data demonstrate a univariate correlation between multiple independent factors and burnout, sleeping at the wheel, having motor vehicle crashes/near-crashes, and fatigue-related medical errors. Less than 4 hours of total sleep and <4 hours of uninterrupted sleep demonstrated a trend toward burnout (75% versus 51.4%, P = .06, and 61.4% versus 48.9%, P = .12, respectively). There was a statistically significant association of sleeping <6 hours with falling asleep at the wheel (43.7% versus 23.7%, P = .04) and fatigue-related medical errors (38.9% versus 18.4%, P = .02). The risk of medical errors showed an even stronger association in respondents reporting <4 hours of uninterrupted sleep (45.7% versus 25.5%, P = .008), as well as a significantly increased risk for motor vehicle crashes/near-crashes (34.3% versus 14.9%, P = .005). Uninterrupted sleep of <4 hours was an independent predictor of motor vehicle crashes/near-crashes (OR, 3.11; 95% CI, 1.28–7.92; P = .01) and medical errors (OR, 2.60; 95% CI, 1.21–5.68; P = .01). In terms of demographics, men were more likely to fall asleep at the wheel (OR, 10.90; 95% CI, 1.83–210.90; P = .03), and women were more likely to report fatigue-related medical errors (OR, 4.17; 95% CI, 1.10–18.52; P = .04).

**DISCUSSION**

NIS may be at high risk of burnout, in large part due to the high proportion of emergency procedures and the frequency of on-call coverage.1,8,19 Among those who participated in our study, we found that increased years of practice and a call frequency greater than or equal to once every 3 days (increased call frequency) were independently associated with burnout. In addition, an increased call frequency was associated with an increased risk of falling asleep at the wheel, motor vehicle crashes/near-crashes, and medical errors. In addition, sleeping <4 hours, which was more commonly encountered during call days, was an independent predictor of motor vehicle crashes and medical errors. To date, there are no standards for call frequency for NIS; when asked about optimal call frequency, most responding physicians selected a maximum of once every 3 days.

In our survey, 54% of respondents reported burnout in at least 1 domain of the CBI survey, with 13.4% reporting burnout in all domains. We used the CBI survey rather than the more commonly used Maslach Burnout Inventory for several reasons. The validity of the CBI has been supported by prior studies and has been used in multiple health care studies.17,20,21 When they are compared directly, the CBI and Maslach Burnout Inventory showed very similar results, but unlike the Maslach Burnout Inventory, the CBI can measure personal burnout as a total score with better psychomotor properties, allowing it to measure the degree of burnout change across time (rather than assuming a stable individual trait).22,23 The CBI is also nonproprietary and open access. In a previous study of burnout, physician well-being, and the correlation to medical errors in 6695 physicians across different medical specialties, 54.3% of physicians reported burnout; 32.8%, excessive fatigue; and 10.5%, a major medical error within the prior 3 months. The study found that burnout and fatigue were independently associated with medical errors.24 Risks for burnout included long working hours, frequent overnight call duties, sleep deprivation and sleep disturbances, high work intensity, and suboptimal compensation among other factors.19 In our study, call burden (being on call once or more every 3 days) was an independent predictor of burnout. This finding aligns with prior studies showing a 3% increased risk for burnout with every extra hour of work per week and a 3%–9% increased risk of burnout for additional nights and weekend call.25

As per the American Heart Association/American Stroke Association guidelines, mechanical thrombectomy is standard-of-care treatment for large-vessel-occlusion acute ischemic strokes with salvageable brain tissue up to 24 hours from symptom onset or time last known well.26,27 Stroke call is inherently stressful due to the challenging, emergent nature of the interventions and the often high morbidity of the disease, with increased burnout also demonstrated among noninterventional stroke neurologists.28 Wilson et al29 demonstrated that almost 60% of stroke consults in a 24-hour shift occurred during nonworking hours. The same study showed increasing stroke thrombectomy rates from once every 5 days to once every 3 days,29 which are expected to further increase with expanding indications and place NIS at an even higher risk of burnout. When asked about the optimal maximal neurointerventional call burden in our survey, approximately 80% of respondents selected a call frequency not to exceed once every 3 days, with 39% selecting once every 4 days as the ideal call frequency, yet nearly half (48%) reported a current call frequency of greater than once every 3 days.

Our finding that >10 years of neurointerventional practice experience independently predicts burnout is contrary to prior studies that showed early-to-middle career physicians work more hours and have lower career satisfaction, less work-life balance, and more burnout and are more likely to quit the practice of medicine.30 The discrepancy may be related to the steep learning curve and time required for proficiency as well as the novel, challenging nature of neurointervention being strong motivators in the early years, whereas senior practitioners are likely to experience greater monotony, frustration, and less opportunity for advancement. As a direct consequence of call burden, sleep deprivation, and burnout, it is important to consider the physical well-being of physicians and the risk of medical errors, patient harm, and litigation. Most studies find that a majority of emergent stroke

| Table 2: Total and uninterrupted sleep hours—on call versus not on call |
|-----------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|
|                             | Total Sleep Hours/Call      | Total Sleep Hours/Not on Call | Uninterrupted Sleep Hours/Call | Uninterrupted Sleep Hours/Not on Call |
| Less than 4                 | 20 (12.2%)                 | 0                           | 70 (42.7%)                  | 2 (1.2%)                    |
| 4–6                         | 106 (64.6%)                | 19 (11.6%)                  | 77 (47%)                    | 31 (18.9%)                  |
| 6–8                         | 38 (23.2%)                 | 145 (88.4%)                 | 17 (10.4%)                  | 131 (79.9%)                 |
| P value                     | .01                        | .05                         | .04                         | .03                         |

Procedural complication rates significantly increased with call-in frequency, and this finding is alarming. The relationship between sleep and cognitive and psychomotor function has been well-established, as well as the impact on medical errors, motor vehicle crashes, and health, such as obesity and heart disease. Sleep is a very complex process and varies significantly from one night to another. Frequent call coverage is likely to cause disturbed sleep. In our survey, 65% of respondents reported <6 hours of total sleep when on call, and 43% reported <4 hours of uninterrupted sleep. While the American College of Graduate Medical Education has regulated minimum hours of protected sleep among trainees, no such rules exist for attending physicians. The American Academy of Sleep Medicine recently published a position statement on sleep, fatigue, and burnout, estimating that maladaptive sleep techniques led to a burnout prevalence of 50%, with sleep deprivation being one of the main culprits. A previous study demonstrated that the risk of procedural complication rates significantly increased if physicians experienced <6 hours of sleep (3.4% versus 6.2% with an OR of 1.72). In our study, having <4 hours of uninterrupted sleep while on call was an independent predictor of motor vehicle crashes/near-crashes and medical errors, whereas we found a nonsignificant trend toward increased burnout. Again, this sounds an alarm on what needs to be done to provide call coverage for emergency stroke cases, without affecting the patients’ outcomes or putting the providers at considerable risk. Should we train more neurointerventionalists to have adequate coverage, and if so, how would that affect the volume for other neurovascular pathologies treated by those physicians and would that eventually reduce individual expertise for treating those pathologies? On the other hand, should there be an alternative training pathway in which physicians are given the opportunity to do either 1 year of training to only perform stroke thrombectomies versus 2 years of training for all neurovascular pathologies, to ensure adequate stroke coverage without affecting the expertise in treatment of other neurovascular pathologies? Should there be a minimum number of emergent large-vessel occlusions in a hospital to allow the hospital to offer stroke thrombectomy service while having enough physicians to cover/backup the call? Should there be a minimum number of neurointerventionalists/stroke interventionists employed by the hospital to provide thrombectomy service?

With regard to compensation models that use productivity/RVU as a basis, other specialties such as Emergency Medicine have developed formulas that assign a positive multiplication factor to RVUs generated during evening/night shifts. Should this model be applied to NIS as well? Given the tremendous societal burden of stroke, should productivity models be used at all for NIS compensation? These are all important questions that need to be addressed on a societal level to ensure continued provision of thrombectomy coverage without putting physicians at significant life-threatening risk or increasing medical errors that would affect patients’ outcomes.

Our study has several limitations. First, the survey results may be distorted by recall and selection bias in that a physician experiencing burnout may be more inclined to respond and lead to an overestimation of the burnout problem. However, the rates of burnout in our survey aligned with previously published data in the neurointerventional surgery field and other studies analyzing burnout in radiology, neurology, and neurosurgery. Second, the small proportion of responses limited the power of our study to find statistically significant associations. Due to the relatively small number of NIS compared with other specialties, we suggest conducting a repeat survey designed by a collaboration of the major neurointerventional societies, distributed more efficiently through conferences and e-mail lists, with emphasis on specific issues identified in these previous studies. Finally, we assessed burnout, accidents, and medical errors as a function of call burden, compensation, and sleep deprivation but did not include other, more difficult-to-categorize personal factors. Controlling for this myriad of influences will always pose a challenge to surveys addressing the complex causes of burnout, fatigue, and sleep disturbances. 

CONCLUSIONS

Call frequency/burden, the number of years in practice, and sleep deprivation are associated with NIS burnout, falling asleep at the wheel, motor vehicle crashes/near-crashes, and fatigue-related medical errors. Our findings add to the increasing literature on physician burnout and point out the increased risk of medical errors in patient care and significant life-threatening risks for physicians, and hopefully, they will guide future society-led surveys and practice-improvement guidelines related to call burden for NIS.

Disclosure forms provided by the authors are available with the full text and PDF of this article at www.ajnr.org.

REFERENCES

5. Spickard A Jr, Gabbe SG, Christensen JF. Mid-career burnout in generalist and specialist physicians. JAMA 2002;288:1447–50 CrossRef Medline
Predictors and Impact of Sulcal SAH after Mechanical Thrombectomy in Patients with Isolated M2 Occlusion

D.Y. Kim, S.H. Baik, C. Jung, J.Y. Kim, S.-G. Han, B.J. Kim, J. Kang, H.-J. Bae, and J.H. Kim

ABSTRACT

BACKGROUND AND PURPOSE: Data on SAH after M2 mechanical thrombectomy are limited. We aimed to determine the prevalence of sulcal SAH after mechanical thrombectomy for M2 occlusion, its associated predictors, and the resulting clinical outcome.

MATERIALS AND METHODS: The study retrospectively reviewed the data of patients with acute ischemic stroke who underwent mechanical thrombectomy for isolated M2 occlusion. The patients were divided into 2 groups according to the presence of sulcal SAH after M2 mechanical thrombectomy. Angiographic and clinical outcomes were compared. Multivariable analysis was performed to identify independent predictors of sulcal SAH and unfavorable outcome (90-day mRS, 3–6).

RESULTS: Of the 209 enrolled patients, sulcal SAH was observed in 33 (15.8%) patients. The sulcal SAH group showed a higher rate of distal M2 occlusion (69.7% versus 22.7%), a higher rate of superior division occlusion (63.6% versus 43.8%), and a higher M2 angulation (median, 128° versus 106°) than the non-sulcal SAH group. Of the 33 sulcal SAH cases, 23 (66.7%) were covert without visible intraprocedural contrast extravasation. Distal M2 occlusion (OR, 12.04; 95% CI, 4.56–35.67; P < .001), superior division (OR, 3.83; 95% CI, 1.43–11.26; P = .010), M2 angulation (OR, 1.02; 95% CI, 1.01–1.04; P < .001), and the number of passes (OR, 1.58; 95% CI, 1.22–2.09; P < .001) were independent predictors of sulcal SAH. However, covert sulcal SAH was not associated with an unfavorable outcome (P = .830).

CONCLUSIONS: After mechanical thrombectomy for M2 occlusion, sulcal SAH was not uncommon and occurred more frequently with distal M2 occlusion, superior division, acute M2 angulation, and multiple thrombectomy passes (≥3). The impact of covert sulcal SAH was mostly benign and was not associated with an unfavorable outcome.

ABBREVIATIONS: AIS = acute ischemic stroke; CA = contact aspiration; EVT = endovascular treatment; GRE = gradient recalled-echo; ICH = intracerebral hemorrhage; MT = mechanical thrombectomy; mTICI = modified TICI; SR = stent retriever; SS = sulcal SAH

Since the publication of a recent endovascular treatment (EVT) trial in 2015,1 many studies have demonstrated the feasibility and safety of mechanical thrombectomy (MT) for treating patients with MCA M2 occlusion, which is a medium-vessel occlusion.2-6 Accordingly, acute ischemic stroke (AIS) due to M2 occlusion has been increasingly treated with EVT despite the lack of clear guideline-based recommendations.7 However, the anatomic features of M2, including smaller diameters, tortuous vessels, and thinner vessel walls could be linked to poor accessibility and high periprocedural complication rates.8

SAH is one of the most concerning periprocedural complications after MT for AIS according to neurointerventionalists.9-11 More distal and narrower M2 vessels could particularly lead to iatrogenic SAH; however, to date, its related procedural factors have not been fully elucidated. In our preliminary experience, sulcal SAH (SS), which was undetected during M2 MT, was observed on postprocedural imaging. Given the technical challenges and lesser severity of M2 stroke, balancing the potentially increased risk of periprocedural complications and the clinical benefit of MT for M2 occlusion is essential.12 However, the clinical impact of SS after M2 MT remains largely unknown.

This study aimed to investigate the frequency and angiographic predictors of SS. We also investigated the clinical impact of SS, focusing on covert SS, which is angiographically occult but is detected by postprocedural imaging in patients who undergo MT for isolated M2 occlusion.
Tense signal lesion in the left Sylvian fissure identified during angiography in 3 experienced neurointerventionalists (C.J., S.H.B., and J.Y.K.) using the femoral artery approach. All procedures were performed by 3 experienced neurointerventionalists (D.Y.K. and S.H.B.) in consensus. The detailed angiographic and imaging findings were independently checked by 2 neurointerventionalists (D.Y.K. and S.H.B.) in consensus.

Endovascular Treatment
All procedures were performed by 3 experienced neurointerventionalists (C.J., S.H.B., and J.Y.K.) using the femoral artery approach with the patient under local anesthesia or conscious sedation. Unless technically infeasible, a balloon-guide catheter was routinely used. The choice of the first-line technique was left to the discretion of the treating operator. All included patients were treated with an SR alone, CA alone, or CA combined with an SR. If successful reperfusion was not achieved with the initially selected first-line MT despite multiple attempts, rescue therapy was performed by switching to the other strategy.

Thrombectomy with SR was performed using an SR device (Solitaire 4 × 20 mm, Medtronic; Trevo 3 × 20/4 × 20 mm, Stryker; or Aperio 3.5 × 28 mm, Acandis). CA thrombectomy was performed using an aspiration catheter (3MAX or 4MAX; Penumbra) or an intermediate catheter (Sofia 5F; MicroVention; or AXS Catalyst 6, Stryker) alone or in combination with an SR. The details of the conventional MT technique have been described previously.9,13

Data Collection and Outcome Measures
The primary outcome was the occurrence of SS after M2 mechanical thrombectomy. Patients were divided into SS and non-SS groups according to the presence of SS after M2 MT. SS was diagnosed by a hypointense and hyperintense lesion in the subarachnoid space, which was located in the Sylvian fissure or cerebral sulci on gradient recalled-echo (GRE) T2* and FLAIR sequences or via a persistent hyperdense lesion on serial noncontrast CT.9,14 The interpretation of SAH with a GRE sequence took precedence over the CT scan because the former can distinguish true SAH from contrast leakage.14 The diagnosis of SS with CT was performed if there was persistent sulcal hyperintensity on serial CT scans to exclude contrast leakage. Regarding the institutional protocol, immediate postprocedural and follow-up MR imaging was performed at our center 3–5 days after EVT. Additionally, secondary SAH that was not detected in the immediate postprocedural CT or MR imaging but was accompanied by hemorrhagic transformation was not included in the SS group.

Patients with SS were further classified into overt or covert SS subgroups according to the presence of intraprocedural contrast extravasation. Overt SS was defined as diffuse or confluent SAH with apparent intraprocedural contrast extravasation during EVT on DSA. Conversely, covert SS was defined as minimal, isolated SAH identified only on postprocedural MR imaging or CT, without intraprocedural contrast extravasation (Figure). All angiographic and imaging findings were independently checked by 2 neurointerventionalists (D.Y.K. and S.H.B.) in consensus.

MATERIALS AND METHODS
Patients
This study was approved by the local institutional review board of the Seoul National University Bundang Hospital, and the requirement for written informed consent was waived because of the retrospective nature of this study.

This retrospective analysis included all consecutive patients with AIS who underwent EVT between January 2013 and July 2021 at our stroke center. The inclusion criteria for the study were as follows: 1) time from symptom onset to groin puncture ≤24 hours; 2) primary isolated MCA M2 segment occlusion visible on CT or MR angiography; 3) baseline NIHSS score ≥2 points; 4) history of immediate postprocedural and follow-up CT or MR imaging; and 5) stent retriever (SR), contact aspiration (CA), or CA with an SR as the primary treatment. The exclusion criteria of this study were as follows: 1) tandem or multiple occlusions, 2) prestroke mRS score ≥2, and 3) insufficient data or poor image quality. This study defined the M2 segment as the MCA segment from the genu to the circular sulcus of the insula; early MCA branches arising from the M1 segment before the genu were not considered.2,3

Measures
Data collection and outcomes were recorded after the acute phase and at 3-month follow-up. The modified Rankin scale (mRS) was used to assess outcome. The primary end point was the occurrence of SS after M2 MT. SS was further classified into overt or covert SS subgroups according to the presence of intraprocedural contrast extravasation during EVT on DSA. Conversely, covert SS was defined as minimal, isolated SAH identified only on postprocedural MR imaging or CT, without intraprocedural contrast extravasation (Figure). The details of the conventional MT technique have been described previously.9,13

Measures
Data collection and outcomes were recorded after the acute phase and at 3-month follow-up. The modified Rankin scale (mRS) was used to assess outcome. The primary end point was the occurrence of SS after M2 MT. SS was further classified into overt or covert SS subgroups according to the presence of intraprocedural contrast extravasation during EVT on DSA. Conversely, covert SS was defined as minimal, isolated SAH identified only on postprocedural MR imaging or CT, without intraprocedural contrast extravasation (Figure). The details of the conventional MT technique have been described previously.9,13

FIGURE. Illustrative case showing covert SS. A patient in her 60s presented with aphasia and right-sided weakness. A, A left ICA lateral angiogram shows occlusion of distal M2 segment (arrow). B, After 3 attempts of thrombectomy using a Trevo 3 × 20 mm (not shown), successful reperfusion was achieved. Note that vasospasm is revealed (arrowheads) without definite contrast extravasation. M2 angulation is measured as 130° on the final angiogram. C, A noncontrast CT scan obtained 1 day after thrombectomy shows a small amount of hyperdense lesions (arrow) in the left Sylvian fissure. D, Axial GRE MR imaging performed 3 days after thrombectomy reveals an apparent hypointense signal lesion in the left Sylvian fissure (arrow), consistent with SAH.
M2 angulation was defined as a total calculated vessel angle that was the sum of the calculated M1–M2 and M2–M2’ angles. The M1–M2 angle was defined as the angle from the M1 segment as it turns superiority (at the M1–M2 junction) to become the M2 segment into which the thrombectomy device is positioned as the vessel courses toward the circular sulcus. M2–M2’ was defined as the angle between the just proximal and distal M2 segment of clot. Each calculated M1–M2 and M2–M2’ angle was obtained by subtracting the measured angle from 180°. Thus, a higher number of M2 angulations indicates greater vessel curvature. For the assessment of vessel angle, the best vessel contrast was selected from the final angiogram without a thrombectomy device in situ to avoid straightening the vessel anatomy. We measured the angles on the frontal projection of 2D DSA from the final angiogram using a PACS tools for angle measurement (Online Supplemental Data).

The demographic information included age, sex, and vascular risk factors (hypertension, diabetes, dyslipidemia, current smoking, coronary artery disease, atrial fibrillation, and previous stroke history). Stroke and treatment information, such as occlusion site mechanism (thromboembolic, in situ thrombosis, or unknown), IV tPA use, admission NIHSS score, baseline ASPECTS, M2 divisions (superior, inferior, or both), and proximal/distal M2 location, were collected. The proximal and distal M2 segments were distinguished by the line delineating the midpoint of the insula.

According to the modified TICI (mTICI) scale, we reported successful and complete reperfusion rates (defined as mTICI 2b–3 and mTICI 3, respectively). The number of thrombectomy passes was counted, and the outcomes and complications were analyzed. The first-pass effect was defined as achieving complete reperfusion with a single thrombectomy device pass. A favorable clinical outcome was defined as a 90-day mRS score of 0–2.

Safety outcomes included procedural (perforation, dissection, vasospasm, and distal embolism) and hemorrhagic complications. Vessel perforation was defined as frank angiographic contrast extravasation that occurred during the procedure. Distal embolism was defined as fragmentation of a primary clot downstream of the primary occlusion and embolization into a new territory. Intracerebral hemorrhage (ICH) was classified according to the European-Australasian Acute Stroke Study classification, and symptomatic intracerebral hemorrhage was defined as any hemorrhage associated with an NIHSS score increase of ≥4 points within 24 hours. Neurologic deterioration associated with SAH was defined as a ≥4-point increase in the NIHSS score assessed 24 hours after MT that was not attributable to any other cause.

**Statistical Analysis**

The differences in the baseline characteristics as well as the procedural and clinical outcomes were compared between patients with and without SS. The Pearson χ² test or the Fisher exact test was used for categoric variables, and the Student t test or Mann-Whitney U test was used for continuous variables. A binary logistic regression analysis was performed to determine the predictors of SS. Finally, the association between covert SS and 90-day clinical outcomes was investigated only in patients without intraprocedural contrast extravasation (overt SS). Variables with a P value < .10 from univariate analysis and those considered clinically relevant were included in a multivariate model. All statistical analyses were performed using R version 3.5.1 (http://www.r-project.org/). Statistical significance was set at P < .05.

**RESULTS**

A total of 1502 patients with AIS underwent EVT between January 2013 and July 2021. Among these, 236 patients who met the inclusion criteria were initially enrolled. Of these, 27 patients were excluded for the following reasons: 1) tandem or multiple occlusions (n = 11); 2) prestroke mRS score of ≥2 (n = 6); and 3) insufficient data or poor image quality (n = 10). Finally, 209 patients (mean age, 69 [SD, 12.4] years; 110 men [56.9%]) with primary isolated M2 occlusions qualified for the final analysis. Of the enrolled 209 patients, SS was observed in 33 (15.8%) patients; the remaining 176 patients (84.2%) were assigned to the non-SS group.

**Baseline and Procedural Characteristics**

The baseline characteristics of the SS and non-SS groups are presented in Table 1. The median NIHSS score at admission was 10 (interquartile range, 7–15). The involved sites were the proximal M2 (69.9%) and the superior division (46.9%). The SS group more frequently had distal M2 (69.7% versus 22.7%, P < .001) and superior division (63.6% versus 43.8%, P = .036) occlusion compared with the non-SS group. Age, vascular risk factors, etiology of the occlusion, intravenous tPA, and admission ASPECTS were comparable between the 2 groups.

The treatment and clinical outcomes are summarized in the Online Supplemental Data. Thrombectomy with an SR was most often used as the first-line treatment (71.8%). Overall, successful recanalization was achieved in 85.2% of the patients. The SS group showed a lower rate of CA thrombectomy (0% versus 11.9%, P < .001), higher M2 angulation (median 128° versus 106°, P < .001), and a larger number of passes (median, 3 versus 1; P < .001) than the non-SS group. Additionally, the SS group showed a longer procedural time (median, 48 versus 28 minutes; P < .001), a lower rate of successful reperfusion (57.6% versus 90.3%, P < .001), and a lower first-pass effect (0% versus 29.0%, P = .001). There were no significant differences in the rates of favorable clinical outcome or mortality between the 2 groups. The incidence of hemorrhagic complications was not significantly different between the 2 groups.

**Characteristics of Sulcal SAH**

Thirty-three patients had SS, of whom 10 (30.3%) had overt SS with intraprocedural contrast extravasation, whereas the remaining 23 (69.7%) patients had covert SS with angiographically occult SAH detected on postprocedural imaging (Table 2). Seven of the 10 patients with overt SS underwent emergent coil embolization, whereas contrast extravasation spontaneously ceased in the remaining 3 patients during the procedure. Covert SS was observed only in the ipsilateral Sylvian fissure (n = 14, 60.9%) and in the Sylvian fissure with other sulci (n = 9, 39.1%) (Fig 1). Of the 23 patients with covert SS, only one (4.3%) was symptomatic with neurologic deterioration, resulting in a prevalence of 0.48%. Conversely, patients with overt SS showed a higher rate of neurologic deterioration (40% versus 4.3%; P = .021) and unfavorable outcome (70% versus 47.8%; P = .283) than those with covert SS.
In the univariate analysis, procedural time, distal M2, superior division, M2 angulation, and number of passes were associated with SS (Table 3). In the multivariable analysis, distal M2 occlusion (OR, 12.04; 95% CI, 4.56–35.67; \( P < .001 \)), superior division (OR, 3.83; 95% CI, 1.43–11.26; \( P = .010 \)), M2 angulation (OR, 1.02; 95% CI, 1.01–1.04; \( P < .001 \)), and number of passes (OR, 1.58; 95% CI, 1.22–2.09; \( P < .001 \)) were independent predictors of SS. Additionally, distal M2 occlusion (OR, 8.53; 95% CI, 2.98–27.33; \( P < .001 \)), superior division (OR, 3.86; 95% CI, 1.30–13.00; \( P = .020 \)), M2 angulation (OR, 1.02; 95% CI, 1.01–1.03; \( P = .005 \)), and number of passes (OR, 1.60; 95% CI, 1.21–2.13; \( P < .001 \)) were also significantly associated with covert SS (Online Supplemental Data).

**Table 1: Baseline characteristics between sulcal SAH versus non-sulcal SAH**

<table>
<thead>
<tr>
<th>Total (( n = 209 ))</th>
<th>Sulcal SAH (( n = 33 ))</th>
<th>Non-Sulcal SAH (( n = 176 ))</th>
<th>( P ) Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (mean) (yr)</td>
<td>69.9 (SD, 12.4)</td>
<td>73.1 (SD, 11.2)</td>
<td>69.3 (SD, 12.6)</td>
</tr>
<tr>
<td>Male</td>
<td>110 (56.9)</td>
<td>16 (48.5)</td>
<td>103 (58.5)</td>
</tr>
<tr>
<td>Risk factor</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hypertension</td>
<td>139 (66.5)</td>
<td>21 (63.6)</td>
<td>118 (67.0)</td>
</tr>
<tr>
<td>Diabetes</td>
<td>71 (34.0)</td>
<td>13 (39.4)</td>
<td>58 (33.0)</td>
</tr>
<tr>
<td>Dyslipidemia</td>
<td>53 (25.4)</td>
<td>11 (33.3)</td>
<td>42 (23.9)</td>
</tr>
<tr>
<td>Smoking</td>
<td>43 (20.6)</td>
<td>10 (30.3)</td>
<td>33 (18.8)</td>
</tr>
<tr>
<td>Coronary artery disease</td>
<td>21 (10.0)</td>
<td>3 (9.1)</td>
<td>18 (10.2)</td>
</tr>
<tr>
<td>Atrial fibrillation</td>
<td>97 (46.4)</td>
<td>13 (39.4)</td>
<td>84 (47.7)</td>
</tr>
<tr>
<td>Previous stroke</td>
<td>30 (14.4)</td>
<td>4 (12.1)</td>
<td>26 (14.8)</td>
</tr>
<tr>
<td>Etiology of occlusion</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Thromboembolic</td>
<td>180 (86.1)</td>
<td>29 (87.9)</td>
<td>151 (85.8)</td>
</tr>
<tr>
<td>In-situ thrombosis</td>
<td>27 (12.9)</td>
<td>3 (9.1)</td>
<td>24 (13.6)</td>
</tr>
<tr>
<td>Intravenous tPA</td>
<td>44 (21.1)</td>
<td>6 (18.2)</td>
<td>38 (21.6)</td>
</tr>
<tr>
<td>Prestroke mRS</td>
<td>0 (0–1)</td>
<td>0 (0–0)</td>
<td>0 (0–1)</td>
</tr>
<tr>
<td>Admission NIHSS(^b)</td>
<td>10 (7–15)</td>
<td>11 (7–15)</td>
<td>10 (7–15)</td>
</tr>
<tr>
<td>ASPECTS(^b)</td>
<td>9 (8–10)</td>
<td>9 (8–9)</td>
<td>9 (8–10)</td>
</tr>
<tr>
<td>Occlusion site</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Proximal</td>
<td>146 (69.9)</td>
<td>10 (30.3)</td>
<td>136 (77.3)</td>
</tr>
<tr>
<td>Distal</td>
<td>63 (30.1)</td>
<td>23 (69.7)</td>
<td>40 (22.7)</td>
</tr>
<tr>
<td>Division</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Superior</td>
<td>98 (46.9)</td>
<td>21 (63.6)</td>
<td>77 (43.8)</td>
</tr>
<tr>
<td>Inferior</td>
<td>106 (50.7)</td>
<td>11 (33.3)</td>
<td>95 (54.0)</td>
</tr>
<tr>
<td>Middle</td>
<td>5 (2.4)</td>
<td>1 (3.0)</td>
<td>4 (2.3)</td>
</tr>
</tbody>
</table>

\(^a\) Data are presented as number (%) except where otherwise noted.

\(^b\) Data are median, and numbers in parentheses are interquartile range.

**Table 2: Characteristics of SS\(^a\)**

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Sulcal SAH (( n = 33 ))</th>
<th>Overt SAH (with Intraprocedural Contrast Extravasation) (( n = 10 ) (30.3%))</th>
<th>Covert SAH (without Intraprocedural Contrast Extravasation) (( n = 23 ) (69.7%))</th>
</tr>
</thead>
<tbody>
<tr>
<td>Management</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Coil embolization</td>
<td>7 (70.0)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Observation</td>
<td>3 (30.0)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Imaging findings</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SAH detected solely by serial CT</td>
<td>5 (50.0)</td>
<td>2 (8.7)</td>
<td></td>
</tr>
<tr>
<td>SAH detected by GRE/FLAIR</td>
<td>5 (50.0)</td>
<td>21 (91.3)</td>
<td></td>
</tr>
<tr>
<td>Location of SAH</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Only Sylvian fissure</td>
<td>0 (0)</td>
<td>14 (60.9)</td>
<td></td>
</tr>
<tr>
<td>Sylvian fissure + 1 sulcus</td>
<td>0 (0)</td>
<td>9 (39.3)</td>
<td></td>
</tr>
<tr>
<td>Sylvian fissure + ≥2 sulci</td>
<td>5 (50.0)</td>
<td>0 (0)</td>
<td></td>
</tr>
<tr>
<td>Diffuse, bilateral</td>
<td>5 (50.0)</td>
<td>0 (0)</td>
<td></td>
</tr>
<tr>
<td>Clinical outcomes</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Neurologic deterioration</td>
<td>4 (40.0)</td>
<td>1 (4.3)</td>
<td></td>
</tr>
<tr>
<td>mRS at 90 days(^b)</td>
<td>4 (4–5)</td>
<td>2 (1–5)</td>
<td></td>
</tr>
<tr>
<td>mRS 0–2 at 90 days</td>
<td>3 (30.0)</td>
<td>12 (52.2)</td>
<td></td>
</tr>
<tr>
<td>Mortality at 90 days</td>
<td>1 (10.0)</td>
<td>3 (13.0)</td>
<td></td>
</tr>
</tbody>
</table>

\(^a\) Data are presented as number (%) except where otherwise noted.

\(^b\) Data are median, and numbers in parentheses are interquartile range.

**Predictors of Sulcal SAH**

In the univariate analysis, procedural time, distal M2, superior division, M2 angulation, and number of passes were associated with SS (Table 3). In the multivariable analysis, distal M2 occlusion (OR, 12.04; 95% CI, 4.56–35.67; \( P < .001 \)), superior division (OR, 3.83; 95% CI, 1.43–11.26; \( P = .010 \)), M2 angulation (OR, 1.02; 95% CI, 1.01–1.04; \( P < .001 \)), and number of passes (OR, 1.58; 95% CI, 1.22–2.09; \( P < .001 \)) were independent predictors of SS. Additionally, distal M2 occlusion (OR, 8.53; 95% CI, 2.98–27.33; \( P < .001 \)), superior division (OR, 3.86; 95% CI, 1.30–13.00; \( P = .020 \)), M2 angulation (OR, 1.02; 95% CI, 1.01–1.03; \( P = .005 \)), and number of passes (OR, 1.60; 95% CI, 1.21–2.13; \( P < .001 \)) were also significantly associated with covert SS (Online Supplemental Data).
In the subgroup analysis excluding 10 patients with overt SS, age (OR, 1.11; 95% CI, 1.05–1.18; P < .001), atrial fibrillation (OR, 0.33; 95% CI, 0.11–0.90; P = .037), admission NIHSS score (OR, 1.15; 95% CI, 1.05–1.26; P = .002), baseline ASPECTS (OR, 0.53; 95% CI, 0.32–0.83; P = .009), and parenchymal hematoma (OR, 21.93; 95% CI, 2.31–50.77; P = .015) were predictors of unfavorable outcome in the multivariate logistic regression analysis. However, covert SS was not significantly associated with unfavorable outcome (P = .830) (Online Supplemental Data).

**DISCUSSION**

In the current study, SS after MT for M2 occlusion was not uncommon, and two-thirds of SS cases were covert SS, which were angiographically occult but revealed by postprocedural imaging. In addition, several procedural factors including distal location, superior division, acute vessel angulation, and multiple passes (≥3) were independently associated with the occurrence of SS. Although common, SS has a non-notable impact and is not associated with unfavorable clinical outcome.

To the best of our knowledge, this is the first study to show the prevalence of SAH as well as related procedural factors and clinical impact in patients undergoing M2 thrombectomy. Although there have been several studies on MT for M2 occlusion, they merely reported either the rate of symptomatic ICH or safety outcomes that focused on intraprocedural SAH or perforation. However, the present study attempted to assess not only overt SS but also covert SS and investigated procedural predictors of SS. The current study indicates that SS following M2 thrombectomy is relatively common, and distally located, superior division, acute-angle M2 occlusion with multiple thrombectomies is likely to result in SS.

The incidence of SAH after MT ranges from 0.5% to 24% according to previous reports, and in our cohort, the observed incidence was 15.8%. In previous M2 studies, SAH after M2 thrombectomy ranged from 0.9% to 7.7%, which was still lower than our data (15.8%). However, if the definition of SAH is restricted to the procedural angiographic findings, intraprocedural SAH was 4.8% in this study, showing similar or lower rates of SAH in other studies. In addition, the incidence of SAH in previous studies might have been under-reported because of the lack of MR imaging or follow-up CT. According to the protocol at our center, most patients with AIS who underwent MT also underwent MR imaging within 3 days after EVT. Therefore, postprocedural MR imaging was available for 184 (88.0%) of the enrolled patients. As described in Table 2, in addition, 71% of angiographically occult SAH cases were found by MR imaging, thus, a higher proportion of SAH might be attributable to the application of the GRE sequence, which offers higher sensitivity than CT alone in diagnosing SAH.

The clinical consequences of SAH differ according to the type of SAH and the co-occurrence of ICH. While isolated SAH after MT does not influence long-term clinical outcomes, the presence of diffuse SAH, including that associated with concomitant parenchymal hematoma, reduces the chances of clinical recovery. Qureshi et al showed that the rates of independent functional outcome were lower among subjects with SAH in intraparenchymal hemorrhage or other ICH but not in subjects with isolated SAH. Renú et al recently reported that the post-MT diffuse subarachnoid hyperattenuation pattern was mostly composed of blood extravasation and emerged as a biomarker of an increased risk of poor outcome and death. In line with these studies, covert SS was not associated with unfavorable outcome, whereas overt SS showed a trend toward unfavorable outcome.

The elevated SAH risk due to distal location and acute M2 angulation in the current study might be explained by several possible mechanisms: First, a more curved, distal location with thinner vessel walls causes difficulties in procedural accessibility and a higher risk of microguidewire perforation and tearing of tiny arterioles. Second, in the distally located M2 segment, because these vessels have a small normal diameter, any reduction in vessel caliber would result in greater friction and traction forces during MT than in larger proximal vessels. Third, acute M2 angulation increases friction between the vessel wall and the device, with increased vessel stretching during stent retrieval. As noted in our study, Ng et al found a trend toward postprocedural SAH occlusion in patients with extreme MCA angulation and distal device positioning. Lee et al also reported that the distal location of vessel occlusion was associated with a higher probability of SAH. The higher number of MT passes was associated with SS in this study. Previous studies have shown that a greater number of thrombectomy device passes increases the prevalence of SAH, supporting our results. This outcome may occur because additional passes of the SR cause repeat traction injury to small perforating branches or venules. In addition, multiple passes of MT necessitate repeat guidewire probing of the occluded vessel, which increases the potential for unrecognized microguidewire perforation or dissection. Microperforation may not result in overt contrast extravasation on DSA or immediate bleeding if the vessel remains occluded or if the vessel immediately develops vasospasm. Subsequent recanalization of an occluded vessel with occult microperforation or dissection may lead to delayed occult SAH.
Most interesting, there was no occurrence of SS in patients treated with CA alone as the primary MT method for M2 occlusion. In contrast, 78.8% of patients in the SS group were treated with an SR alone. Similar to our findings, Renieri et al.\textsuperscript{21} recently reported that SR and combined techniques were associated with higher rates of intraprocedural SAH. Theoretically, SRs result in more extensive endothelial injury than aspiration catheters during stent retrieval because they exert a continuous radial action against the vessel wall.\textsuperscript{22,23} Additionally, it has been suggested that an SR exerts traction forces applied to the vessel, and deformation of the adjacent anatomy causes stretching and rupture of small arterioles or venules.\textsuperscript{29} Because distal M2 branches typically have a small diameter ($\leq 2.0$ mm), a higher traction force might be required during SR thrombectomy, which increases the likelihood of stretch injury to M2 perforating arterioles, and this phenomenon might be exacerbated by the greater M2 angulation compared with a proximal and smaller M2 angulation.\textsuperscript{15,27}

In our study, although clinical consequences were different between overt and covert SS, distal M2 occlusion and acute M2 angulation were associated with both overt and covert SS. Therefore, when planning a procedural strategy, identifying these angiographic findings is important, and when performing M2 thrombectomy under these anatomic conditions, a tailored thrombectomy technique as well as delicate microguidewire navigation is required to reduce SS occurrence. This study has several limitations. First, inherent selection bias was inevitable because of the nonrandomized and retrospective study design. In particular, it is challenging to deliver a thrombectomy catheter to the face proximal to the clot, especially in the distally located or curved M2, and this issue may influence the selection of first-line MT devices. Thus, careful interpretation of the results is required. Second, the sample size may not have been large enough to show statistical differences between the subgroups of this cohort from a single center. Most important, the sample size of the SS subgroups was very small, thus hampering appropriate analysis of their association with clinical outcome variables. Additionally, the application rate of CA was low (10.0%), and the differential effect derived from the use of the device on SS was not sufficient for assessment. Third, the wide range of the study period, including the potential effect of advancements in endovascular techniques and operator skill on treatment outcomes, is another potential limitation of this study.

CONCLUSIONS

After MT for M2 occlusion, SS was not uncommon and occurred more frequently with distal M2 occlusion, superior division, acute M2 angulation, and a higher number of thrombectomy passes. The clinical course of SS was different according to the type of SS. The impact of covert SS was mostly benign and was not associated with unfavorable outcome, whereas overt SS was symptomatic.

Disclosure forms provided by the authors are available with the full text and PDF of this article at www.ajnr.org.

REFERENCES


ABSTRACT

BACKGROUND AND PURPOSE: Because stroke therapy has changed with the introduction of endovascular stroke treatment as a standard approach, studies on intrahospital causes of death from stroke are no longer up-to-date. The purpose of this observational study was to present the causes of death during hospitalization of patients with ischemic stroke who received endovascular stroke treatment, with the focus on a differentiation of curative and secondary palliative treatment.

MATERIALS AND METHODS: We studied a total cohort of 1342 patients who received endovascular stroke treatment in a tertiary stroke center (Aachen, Germany) between 2010 and 2020 and analyzed the causes of death in all 326 consecutive deceased patients. We distinguished between curative treatment and a secondary palliative approach and analyzed causes of death and treatment numbers across the years.

RESULTS: In the entire cohort of 326 deceased patients, the most common cause of death was of a cerebrovascular nature (51.5%), followed by pneumonia and sepsis (25.8%) and cardiovascular causes (8.3%). Neurovascular causes constituted 75.8% of reasons for palliation. In the group with a secondary palliative approach, causes of death were neurovascular in 54.0% of patients and pneumonia and sepsis in 26.0% of patients.

CONCLUSIONS: Cerebrovascular causes in patients with stroke play a major role in the intrahospital causes of death and reasons for palliation. Considering the large proportion of secondarily palliative-treated patients, reasons for palliation should be considered instead of causes of death to avoid concealment by, for example, life-terminating measures.

STROKE IS RANKED BY THE WORLD HEALTH ORGANIZATION AS THE SECOND LEADING CAUSE OF DEATH WORLDWIDE IN 2019 AND FORMS THE THIRD MOST COMMON CAUSE OF DEATH IN GERMANY.1,2 Feigin et al3 confirmed the increasing burden of stroke on patients globally, but especially in low-income and middle-income countries. Depending on the type of stroke and the therapy administered, the mortality in untreated patients can be as high as 80%.4

It has been shown that there is an increased risk of death in the acute phase after stroke and a long-term risk of poststroke death that is twice as high as in the healthy population.5-7 Before endovascular stroke treatment was established, various studies showed that the most common cause of death in the first 7 days was due to cerebrovascular issues, and most deaths within the first 30 days can be attributed to the initial infarction.8,9 The profile of the causes of death after ischemic stroke is reported to change with time: In the first 5 years after stroke, cardiovascular causes of death were shown to be most prominent, whereas nonvascular events accounted for most causes of death during the poststroke period of 5–10 years.10 Equally large but more recent studies are rare: D’Alton et al11 reported pneumonia as the most common cause of death in patients with both hemorrhagic and ischemic stroke; in contrast Aked et al12 reported a majority of cerebrovascular causes of death after 3 years, followed by cardiovascular deaths.

However, the standards in the treatment of patients with ischemic stroke have changed across the years, and there are few records with more recent and larger data sets that would allow an analysis of changes in causes of death resulting from the increasing use of endovascular stroke treatment. In patients with emergent, large-vessel-occlusion stroke, thrombectomy results in a better functional outcome and shows no increased mortality rates compared with intravenous thrombolysis or standard therapy only.13-15 Hence, it is equally conceivable that causes of death vary depending on...
treatment type: while thrombolytic therapies carry a risk of intracranial bleeding, endovascular stroke treatment is additionally associated with technical complications such as vascular dissection, vasospasm, embolus formation, bleeding, and device failure.\textsuperscript{16–18} The objective of this study was to determine intrahospital causes of death in patients receiving endovascular stroke treatment in a tertiary stroke center during 10 years.

**MATERIALS AND METHODS**

This study is based on a prospective registry of consecutive patients with acute ischemic stroke admitted to a tertiary stroke center of the University Hospital RWTH Aachen (Aachen, Germany). The study was approved by our local ethics committee. A need for written consent for this analysis was waived by this committee.

Our university hospital is a tertiary stroke center that serves an area of approximately 1 million inhabitants. In our regional stroke network of 4 hospitals, only 2 hospitals provide endovascular stroke therapy, with our university hospital being the only hospital that provides endovascular stroke therapy 24 hours a day and 7 days a week. Most patients eligible for endovascular stroke therapy are either directly admitted to our institution or transferred. Our standard is to continue treatment in our hospital and not to transfer patients back to their referring hospital.

We included all consecutive patients with acute ischemic stroke submitted to endovascular stroke treatment (including mechanical thrombectomy and/or intra-arterial thrombolysis, in combination or not with intravenous thrombolysis) between January 2010 and September 2020. The applied diagnostic methods and indicators for therapeutic measures used have already been described in a previous publication.\textsuperscript{19}

We collected the following variables from the prospective registry and from the patients’ clinical records when needed: demographic information, comorbidities, initial NIHSS score, ASPECTS, large-vessel occlusion site, established concept of treatment after endovascular stroke treatment, poststroke mRS, length of stay, intrahospital mortality, and causes of intrahospital death. Missing data were marked as “missing/unknown,” whenever retrospective analysis did not allow completion of data. The concept of treatment and causes of intrahospital death were retrieved from the patient’s clinical records and independently reviewed by 2 senior neurologists. Disagreements were settled in a consensus reading. We specifically focused on the spectrum of causes of death during approximately 1 decade rather than analyzing risk factors leading to death in endovascularly treated patients with stroke. We assessed baseline clinical characteristics and treatment modalities.

The established concept of clinical treatment after endovascular stroke treatment was classified into the following categories: curative care (maximal therapy during hospital stay) and secondary palliative care (palliative care decided by the treating physicians together with the patient or with the patient’s legal representatives or care partners, taking into consideration the patient’s will and expected outcome). The decision to establish a secondary palliative care concept in our institution is multidisciplinary and is always documented in the patient’s clinical record. Palliative care was performed in-hospital and based on generally accepted recommendations; patients were not transferred to external facilities for secondary palliative care.\textsuperscript{20}

Causes of death were classified into the following categories: cerebrovascular, pneumonia and/or sepsis, cardiovascular, other (eg, renal failure), and a combination of multiple causes. This classification was based on previous studies and adapted to the intrahospital setting of our study.\textsuperscript{11} For the secondary palliative care group, reasons for palliation were collected and the same categories were used.

**Statistics**

We analyzed the baseline data of the overall collective of endovascularly treated patients with stroke and compared the baseline characteristics of curative and secondary palliative care groups using \( \chi^2 \) tests or Mann-Whitney \( U \) tests as appropriate. All values are indicated as frequencies or as median with interquartile range (IQR) due to the nonparametric nature of our data. We characterized causes of death in the overall study population but also separately for the curative care group and the secondary palliative group. Additionally, we characterized reasons for establishing a secondary palliative care concept. To assess changes across time, we analyzed the causes of death and reasons for secondary palliative care during the years of the study using trend analyses for proportions. Likewise, changes of continuous baseline variables across the study period were tested using the Cuzick nonparametric test. The Wilcoxon signed-rank test was used to compare the reasons for palliation with the actual causes of death in the secondary palliative group. We also compared the extreme ends of our observation period, namely patients in 2010–2011, when we established thrombectomy as a standard of care in our department, and patients in 2019, a more recent time period.

Statistical analyses were performed with SPSS Statistics 26 (IBM) and Stata Statistical Software, Release 16.1 (StataCorp). Statistical significance was set at an \( \alpha \) value <.05.

**RESULTS**

During the study period, 2846 patients with acute ischemic stroke underwent acute reperfusion treatment, of whom 1342 received endovascular treatment and were included in our study. Among the latter, 597 patients (44.5%) received isolated mechanical thrombectomy, 722 patients (53.8%) received mechanical thrombectomy in combination with IV thrombolysis, and 23 patients (1.7%) received isolated intra-arterial thrombolysis. The distribution of treatment modalities was similar among patients who died in the curative care group and in the secondary palliative care group \((P = .840)\).

The median age of all patients was 75 years (IQR, 64–82 years); 667 patients (49.7%) were women (median NIHSS score, 16; IQR, 10–20). We focused our analysis on all 326 patients (24.3%) who died during hospitalization in our institution. Among patients who died in the hospital, a curative care concept had been pursued in 37 patients (11.3%) and a secondary palliative care concept had been established in 289 patients (88.7%). Baseline characteristics of the study population are presented in the Table. Patients who died under curative care were significantly younger (median age, 72 versus 80 years; \( P < .001 \)) than patients for whom secondary palliative care was established and had a shorter median length of stay \( (3 \text{ versus } 5 \text{ days}, P = .005) \). A detailed analysis of the time period from stroke onset to death is found in the Online Supplemental Data. In summary, cerebrovascular causes were the earliest to
cause death (median of 4 days), followed by cardiovascular, other, and a combination of causes (median of 7 days each), and pneumonia and sepsis (median of 11 days). The median onset to death was significantly shorter in the curative group compared with the secondary palliative group when the cause of death was cerebrovascular (2.5 days versus 4 days, \( P = .016 \)) or cardiovascular (2 days versus 8 days, \( P = .027 \)).

The Figure shows the causes of death and reasons for establishing a secondary palliative care concept. The most common cause of death in the entire cohort as well as in the curative and the secondary palliative care groups was cerebrovascular. However, the groups differed regarding the subsequent causes of death: In the entire cohort, most patients (51.5%; 168/326) died from cerebrovascular causes, with pneumonia and sepsis (25.8%; 84/326) being the second most frequent cause of death, whereas cardiovascular reasons (8.3%; 27/326) were less common. In the curative group, cerebrovascular deaths (32.4%; 12/37) were also the most common cause, with cardiovascular events (27.0%; 10/37) being the second most frequent cause of death, closely followed by pneumonia and sepsis (24.3%; 9/37). In the secondary palliative group, cerebrovascular deaths (54.0%; 156/289) were also the most common cause, with pneumonia and sepsis (26.0%; 75/289) being the second most frequent cause of death, whereas cardiovascular reasons (5.9%; 17/289) were markedly less frequent. The most common combination cause of death was pneumonia and sepsis and cardiovascular diseases (57%; 13/23). This was followed by the combination of cerebrovascular causes and pneumonia and sepsis (22%; 5/23). The most common combination cause of palliation was pneumonia and sepsis and cardiovascular causes (26%; 11/42), followed by pneumonia and sepsis and other causes of palliation (19%; 8/42). Causes of death differed significantly (\( P = .011 \)) between the curative and secondary palliative groups. In contrast, cerebrovascular causes (75.4%; 218/289) were the main reason to pursue secondary palliative care in most

![FIGURE. Causes of death in the overall, curative, and secondary palliative groups as well as reasons for palliation (absolute numbers and percentage). The exact reason for palliation was not determinable with sufficient certainty in 1 case.](www.ajnr.org)

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Overall Collective ((n = 1342))</th>
<th>Overall ((n = 326))</th>
<th>Secondary Palliative ((n = 289))</th>
<th>Curative ((n = 37))</th>
<th>(P) Valuea</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (median) (IQR) (yr)</td>
<td>75 (64–82)</td>
<td>80 (71–86)</td>
<td>80 (72–87)</td>
<td>72 (62–82)</td>
<td>.001b</td>
</tr>
<tr>
<td>Female sex (No.)</td>
<td>667 (49.7%)</td>
<td>163 (50.0%)</td>
<td>147 (50.9%)</td>
<td>16 (43.2%)</td>
<td>.383</td>
</tr>
<tr>
<td>Hypertension (No.) ((n = 2) missing)</td>
<td>1067 (79.5%)</td>
<td>260 (79.8%)</td>
<td>232 (80.3%)</td>
<td>28 (75.7%)</td>
<td>.427</td>
</tr>
<tr>
<td>Cardiovascular disease (No.) ((n = 4) missing)</td>
<td>657 (49%)</td>
<td>167 (51.2%)</td>
<td>146 (50.5%)</td>
<td>21 (56.8%)</td>
<td>.367</td>
</tr>
<tr>
<td>Diabetes mellitus (No.) ((n = 3) missing)</td>
<td>342 (25.5%)</td>
<td>97 (29.8%)</td>
<td>78 (27%)</td>
<td>19 (51.4%)</td>
<td>.809</td>
</tr>
<tr>
<td>Obesity (No.) ((n = 4) missing)</td>
<td>374 (27.9%)</td>
<td>78 (23.9%)</td>
<td>69 (23.9%)</td>
<td>9 (24.3%)</td>
<td>.360</td>
</tr>
<tr>
<td>Atrial fibrillation (No.) ((n = 3) missing)</td>
<td>640 (47.7%)</td>
<td>168 (51.5%)</td>
<td>153 (52.9%)</td>
<td>15 (40.5%)</td>
<td>.304</td>
</tr>
<tr>
<td>Prior stroke (No.) ((n = 2) missing)</td>
<td>255 (19%)</td>
<td>79 (24.2%)</td>
<td>72 (24.9%)</td>
<td>7 (18.9%)</td>
<td>.919</td>
</tr>
<tr>
<td>NIHSS score (median) (IQR)</td>
<td>16 (10–20)</td>
<td>18 (15–21)</td>
<td>18 (15–21)</td>
<td>20 (16–23)</td>
<td>.381</td>
</tr>
<tr>
<td>mRS at discharge (median) (IQR)</td>
<td>4 (2–5)</td>
<td>Noncalculable</td>
<td>Noncalculable</td>
<td>Noncalculable</td>
<td>NA</td>
</tr>
<tr>
<td>Length of stay (median) (IQR) (day)</td>
<td>12 (6–22)</td>
<td>5 (3–12)</td>
<td>5 (3–13)</td>
<td>3 (1–8)</td>
<td>.005b</td>
</tr>
</tbody>
</table>

Note: NA indicates noncalculable.

a Comparison of secondary palliative and curative groups.

b Statistically significant.
patients, with a combination of causes (14.5%; 42/289) being the second most frequent reason for secondary palliative care. The reason for palliation could not be specified with sufficient certainty in 1 patient.

A comparison of reasons for palliation and causes of death in the secondary palliative group showed no significant alteration (*P* = .169).

**Trends across the Study Period**

An analysis of treatment numbers during 2010–2019 shows an increase in endovascular stroke treatment, ranging from 27 (31.0%) cases in 2010 to a maximum of 210 (61.4%) cases in 2019, with isolated mechanical thrombectomy being the most frequent approach after 2016. During the study period, the median age of patients undergoing endovascular treatment increased significantly (*P* < .001) and the median NIHSS score decreased significantly in the entire cohort (*P* < .001) and in the secondary palliative group (*P* < .001). No time trend was observed for in-hospital mortality for patients who underwent endovascular treatment during the study period (*P* = .384). However, there was a higher proportion of patients receiving palliative care (*P* = .045) and a lower proportion of curative care deaths (*P* < .001) across time. Our trend analysis also revealed that the proportion of cardiovascular deaths among patients who died decreased across the study period (*P* = .026) and that specifically in the curative group, the proportion of cerebrovascular deaths (*P* = .003) and cardiovascular deaths (*P* = .002) also decreased. Detailed information on the trend analyses and comparison of 2010–2011 versus 2019 is found in the Online Supplemental Data.

**DISCUSSION**

An initial objective of our study was to identify the intrahospital causes of death in endovascularly treated patients with stroke. Our analysis shows that in patients in whom a curative approach was pursued throughout, cerebrovascular causes and cardiovascular causes, and pneumonia and sepsis were the 3 main causes of death (sorted in order). This finding is in accordance with previous studies that demonstrated that cerebrovascular causes constitute most causes of death a short time after stroke.7–10,12 This is also in accordance with previous studies that demonstrated the importance of pneumonia as a main cause of death after stroke, which usually occurs due to prolonged ventilation times or dysphagia.9,11,24 Some authors report that pneumonia may play a particular role in patients with intracranial hemorrhage, who are reported to be likely to have dysphagia and subsequent pneumonia.22,23 The high proportion of cardiovascular deaths in the curative group is rather surprising, considering that previous data revealed an increase of cardiovascular deaths only in the first months poststroke.6,7,24 Acknowledging that cardiovascular reasons are less likely in our overall cohort and in our secondary palliative group, a possible explanation for the excess of cardiovascular causes of death in the curative group may be that patients who had previously died from large-vessel stroke now survive their stroke due to endovascular treatment but might die from their concomitant cardiovascular diseases. This finding is supported by our observation that in our curative cohort, cardiovascular disease was the earliest cause of death. However, our cohort is too small to draw definite conclusions. Also, previous studies were based on data from before endovascular stroke treatment was established and mainly focused on long-term analyses of causes of death and are, therefore, difficult to compare with our study that focuses on intrahospital deaths after endovascular stroke treatment.

**Curative versus Secondary Palliative Care**

A novel finding of our analysis is that a differentiation must be made between patients receiving secondary palliative therapy and those treated with curative intent throughout because their causes of death differed considerably. Cerebrovascular causes, cardiovascular causes, and pneumonia and sepsis are the 3 main causes of death (sorted in order) in our patients, but these results must be interpreted with great caution because our results show that the reasons for death and palliation differed, albeit not significantly. Our analysis showed that because of the therapeutic switch, the causes of death of patients receiving secondary palliative care could not be equated to those of the curative group. It was interesting to compare the reasons for switching to the palliative approach with the actual causes of death. In line with the palliative concept, minimized therapeutic intervention results in a high number of pulmonary, cardiovascular, and other causes of death. At the same time, the most common reason for palliation appears to be neurovascular. Supporting data can be found in the literature indicating that withdrawal of life-sustaining treatment is the most common cause of death in ventilated patients in the intensive care unit and is primarily associated with a severe neurologic condition.25,26 On the basis of these findings, further analyses regarding case fatality and causes of death should pay attention to the large proportion of patients receiving palliative care. In accordance with Singh et al.,27 the quality of acute hospital care should not depend solely on the mortality rate, given the varying frequency of palliative concepts used.

**Trends across the Study Period**

Given a shift toward isolated mechanical thrombectomy across time as well as an increasing median age of patients and a decreasing median NIHSS score on admission, a change in causes of death with time would not have been surprising, especially with regard to the inclusion of elderly patients who are more likely to be treated with a palliative approach.28 In fact, there was a higher proportion of patients receiving palliative care across time in our cohort. Even though the overall mortality did not change with time, there was a trend toward a lower proportion of cardiovascular deaths across time. Additionally, we found a time trend for decreasing cardiovascular and cerebrovascular deaths in the curative group. Higher rates of palliation on the one hand and lower rates of cardiovascular and cerebrovascular deaths in the curative group on the other hand may be explained by the inclusion of a wider spectrum of patients across time, with older patients on the one hand and patients with less severe stroke on the other receiving endovascular stroke therapy. This trend may also be explained by imbalances in the distribution of comorbidities, vascular risk factors, and frailty status, which were not the focus of this analysis. Because subsequent increases of other causes of death do not appear to have had a significant impact in the curative group, a note of caution is due here because the number of patients in each group across the years was very small, especially within the curative cohort.
**Limitations**

The monocentric approach of our study can be seen as both an advantage and a disadvantage. Systematic bias occurs due to internal standards for inclusion of patients and implementation of therapies, such as general anesthesia for thrombectomies. On the other hand, this bias can be seen as an advantage because the same conditions and criteria apply to the therapy of all patients. Selection and attrition biases are expected to be negligible because most patients eligible for endovascular stroke therapy are admitted to our institution by the regional emergency service or transferring hospitals and only 1 patient was transferred back to their referring hospital immediately after stroke therapy due to capacity reasons. Nonetheless, even though we included a very wide spectrum of patients, the small sample size within the individual groups (especially in our trend analyses) requires a cautious interpretation of our results. Also, causes of death could not be determined in a blinded fashion because the treating clinicians and the reviewing neurologists needed to be aware of the clinical course of patients for their assessment. To develop a full picture of intrahospital mortality, causes of death, and changes due to increased use of endovascular therapy, additional studies will be needed that include additional treatment groups (eg, intravenous thrombolysis) or data of different stroke units.

**CONCLUSIONS**

The most common intrahospital causes of death in patients with acute stroke who received endovascular therapy are cerebrovascular causes, cardiovascular causes followed by pneumonia and sepsis. One of the most striking findings to emerge from this study is that a large proportion of deceased patients with stroke were treated secondarily with a palliative approach; here, the causes of death should be considered with caution because the reasons for palliation and causes of death differ, albeit not significantly. The reasons for palliation are less vulnerable to bias by life-terminating measures and criteria apply to the therapy of all patients. Selection and attrition biases are expected to be negligible because most patients eligible for endovascular stroke therapy are admitted to our institution by the regional emergency service or transferring hospitals and only 1 patient was transferred back to their referring hospital immediately after stroke therapy due to capacity reasons. Nonetheless, even though we included a very wide spectrum of patients, the small sample size within the individual groups (especially in our trend analyses) requires a cautious interpretation of our results. Also, causes of death could not be determined in a blinded fashion because the treating clinicians and the reviewing neurologists needed to be aware of the clinical course of patients for their assessment. To develop a full picture of intrahospital mortality, causes of death, and changes due to increased use of endovascular therapy, additional studies will be needed that include additional treatment groups (eg, intravenous thrombolysis) or data of different stroke units.

**Disclosure forms** provided by the authors are available with the full text and PDF of this article at www.ajnr.org.

**REFERENCES**

Endarterectomy, Stenting, or Medical Treatment for Symptomatic Carotid Near-Occlusion: Results from CAOS, a Multicenter Registry Study


ABSTRACT

BACKGROUND AND PURPOSE: The treatment of symptomatic carotid near-occlusion is controversial. Our aim was to analyze the results of carotid endarterectomy and carotid artery stent placement in patients with symptomatic carotid near-occlusion and to identify factors related to technical failure, periprocedural complications, and restenosis.

MATERIALS AND METHODS: We conducted a multicenter, prospective nonrandomized study. Patients with angiography-confirmed carotid near-occlusion were included. We assessed the revascularization rate and periprocedural stroke or death. Twenty-four-month clinical and carotid imaging follow-up was performed, and rates of carotid restenosis or occlusion, ipsilateral stroke, and mortality were analyzed. Carotid artery stent placement, carotid endarterectomy, and medical treatment were compared.

RESULTS: One hundred forty-one patients were included. Forty-four carotid artery stent placement and 23 carotid endarterectomy procedures were performed within 6 months after the event. Complete revascularization was achieved in 83.6%, 81.8% in the carotid artery stent placement group and 87% with carotid endarterectomy (P = .360). Periprocedural stroke or death occurred in 6% (carotid artery stent placement = 2.3%; carotid endarterectomy = 13%; P = .077) and was not related to revascularization failure. The carotid restenosis or occlusion rate was 8.3% (5% restenosis, 3.3% occlusion); with carotid artery stent placement it was 10.5%; and with carotid endarterectomy it was 4.5% (P = .419). The 24-month cumulative rate of ipsilateral stroke was 4.8% in the carotid artery stent placement group, 17.4% for carotid endarterectomy, and 13.1% for medical treatment (P = .223). Mortality was 12%, 4.5%, and 5.6%, respectively (P = .422). Revascularization failure and restenosis occurred more frequently in patients with full collapse compared with patients without full collapse (33.3% versus 5.6%, P = .009; 21.4% versus 2.9%, P = .032, respectively).

CONCLUSIONS: Carotid artery stent placement and carotid endarterectomy are associated with high rates of failure and periprocedural stroke. Carotid near-occlusion with full collapse appears to be associated with an increased risk of technical failure and restenosis. Carotid near-occlusion revascularization does not seem to reduce the risk of stroke at follow-up compared with medical treatment.

ABBREVIATIONS: CAS = carotid artery stent placement; CEA = carotid endarterectomy; CHS = cerebral hyperperfusion syndrome; CNO = carotid near-occlusion; IQR = interquartile range

The treatment of symptomatic carotid near-occlusion (CNO) is controversial. Post hoc analyses of the NASCET and the European Carotid Surgery Trial (ECST) conducted in the 1990s revealed that the risk of recurrent stroke could be lower in

Received March 15, 2022; accepted after revision June 17.

From the Department of Neurology [A.G.-P., A.G.-N., E.C.-R.], Hospital General Universitario Gregorio Marañón, Madrid, Spain; Department of Neurology (J.M.-R.-M.), Hospital Universitario Infanta Cristina, Badajoz, Spain; Department of Neurology (N.G.-N., J.T.), Complejo Asistencial Universitario de León, Neurology, León, Spain; Department of Neurology (F.M.), Hospital Universitario Virgen del Rocío, Sevilla, Spain; Department of Neurology (J.C.P.-C.), Hospital San Pedro Alcántara, Cáceres, Spain; Department of Neurology (P.M.-S., B.F.), Hospital Universitario La Paz, Madrid, Spain; Department of Neurology (M.A.G.-G.), Hospital Universitario Virgen Macarena, Sevilla, Spain; Department of Neurology (M.A.d.L., J.M.), Hospital Universitario Ramón y Cajal, Madrid, Spain; Department of Neurology (D.C.V.), Corporación Sanitaria Parc Taulí, Sabadell, Spain; Department of Neurology (Y.A.), Hospital Universitario de Getafe, Getafe, Spain; Department of Neurology (V.P., A.L.), Hospital Universitari La Fe, Valencia, Spain; Department of Neurology (A.M.d.A.-B.), Hospital Universitario de Donostia, Donostia, Spain; Department of Neurology (M.U.-R.), Hospital Universitario de Valladolid, Valladolid, Spain; Department of Neurology (R.D.-M.), Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; Department of Neurology (A.P.), Hospital General Universitario de Alicante, Alicante, Spain; Department of Neurology (A.X.-C.), Hospital Universitario de La Princesa, Madrid, Spain; and Department of Neurology (M.B.-I.), Hospital Universitario de Burgos, Burgos, Spain. Please address correspondence to Andrés García-Pastor, MD, Stroke Center, Vascular Neurology Section, Hospital General Universitario Gregorio Marañón, Madrid, Spain, C/Dr Esquerdo 46, 28007 Madrid, Spain; e-mail: angarpas@yahoo.es; @angarpas

http://dx.doi.org/10.374/ajnr.A7617
patients with CNO than in patients with conventional severe carotid stenosis and that patients with CNO might not benefit from revascularization. On the basis of this evidence, the latest guidelines of the European Society for Vascular Surgery do not recommend revascularization in patients with CNO. However, recent studies have reported a higher recurrence rate in patients with CNO, especially when associated with full collapse, and several meta-analyses have shown the nonsuperiority of best medical treatment over revascularization therapies.

Many case series have shown that both carotid endarterectomy (CEA) and carotid artery stent placement (CAS) are effective and safe in patients with CNO. However, most of these studies are retrospective single-center series that do not even compare the 2 techniques. To date, only 2 retrospective studies have directly compared CEA and CAS in patients with CNO with similar rates of periprocedural complications and long-term recurrences. Additionally, recent pooled analyses did not show relevant differences between CEA and CAS in both periprocedural and long-term follow-up. Unfortunately, we do not have better quality evidence because the latest clinical trials comparing CAS and CEA in the treatment of symptomatic carotid stenosis did not include patients with CNO.

The objectives of this study were to analyze the results obtained with revascularization and medical treatment in patients with symptomatic CNO, to compare periprocedural and follow-up results of CEA and CAS, and to identify factors related to technical failure, periprocedural complications, and restenosis.

MATERIALS AND METHODS

Study Design and Patient Selection

The CAOS study (in Spanish “CAsi Oclusión Sintomática”) is a nonrandomized, prospective, observational, multicenter registry study conducted in 17 Spanish university hospitals from January 2010 to May 2016. The CAOS study methodology has been described previously. The study population comprised adult patients with an angiography-confirmed diagnosis of atherosclerotic CNO and ipsilateral ischemic stroke, TIA, or retinal ischemia in the previous 6 months. This study was supported by the “Stroke Project” initiative of the Spanish Cerebrovascular Diseases Study Group and obtained ethics approval from “Comité de Ética e investigación Clínica Hospital General Universitario Gregorio Marañón,” with ID number of the approval: 122/09. Participants gave informed consent before taking part in the study.

CNO was diagnosed in all patients using DSA. On the basis of the report by Fox et al, diagnosis of ICA near-occlusion was confirmed when the angiographic findings fulfilled at least 2 of the following 4 criteria: 1) delayed cranial arrival of ICA contrast compared with the external carotid artery, 2) intracranial collaterals seen as cross-filling of contralateral vessels or ipsilateral contrast dilution, 3) frank reduced diameter of the ICA compared with the contralateral ICA, and 4) reduced ICA diameter compared with the ipsilateral external carotid artery. The presence or absence of a full collapse was determined by each participating center using DSA and/or CT angiography and defined as a “threadlike” lumen distal to the stenosis.

The treatment decision (medical therapy versus revascularization) as well as the type of revascularization treatment (CEA or CAS) was based on the criteria and routine practice of each participating center. Patients who underwent revascularization beyond 6 months were included in the medical treatment group, and their follow-up was censored at the time of the intervention.

Follow-up and Outcome Measures

The immediate result of the revascularization procedure was assessed in the CAS group by performing an angiographic control series after carotid stent implantation. In the surgical group, a non-invasive carotid imaging test (usually CT angiography or carotid sonography) was performed within 48 hours of the procedure. The result of the revascularization procedure was classified as follows: 1) complete revascularization if a complete or almost-complete recovery of the distal caliber of ICA was achieved, 2) incomplete revascularization when the distal ICA collapse persisted after the intervention, and 3) carotid occlusion when the procedure resulted in complete occlusion of the treated ICA. Revascularization failure was defined as incomplete revascularization or a complete occlusion occurring immediately after the procedure.

Carotid imaging follow-up of the near-occlusion using carotid sonography, CT angiography, and/or MR angiography was performed at 6, 12, and 24 months. Restenosis (defined as a stenosis of >50% of the treated ICA) and complete ICA occlusion rates at 24-month follow-up were collected. Any periprocedural (ie, within 30 days after the procedure) stroke or death rate and other complications were recorded. A clinical follow-up was performed at 3, 6, 12, and 24 months after the presenting event.

The 24-month ipsilateral ischemic stroke rate (including periprocedural events) and mortality were also assessed. Disabling stroke was defined as a stroke associated with a 3-month mRS score of 3–5.

Statistical Analysis

Statistical analyses were performed using the SPSS Statistics 23.0 software package for Windows (IBM). The results were expressed as proportions for categorical variables and as mean (SD) or medians and interquartile range (IQR) for continuous variables. Categorical variables were compared using the χ² test or 2-tailed Fisher exact test. Continuous variables were compared using a 2-sample t test or the Mann-Whitney test. Univariate and age- and revascularization procedure-adjusted multivariate logistic regression analyses were performed to determine factors related to revascularization failure, periprocedural stroke, or death and restenosis. The cumulative incidences were calculated using Kaplan-Meier curves. Differences among treatment groups were determined using the log-rank test. P values ≤ .05 were considered statistically significant.

RESULTS

A total of 141 patients with angiography-confirmed CNO were recruited. Most patients were men (120; 85.1%), with a mean age of 68.71 (SD, 9.05) years.

Seventy patients underwent revascularization. In 3 of them, the procedure was performed beyond 6 months, and patients were assigned to the medical treatment group. Therefore, 74 patients were included in the medical treatment group, and 67, in the revascularization group (44 CAS and 23 CEA procedures). No
significant differences were observed in the baseline characteristics among CEA, CAS, and medical treatment groups (Table 1).

The median time from the presenting event to the revascularization was 21 days (IQR, 11–43 days), 22 for CEA and 21 for CAS. Ultra-early treatment (ie, within 24 hours) was performed in 4 patients, and 28 patients (41.8%) were treated in the 15 days following the event. One patient had an ipsilateral retinal infarct while awaiting CEA.

Complete revascularization was achieved in 56 patients (83.6%). Revascularization failure was observed in 11 patients (16.4%), incomplete revascularization occurred in 8 patients, and carotid occlusion during the procedure, in 3. No significant differences in the proportion of complete revascularization or failure were observed between CAS and CEA (Table 2).

Six patients (8.9%) had a periprocedural stroke or TIA, all of them ipsilateral to the treated CNO. Three strokes or TIsAs occurred in the CAS group (6.8%, 1 disabling stroke and 2 TIsAs), and the other 3 cases, in the CEA group (13%, all of them nondisabling strokes). The rate of periprocedural stroke or death was 6% (n = 4) and tended to be higher for CEA (13% versus 2.3%, P = .077). Revascularization failure was not associated with an increased risk of periprocedural events: Only 1 patient treated with CAS had an ICA occlusion and ipsilateral disabling stroke. None of the patients died within the first 30 days following the procedure, though 1 patient treated with CAS who had a cerebral hyperperfusion syndrome (CHS) died 67 days after the procedure. Twelve other periprocedural complications were registered (Table 2). CHS was recorded in 2 cases (3%), with no differences between surgical and endovascular treatments.

Carotid imaging follow-up was performed in 60 patients. Restenosis or ICA occlusion was detected in 5 patients (8.3%). Restenosis occurred in 3 patients (5%), all of them treated with CAS. In 1 patient, restenosis was symptomatic, presenting as an ipsilateral TIA. Progression to complete ICA occlusion was observed in 2 patients (3.3%), one (4.8%) in the surgical group and another (2.3%) in the CAS group (P = .636). The patient who progressed to ICA occlusion after endovascular treatment had a disabling ipsilateral stroke (Table 2).

Revascularization failure occurred more frequently in patients with full collapse: 33.3% compared with 5.6% (P = .009). Additionally, restenosis or ICA occlusion was more frequent in patients with CNO with full collapse (21.4% versus 2.9%, P = .032). No significant relationship was observed between the presence of full collapse and the risk of periprocedural stroke or death (6.7% in CNO with full collapse and 8.3% in CNO without full collapse, P = .840) or with CHS (6.7% and 2.8%, P = .514). In the multivariate analysis, the presence of full collapse was the only factor independently related to an increased risk of revascularization failure (OR, 11.6; 95% CI, 1.6–84.6) and restenosis at follow-up (OR, 27.4; 95% CI, 1.3–567.7) (Table 3).

Fifteen patients had an ipsilateral ischemic stroke during the 24-month follow-up, resulting in a cumulative rate of 11.1% (95% CI, 5.8%–16.4%). Two ipsilateral strokes occurred in the CAS group (cumulative rate, 4.8%; 95% CI, 0%–11.3%), 4 in the surgical group (1 before CEA and 3 in the periprocedural period, cumulative rate, 17.4%; 95% CI, 1.9%–32.9%), and 9 in the medical treatment group (13.1%; 95% CI, 5.1%–21.1%; P = .223) (Figure). We recorded 6 disabling strokes: 2 in the endovascular

---

### Table 1: Baseline characteristics of the patients

<table>
<thead>
<tr>
<th></th>
<th>CEA (n = 23)</th>
<th>CAS (n = 44)</th>
<th>Medical Treatment (n = 74)</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Demographics</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age (mean) (SD) (yr)</td>
<td>68.6 (7.9)</td>
<td>68.4 (10.9)</td>
<td>69.0 (8.3)</td>
<td>.946</td>
</tr>
<tr>
<td>Age younger than 65 yr (No.) (%)</td>
<td>7 (30.4)</td>
<td>13 (29.5)</td>
<td>22 (31.1)</td>
<td>.985</td>
</tr>
<tr>
<td>Age 65–74 yr (No.) (%)</td>
<td>9 (39.1)</td>
<td>16 (36.4)</td>
<td>30 (40.5)</td>
<td>.904</td>
</tr>
<tr>
<td>Age 75 yr or older (No.) (%)</td>
<td>7 (30.4)</td>
<td>15 (34.1)</td>
<td>21 (28.4)</td>
<td>.809</td>
</tr>
<tr>
<td>Male sex (No.) (%)</td>
<td>19 (82.6)</td>
<td>39 (88.6)</td>
<td>62 (83.8)</td>
<td>.723</td>
</tr>
<tr>
<td>Risk factors</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hypertension (No.) (%)</td>
<td>15 (65.2)</td>
<td>35 (79.5)</td>
<td>51 (68.9)</td>
<td>.352</td>
</tr>
<tr>
<td>Diabetes mellitus (No.) (%)</td>
<td>10 (43.5)</td>
<td>12 (27.3)</td>
<td>29 (39.2)</td>
<td>.311</td>
</tr>
<tr>
<td>Dyslipidemia (No.) (%)</td>
<td>13 (56.5)</td>
<td>21 (47.7)</td>
<td>39 (52.7)</td>
<td>.770</td>
</tr>
<tr>
<td>Current smoker (No.) (%)</td>
<td>9 (39.1)</td>
<td>17 (38.6)</td>
<td>23 (31.1)</td>
<td>.629</td>
</tr>
<tr>
<td>Ischemic heart disease (No.) (%)</td>
<td>2 (8.7)</td>
<td>8 (18.2)</td>
<td>13 (17.6)</td>
<td>.556</td>
</tr>
<tr>
<td>Atrial fibrillation (No.) (%)</td>
<td>0</td>
<td>1 (2.3)</td>
<td>6 (8.1)</td>
<td>.180</td>
</tr>
<tr>
<td>Previous stroke/TIA (No.) (%)</td>
<td>4 (17.4)</td>
<td>11 (25)</td>
<td>20 (27)</td>
<td>.646</td>
</tr>
<tr>
<td>Peripheral artery disease (No.) (%)</td>
<td>3 (13)</td>
<td>5 (11.4)</td>
<td>5 (6.8)</td>
<td>.554</td>
</tr>
<tr>
<td>Clinical presentation</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ipsilateral ischemic stroke or retinal infarct (No.) (%)</td>
<td>17 (73.9)</td>
<td>31 (70.5)</td>
<td>47 (63.5)</td>
<td>.566</td>
</tr>
<tr>
<td>Ipsilateral transient symptoms (No.) (%)</td>
<td>6 (26.3)</td>
<td>13 (29.5)</td>
<td>27 (36.5)</td>
<td>.566</td>
</tr>
<tr>
<td>Ipsilateral recurrent events (No.) (%)</td>
<td>4 (17.4)</td>
<td>7 (15.9)</td>
<td>13 (17.6)</td>
<td>.972</td>
</tr>
<tr>
<td>Full collapse (No.) (%)</td>
<td>5 (23.8)</td>
<td>10 (33.3)</td>
<td>26 (41.3)</td>
<td>.332</td>
</tr>
</tbody>
</table>

* The history of stroke/TIA before the index event.
* The presence or absence of full collapse could be determined in 114 patients.
group (cumulative rate, 4.8%), none in the CEA group, and 4 in the medical treatment group (5.8%, \( P = .518 \)).

Ten patients died during follow-up. The 24-month cumulative mortality rate was 7.5% (95% CI, 3.0%–12.0%). Five deaths occurred in the endovascular group (12%; 95% CI, 2.2%–21.8%), 1 patient died in the CEA group (4.5%; 95% CI, 0%–13.1%), and 4, in the group of patients treated medically (5.6%; 95% CI, 0.3%–10.9%) (\( P = .422 \); Figure).

**DISCUSSION**

In the present study, a revascularization rate of 84% was obtained with no significant differences between CEA and CAS. Our revascularization results are lower than those observed in previous series with success rates well above 90%.\(^{10,11,15-17}\) However, these results come from retrospective single-center studies in which selection biases cannot be ruled out.

Traditionally, CNO revascularization has been associated with a high risk of complications. However, the NASCET and ECST studies showed similar periprocedural stroke and death rates for CNO and conventional ICA stenosis (5.4% and 6.2%, respectively),\(^2\) and a recent meta-analysis found a perioperative risk of 4.8% for CEA and 5.4% for CAS.\(^8\) The periprocedural stroke and death rate was 6% in our study and was especially high in the CEA group (13% versus 2.3%). These poor results should be viewed with caution considering the small number of patients included in each treatment group, which could be overstating some of our results. Furthermore, all 3 perioperative strokes that occurred in the CEA group were nondisabling.

The incidence of CHS after carotid revascularization ranges between 0% and 3%.\(^{22}\) However, a recent meta-analysis described a higher incidence for patients treated with CAS, reaching 4.6%.\(^{23}\) The incidence of CHS could also be higher in patients with CNO: Cay et al\(^{24}\) reported an 8.6% rate after CAS and observed a significantly higher risk among patients with full collapse (30% compared with 4.2% in CNO without full collapse). A decreased cerebral autoregulation or underlying blood-brain barrier damage has been proposed to explain this finding. In our study, CHS occurred in 3% of cases, and no differences were observed between CAS and CEA or between CNO with or without full collapse.

Restenosis or ICA occlusion at 2-year follow-up was detected in 8.3% of our patients and occurred more frequently with CAS (10.5% versus 4.5%), though the difference did not reach statistical significance. Pooled analyses found a rate of restenosis in patients with CNO that ranged between 4% and 6.4% for CEA and 4.1% and 7.5% for CAS,\(^{8,9}\) not very different from the restenosis rate of 4%–5% at 1 year for conventional ICA stenosis described in the Carotid Revascularization Endarterectomy Versus Stenting Trial (CREST).\(^{18}\) However, Kim et al\(^{17}\) observed a higher proportion of restenosis in CNO, reaching 20% for CAS and 17.4% for CEA.
Recent meta-analyses have described a long-term stroke rate below 5% in patients with CNO who undergo revascularization. The 24-month cumulative stroke rate is strikingly higher in our study, especially for CEA, reaching 17%. These results are clearly related to the high rate of periprocedural stroke observed in proportion to the small number of patients included in this treatment group. On the other hand, if we re-analyze the cumulative recurrence rate in the CEA group and consider the event that occurred before surgery as a recurrence in the medical treatment group, the cumulative rates of both groups would be similar (13.6% for CEA and 14.3% for medical treatment). In any case, our study has not been able to show clear differences in the risk of recurrent stroke at 2 years among the different treatment groups.

Full collapse has been associated with an increased risk of recurrence in medically treated patients with CNO, though this effect has not been confirmed in all studies. On the other hand, the impact of full collapse on the results of the revascularization of CNO has been less often studied. In our study, CNO with full collapse was associated with a greater

### Table 3: Factors related to revascularization failure, periprocedural stroke or death, and carotid restenosis

<table>
<thead>
<tr>
<th></th>
<th>Univariate Analysis</th>
<th>Multivariate Analysisa</th>
<th>Univariate Analysis</th>
<th>Multivariate Analysisa</th>
<th>Univariate Analysis</th>
<th>Multivariate Analysisa</th>
</tr>
</thead>
<tbody>
<tr>
<td>Revascularization Failure</td>
<td></td>
<td></td>
<td>Periprocedural Stroke or Death</td>
<td></td>
<td></td>
<td>Carotid Restenosis or Occlusion at Follow-up</td>
</tr>
<tr>
<td>Age 75 yr or older</td>
<td>1.91 (0.51–7.13)</td>
<td></td>
<td>2.15 (0.28–16.38)</td>
<td></td>
<td>3.66 (0.56–24.00)</td>
<td></td>
</tr>
<tr>
<td>Male sex</td>
<td>0.64 (0.12–3.61)</td>
<td></td>
<td>0.44 (0.04–4.72)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hypertension</td>
<td>4.00 (0.47–33.86)</td>
<td></td>
<td>1.02 (0.10–10.53)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diabetes mellitus</td>
<td>0.40 (0.08–2.03)</td>
<td></td>
<td>2.15 (0.28–16.38)</td>
<td></td>
<td>0.51 (0.05–4.94)</td>
<td></td>
</tr>
<tr>
<td>Dyslipidemia</td>
<td>0.30 (0.07–1.26)</td>
<td></td>
<td>0.97 (0.13–7.31)</td>
<td></td>
<td>1.56 (0.24–10.05)</td>
<td></td>
</tr>
<tr>
<td>Current smoker</td>
<td>0.54 (0.13–2.25)</td>
<td></td>
<td>1.63 (0.22–12.31)</td>
<td></td>
<td>1.00 (0.15–6.48)</td>
<td></td>
</tr>
<tr>
<td>Ischemic heart disease</td>
<td>2.63 (0.56–12.31)</td>
<td></td>
<td>2.00 (0.19–21.41)</td>
<td></td>
<td>1.71 (0.17–17.63)</td>
<td></td>
</tr>
<tr>
<td>Previous stroke/TIA</td>
<td>1.375 (0.32–6.00)</td>
<td></td>
<td>1.17 (0.11–12.11)</td>
<td></td>
<td>0.90 (0.09–8.78)</td>
<td></td>
</tr>
<tr>
<td>Clinical presentation as transient symptoms</td>
<td>0.37 (0.04–3.16)</td>
<td></td>
<td>1.42 (0.14–14.84)</td>
<td></td>
<td>3.41 (0.50–23.39)</td>
<td></td>
</tr>
<tr>
<td>Full collapse</td>
<td>8.50 (1.43–50.66)b</td>
<td>11.60 (1.59–84.63)c</td>
<td>0.79 (0.08–8.22)</td>
<td>9.27 (0.87–98.51)d</td>
<td>27.40 (1.32–567.74)e</td>
<td></td>
</tr>
<tr>
<td>CEA vs CAS</td>
<td>0.68 (0.16–2.84)</td>
<td></td>
<td>6.45 (0.63–65.93)</td>
<td></td>
<td>0.41 (0.04–3.87)</td>
<td></td>
</tr>
</tbody>
</table>

a Age- and revascularization procedure–adjusted multivariate logistic regression analysis.
b P = .019.
c P = .016.
d P = .065.
e P = .003.

FIGURE. Kaplan-Meier curves comparing the effect of CAS (green line), CEA (blue line), and medical treatment (black line) on the cumulative rate of ipsilateral ischemic stroke (A) and mortality (B).
probability of revascularization failure (33% versus 6%). This finding may be explained by the technical difficulties involved in fully expanding the stent in a narrow artery or in implanting a shunt in patients treated with CEA. The study by Neves et al.26 also showed a high failure rate with CAS (21%) in patients with CNO and full collapse. Other studies do not seem to confirm these findings.24,27 We also observed an increased risk of restenosis or ICA occlusion in patients with collapsed CNO. Meershoek et al.27 did not record restenosis in their 17 patients with CNO with full collapse treated with CEA, and Neves et al described 2 occlusions during follow-up in their 19 patients treated with CAS. Recently, Johansson et al.28 have described a high rate of postprocedural stroke or death in patients with CNO and full collapse (2 of 10 versus 0 of 43 in CNO without full collapse and 5 of 166 in conventional carotid stenosis). Most interesting, the 2 cases described were intracerebral hemorrhages. In our study, no association was observed between the presence of full collapse and the risk of periprocedural stroke or death.

This study has some limitations. First, this is a subanalysis of a previous study, which was not specifically designed to compare CEA, CAS, and medical treatment. Second, the sample size of the study does not have sufficient statistical power for an adequate comparison between CEA and CAS; therefore, the periprocedural stroke rate in the CEA group could have been overestimated. On the other hand, the small number of patients with CNO and full collapse may have affected the precision of the multivariate analysis. Third, patients were not randomized to medical or revascularization treatment and CEA or CAS; treatment decisions were based on the criteria of each participating center. Fourth, the study provides limited information on the technical aspects of the different treatments used. The main strength of this study is its prospective design and the use of predefined diagnostic criteria for CNO.

CONCLUSIONS

Our results suggest that revascularization of CNO is a technically challenging procedure with a high failure rate and an increased risk of periprocedural stroke and other potentially serious complications such as CHS. In addition, revascularization in patients with CNO with full collapse appears to be associated with a higher risk of technical failure and restenosis. On the other hand, CAS or CEA was not associated with a significant reduction of ipsilateral stroke at follow-up compared with medical treatment.

These findings raise new questions about the optimal management of CNO and force us to consider the risk-benefit balance between medical treatment and revascularization in this group of patients.

Future research in CNO should focus on the following:

- A better understanding of the pathophysiology and natural history of CNO
- Elucidating the impact that the presence or absence of full collapse may have in patients with CNO
- Identifying other factors associated with an increased risk of stroke

- Studies specifically designed to allow comparison between medical treatment and revascularization and between CEA and CAS.

Disclosure forms provided by the authors are available with the full text and PDF of this article at www.ajnr.org.

REFERENCES


Comparison of 30-Day Outcomes after Carotid Artery Stenting in Patients with Near-Occlusion and Severe Stenosis: A Propensity Score Matching Analysis

C. Štěchovský, K. Hulíková Tesářková, P. Hájek, M. Horváth, E. Hansvenclová, and J. Veselka

ABSTRACT

BACKGROUND AND PURPOSE: Carotid artery near-occlusion is a type of severe stenosis with complete or partial distal luminal collapse and intracranial collaterals. This study aimed to compare 30-day outcomes and 10-year survival in patients undergoing carotid artery stenting for near-occlusion with a control group of patients with severe stenosis.

MATERIALS AND METHODS: We used data from a registry of 639 patients who underwent 789 carotid artery stenting procedures between 2005 and 2021. The primary end point was any stroke or death within 30 days after carotid artery stenting. Patients were matched using propensity scores based on 6 variables.

RESULTS: Propensity score matching yielded 84 subjects in the near-occlusion group matched with 168 subjects in the control group. In the matched cohort, the primary end point occurred in 7 (8.3%) and 11 (6.6%) patients in the near-occlusion and control groups, respectively ($P = .611$). In the unmatched cohort, the primary end point occurred in 7 (8.3%) and 19 (4.1%) patients ($P = .101$). Survival in the near-occlusion group versus the control group in the matched cohort at 5 and 10 years was 69.8% (95% CI, 58.0%–78.8%) versus 77.3% (95% CI, 70.0%–83.1%) and 53.3% (95% CI, 39.9%–65.0%) versus 53.3% (95% CI, 44.5%–61.4%) (log-rank, $P = .798$).

CONCLUSIONS: Carotid stent placement in patients with ICA near-occlusion was not associated with an increased 30-day risk of stroke or death compared with severe stenosis. Survival up to 10 years after carotid artery stenting was similar in both groups.

ABBREVIATIONS: CAS = carotid artery stenting; ECA = external carotid artery; ESC = European Society of Cardiology; ESVS = European Society for Vascular Surgery

Carotid artery near-occlusion is a type of severe stenosis with complete or incomplete distal luminal collapse and intracranial collaterals. Various terms have been used to describe near-occlusion: subtotal stenosis or occlusion, functional occlusion, string sign, slim sign, critical stenosis, and others. Calculating the percentage stenosis for ICA near-occlusion according to the NASCET criteria is a fallacious approach. Near-occlusion can be confused with complete occlusion or severe stenosis when imaging with CTA or sonography is suboptimal. The multitude of terms, subtle variation in the definition, and diagnostic ambiguity lead to uncertainty about the true incidence, prognosis, and optimal treatment of ICA near-occlusion. Some early observational studies suggested that near-occlusion carries a high risk of stroke and should be promptly recognized and treated by endarterectomy. This suggestion was later negated by the re-analysis of the NASCET and the European Carotid Surgery Trial. Patients with near-occlusion were either excluded or not assessed or reported in further randomized clinical trials comparing surgery or conservative treatment of asymptomatic stenosis. Both current European and American guidelines state that there is no clear evidence that endarterectomy or carotid artery stenting (CAS) prevents stroke in patients with near-occlusion of the ICA. Another position paper admits that the prognoses of asymptomatic near-occlusion and periprocedural risks of CAS or endarterectomy are unknown. A recent meta-analysis showed that the 30-day risk of stroke or death after endarterectomy or CAS for symptomatic ICA near-occlusion was 2%.

In this study, we report 30-day outcomes after CAS in patients with ICA near-occlusion and compare them with a control group of patients with severe stenosis after CAS using a propensity score matching analysis. Additionally, we report 10-year survival after CAS.
MATERIALS AND METHODS
We retrospectively analyzed data from a single-center (Motol University Hospital) registry of 639 patients who underwent 789 CAS procedures between 2005 and 2021. Patients who had bilateral CAS or CAS for in-stent restenosis were excluded from the analysis. Some of the patients were included in previous studies.¹²⁻¹⁶

Patient Assessment, Procedure, and Follow-up
Patients were referred to carotid angiography and CAS by a neurologist, cardiologist, or vascular surgeon on the basis of Doppler sonography and/or CTA. Patient characteristics are listed in Table 1, and their medication before CAS is found in the Online Supplemental Data. After CAS, patients were examined by a physician, and all symptomatic patients were examined by a neurologist. Postprocedural CTA or MR imaging was performed to distinguish near-occlusion from conventional stenosis of the ICA in a patient who was considered eligible for CAS. Carotid stenosis was considered symptomatic if the patient had a stroke, TIA, or amaurosis fugax ipsilateral to the stenosis in the previous 6 months. All patients provided written informed consent for the procedure. Procedures were performed via the femoral artery using a 7F or 8F guiding catheter or a long 6F sheath. The antithrombotic regimen included administration of 500 mg of aspirin and 300 mg of clopidogrel before CAS in naive patients; a bolus of heparin (70 IU/kg) was administrated at the beginning of CAS. Types and manufacturers of stents and embolic protection devices were at the operator’s discretion and current availability. Detailed angiographic and procedural characteristics are listed in the Online Supplemental Data. After CAS, patients were examined by a physician, and all symptomatic patients were examined by a neurologist. Postprocedural CTA or MR imaging was performed in all cases of clinically suspected stroke. Patients were discharged with dual antiplatelet therapy for 1 month and single antiplatelet therapy and high-dose statin therapy life-long. Follow-up consisted of a history and review of medical documentation if the patient had neurologic symptoms and Doppler sonography at 1, 6, and 12 months after CAS. Information about vital status was retrieved from the National Death Index. In the deceased patients, cause of death was adjudicated as cardiovascular or noncardiovascular. The study was conducted in accordance with the Declaration of Helsinki principles.

Definitions and End Points
Patients in the registry were divided into near-occlusion and control groups. Angiographic criteria described in the NASCET were used to distinguish near-occlusion from conventional stenosis: 1) partial or complete collapse of the distal lumen (diameter of the ipsilateral distal ICA less than that of the contralateral distal ICA), 2) diameter of ipsilateral distal ICA less than that of the ipsilateral external carotid artery (ECA), 3) delayed filling of the ipsilateral distal ICA, and 4) intracranial collaterals (Fig 1). Two

Table 1: Patient characteristics

<table>
<thead>
<tr>
<th></th>
<th>Unmatched Cohort</th>
<th>Matched Cohort</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Near-Oclusion</td>
<td>Control Group</td>
<td>Near-Oclusion</td>
</tr>
<tr>
<td>(n = 84 Patients)</td>
<td>(n = 460 Patients)</td>
<td>(n = 84 Patients)</td>
<td>(n = 168 Patients)</td>
</tr>
<tr>
<td>Age (mean) (yr)</td>
<td>70.3 (SD, 9.7)</td>
<td>68.6 (SD, 8.3)</td>
<td>70.3 (SD, 9.7)</td>
</tr>
<tr>
<td>Men</td>
<td>68%</td>
<td>65%</td>
<td>68%</td>
</tr>
<tr>
<td>Current smokers</td>
<td>43%</td>
<td>40%</td>
<td>43%</td>
</tr>
<tr>
<td>Arterial hypertension</td>
<td>88%</td>
<td>88%</td>
<td>88%</td>
</tr>
<tr>
<td>Total plasma cholesterol level (mean) (mmol/L)</td>
<td>4.4 (SD, 1.1)</td>
<td>4.2 (SD, 1.0)</td>
<td>3.26</td>
</tr>
<tr>
<td>LDL cholesterol level (mean) (mmol/L)</td>
<td>2.6 (SD, 0.9)</td>
<td>2.4 (SD, 0.8)</td>
<td>.371</td>
</tr>
<tr>
<td>HDL cholesterol level (mean) (mmol/L)</td>
<td>1.06 (SD, 0.3)</td>
<td>1.09 (SD, 0.3)</td>
<td>.695</td>
</tr>
<tr>
<td>Plasma triglyceride level (mean) (mmol/L)</td>
<td>1.93 (SD, 1.2)</td>
<td>1.8 (SD, 1.1)</td>
<td>.638</td>
</tr>
<tr>
<td>CRP level (median) (IQR) (mg/L)</td>
<td>3.6 (1.1–8.6)</td>
<td>2.3 (0.8–5.5)</td>
<td>.008</td>
</tr>
<tr>
<td>Body mass index (mean)</td>
<td>28.6 (SD, 4.8)</td>
<td>28.1 (SD, 4.4)</td>
<td>.483</td>
</tr>
<tr>
<td>Diabetes</td>
<td>33%</td>
<td>42%</td>
<td>33%</td>
</tr>
<tr>
<td>Chronic kidney disease</td>
<td>27%</td>
<td>22%</td>
<td>27%</td>
</tr>
<tr>
<td>Chronic bronchopulmonary disease</td>
<td>14%</td>
<td>13%</td>
<td>14%</td>
</tr>
<tr>
<td>Peripheral arterial disease</td>
<td>32%</td>
<td>39%</td>
<td>32%</td>
</tr>
<tr>
<td>Heart failure with reduced ejection fraction</td>
<td>15%</td>
<td>11%</td>
<td>15%</td>
</tr>
<tr>
<td>Previous coronary artery bypass</td>
<td>20%</td>
<td>18%</td>
<td>20%</td>
</tr>
<tr>
<td>Need for heart surgery within 30 days</td>
<td>5%</td>
<td>9%</td>
<td>5%</td>
</tr>
<tr>
<td>Previous myocardial infarction</td>
<td>24%</td>
<td>28%</td>
<td>24%</td>
</tr>
<tr>
<td>Previous percutaneous coronary artery intervention</td>
<td>23%</td>
<td>32%</td>
<td>23%</td>
</tr>
<tr>
<td>Known multivessel coronary artery disease</td>
<td>39%</td>
<td>40%</td>
<td>39%</td>
</tr>
<tr>
<td>Previous stroke</td>
<td>37%</td>
<td>30%</td>
<td>37%</td>
</tr>
<tr>
<td>Ipsilateral cerebral ischemic symptoms in the past month</td>
<td>37%</td>
<td>21%</td>
<td>.003</td>
</tr>
<tr>
<td>Ipsilateral cerebral ischemic symptoms in the past 6 months (ie, symptomatic stenosis)</td>
<td>45%</td>
<td>29%</td>
<td>.005</td>
</tr>
<tr>
<td>Patients with ≥1 risk factors for endarterectomya</td>
<td>82%</td>
<td>80%</td>
<td>.766</td>
</tr>
</tbody>
</table>

Note: IQR indicates interquartile range; CRP, C-reactive protein.

*a One of the following: left ventricle ejection fraction of ≤40%, chronic bronchopulmonary disease, prior myocardial infarction, coronary artery bypass grafts, or age 75 years or older.
of the 4 criteria were required for the diagnosis. In patients without acute neurologic symptomatology, intracranial collaterals must always be present in the near-occlusion. The primary end point consisted of any stroke or death within 30 days after CAS. Ischemic stroke was defined as an acute neurologic event with focal symptoms, lasting for $24$ hours. Minor stroke was defined as a new neurologic deficit that resolved within 30 days without any limiting disability ($\leq 1$ on the mRS) or return to baseline status. Major stroke was defined as a new neurologic deficit with persisting disability ($\geq 2$ on mRS). TIA was defined as an episode of new neurologic dysfunction attributed to focal cerebral ischemia, with resolution within 24 hours.

**Statistical Analysis**

Statistical analyses were performed using SAS software, Version 9.4 (SAS Institute). Data are presented as means (SD) or median and interquartile range or counts and proportions. The Student $t$ test or Mann-Whitney $U$ test was used to evaluate the difference among continuous variables, and the Fisher exact test was used for the evaluation among categoric variables. Kaplan-Meier survival analysis was used to estimate long-term survival in patients after CAS with 95% confidence intervals. Given the inherent differences between patients with near-occlusion and the control group, using the logit model, we calculated propensity scores for the following variables as covariates: age, sex, total plasma cholesterol, diabetes, previous percutaneous coronary intervention, and ipsilateral cerebral ischemic symptoms in the past 6 months. Other potential covariates were confirmed as nonsignificant or highly correlated to other variables. Matching on the propensity scores was performed using the 1:2 nearest neighbor method without replacement. A 2-sided $P$ value $\leq .05$ was considered to indicate statistical significance.

**RESULTS**

A total of 544 patients were analyzed, 84 (15%) in the near-occlusion group and 460 (85%) in the control group. Propensity score matching yielded 84 subjects in the near-occlusion group matched with 168 subjects in the control group (Table 1 and Online Supplemental Data). Patients in the unmatched cohort with near-occlusion had symptomatic stenosis significantly more often, higher median C-reactive protein levels, used less statin therapy, had longer fluoroscopic times, and more often required predilation ($P < .05$ for all) (Table 1 and Online Supplemental Data). After matching, patients with near-occlusion had significantly higher median C-reactive protein levels and longer fluoroscopy time and more often required predilation ($P < .05$ for all) (Table 1 and Online Supplemental Data).

Data on major adverse in-hospital and 30-day events were available in 544 (100%) and 527 (97%) patients, respectively. Vital status at the end of the follow-up was available in all patients from the National Death Index. In the unmatched cohort, the primary end point occurred in 7 (8.3%) patients in the near-occlusion group and 19 (4.1%) patients in the control group ($P = .101$) and in the matched cohort in 7 (8.3%) and 11 (6.6%) patients ($P = .611$). Individual components of the end point are summarized in Table 2. In the matched subgroup of symptomatic patients, the primary end

**FIG 1.** An angiogram in a patient with right ICA near-occlusion. A, In a selective angiogram of the left carotid artery, no stenosis is present; the diameter of the ICA is larger than that of the ECA; and there is rapid filling of the intracranial circulation and intracranial collaterals to the right ACA and MCA. B, Near-occlusion of the right ICA. The diameter of the distal ICA (thick arrow) is smaller than that of the ECA (thin arrow) and much smaller than that of the contralateral ICA. Late filling of the distal ICA. C, In the late phase of the angiogram, the contrast filling stops at the level of carotid siphon (thick arrow). The intracranial circulation is not visualized because the contrast is diluted by collateral flow. ACA indicates anterior cerebral artery.
point occurred in 4 (10.5%) patients in the near-occlusion group and 7 (9%) patients in the control group ($P = .748$). In the asymptomatic patients, the primary end point occurred in 3 (6.3%) patients in the near-occlusion group and 4 (4.4%) patients in the control group ($P = .473$). The results for the symptomatic and asymptomatic patients are summarized in the Online Supplemental Data.

In the unmatched cohort, the mean follow-up was 5.9 (SD, 4.1) years in the near-occlusion group and 6.5 (SD, 4.1) years in the control group, which yielded 499 and 2980 patient-years of follow-up. Thirty-three (39.3%) patients in the near-occlusion group and 202 (43.9%) patients in the control group died ($P = .473$), which translated into 6.6 and 6.8 deaths per 100 patient-years, respectively. In the matched cohort, the mean follow-up was 5.9 (SD, 4.1) years in the near-occlusion group and 7.0 (SD, 4.2) years in the control group, which yielded 499 and 1176 patient-years of follow-up. In the matched cohort, 33 (39.3%) patients in the near-occlusion group and 76 (45.2%) patients in the control group died ($P = .419$), which translated into 6.6 and 6.5 deaths per 100 patient-years, respectively. In the matched cohort, survival in the near-occlusion group versus the control group at 5 and 10 years was 69.8% (95% CI, 58.0%–78.8%) versus 77.3% (95% CI, 70.0%–83.1%) and 53.3% (95% CI, 39.9%–65.0%) versus 53.3% (95% CI, 44.5%–61.4%) (log-rank, $P = .798$) (Fig 2A). In the unmatched cohort, survival at 5 and 10 years was similar (log-rank, $P = .965$) (Fig 2B).

During the follow-up, 9 (10.7%) patients and 19 (4.1%) patients underwent re-intervention for in-stent restenosis in the near-occlusion and control groups, respectively ($P = .026$) (Fig 3A). After matching, the difference was still statistically significant, 10.7% versus 3.6% ($P = .044$) (Fig 3B).

**DISCUSSION**

Results of our observational study suggest that patients with near-occlusion had a higher incidence of stroke or death within 30 days after CAS (8.3%) and high annual mortality (6.7%). However, the risk was not significantly different from that of severe stenosis after the adjustment using the propensity score matching. Although we observed a trend toward higher periprocedural risk in the near-occlusion group, which was numerically 2-fold, it did not reach statistical significance. The difference in the primary end points was even smaller after the adjustment. We believe that this difference is due to the higher proportion of symptomatic patients in the near-occlusion group. However, it could be related to the number of patients in the registry and confounders. The NASCET and European Carotid Surgery Trial included 262 cases of near-occlusion. The risk of periprocedural stroke and death was similar in near-occlusion (5.4%) and 70%–99% stenosis (6.2%), and lower periprocedural risks have been reported since then. Later, trials comparing endarterectomy and CAS either excluded patients with near-occlusion or did not assess near-occlusion. The real-world registry might provide valuable information about the early risk of CAS for near-occlusion in a population of patients with high cardiovascular comorbidity that is not typically represented in randomized trials. Given the differences in the population
of patients with near-occlusion and conventional severe stenosis and a most notably higher incidence of symptomatic stenosis in the near-occlusion group, we decided to compare the groups with the propensity score matching analysis to balance the baseline characteristics in both groups and lower the risk of selection bias.

The high periprocedural risk of stroke in ICA near-occlusion might be explained by the slow flow of blood distal to the lesion, which promotes in situ thrombosis that is embolized during CAS or protrudes through the stent struts and embolizes in the early postprocedural period. Angiography might not be able to distinguish ruptured atherosclerotic plaque with mural thrombus or mural thrombus in the distal ICA. Some cases of near-occlusion are actually recanalized thrombotic occlusions. Indeed, Hirata et al20 reported that those old, organized thrombi were more frequently found in the endarterectomy specimens from near-occlusions than in high-grade stenoses. In our study, the 30-day stroke or death rate in the near-occlusion group (8.3%) was higher than that in a recent meta-analysis of some 703 patients with near-occlusion (226 underwent CAS; the 30-day stroke or death rate was 2.2%).11 Individual observational studies included in the meta-analysis reported a 30-day stroke or death rate after CAS between 0% and 7%.21-25 These studies had only 1 arm and did not compare the risk of CAS for near-occlusion with that in a control group. The high variability in the reported periprocedural risks might reflect different baseline characteristics and selection of patients rather than procedural techniques. It is also possible that the periprocedural stroke and death risk reported in the meta-analysis by Meershoek et al11 underestimated the true risk because of bias in the reporting of small observational studies with unfavorable results.

The high all-cause mortality rate in our study is in contrast to the much lower mortality in the long-term follow-up of a recent, large, randomized Second Asymptomatic Carotid Surgery Trial (ACST-2: 330 deaths in 1811 patients randomized to CAS with a mean follow-up of 5 years and an annual mortality of \( \approx 3.6\% \)).26 On the other hand, a study that analyzed data from Medicare

FIG 2. Kaplan-Meier estimate of 10-year survival after carotid stent placement in the near-occlusion-versus-control groups in the matched (A) and unmatched (B) cohorts.

FIG 3. Kaplan-Meier estimate of freedom from re-intervention for in-stent restenosis after carotid stent placement in the near-occlusion-versus-control groups in the unmatched (A) and matched (B) cohorts.
beneficiaries treated with CAS reported a mortality rate of 8.0% per year after the periprocedural period.27 This study included older patients than in our registry, but other baseline characteristics were similar, with high cardiovascular comorbidity. These differences indicate that clinical trials enroll populations different from high-risk patients in whom the investigated technique is used in clinical practice.

We should carefully consider performing CAS in a patient with ICA near-occlusion, given the substantial periprocedural risk and life expectancy that might be shorter than 5 years reported by the European Society of Cardiology (ESC) and the European Society for Vascular Surgery (ESVS).28 Meershoek et al29 suggested that although the initial approach to symptomatic near-occlusion with full distal luminal collapse should be conservative, patients with recurrent events may be treated with endarterectomy. There is a need for further studies that could be based on large registries like the mandatory German Carotid National Registry.30 We believe that the treatment of patients with ICA near-occlusion is one of the important topics in the field of carotid interventions that will require continued research before more evidence-based recommendations can be made.

The study is not without limitations. First, data were collected from a single center for 16 years. Although operators and procedural techniques remained unchanged, protection devices and stents changed across time. Referral of patients for carotid angiography and the criteria for selection of patients who would benefit from CAS changed during that time, with updated ESC/ESVS guidelines and results of randomized controlled trials.26,28 The proportion of patients with near-occlusion and conventional stenosis who were selected for CAS compared with endarterectomy or medical therapy is unknown. Our results cannot be generalized to all patients with ICA near-occlusion. Second, propensity score matching is associated with inherent limitations. Although the matched cohort might seem well-balanced for baseline characteristics, there is always a risk of confounding bias. Third, we did not systematically collect data on major adverse cardiovascular events beyond the 30-day period after CAS; therefore, we reported only data on long-term survival.

CONCLUSIONS
Carotid stent placement in patients with ICA near-occlusion was not associated with an increased 30-day risk of stroke or death compared with severe stenosis. Survival up to 10 years after CAS was similar in both groups.

Disclosure forms provided by the authors are available with the full text and PDF of this article at www.ajnr.org.

REFERENCES


Clinical Validation and Extension of an Automated, Deep Learning–Based Algorithm for Quantitative Sinus CT Analysis


ABSTRACT

BACKGROUND AND PURPOSE: Sinus CT is critically important for the diagnosis of chronic rhinosinusitis. While CT is sensitive for detecting mucosal disease, automated methods for objective quantification of sinus opacification are lacking. We describe new measurements and further clinical validation of automated CT analysis using a convolutional neural network in a chronic rhinosinusitis population. This technology produces volumetric segmentations that permit calculation of percentage sinus opacification, mean Hounsfield units of opacities, and percentage of osteitis.

MATERIALS AND METHODS: Demographic and clinical data were collected retrospectively from adult patients with chronic rhinosinusitis, including serum eosinophil count, Lund-Kennedy endoscopic scores, and the SinoNasal Outcomes Test-22. CT scans were scored using the Lund-Mackay score and the Global Osteitis Scoring Scale. CT images were automatically segmented and analyzed for percentage opacification, mean Hounsfield unit of opacities, and percentage osteitis. These readouts were correlated with visual scoring methods and with disease parameters using the Spearman ρ.

RESULTS: Eighty-eight subjects were included. The algorithm successfully segmented 100% of scans and calculated features in a diverse population with CT images obtained on different scanners. A strong correlation existed between percentage opacification and the Lund-Mackay score (ρ = 0.85, P < .001). Both percentage opacification and the Lund-Mackay score exhibited moderate correlations with the Lund-Kennedy score (ρ = 0.58, P < .001, and ρ = 0.58, P < .001, respectively). The percentage osteitis correlated moderately with the Global Osteitis Scoring Scale (ρ = 0.48, P < .001).

CONCLUSIONS: Our quantitative processing of sinus CT images provides objective measures that correspond well to established visual scoring methods. While automation is a clear benefit here, validation may be needed in a prospective, multi-institutional setting.

ABBREVIATIONS: AI = artificial intelligence; CRS = chronic rhinosinusitis; CNN = convolutional neural network; GOSS = Global Osteitis Scoring Scale; LKS = Lund-Kennedy score; LMS = Lund-Mackay score; mHU = mean Hounsfield Units; %OST = percentage of osteitis; %SO = percentage sinus opacification; SNOT-22 = SinoNasal Outcomes Test-22

CT provides invaluable visualization of sinus anatomy and plays an essential role in the work-up of chronic rhinosinusitis (CRS), with an estimated 713,482 scans ordered in 2010 by otolaryngologists alone.1 The presence of sinus inflammation on CT is an objective diagnostic criterion for CRS.2–4 While CT has been used for objective sinus evaluation for decades, visual assessment of images is limited by variable interpretations, and results are generally reported in nonstandard or imprecise terms, which may or may not carry particular clinical significance.5 There exists a clear need for efficient, quantitative assessment of the degree of paranasal sinus inflammation on CT. Detailed, reproducible, and objective reports could be extremely valuable in...
clinical and research settings if performed in a simple, automated, and universal fashion.

Our group has developed a novel approach that uses deep learning, a form of artificial intelligence (AI) whereby a computer algorithm may “learn” to recognize image patterns in exemplar data.6,7 Using a convolutional neural network (CNN), one of the primary information-processing models of deep learning, this fully automated system produces precise 3D segmentations of the individual paranasal sinuses and allows quantitation of sinus cavity opacification (Fig 1). Initial validation of this approach was recently published, examining all comers presenting for multidisciplinary airway evaluation at a single tertiary care respiratory institution, and demonstrated very good correlation of the algorithm to the existing criterion standard visual scoring system, the Lund-Mackay score (LMS). However, certain outcome measures were not universally available in that cohort, such as surgical status, disease-specific quality-of-life indices, and endoscopic scores, and images were obtained from only 2 scanners at a single institution.

The objectives of the current investigation expand the initial study in a number of ways. Here, we aimed to test a refinement of the initial algorithm, now capable of segmenting separate sinus cavities, in a strict CRS cohort with an extended set of disease-specific outcomes. Furthermore, segmentation and analysis were applied to images obtained from a variety of scanners and protocols commonly used in clinical practice to ascertain real-world applicability. Finally, we introduced and performed initial clinical validation of algorithmic characterization of 2 potentially important radiologic biomarkers in CRS, sinus osteitis and opacification density.

**MATERIALS AND METHODS**

**Study Population**

Subjects were enrolled from an institutional review board-approved (Colorado Multi-Institutional Review Board No. 14–0269) prospective cohort of patients undergoing rhinologic surgery at the University of Colorado Hospital from 2012 to 2018. Subjects who met the diagnostic criteria for CRS were included in the present study when all the following were available: thin cut (<1.25 mm) sinus CT images, serum eosinophil count within 6 months of surgery, and corresponding surgical pathology specimens stored at the University of Colorado Biorepository. Demographic and clinical data from these subjects were prospectively collected, including preoperative SinoNasal Outcomes Test 22 (SNOT-22) and the Lund-Kennedy score (LKS), performed and documented on the day of surgery by the senior surgeon (V.R.R.).

**CT Image Acquisition and Quantitative Analysis**

Subjects underwent sinus CT at the University of Colorado Hospital system as well as a number of different institutions in the metropolitan Denver area and beyond, with scans being performed on machines from various manufacturers. Scans were generally completed within 6 months before the date of surgery. Patients with scans obtained using in-office conebeam CT were excluded due to the substantial differences in image characteristics compared with traditional CT and the lack of pixel-intensity standardization to the Hounsfield unit scale. All CT examinations were downloaded from the PACS at the University of Colorado Hospital, de-identified, and then electronically transferred to the Quantitative Imaging Laboratory at National Jewish Health for analysis.

An initial CNN was developed, trained, tested, and validated as previously described.6 Details regarding the development of the current CNN are described in the Online Supplemental Data. The resulting algorithm was used to perform all quantitative analyses on the transferred scans using an Intel Core i9 7980XE CPU, Dual NVIDIA GeForce GTX 1080Ti GPUs, and 64GB RAM. The algorithm segments each sinus cavity individually, combining left and right sides except for the maxillary sinuses, which are segmented separately. A visual, qualitative assessment was performed on each segmentation produced by the algorithm to grossly check for accuracy.

Percentage sinus opacification (%SO) is determined by calculating the percentage of each segmentation cavity volume occupied by CT pixels ranging from -500 to +200 HU, a range corresponding to soft-tissue density; the individual cavity percentage volume opacifications were then averaged to control the effects of volume as follows:

\[
\%SO = \frac{\text{[Left Maxillary] + [Right Maxillary] + [Anterior Ethmoid] + [Posterior Ethmoid] + [Frontal] + [Sphenoid]}}{6}
\]

We used an averaged sinus volume to calculate %SO as opposed to an overall total opacification percentage, given that the LMS does not factor in cavity size into its scoring system.

mHU is the mean Hounsfield unit value of the opacified regions within the total segmentation cavity, and it was applied to investigate soft-tissue hyperdensity that may be indicative of eosinophilic processes.\(^8\) The algorithm was also used to assess osteitis by generation of a 7-mm “ring” around the sinus cavity (Fig 2). This was achieved through dilation of the segmented sinus cavities by 5 mm, with subsequent subtraction of a copy of the sinus cavity.
segmentation that had been eroded by 2 mm. The percentage of this space occupied by bone (corresponding to a Hounsfield unit of $150$) was used to calculate the percentage of osteitis (%OST). Additional details, including a schematic of the image-processing operations used to achieve %OST, are found in the Online Supplemental Data. This operation works to capture any bony expansion of the sinus cavity that one would expect in osteitic disease states.10

Visual Scoring

Lund-Mackay scoring was performed by 2 independent scorers (C.J.M., V.R.R.). Any difference of $>1$ between scores was resolved by consensus between the 2 parties. Scores differing by 1 point were averaged. If consensus was not achieved, a third party would decide the score (L.R.). Osteitis was assessed using the Global Osteitis Scoring Scale (GOSS).10 Scoring was also performed by 2 independent assessors (C.J.M., L.R.). A difference of $>2$ between scores was resolved in a similar fashion to that of the LMS with a third-party evaluator (V.R.R.). Scores differing by $\leq 2$ points were averaged. All scorers had considerable experience interpreting sinus CT as senior rhinology faculty (V.R.R.) or otolaryngology resident physicians (C.J.M., L.R.).

Quantification of Tissue Eosinophilia

H&E-stained sections of sinus mucosa from surgical pathology specimens were retrieved from the University of Colorado Biorepository. Tissue eosinophil counts were performed as previously described, blinded to patient metadata and CT.11 Counts were performed in areas of densest cellular infiltrate to consistently determine eosinophil levels on the basis of areas of high inflammation. The absolute number of eosinophils per high-power field was recorded. This process was repeated in triplicate for each specimen, and the counts were averaged.

Statistical Analysis

Descriptive statistics on the study population were generated and reviewed. Univariate associations between algorithm-generated readouts, eg, %SO and %OST, and various clinical parameters were analyzed with the Spearman rank correlation. All statistical calculations and data visualization were performed in R, Version 3.6.0 (April 16, 2019; http://www.r-project.org/).

RESULTS

Study Population

Eighty-eight subjects met the inclusion criteria (Fig 3). Demographic data are summarized in Table 1. The mean age was 48.5 years, and 59% of subjects were women. Sixty-seven percent of subjects had a diagnosis of CRS with nasal polyps; 60% had comorbid asthma. Fifty-five percent of subjects reported a history of prior sinus surgery; validation of algorithmic performance in postsurgical patients has been previously performed.6 SNOT-22 and LKSs were incomplete or missing in 7 and 4 subjects, respectively.

Quantitative Percentage Opacification and Correlation with LMS

The CNN-based algorithm successfully segmented all 88 scans, which were acquired on scanners from 4 different manufacturers using 10 different reconstruction kernels (Table 2). The study population average %SO was 60.1% (range, 20.7%–99.6%). %SO

Table 1: Demographics of the study population

<table>
<thead>
<tr>
<th>Cohort Features</th>
<th>n = 88 (% or range)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Female (%)</td>
<td>52 (59)</td>
</tr>
<tr>
<td>Avg. age (yr)</td>
<td>48.5 (22–78)</td>
</tr>
<tr>
<td>White (%)</td>
<td>70 (80)</td>
</tr>
<tr>
<td>Polyps (%)</td>
<td>59 (67)</td>
</tr>
<tr>
<td>Asthma (%)</td>
<td>53 (60)</td>
</tr>
<tr>
<td>AERD (%)</td>
<td>8 (9)</td>
</tr>
<tr>
<td>Never smoker (%)</td>
<td>55 (62)</td>
</tr>
<tr>
<td>Prior surgery (%)</td>
<td>48 (55)</td>
</tr>
<tr>
<td>Avg. absolute serum eosinophils $\times 10^9$/L</td>
<td>0.31 (0–2.6)</td>
</tr>
<tr>
<td>Avg. tissue eosinophils per HPF</td>
<td>80 (0–413)</td>
</tr>
<tr>
<td>Avg. SNOT-22</td>
<td>49.6 (15–95)</td>
</tr>
<tr>
<td>Avg. LKS</td>
<td>6.8 (1–12)</td>
</tr>
<tr>
<td>Avg. LMS</td>
<td>13.5 (2–24)</td>
</tr>
<tr>
<td>Avg. GOSS</td>
<td>2.7 (0–35)</td>
</tr>
<tr>
<td>Avg. sinus cavity volume (mL)</td>
<td>60.8 (24.8–109.0)</td>
</tr>
<tr>
<td>Avg. %SO</td>
<td>60.1 (20.7–99.6)</td>
</tr>
<tr>
<td>Avg. mHU</td>
<td>10.5 (–139.2 to +57.4)</td>
</tr>
<tr>
<td>Avg. %OST</td>
<td>41.4 (32.1–52.2)</td>
</tr>
</tbody>
</table>

Note—AERD indicates aspirin-exacerbated respiratory disease; HPF, high-power field; Avg., average.
Table 2: CT scanner metrics and acquisition protocols used for the included scans

<table>
<thead>
<tr>
<th>Model (No.)</th>
<th>Reconstruction Kernel (No.)</th>
<th>Tube Potential (No.)</th>
<th>Tube Current (No.)</th>
<th>Pitch (No.)</th>
<th>Axial Section Thickness (No.)</th>
<th>Axial Section Spacing (No.)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Siemens (n = 77)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sensation 64 (42)</td>
<td>H3s (2)</td>
<td>100 kVp (2)</td>
<td>Modulated (22)</td>
<td>0.7 (43)</td>
<td>1.0 mm (77)</td>
<td>0.6 mm (2)</td>
</tr>
<tr>
<td>Definition (4)</td>
<td>H60f (2)</td>
<td>120 kVp (75)</td>
<td>91 mA (41)</td>
<td>0.8 (19)</td>
<td>0.9 mm (63)</td>
<td>1.0 mm (12)</td>
</tr>
<tr>
<td>Definition A5 (3)</td>
<td>H60s (1)</td>
<td>100 mA (8)</td>
<td>0.9 (4)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Definition A5+ (4)</td>
<td>H70h (54)</td>
<td>108 mA (6)</td>
<td>1.0 (1)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Definition Flash (18)</td>
<td>J40s\2 (1)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Biograph 40 (6)</td>
<td>J70h\2 (17)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>GE Healthcare (n = 5)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>LightSpeed Pro 16 (1)</td>
<td>Bone (5)</td>
<td>120 kVp (5)</td>
<td>110 mA (1)</td>
<td>0.50–0.75 (2)</td>
<td>0.625 mm (3)</td>
<td>0.625 mm (3)</td>
</tr>
<tr>
<td>LightSpeed VCT (1)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Optima CT540 (2)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Optima CT660 (1)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Philips Healthcare (n = 4)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Brilliance 64 (4)</td>
<td>YC (3)</td>
<td>120 kVp (4)</td>
<td>85 mA (1)</td>
<td>1.0 (4)</td>
<td>1.0 mm (4)</td>
<td>0.8 mm (1)</td>
</tr>
<tr>
<td></td>
<td>YD (1)</td>
<td></td>
<td>119 mA (2)</td>
<td></td>
<td>0.9 mm (3)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Toshiba/Canon (n = 2)</td>
<td>FC30 (2)</td>
<td>120 kVp (2)</td>
<td>150 mA (1)</td>
<td>1.0 (2)</td>
<td>1.0 mm (2)</td>
<td>0.8 mm (1)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>200 mA (1)</td>
<td></td>
<td></td>
<td>1.0 mm (1)</td>
</tr>
</tbody>
</table>

FIG 4. Scatterplot demonstrating algorithm-generated %SO versus LMS. The gray shaded area represents a 95% confidence interval for the regression line ($\rho = 0.85, P < .001$). The intraclass correlation coefficient between LMS scorers demonstrated strong agreement ($\rho = 0.92, P < .001$).

FIG 5. Algorithm-derived %OST versus total GOSS as stratified by surgical status. Overall $\rho = 0.48 (P < .05)$. For surgically naïve patients, $\rho = 0.29 (P = .08)$, and for postoperative subjects, $\rho = 0.59 (P < .001)$.

**Osteitis Quantitation and Correlation with GOSS**

The overall average percentage of pixels corresponding to bone contained within the 7-mm segmentation rind (%OST) was 41% (range, 32%–52%). %OST exhibited a moderate-but-significant correlation with GOSS ($\rho = 0.48, P < .001$). The surgical status impacted correlation, with a weaker correlation demonstrated in the surgically naïve patients compared with patients with prior surgery, as shown in Fig 5. Linear regression was used to assess the impact of sinus cavity volume on the interaction between GOSS and %OST ($R^2 = 0.20$, and 0.24 when adjusted for volume). The intraclass correlation coefficient between GOSS scorers demonstrated strong agreement ($\rho = 0.83, P < .001$).

**Associations between Algorithm-Derived Readouts and Clinical Parameters (LKS, SNOT-22, Tissue and Serum Eosinophil Levels)**

Moderate associations were seen between algorithm-derived readouts (%SO, mHU) and endoscopic LKS. Weak associations were seen between algorithm-derived readouts and tissue eosinophil levels. Weak correlations were seen across the board with serum eosinophil counts, though statistical significance for mHU was not reached. No correlation was seen between CT-derived measures and SNOT-22. Associations between LMS and clinical parameters were similar to algorithm-generated associations and are presented in Table 3.

Correlation between clinical parameters and percentage sinus opacification was also performed and is shown in Table 4. In general, stronger correlations were seen in the anterior and posterior ethmoid cavities for LKS, absolute serum eosinophil counts, and tissue eosinophil counts. These correlations illustrate that the
bulk of the correlation strength seen in overall %SO is carried by these cavities.

**DISCUSSION**

Objective quantification of sinus mucosal disease is important for several reasons. From a clinical perspective, detailed quantification would allow a more nuanced understanding of inflammatory burden and response to therapy. For researchers, quantification systems are frequently used to objectively compare disease burden among different patients in cross-sectional analysis or longitudinally within-subject to document the efficacy of therapeutic interventions. Current objective CT scoring measures may not allow a more nuanced understanding of inflammatory severity involving visual estimation of sinus opacification and grading with standardized scoring systems. While dozens of such scoring systems exist, the most widely accepted method used today is the LMS. While the LMS has demonstrated good interrater reliability and relative ease of use, a drawback of the LMS is that a score of 1 for a given cavity encompasses 99% of the radiologic disease spectrum, under which most sinus cavities will likely be classified. In other words, the LMS can distinguish those without disease and those with the most severe disease but has poor discrimination among patients with mild-to-moderate levels of disease for a given sinus cavity. Furthermore, the importance of ostiomeatal complex opacification has been reconsidered, and given the potential subjectivity of the 0-versus-2 score, it is not clear whether this measure is truly meaningful.

Several groups have recognized this shortcoming and have sought to improve the LMS using computer-assisted volumetric analysis of sinus opacification. These methods aim to calculate the percentage of sinus cavity occupied by soft-tissue density, allowing characterization of mucosal inflammation on a continuous scale. While shown to improve the clinical utility of the LMS for the most part, these staging systems have failed to gain wide acceptance due to their unwieldy implementation. These methods rely on an experienced clinician or radiologist with knowledge of complex sinus anatomy to manually segment the sinus cavities for each patient. Even when using semiautomated computerized techniques, these methods are heavily time-consuming and potentially prone to human error.

Methods that strive to create more objective computer analysis of sinus CT have surfaced only recently. Chowdhury et al used deep learning to classify opacification of the ostiomeatal complex on selected 2D coronal sections. Using a CNN trained on 296 CT scans from patients with CRS, the authors reported that their method was able to correctly detect ostiomeatal complex opacification 85% of the time. To our knowledge, our group was the first to develop, test, and validate a fully automated deep learning–based algorithm capable of 3D volumetric segmentation of the paranasal sinuses on CT. In this proof-of-principle study, the algorithm was tested on subjects presenting for multidisciplinary respiratory evaluation at a single institution. The results showed that algorithm-derived quantitative assessment of the total percentage sinus opacification correlated well with the current criterion standard visual grading system, the LMS.

The current study expands on this work in several ways, with an overarching goal being further demonstrating the applicability and utility of a fully automated system for disease quantification, while also exploring novel radiologic disease-specific readouts. The current algorithm is capable of individual sinus cavity segmentation, a feature that was not yet developed in our initial report of our technique. Averaging of individual sinus cavities represents an improvement in overall characterization of sinus disease burden, considering that in this work, we demonstrate an overall %SO-versus-LMS correlation of 0.85, which is an increase compared with our initial work in which we reported a correlation of 0.82. While the study cohort in this work is smaller, it is an independent cohort consisting exclusively of patients with well-characterized CRS. We used a number of disease-specific metrics that were not available in the initial study, including polyp status, endoscopic disease assessments, quality-of-life surveys, and serum/tissue eosinophil measurement. Additionally, CT scans in the present study were obtained using several different scanner manufacturers with varied reconstruction kernel protocols, illustrating potential broad applicability of such an algorithm. That this approach was capable of successfully analyzing a diverse set of scans while producing an improved association with LMS to the initial study demonstrates promise in the wide-spread application of this AI technology.

---

**Table 3: Correlation (ρ) values for CT-derived metrics and clinical parameters**

<table>
<thead>
<tr>
<th>Clinical Parameter</th>
<th>(%SO)</th>
<th>LMS</th>
<th>mHU of Opacified Regions</th>
</tr>
</thead>
<tbody>
<tr>
<td>LKS</td>
<td>0.58&lt;sup&gt;a&lt;/sup&gt;</td>
<td>0.58&lt;sup&gt;a&lt;/sup&gt;</td>
<td>0.48&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td>SNOT-22</td>
<td>0.05</td>
<td>−0.02</td>
<td>0.08</td>
</tr>
<tr>
<td>Absolute serum eosinophils</td>
<td>0.26&lt;sup&gt;b&lt;/sup&gt;</td>
<td>0.34&lt;sup&gt;b&lt;/sup&gt;</td>
<td>0.14</td>
</tr>
<tr>
<td>Tissue eosinophil count</td>
<td>0.31&lt;sup&gt;b&lt;/sup&gt;</td>
<td>0.33&lt;sup&gt;b&lt;/sup&gt;</td>
<td>0.22&lt;sup&gt;b&lt;/sup&gt;</td>
</tr>
</tbody>
</table>

<sup>a</sup>P < .001  
<sup>b</sup>P < .05

**Table 4: Correlation (ρ) values for percentage sinus opacification stratified by sinus cavity and clinical parameters**

<table>
<thead>
<tr>
<th>Clinical Parameter</th>
<th>Left Maxillary</th>
<th>Right Maxillary</th>
<th>Anterior Ethmoid</th>
<th>Posterior Ethmoid</th>
<th>Frontal</th>
<th>Sphenoid</th>
</tr>
</thead>
<tbody>
<tr>
<td>LKS</td>
<td>0.43&lt;sup&gt;a&lt;/sup&gt;</td>
<td>0.34&lt;sup&gt;b&lt;/sup&gt;</td>
<td>0.64&lt;sup&gt;a&lt;/sup&gt;</td>
<td>0.56&lt;sup&gt;a&lt;/sup&gt;</td>
<td>0.53&lt;sup&gt;a&lt;/sup&gt;</td>
<td>0.35&lt;sup&gt;b&lt;/sup&gt;</td>
</tr>
<tr>
<td>SNOT-22</td>
<td>0.10</td>
<td>0.06</td>
<td>0.06</td>
<td>−0.03</td>
<td>0.10</td>
<td>−0.10</td>
</tr>
<tr>
<td>Absolute serum eosinophils</td>
<td>0.03</td>
<td>0.15</td>
<td>0.23&lt;sup&gt;b&lt;/sup&gt;</td>
<td>0.26&lt;sup&gt;b&lt;/sup&gt;</td>
<td>0.21</td>
<td>0.18</td>
</tr>
<tr>
<td>Tissue eosinophil count</td>
<td>0.13</td>
<td>0.21</td>
<td>0.37&lt;sup&gt;b&lt;/sup&gt;</td>
<td>0.39&lt;sup&gt;a&lt;/sup&gt;</td>
<td>0.23&lt;sup&gt;b&lt;/sup&gt;</td>
<td>0.11</td>
</tr>
</tbody>
</table>

<sup>a</sup>P < .001  
<sup>b</sup>P < .05
We also explored the clinical significance of novel automated CT metrics that have been proposed in the literature. The significance of Hounsfield unit values of sinus opacities has been investigated previously, with 1 study showing that when the LMS is weighted by certain Hounsfield unit values, correlation of the weighted LMS score to symptom indices increased.\(^{17}\) Opacification hyperdensity has also been found to be a key radiologic biomarker for certain CRS subtypes, such as allergic fungal rhinosinusitis\(^{18}\) and eosinophilic mucin rhinosinusitis. Our algorithm is capable of calculating the mHU of opacified regions across all sinus cavities for a given study, a readout that has not been studied before. In the current study, mHU correlations to clinical parameters, in particular tissue and serum eosinophils, were lower than we had expected.

While we had hypothesized that radiologic density measures would have correlated with eosinophilic inflammatory markers based on the known relationship between allergic fungal concretions and eosinophilic mucin, there is, in fact, a dearth of published data to support this theory, probably, in part, because an objective radiologic metric examining this issue has not been easily obtainable until now. Furthermore, our study was not powered to examine opacification density characteristics for diseases in which this may be important, such as eosinophilic CRS or allergic fungal rhinosinusitis. More study is needed to examine how this newly available radiologic measure can be used in these conditions.

We also investigated osteitis of bony lamellae in the sinus cavities, an important clinical marker that typically indicates recalcitrant or long-standing CRS disease status and may portend worse outcomes after endoscopic sinus surgery.\(^{19-22}\) This investigation was performed by assessing a 7-mm rind along the perimeter of each sinus cavity and determining what percentage of the rind was occupied by bone. We hypothesized that subjects with a greater degree of bony thickening would correlate to having a higher total GOSS, a currently applied radiologic measure of parasanal sinus osteitis. Our results showed a moderate correlation between the algorithm readout and the visual assessment. Stratifying the correlation by surgical status strengthened the correlation in postoperative subjects, possibly because these patients had more recalcitrant disease or from repeat insults from the surgery itself. Our initial method of assessment may be limited by patients who naturally have thicker bone but lack osteitic change; further refinement of this technique may be needed in the future.

We had hypothesized that an AI-based quantitative algorithm would offer a sensitive method to measure disease severity, and it seems to have performed similar to LMS measurements. Neither LMS nor quantitative %SO demonstrated any meaningful association with SNOT-22 scores in this cohort, supporting prior literature observations that likewise showed no relationship between CT disease burden and symptoms.\(^{23-25}\) As has been proposed in other work, biologic factors may play only a partial role in the determination of symptom burden and expression,\(^{26}\) and we are still a long way from deciphering how certain radiologic findings such as Hounsfield units can be used as biomarkers or as a method of endotyping patients with CRS.

Performing well compared with the criterion standard LMS, our AI-based approach has marked and obvious advantages in that it is rapid and completely automated and eliminates any bias or human error that may be part of a visual assessment. The algorithm, now demonstrating successful segmentation from scanners from multiple different manufacturers, also allows quantitation or detection of other important radiologic entities for clinical and research purposes, such as osteitis and assessment of opacification density.

Limitations of the current work include the retrospective study design. While use of a diverse set of scans may be argued as a potential drawback for a validation study, we think that this, in fact, represents a strength that showcases algorithm robustness with respect to varied scan-acquisition parameters, especially because initial validation work using a homogeneous cohort of scans has already been published by our group. Further validation and utility assessment will be of interest in a prospective multi-institutional trial setting.

**CONCLUSIONS**

Our CNN-based approach to sinus CT evaluation is capable of rapid and automated quantitative assessment, as demonstrated in this CRS cohort with images obtained from a diverse set of scanners. This AI technology performs well compared with the current criterion standard visual-assessment system. With further testing and continued refinement, quantitative assessment of sinus CT enabled by AI is poised to become a valuable tool for quantification of radiologic disease burden in both clinical and research applications.

Disclosure forms provided by the authors are available with the full text and PDF of this article at www.ajnr.org.

**REFERENCES**

12. Lund VJ, Mackay IS. Staging in rhinosinusitis. Rhinology 1993;31:183–84 Medline
Differentiation of Skull Base Chondrosarcomas, Chordomas, and Metastases: Utility of DWI and Dynamic Contrast-Enhanced Perfusion MR Imaging

Y. Ota, E. Liao, A.A. Capizzano, A. Baba, R. Kurokawa, M. Kurokawa, and A. Srinivasan

ABSTRACT

BACKGROUND AND PURPOSE: Differentiation of skull base tumors, including chondrosarcomas, chordomas, and metastases, on conventional imaging remains a challenge. We aimed to test the utility of DWI and dynamic contrast-enhanced MR imaging for skull base tumors.

MATERIALS AND METHODS: Fifty-nine patients with chondrosarcomas, chordomas, or metastases between January 2015 and October 2021 were included in this retrospective study. Pretreatment normalized mean ADC and dynamic contrast-enhanced MR imaging parameters were calculated. The Kruskal-Wallis H test for all tumor types and the Mann-Whitney U test for each pair of tumors were used.

RESULTS: Fifteen chondrosarcomas (9 men; median age, 62 years), 14 chordomas (6 men; median age, 47 years), and 30 metastases (11 men; median age, 61 years) were included in this study. Fractional plasma volume helped distinguish all 3 tumor types (P = 0.003, <.001, and <.001, respectively), whereas the normalized mean ADC was useful in distinguishing chondrosarcomas from chordomas and metastases (P < .001 and P < .001, respectively); fractional volume of extracellular space, in distinguishing chondrosarcomas from metastases (P = .02); and forward volume transfer constant, in distinguishing metastases from chondrosarcomas/chordoma (P = .002 and .002, respectively) using the Kruskal-Wallis H test. The diagnostic performances of fractional plasma volume for each pair of tumors showed areas under curve of 0.86–0.99 (95% CI, 0.70–1.0); the forward volume transfer constant differentiated metastases from chondrosarcomas/chordomas with areas under curve of 0.82 and 0.82 (95% CI, 0.67–0.98), respectively; and the normalized mean ADC distinguished chondrosarcomas from chordomas/metastases with areas under curve of 0.96 and 0.95 (95% CI, 0.88–1.0), respectively.

CONCLUSIONS: DWI and dynamic contrast-enhanced MR imaging sequences can be beneficial for differentiating the 3 common skull base tumors.

ABBREVIATIONS: AUC = area under the curve; DCE-MR imaging = dynamic contrast-enhanced perfusion MR imaging; IQR = interquartile range; Ktrans = forward volume transfer constant; Ve = fractional volume of extracellular space; Vp = fractional plasma volume; nADCmean = normalized mean ADC

The skull base is involved in a wide variety of neoplasms.1 They include primary bone tumors such as chondrosarcomas and chordomas, both of which show similarities in anatomic location, clinical manifestations, and conventional imaging findings, with a combined annual incidence of approximately 1 per 100,000.2 Chondrosarcomas arise from the embryonic rest of the cartilaginous matrix of the cranium and tend to be centered at the petrous apex or petro-occipital fissure,3 compared with chordomas that arise from remnants of the notochord and are typically centered on the clivus. However, both tumors tend to be locally aggressive, limiting the feasibility and diagnostic utility of establishing the site of origin on conventional CT and MR imaging.4 In the skull base, especially in the clivus and petrous regions, skull base metastases are also diagnostic considerations. The prevalence of skull base metastases among patients with cancer remains to be revealed, but it has been suggested that it is underreported.5 Breast, lung, prostate, and head and neck cancers, as well as melanomas have been reported.6,7 Skull base metastases of unknown origin have been reported as well.8 Conventional MR imaging has been reported as a sensitive tool to detect abnormalities in the skull base,8 but MR imaging features are not specific and may overlap between chondrosarcomas and chordomas.4 The
MRI can characterize cellularity and unique microstructures, and dynamic contrast-enhanced MR imaging (DCE-MR imaging) can evaluate permeability patterns and vascularity and is increasingly used for tumor differentiation and evaluation of treatment effects. The ADC value has been shown to assist in the differentiation of chondrosarcomas and chordomas, but the differentiation of metastases from chondrosarcomas and chordomas has not been fully explored. Recently, DCE-MR imaging has been used to differentiate bone metastases from benign lesions. However, no studies have explored the differentiation of these 3 tumor types using DCE-MR imaging. The calculated parameters from DCE-MR imaging include fractional plasma volume (Vp), which can reflect tumor vascularity, as well as fractional volume of extracellular space (Ve) and forward volume transfer constant (Ktrans), which can represent permeability. Chondrosarcomas, chordomas, and metastases can show different internal structures, microvascularization, and permeability, suggesting that DWI and DCE-MR imaging can be helpful in the differentiation of the 3 tumor types.

In this study, we aimed to test the ability of DWI and DCE-MR imaging to differentiate chondrosarcomas, chordomas, and metastases in the skull base.

**MATERIALS AND METHODS**

**Study Population**

This retrospective single-center study was approved by University of Michigan institutional review board, and the requirement of informed consent was waived. Data were acquired and de-identified before any analysis, in compliance with all applicable Health Insurance Portability and Accountability Act regulations. We reviewed the medical records of 368 patients, including 68 patients diagnosed with chondrosarcomas, 60 patients with chordomas, and 240 patients with skull base metastases from January 2015 to October 2021 in a single center. Patients with chondrosarcomas and classic chordomas were diagnosed pathologically. Skull base metastases were diagnosed by biopsy or on the basis of the clinical evidence of confirmed primary cancers, other biopsy-confirmed metastatic lesions, and skull base lesions detected on conventional CT/MR imaging and FDG-PET/CT. Cases without pretreatment DWI or DCE-MR imaging (including biopsy, surgery, or radiation therapy) (n = 295) or poor image quality (n = 14) were excluded.

All 30 patients with skull base metastases had confirmed primary cancers. Six of 30 patients underwent a biopsy (3 lung cancers, 2 breast cancers, and 1 renal cell carcinoma), and 24 of 30 patients were clinically diagnosed on the basis of all 24 patients having histories of confirmed primary cancers, biopsy-confirmed metastatic lesions in the other regions, and positive conventional head and neck CT/MR imaging and PET/CT findings in the skull base. For patients diagnosed with skull base metastases, the treatment response of the skull base lesions following chemotherapy or chemotheraphy plus radiation therapy was confirmed on follow-up CT or MR imaging. Corresponding treatments such as chemotherapy (n = 18) or chemotherapy plus radiation therapy (n = 12) were used, and a decrease in size was observed on CT or MR imaging.

In total, 59 patients (20 men, 39 women; median age, 61 years; interquartile range [IQR], 45–70 years) with 15 chondrosarcomas, 14 chordomas, and 30 skull base metastases were included in this study. Patient demographics such as age and sex for all tumor types and primary cancers for skull base metastases were reviewed from medical records.

**MR Imaging Protocol**

Head and neck MR imaging examinations were performed using a 1.5T or 3T system (Ingenia; Philips Healthcare) with patients in the supine position. The acquired sequences were axial plane T1WI, T2WI, FLAIR, and contrast-enhanced fat-saturated T1WI and coronal plane contrast-enhanced fat-saturated T1WI. DWI was performed using echo-planar imaging with the following DWI parameters: TE range, 58–106 ms; TR range, 5000–9500 ms; number of excitations, 1; section thickness and gap, 3.5–4 and 0–1 mm; FOV, 220–240 mm; matrix size, 128 × 128 to 200 × 200; and 3 direction diffusions. Sensitizing diffusion gradients were sequentially applied. B values were 0 and 1000 s/mm².

A DCE-MR imaging sequence was performed using a 3D T1-weighted fast-field echo technique with a 16-channel Neurovascular coil. Twenty milliliters of gadobenate dimeglumine (MultiHance; Bracco Diagnostics) was administered through a peripheral arm vein using a power injector at a flow rate of 5.0 mL/s and followed by a 20-mL saline flush. DCE-MR imaging was sequentially acquired with the following parameters of 3D-T1 fast-field echo: TE, 1.86 ms; TR, 4.6 ms; flip angle, 30°; section thickness, 5.0 mm; FOV, 240 × 240 mm²; voxel size, 1.0 × 1.0 × 5.0 mm³; number of excitations, 1; number of slices per dynamic scan, 48; temporal resolution, 8.4 seconds; dynamic phase, 30 dynamics; total acquisition time, 4 minutes 24 seconds.

**Imaging Processing and Analysis**

Two board-certified radiologists with 7 and 10 years of experience independently performed DWI and DCE-MR imaging analyses. The same board-certified radiologist with 7 years of experience reviewed conventional MR imaging. The 2 readers were blinded to the histologic results.

**Conventional Imaging**

The maximum axial diameter was measured using contrast-enhanced axial and coronal fat-saturated T1WI. As conventional MR imaging features, the main skull base location was identified using axial and coronal contrast-enhanced fat-saturated T1WI and recorded as the clivus or petrous bone. In addition, both radiologists evaluated the following imaging characteristics with consensus and recorded them as binary variables:

1. Cystic changes, defined as focal areas with nonenhancing, predominantly T2-hyperintense areas and necrotic changes defined as focal areas with nonenhancing, predominantly T1-hypointense and heterogeneously T2-hyperintense areas.
2. T2 hyperintensity or iso-/hypointensity in the lesion relative to the brain parenchyma, evaluated on T2WI, excluding the areas of cystic/necrotic changes.
3) Enhancement patterns (homogeneous or heterogeneous), evaluated on postcontrast fat-saturated T1-weighted images.
4) Other metastatic lesions in the FOV of the head and neck scan, evaluated on T1WI, T2WI, and postcontrast T1WI.

**DWI Analysis**
The same 2 board-certified radiologists with 7 and 10 years of experience manually delineated a single freehand ROI on the axial contrast-enhanced fat-saturated T1WI. ADC maps were constructed using commercially available software (Olea Sphere, Version 3.0; Olea Medical). On the ADC maps, the corresponding ROIs were again contoured with reference to the ROIs delineated on axial postcontrast T1WI. The 2 readers adhered to the following procedure:

1) ROIs were encompassed in the areas on axial postcontrast fat-saturated T1WI where the tumors showed solid enhancing components, excluding necrotic or cystic regions. When the lesions extended beyond the clivus into surrounding soft tissues, both the bony and soft structures were included in a ROI.
2) The peripheral 2 mm of the lesions were excluded from an ROI to avoid volume averaging.
3) The ROIs were manually adjusted on the ADC map if geometric artifacts were observed.
4) An ROI was placed within the medulla oblongata as an internal control. The mean ADC values of the tumor were divided by the mean ADC values of the medulla oblongata, and the normalized mean ADC (nADCmean) was calculated.

**DCE-MR Imaging Analysis**
Quantitative analyses were performed using the Olea Sphere 3.0 software. An arterial input function was automatically computed. While this process was automated, the corresponding time-intensity curves that demonstrated a rapid increase in attenuation with sharp peaks were deemed appropriate and accurate for delineation. The permeability module was based on the extended Tofts model, and pixel-based parameter maps were calculated from time-intensity curves. ROIs were placed by means of the method used for the DWI analysis. Quantitative parameters, Vp, Ve, and Ktrans, were calculated.

**Statistical Analysis**
nADCmean and Ve, Ktrans, and Vp were compared among the 3 tumor types using the Kruskal-Wallis H test and the post hoc test with Bonferroni correction and were described as medians (IQR). The conventional MR imaging features were compared between each pair of tumor types by the Fisher exact test. For each pair of tumor type (chondrosarcomas and chordomas, chondrosarcomas and metastases, and chordomas and metastases), the parameters from DWI and DCE-MR imaging analyses were compared using the Mann-Whitney U test with a Bonferroni correction and described as median (IQR). For statistically significant diagnostic parameters, receiver operating characteristic analysis was performed with the optimal cutoff values, which were determined to maximize the Youden index (sensitivity + specificity - 1). The intraclass correlation coefficient was used to assess the interobserver agreement for DWI and DCE-MR imaging parameters. All statistical calculations were conducted using R statistical and computing software (http://www.r-project.org/). Variables with P values < .05 were considered statistically significant.

**RESULTS**

**Patient Demographics**
There were 15 chondrosarcomas (9 men; median age, 62 years; IQR, 46–70 years), 14 chordomas (6 men; median age, 47 years; IQR, 32–58 years), and 30 metastases (11 men; median age, 61 years; IQR, 47–70 years) in this study. Patient demographic and tumor characteristics are summarized in Table 1. As shown in Table 1, the metastatic cohort was a heterogeneous group of primary cancer types. The 3 most frequently seen primary cancers were breast (37%, 11/30), lung (20%, 6/30), and malignant melanomas (20%, 6/30).

**Conventional MR Imaging Features**
The results of the comparisons between chondrosarcomas versus chordomas and between chondrosarcomas and chordomas versus metastases are presented in Table 2.

**Chondrosarcomas versus Chordomas**
There was no significant difference in main locations, the presence of cystic/necrotic changes, signal intensity (T2 hyperintensity or iso-/hypointensity), and enhancement patterns (P = .08–1.0).

**Chondrosarcomas versus Metastases**
T2 hyperintensity in the lesion was more often seen in chondrosarcomas than in metastases (10/15 versus 9/30, P = .027). Otherwise, there was no significant difference in main locations and the presence of cystic/necrotic changes or enhancement patterns between them (P = .14–.29).

**Chordomas versus Metastases**
T2 hyperintensity in the lesion was more often seen in chordomas than in metastases (9/14 versus 9/30; P = .049). Otherwise, there was no significant difference in other conventional imaging features between them (P = .29–.65).

### Table 1: Patient demographics

<table>
<thead>
<tr>
<th>No. of patients</th>
<th>Chondrosarcoma</th>
<th>Chordoma</th>
<th>Metastasis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sex (male/total)</td>
<td>9/15</td>
<td>6/14</td>
<td>11/30</td>
</tr>
<tr>
<td>Age (yr)</td>
<td>62 (46–70)</td>
<td>47 (32–58)</td>
<td>61 (47–70)</td>
</tr>
<tr>
<td>Maximum axial diameter (mm)</td>
<td>29.5 (24–36)</td>
<td>33 (24–40)</td>
<td>18.5 (15–23)</td>
</tr>
<tr>
<td>Primary cancer type</td>
<td>NA</td>
<td>NA</td>
<td>11 Breast, 6 lung, 6 malignant melanoma, 4 head and neck, 2 sarcoma, 1 kidney</td>
</tr>
</tbody>
</table>

Note: NA indicates not applicable.

* Values are presented as the median (IQR).
Table 2: Conventional imaging characteristics of chondrosarcomas, chordomas, and metastases

<table>
<thead>
<tr>
<th>Main location (petrous bone/clivus)</th>
<th>Chondrosarcoma</th>
<th>Chordoma</th>
<th>Metastasis</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cystic/necrotic changes</td>
<td>2/15</td>
<td>7/14</td>
<td>10/30</td>
<td>P = .001</td>
</tr>
<tr>
<td>T2 hyperintensity or iso-/hypointensity relative to the brain parenchyma [T2 hyperintensity/total]</td>
<td>10/15</td>
<td>9/14</td>
<td>9/30</td>
<td>P = .001</td>
</tr>
<tr>
<td>Enhancement patterns (heterogeneous/total)</td>
<td>15/15</td>
<td>14/14</td>
<td>26/30</td>
<td>P = .001</td>
</tr>
<tr>
<td>Other metastatic lesions in the head and neck</td>
<td>NA</td>
<td>NA</td>
<td>5/30</td>
<td>P = .001</td>
</tr>
</tbody>
</table>

Note: — P is from a comparison between chordosarcoma and chordoma; P, from a comparison between chordosarcomas and metastases, and P, from a comparison between chordoma versus metastasis.

Table 3: DWI and DCE-MR imaging parameters of chondrosarcoma, chordoma, and metastasis using the Kruskal-Wallis H test and the post hoc test with Bonferroni correction

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Chondrosarcoma</th>
<th>Chordoma</th>
<th>Metastasis</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>nADC&lt;sub&gt;mean&lt;/sub&gt;</td>
<td>2.44 (1.27–2.73)</td>
<td>1.30 (1.07–1.73)</td>
<td>1.39 (1.21–1.70)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Ve</td>
<td>0.015 (0.03–0.028)</td>
<td>0.045 (0.04–0.068)</td>
<td>0.12 (0.09–0.14)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Ve&lt;sub&gt;trans&lt;/sub&gt; (minute&lt;sup&gt;-1&lt;/sup&gt;)</td>
<td>0.25 (0.15–0.33)</td>
<td>0.35 (0.30–0.40)</td>
<td>0.48 (0.34–0.63)</td>
<td>&lt;.007</td>
</tr>
</tbody>
</table>

**DWI and DCE-MR Imaging Analysis**

The intraclass correlation coefficient for DWI and DCE-MR imaging parameters was excellent (nADC<sub>mean</sub>, 0.94; Vp, 0.95; K<sub>trans</sub>, 0.97; Ve, 0.95).

In the Kruskal-Wallis H test and the post hoc test with a Bonferroni correction, there were statistically significant differences in nADC<sub>mean</sub>, Vp, Ve, and K<sub>trans</sub> among all tumor types (nADC<sub>mean</sub>, P < .001; Vp, P < .001; Ve, P = .007; and K<sub>trans</sub>, P < .001). Vp showed significant differences in each pair of tumors (chondrosarcomas versus chordomas, P = .003; chondrosarcomas versus metastases, P < .001; and chordomas versus metastases, P < .001, respectively). Table 3 and Fig 1 summarize the comparisons of DWI and DCE-MR imaging parameters among the 3 tumors.

**Chondrosarcomas versus Chordomas**

The median nADC<sub>mean</sub> was significantly higher and the median Vp was significantly lower in chordosarcomas than in chordomas (nADC<sub>mean</sub>: 2.4 [IQR, 2.3–2.7] versus 1.30 [IQR, 1.07–1.73]; P < .001; Vp: 0.015 [IQR, 0.01–0.028] versus 0.045 [IQR, 0.04–0.068]; P = .012), while the median Ve and K<sub>trans</sub> were insignificantly different (Ve: 0.25 [IQR, 0.15–0.31] versus 0.35 [IQR, 0.30–0.40]; P = .57; K<sub>trans</sub>: 0.08 [IQR, 0.06–0.17] versus 0.16 [IQR, 0.13–0.20]; P = .64).

**Chondrosarcomas versus Metastases**

nADC<sub>means</sub> were significantly higher, and Vp and K<sub>trans</sub> were significantly lower in chordosarcomas than in metastases (nADC<sub>mean</sub>: 2.44 [IQR, 2.27–2.71] versus 1.39 [IQR, 1.21–1.70]; P < .001; Vp: 0.015 [IQR, 0.01–0.028] versus 0.12 [IQR, 0.09–0.14]; P < .001; K<sub>trans</sub>: 0.08 [IQR, 0.06–0.17] versus 0.39 [IQR, 0.20–0.63]; P = .008), while Ve was insignificantly different (Ve: 0.25 [IQR, 0.15–0.31] versus 0.48 [IQR, 0.34–0.63]; P = .09).

**Chordomas versus Metastases**

Median Vp and K<sub>trans</sub> were significantly lower in chordomas than in metastases (Vp: 0.045 [IQR, 0.04–0.068] versus 0.12 [IQR, 0.09–0.14]; P < .001; K<sub>trans</sub>: 0.16 [IQR, 0.13–0.20] versus 0.39 [IQR, 0.20–0.63]; P = .008), while nADC<sub>mean</sub> and Ve were insignificantly different (nADC<sub>mean</sub>: 1.30 [IQR, 1.07–1.73] versus 1.39 [IQR, 1.21–1.70]; P = 1.0; Ve: 0.35 [IQR, 0.30–0.4] versus 0.48 [IQR, 0.34–0.63]; P = .68).

**Diagnostic Performance of DWI and DCE-MR Imaging**

The diagnostic performance of parameters of DWI and DCE-MR imaging analyses, which showed significant differences between chondrosarcomas versus chordomas, chondrosarcomas versus metastases, and chordomas versus metastases is demonstrated in Table 4 and Fig 2.

nADC<sub>mean</sub> showed areas under the curve (AUCs) of 0.96 and 0.95 (95% CI, 0.88–1.0) between chondrosarcomas and chordomas and between chordosarcomas and metastases, respectively. Vp showed AUCs of 0.86, 0.99, and 0.92 (95% CI, 0.72–1.0) between chordosarcomas and chordomas, between chordosarcomas and metastases, and between chordomas and metastases, respectively.
Representative cases of chondrosarcoma, chordoma, and metastasis with DWI and DCE-MR imaging analyses are shown in Figs 3–5.

**DISCUSSION**
This study aimed to test the utility of DWI and DCE-MR imaging for skull base chondrosarcomas, chordomas, and metastases. nADCmean, Vp, Ve, and \( K^{\text{trans}} \) showed significant differences among all tumor types, and Vp showed significant differences between each pair of tumor comparisons using the Kruskal-Wallis H test. In the Mann-Whitney U test for each pair of 2 tumors, Vp distinguished all tumor types with AUCs of 0.86–0.99 with cutoffs of 0.03–0.09, \( K^{\text{trans}} \) distinguished metastases from chondrosarcomas and chordomas with an AUC of 0.82 with cutoffs of 0.12 and 0.30, and nADCmean distinguished chondrosarcomas from chordomas and metastases with AUCs of 0.96 and 0.95 and cutoffs of 1.99 and 2.09, respectively. Ve was not a significant differentiator of tumor types.

Regarding conventional MR imaging features, T2 hyperintensity of the lesion was shown to be significantly higher in chondrosarcomas and chordomas than in metastases, which can be used as a differentiator from metastases between chondrosarcomas and chordomas. Other imaging features such as main locations, cystic/necrotic changes, or enhancement patterns did not identify any significant difference between each pair of tumor type. Also, in patients with metastases, only 5 of 30 patients showed other metastatic lesions in head and neck MR imaging, suggesting that other metastatic lesions may not be a decisive factor for differentiation of these tumors.

Regarding DWI analysis, ADC values were lower in chordomas than in chondrosarcomas in this study, as suggested by a previous study.\(^{17}\) It has been suggested that the difference in tumoral microstructure, such as cartilaginous stroma with varying degrees of cellularity in chondrosarcomas as well as myxoid stroma arranged through sheets of physaliferous cells in chordoma, contributes to the difference in ADC values.\(^{17}\) ADC values were also lower in metastases than in chondrosarcomas. Generally, malignant tumors show

---

**Table 4: Diagnostic performance of DCE-MR imaging parameters for each tumor comparison**

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Chondrosarcoma vs Chordoma</th>
<th>Chondrosarcoma vs Metastasis</th>
<th>Chordoma vs Metastasis</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>nADCmean</td>
<td>Vp</td>
<td>nADCmean</td>
</tr>
<tr>
<td>Cutoff</td>
<td>1.99</td>
<td>0.03</td>
<td>2.09</td>
</tr>
<tr>
<td>Sensitivity</td>
<td>1.0 (0.68–1)</td>
<td>0.93 (0.66–0.99)</td>
<td>0.93 (0.76–0.99)</td>
</tr>
<tr>
<td>Specificity</td>
<td>0.86 (0.57–0.98)</td>
<td>0.71 (0.42–0.92)</td>
<td>0.87 (0.60–0.98)</td>
</tr>
<tr>
<td>PPV</td>
<td>0.88 (0.62–0.98)</td>
<td>0.77 (0.50–0.93)</td>
<td>0.93 (0.76–0.99)</td>
</tr>
<tr>
<td>NPV</td>
<td>1.0 (0.64–1)</td>
<td>0.91 (0.59–0.99)</td>
<td>0.87 (0.60–0.98)</td>
</tr>
<tr>
<td>Accuracy</td>
<td>0.93 (0.78–0.99)</td>
<td>0.82 (0.63–0.94)</td>
<td>0.91 (0.77–0.97)</td>
</tr>
<tr>
<td>AUC</td>
<td>0.96 (0.90–1)</td>
<td>0.86 (0.72–1)</td>
<td>0.95 (0.88–1)</td>
</tr>
</tbody>
</table>

Note: PPV indicates positive predictive value; NPV, negative predictive value.

*Numbers in parentheses represent 95% CIs.*
high cellularity, which is assumed to result in low ADC values in metastases. In contrast, nADCmean was not a significant differentiator between chordomas and metastases, which is thought to stem from the complexity of internal structures and cellularity of each tumor group or from the heterogeneity of primary cancers of metastases. We divided the ADC values of the tumors by those of the medulla oblongata for normalization to minimize variations due to differences in magnetic field and scanner parameters. The medulla is usually included within the FOV of head and neck protocols and is rarely affected by chronic microvascular diseases, offering easy reproducibility of the internal standard reference. This standardization method was thought to make our results robust.

Regarding DCE-MR imaging analysis, Vp, which is a marker of microvascul arity, was lowest in chondrosarcomas, intermediate in chordomas, and highest in metastases, with significant differences, and showed promising diagnostic performances in the receiver operating characteristic analysis. Both chondrosarcomas and chordomas are known to have poor vascularity, and DCE-MR imaging has been used to investigate each tumor type separately. However, there have been no studies that compared perfusion characteristics between chondrosarcomas and chordomas using DCE-MR imaging perfusion. On the basis of our study, Vp and ADC values can be significant differentiators between the 2 tumors, with promising diagnostic performance. In addition, clival metastases, which included a variety of primary cancer types such as breast, lung, melanoma, and head and neck cancers, showed significantly higher Vp values than chondrosarcomas and chordomas. Previous studies have shown that there were no significant differences in Vp between vertebral hematologic malignancies and solid malignancy metastases or between breast and lung cancer metastases. However, a study showed higher Vp in vertebral metastasis from renal cancer (known as a hypervascular tumor) than from prostate cancer metastases (known as a hypovascular tumor). This finding suggests that Vp in bone metastases can vary according to the primary cancer type. Nevertheless, when

FIG 2. Receiver operating characteristic curves of chondrosarcoma versus chordoma (A), chondrosarcoma versus metastasis (B), and chordoma versus metastasis (C) are shown.

FIG 3. A 56-year-old man with a chondrosarcoma in the left petrous apex. A, Axial fat-saturated postcontrast T1-weighted image shows a heterogeneously enhancing mass in the left petrous apex. B, An ROI was placed on the ADC map, and the nADCmean was calculated. Mean ADC and ADC values in the medulla were 2.05, and 0.80 × 10⁻³ mm²/s, respectively. The nADCmean was 2.56. C, An ROI was placed on the permeability map, and Vp, Ktrans, and Ve were calculated. D, Vp is 0.01.
metastatic lesions are grouped together as a general population, irrespective of the primary cancer type, our results suggest that $V_p$ remains a significant differentiator from primary bone lesions, such as chordomas or chondrosarcomas.

$K_{trans}$, which is a marker of tumor permeability, was higher in metastases than in the chondrosarcomas and chordomas in our study. Malignant tumors generally show higher tumor permeability than benign tumors. Similar to $V_p$, $K_{trans}$ within the metastatic cohort can demonstrate variation on the basis of the type of primary malignancy, though our overall results suggest that the general population of metastatic lesions will demonstrate significantly higher $K_{trans}$ than primary bone lesions such as chordomas or chondrosarcomas. There were no significant differences in $K_{trans}$ between chondrosarcomas and chordomas; therefore, it was not applicable for the differentiation of the 2 tumors on the basis of our results.

In our study, nADCmean showed the highest diagnostic performance in differentiating chondrosarcomas from chordomas, while $V_p$ distinguished skull base metastases from chondrosarcomas and chordomas with the highest diagnostic performance. A biopsy is typically required for definite diagnosis and management. However, there are some clinical situations in which the invasive diagnostic procedure could be avoided. In fact, avoiding a biopsy in favor of short-term follow-up scans is often recommended at multidisciplinary conferences when the lesions are located close to or involve the vasculature or when the patients tend to have comorbidities that put them at higher risk of hemorrhage. In these clinical settings, adding DWI and DCE-MR imaging can be beneficial for clinical judgment and further management. In addition, when conventional imaging is indeterminate or PET/CT is not available or feasible at the time of diagnosis, DWI and DCE-MR imaging can enhance the confidence in the diagnosis when combined with the conventional imaging findings and can assist in proper clinical management.

There were several limitations to this study. First, it was retrospectively conducted at a single institution and included a relatively small population. In addition, we could not include head and neck CT imaging features because head and neck CT was not performed in all included patients. Second, most metastases ($n = 24$) could not be histologically confirmed owing to the anatomic accessibility of the skull base and risk of complications. However, all cases had confirmed primary cancers with abnormal skull base findings on CT or MR imaging and PET/CT, and other metastatic lesions were detected by biopsy or surgery. Third, this study used 1.5T and 3T scanners, which might result

![FIG 4](https://www.ajnr.org/content/43/12/1325/F4)

**A**. A 16-year-old boy with a chordoma in the clivus. *A*, Axial fat-saturated postcontrast T1-weighted image shows a heterogeneously enhancing mass in the clivus. *B*, An ROI was placed on the ADC map, and the nADCmean was 1.5. *C*, An ROI was placed on the permeability map, and $V_p$, $K_{trans}$, and $V_e$ were calculated. *D*, $V_p$ is 0.08.

**FIG 5.** A 39-year-old woman with a metastatic breast cancer lesion in the clivus. *A*, Axial fat-saturated postcontrast T1-weighted image shows a heterogeneously enhancing mass in the clivus. *B*, An ROI was placed on the ADC map, and the nADCmean was 0.97. *C*, An ROI was placed on the permeability map, and $V_p$, $K_{trans}$, and $V_e$ were calculated. *D*, $V_p$ showed 0.23.
in heterogeneity of DCE-MR imaging parameters. Forth, we did not conduct out-of-sample validation in statistical analysis, which potentially caused overly optimistic results in the diagnostic performance of DWI and DCE-MR imaging parameters. Finally, we included heterogeneous primary cancer diseases in patients with metastases, though this heterogeneous group can represent general populations of patients with cancer.

CONCLUSIONS

DWI and DCE-MR imaging sequences can help differentiate chordosarcomas, chordomas, and metastases. When a skull base lesion is indeterminate on conventional imaging and/or a biopsy should be avoided due to the location of the lesion in close proximity to major vasculature or the patient’s underlying comorbidities, DWI and DCE-MR imaging sequences can enhance the confidence in arriving at an appropriate diagnosis.

Disclosure forms provided by the authors are available with the full text and PDF of this article at www.ajnr.org.

REFERENCES

Duct-like Recess in the Infundibular Portion of Third Ventricle Craniopharyngiomas: An MRI Sign Identifying the Papillary Type

J.M. Pascual, R. Carrasco, L. Barrios, and R. Prieto

ABSTRACT

BACKGROUND AND PURPOSE: Papillary craniopharyngiomas (PCPs) are particularly challenging lesions requiring accurate diagnosis to plan the best therapy. Our aim was to define a narrow duct-like recess identified on MR imaging at the base of papillary craniopharyngiomas with a strict third ventricle location.

MATERIALS AND METHODS: A duct-like recess at the infundibular portion of craniopharyngiomas was observed on conventional T1WI and T2WI in 3 strict third ventricle papillary craniopharyngiomas in our craniopharyngioma series (n = 125). We systematically investigated this finding on the MR imaging of 2582 craniopharyngiomas and 10 other categories of third ventricle tumors (n = 690) published in the modern era (1986–2020). The diagnostic value and significance of this finding are addressed.

RESULTS: The duct-like recess was recognized in 52 papillary craniopharyngiomas, including 3 of our own cases, as a narrow canal-shaped cavity invaginated at the tumor undersurface, just behind the optic chiasm. This structure largely involves papillary craniopharyngiomas with a strict third ventricle topography (96%), follows the same diagonal trajectory as the pituitary stalk, and finishes at a closed end. The duct-like recess sign identifies the papillary craniopharyngioma type with a specificity of 100% and a sensitivity of 38% in the overall craniopharyngioma population. This finding can also establish the strictly intra-third ventricle location of the lesion with a 90% specificity and 33% sensitivity. These recesses appear as hypointense circular spots on axial/coronal T1WI and T2WI. Their content apparently corresponds to CSF freely flowing within the suprasellar cistern.

CONCLUSIONS: The presence of a duct-like recess at the infundibular portion of a third ventricle tumor represents a distinctive hallmark of papillary craniopharyngiomas that can be used as a simple MR imaging sign to reliably diagnose these lesions.

ABBREVIATIONS: ACP = adamantinomatous craniopharyngioma; CP = craniopharyngioma; CP-DR = CPs with a basal duct-like recess; CP-nDR = CPs without a basal duct-like recess; DR = duct-like recess; PCP = papillary craniopharyngioma; PS = pituitary stalk; 3V = third ventricle; 3VF = third ventricle floor

Papillary craniopharyngiomas (PCPs) comprise >10%–20% of all craniopharyngioma (CP) cases, affect almost exclusively adult patients, and typically grow within the third ventricle (3V) as purely solid masses or unilocular cysts lined with papillomatous excrescences of stratified squamous epithelium.1 From a surgical viewpoint, PCPs are a particularly challenging group of lesions owing to their intra-3V location and tenacious attachment to the infundibulotuberal region of the hypothalamus.2 The discovery of BRAF V600E oncogene mutations specific to this CP type has prompted the use of targeted chemotherapies with preliminary, successful results.3 Therefore, an accurate preoperative diagnosis of PCPs is essential for planning a proper surgical approach, or, alternatively, choosing nonsurgical therapies such as radiosurgery or chemotherapy.

During the past decade, our group has systematically analyzed the most pertinent information from conventional MR imaging to make reliable preoperative diagnoses of the PCP variant and to accurately define the tumor topography and adherence.4,5 After thoroughly examining MR images of >3000 CP records, we have identified some specific morphologic features predictive of the papillary type, such as tumor consistency, anatomic appearance of the pituitary stalk (PS), and the position of the hypothalamus relative to the tumor.5 In the present work, we describe and characterize an additional specific MR imaging sign identified in a subgroup of PCPs primarily developed within the 3V: a duct-like recess (DR) extending from the undersurface of the lesion toward its center and connected to the suprasellar cistern. This MR imaging finding,
clearly distinguishable on midsagittal and coronal transinfundibular T1WI and T2WI, has never been observed in adamantinomatous CPs (ACP) or in other pathologic categories of 3V tumors. Consequently, we consider that it constitutes a distinctive sign of the PCP type. The present work morphologically and neuroradiologically characterizes this CP finding and analyzes its potential diagnostic significance.

**MATERIALS AND METHODS**

**DR Sign in Craniopharyngiomas: MR Imaging Definition**

The DR is defined as a narrow and hollow duct-like cavity invaginated at the infundibular portion of a 3V tumor that follows a diagonal trajectory toward the center of the lesion through its midsagittal plane. DRs have a variable length, and they are closed at the top end and open at the bottom and show the same homogeneous hypointense signal on T1WI and hyperintensity on T2WI sequences as CSF, which can apparently flow freely between the suprasellar cistern and these tubular structures.

**Case Series Generation and Inclusion Criteria**

We conducted a systematic review of the well-described CP cases reported in the MR imaging era, from 1984 to June 2020 (n = 3352), according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) criteria (Online Supplemental Data). This study involved CPs reported in journals from the PubMed and MEDLINE databases (n = 2036) and CPs discussed either in specialized monographs (n = 796) or in professional Web pages (n = 520) focused on the treatment of pituitary/3V tumors. Likewise, an exhaustive search was made for primarily 3V tumors different from CPs published between 1984–2020 (n = 690), including 10 major pathologic categories detailed in the Online Supplemental Data. Finally, the medical charts and MR imaging studies of CPs treated from 1994 to 2020 in the authors’ departments of neurosurgery (n = 125; 106 ACPs/19 PCPs) were retrospectively examined.

From these databases, 2582 well-documented CPs were deemed eligible for neuroradiologic assessment, among them 2426 ACPs and 156 PCPs, according to the following criteria: 1) Cranioopharyngioma diagnosis was confirmed pathologically (CP histology verified in 81% of ACPs and 77% of PCPs, the remaining 23% showing MR imaging macroscopic features typical of the papillary type); 2) Preoperative midsagittal and/or coronal transinfundibular MR images of the lesion obtained with T1WI and/or T2WI sequences were given in the scientific report/Web page/clinical chart showing the presence of a DR at the tumor base; 3) A brief description of epidemiologic/clinical/pathologic and/or surgical findings of the case was provided. On the basis of these criteria, a collection of 52 CPs with a basal duct-like recess reported from 1994 to 2020 was finally included in this cohort, named the CPs with basal duct-like recess cohort (CP-DR).

**Assessment of Histologic and Topographic Diagnostic Accuracy of the DR Sign**

With the aim of ascertaining the diagnostic accuracy of the DR sign identified on MR imaging to establish the papillary histology and the strict 3V CP topography, we tested the specificity and sensitivity of this finding in the cohort of 200 CPs used by our group in 2017 to analyze the MR imaging reliability for the definition of the CP topography (CP MR imaging 200 control cohort). This series, which formed part of the data bank of 2582 CPs examined for the present study, included 14 CP-DR cases and had the advantage of having a balanced distribution of CP histologies (163 ACPs/37 PCPs), patient ages (148 adults/37 pediatric cases), and CP topographies (47% sellar/suprasellar; 32% infundibulotuberal; 21% strict 3V), all of these rates being similar to those observed in the overall CP population.

In addition, the diagnostic reliability of the DR MR imaging sign for establishing the papillary type was evaluated in a cohort of 106 strictly 3V CPs (CP strict 3V 106 control cohort) obtained from our recent review of the CP cases reported with a verified strictly 3V topography. This cohort, formed of 74 PCPs and 32 ACPs, included 49 CP-DR cases. Similarly, the DR MR imaging sign specificity and sensitivity for accurately classifying the strictly 3V tumor location were tested in a large cohort of 142 papillary CPs (PCP 142 control cohort) diagnosed with MR imaging and obtained from our recent comprehensive research on 350 well-described CP cases from the medical literature, which included 50 CP-DR cases.1

**Comparison Cohort of CPs without Basal DR**

To differentiate the clinicopathologic and MR imaging features of the tumors in the CP-DR cohort, formed of only adult patients, from the general population of adult CPs, a comparison cohort of adult CPs without a basal DR was created (CP-nDR). This comparison cohort formed part of the 2582 CP data bank eligible for this study and was gathered from our prior studies analyzing the MR imaging signs defining CP topography and adherence by arbitrarily selecting the consecutive 52 well-described CPs without a DR published in the most recent period (2004–2016). These cases met the same inclusion criteria as those defined for the CP-DR, except for the presence of a DR. Systematic bivariate analyses were then performed for clinicopathologic and MR imaging characteristics differentiating the CP-DR and the CP-nDR cohorts.

**RESULTS**

**DR in Papillary CPs: MR Imaging Characteristics**

The Online Supplemental Data present the main clinicopathologic and neuroradiologic features of the 52 CPs with a DR identified on preoperative MR images in the medical literature, including the 3 new cases from our own series. The DR can be observed on routine T1WI and T2WI midsagittal sections as a narrow hollow canal-shaped structure with a diagonal upward course along the midsagittal plane of the CP (Fig 1). All recesses follow the same diagonal trajectory as the PS and are open at the tumor undersurface, just at the area of the third ventricle floor (3VF), where the PS joins the infundibulum, connecting the recess cavity with the suprasellar or chiasmatic cistern. All DRs appear homogeneously hypointense on T1WI and T2WI (Figs 1A, 1B) and homogeneously hyperintense on T2WI (Fig 4B), with an intensity identical to that of the CSF, a sign indicating that CSF may flow freely into and out of the DR.

According to their length, DRs can be classified into 2 major types: long DRs (Fig 1A), with a length ranging between 10 and 15 mm (n = 33, 63.5%) and short DRs (Fig 4C), which invaginate into the tumor ≤5 mm (n = 19, 36.5%). No DR enhancement

---

1. Pascual Sep 2022 www.ajnr.org
after gadolinium administration was observed in any of the cases, nor were any recognizable vascular structures identified, except in 1 case (with gadolinium). On coronal/axial MR imaging sections, all recesses have a circular outline and are engulfed by the central bulk of the tumor (Fig 1A3). From all these MR imaging data, the recesses seem to represent tubular invaginations of the 3VF infundibular region into the base of 3V CPs.

**CP-DR Cohort: MR Imaging Characterization**

The Online Supplemental Data show the categorization of the main clinicopathologic, neuroradiologic, and surgical variables analyzed in the CP-DR cohort. Contrary to the balanced sex division and age distribution in pediatric/adult cases in the general CP population, all CP-DR cases occurred in patients older than 20 years of age, affecting mostly men (73%) (Fig 2A). Clinically, headache was the most frequent symptom (75%), and it showed an almost perfect correlation with the presence of obstructive hydrocephalus (71%). Notably, the rates of psychiatric disturbances (58%) and other hypothalamic alterations (20.5%) were markedly high, in accordance with the expansion of these lesions within the 3V, causing mass effect on the hypothalamus. Conversely, visual defects and endocrine deficits due to hypopituitarism were described in a relatively small number of patients, given the preserved anatomic integrity of the optic chiasm and P5 in many cases.

Morphologically, we differentiated 2 main tumor patterns: 1) the most common group of pure solid and round lesions, homogeneously isointense on T1WI, showing homogeneous gadolinium enhancement (90%); and 2) the less frequent subgroup of unicellular cystic lesions with a cauliflower-like solid nodule at the base of the cyst (Fig 2C). Both macroscopic architectures markedly differed from the multicellular, solid-cystic consistency usually found in ACPs and were certainly influenced by the papillary histology and the intra-3V development of all CP-DRs (Fig 2B, D). Histologic confirmation of the papillary type was provided in all except 3 cases, which showed on MR imaging a gross berrylike morphology with papillary protrusions at the tumor surface, identical to all the other counterparts with a verified histology.

**Diagnostic Accuracy of the DR Sign to Define the CP Histology and Topography**

The DR occurred in 16% of PCPs in our own series (n = 125), a rate that increased to 27% when considering only the PCPs with a strict 3V topography. The DR was also present in 33% of the 156 PCPs with available MR imaging examined from the literature for this study. The specificity of the DR sign to define the papillary histology on MR imaging was 100% in both the CP MR imaging 200 and the CP strict 106 control cohorts. This finding validates the DR as a hallmark of PCPs. The sensitivity of this sign was 37.8% when tested in the CP MR imaging 200 control cohort and 66% in the CP strict 106 control cohort. This means that the finding of the DR alone permits the accurate diagnosis of the papillary histology in about 38% of PCPs spanning all kinds of topographies and in two-thirds of the PCPs with a strict 3V topography.

Concerning the definition of CP topography, the DR sign specificity for establishing the strictly 3V CP location was 100% in the CP MR imaging 200 control cohort and 90% in the CP papillary 142 control cohort, whereas the sensitivity rates for this strict 3V topography were 33.3% and 53%, respectively. This finding means that the DR sign by itself reliably allows the diagnosis of the strict 3V topography in one-third of CPs with such a topography and in more than half of all PCPs.

**Pathologic and Topographic Differentiation of CPs with a Basal DR**

The Table shows a comparative analysis of the clinical and anatomo-pathologic features that best differentiate the CP-DR cohort, formed exclusively of adult patients, and the CP-nDR comparison cohort, representative of the adult CP population. The essential pathologic characteristic differentiating both cohorts was the diagnosis of the papillary variant in 100% of the cases in the former (Fig 2B). This papillary architecture definitely influenced the predominant solid tumor consistency (Fig 2C) and lack of calcifications in CP-DR tumors. Second, most CP-DR cases primarily developed within the 3V, above an intact 3VF. This is an exceedingly rare topography among CPs, even among adult patients (Fig 2D). Such a pure intra-3V CP location determines theatomic intactness of the pituitary-hypothalamic axis structures confirmed on preoperative MR imaging in many patients with CP-DR, in particular an anatomically intact P5 in 84.5% of strictly 3V PCPs (Fig 3A). The position of the hypothalamus around the lower portion of the tumor on coronal transinfundibular MR images, observed in 74.5% of strict 3V cases, was also a defining feature of the CP-DR cohort (Fig 3C). However, even though these MR imaging signs strongly point to a strictly 3V CP location, the complete integrity of the 3VF beneath the tumor could only be confirmed in 61% of cases on preoperative MR imaging (Fig 3B). Notably, the identification of a DR yielded better results than all
these aforementioned MR imaging signs to achieve an accurate topographic diagnosis of a strictly 3V CP in 96% of cases.

**DISCUSSION**

**Basal DR: A Hallmark of Strictly 3V CPs of the Papillary Type**

In 1990, Fukushima et al. first noticed a linear hypointense zone on the midsagittal T1WI of an intraventricular PCP (Fig 4A1 and A2). A more detailed description of a similar tube-shaped basal hypointensity in a 3V CP was provided by Urbach et al., who pointed out that it could represent a diagnostic sign specific to the solid papillary CP variant. No additional insights about the nature or diagnostic significance of this MR imaging sign could be gained from the medical literature. The papillary variant constitutes a minority of CPs (10%–20% of cases), usually developing at the infundibulum or entirely within the 3V.1,6 Radical excision of 3V CPs is commonly associated with a high surgical risk, owing to the mass effect on the hypothalamus and tight tumor attachments to the 3VF.1,7 In addition, many CPs affect elderly patients in poor clinical condition, precluding any complex neurosurgical procedure. Consequently, achieving a correct preoperative diagnosis of 3V CPs is essential to plan the most judicious treatment to diminish the risk of surgical hypothalamic injury.10

A papillary histology can be suspected on preoperative MR imaging mainly by assessing some CP features, such as a spherical shape, a homogeneous solid consistency, and a lack of calcifications within the tumor.4,5,10,11 The strictly 3V topography can be even more difficult to ascertain because CP boundaries are usually fused to the 3VF, which can become an unrecognizable structure on preoperative MR imaging.4,6,10 Moreover, many other strictly 3V tumors such as chordoid gliomas, astrocytomas, germinomas, and ependymomas are round with a solid consistency similar to features of PCPs.12 Therefore, verifying a duct-like recess at the base of a 3V tumor represents a novel, valuable diagnostic sign, permitting not only the pathologic diagnosis of a PCP but also a reliable definition of a strictly 3V topography in about 90% of cases.

A DR in a CP represents a morphologic feature 100% specific to the papillary type, with the sensitivity of this finding ranging between 33% in the global PCP population and 66% in the
subpopulation of CPs with a strict 3V topography. The papillary variant represents between 10% and 20% of all CP cases, but because this type almost exclusively affects adult patients, the PCP rate can reach a peak of 30% in the age interval between 30 and 80 years, as observed in the recent study by Momin et al. Given the CP incidence of between 1.3 and 1.6 cases/million people observed in the United States, about 600 new cases/year, the identification of the DR sign alone on a preoperative MR imaging could confirm the certain diagnosis of a PCP in approximately 45 tumors from the pool of around 140 PCPs diagnosed every year in the United States. Moreover, the DR is an invaluable MR imaging sign to establish the strict 3V location of the lesion, with a 90% specificity and a sensitivity ranging between 33% in the overall CP population and 53% in the subpopulation of PCPs. This topographic information is of the utmost importance for neurosurgeons to plan the proper surgical approach for lesions known to be wholly confined within the 3V.

### CP-DR Cohort: Differences from the General Adult CP Population

The unique pathologic characteristics of the CP-DR cohort, formed exclusively of PCPs with a 3V topography, contrasted markedly with those observed in the overall population of adult CP cases, which largely consist of ACPs developed either beneath the 3V (sellar/suprasellar, 60%) or within the 3VF itself (infundibulo-tuberal, 40%) (Table). These crucial differences definitely influenced the significant morphologic and clinical discrepancies between both cohorts. Symptoms of hypothalamic impairment, including psychiatric and cognitive disturbances, were prominent among CP-DR lesions, which caused severe compression and edema in the hypothalamic region. By contrast, visual disturbances due to optic chiasm stretching, usually caused CPs originating beneath the 3V, predominated in the CP-nDR cohort. The prevailing 3V topography among CP-DR lesions also determined the high rate of obstructive hydrocephalus and the round shape and solid consistency of these PCPs, tumor features that differed from the typical solid-cystic multilobulated morphology observed among ACPs. Finally, PCP-DR tumors affected male patients more frequently, a tendency not present among ACPs, plausibly attributable to genetic causes and deserving further investigation.

### DR: A Sign Differentiating PCPs from Other 3V Tumors

The identification on conventional MR imaging of a hollow recess at the infundibular midline region of a solid 3V tumor distinguishes a particular subpopulation of 3V PCPs. We were able to confirm this finding after methodically reviewing the MR images displayed in a total of 2582 CPs. The DR was never observed in
ACPs nor among PCPs growing beneath the 3VF. Very important, after systematically reviewing the MR images of 500 3V tumors of various pathologic diagnoses other than CP, we were unable to find any similar duct-like structures (Fig 1). Among originally developing 3V tumors, neither chordoid gliomas (n = 128) nor ependymomas (n = 116) showed, in any of the reports examined, a DR structure resembling those observed in the PCPs of the present cohort, nor in any of the secondary 3V tumor categories investigated, such as germinomas (n = 73), lymphomas (n = 58), epidermoids (n = 36), and teratomas (n = 66), could a similar tubular recess be recognized. This finding suggests the existence of a pathogenetic mechanism specific for the presence of a DR in 3V PCPs.

The category of 3V choroid plexus papillomas (n = 84), lesions with a macroscopic papillary architecture mimicking PCPs, may show multiple fissures and crevices somewhat resembling the DR.14 The DR in PCPs could then be interpreted as a large crack or fissure formed by the natural process of dehiscence of the squamous epithelium that gives these lesions a pseudopapillary appearance.1 However, small cracks and fissures are randomly present all around the tumor surface in both choroid plexus papillomas and PCPs, whereas the DR shows a consistent tubular shape and a constant position at the PCP midline undersurface, following the same course as the PS, evidence that goes against this view. Rather, the morphologic DR characteristics suggest a pathogenetic link between the intra-3V location of CP precursors and the embryogenesis of the pituitary-hypothalamic axis.

**DR in 3V PCPs: Anatomic Clues Pointing toward an Embryologic Pathogenesis**

The hollow, duct-like cavity identified in 3V PCPs in this study can also be defined as a tumor recess, because it presumably corresponds to the intratumor extension of the suprasellar (subarachnoid) space, filled with CSF. Anatomically, the 3VF is shaped like 2 recesses, the chiasmatic recess, a V-shaped 3V extension above the optic chiasm, and the infundibular recess, the funnel-shaped 3V downward extension into the PS.15 This anatomy raises the question as to whether the DR may represent a residual, patent portion of the infundibular recess invaginated within the lesion. Such an interpretation seems highly implausible because tumors expanding within the 3V, including CPs, usually compress the 3VF downward and obliterate the 3V recesses rather than filling in these spaces.6 Alternatively, the DR could be interpreted as a fibrovascular core providing the blood supply to the tumor. However, the basal stemlike fibrovascular attachment feeding 3V PCPs has a solid structure, not a hollow one.1 No blood vessels within the DR could be identified on the MR images available in this cohort, with the exception of the case by Sartoretti-Sheffer et al,1 in which a narrow vessel running along the anterior aspect of the PS penetrates the DR.16 Instead, the duct-like shape of the CP recess, its variable length, and, above all, its diagonal trajectory following the same course as the PS axis suggest that the DR formation could be linked to the embryologic process of the pituitary axis development from the Rathke pouch.

Most PCPs with a basal recess have a strict 3V location. How a tumor apparently originating from remnants of an extraventricular structure such as the Rathke pouch could develop exclusively within the 3V, a portion of the closed neural tube, has been a source of puzzlement since strictly 3V CPs were first identified at postmortem examination.17 In the 1980s, Ciric and Cozzens18 theorized that strictly 3V CPs could originate from the Rathke pouch cells if this embryonic structure merged with the 3VF before the pia mater was formed.15 Indeed, a close attachment between the ventral neural tube and the roof of an embryo’s primitive mouth occurs at the earliest stages of pituitary gland organogenesis, and
extends to the tumor center, following the same trajectory as the PS.

The hyperintense signal of the duct, identical to that in the CSF (papillary CP (Online Supplemental Data). This midsagittal T2WI shows the hypointense signal of the recess identical to CSF, indicating free passageway of CSF between the suprasellar cistern and the recess and the rounded dead end of the recess at the tumor center. Reproduced with permission from the Fukushima et al. 

B. Duct-like long-recess type in a strict papillary CP (Online Supplemental Data). This midsagittal T2WI shows the hypointense signal of the duct, identical to that in the CSF (white arrow). Reproduced with permission Gu et al. 

C. Coronal-transfundibular TIWI of a short-type basal DR in a strict 3V PCP (Online Supplemental Data). Note the isointense rim of the 3V floor covering the undersurface of this solid homogeneously gadolinium-enhancing tumor and how the 3VF invaginates at the midline of the basal pole of the CP to form the recess (white arrow). Reproduced with permission from Rambarki and Rajesh.

PG indicates pituitary gland; MB, mammillary body; OC, optic chiasm.

this union could explain the inclusion of CP ectodermal cell precursors within the 3V. The presence of a DR at the base of 3V PCPs supports a dysembryogenetic origin of this histologic variant, linking PCPs with the developing course of stomodeal precursors moving with the Rathke pouch along the migratory pathway followed by the craniopharyngeal canal. The DR extending upward into the 3V can be judged to be an equivalent of the duct-like downward passageway between the 3V and the sella turcica, known as a persisting embryonal infundibular recess, likewise thought to be the result of a failed obliteration of the infundibular recess during pituitary organogenesis.

CONCLUSIONS

The presence of a DR at the infundibular portion of a solid 3V tumor represents an MR imaging sign diagnostic of the papillary CP type with a specificity of 100% and a sensitivity of 33% in the global population of PCPs. This finding is also a reliable MR imaging sign for establishing the strictly 3V topography, with a specificity of 90% and a sensitivity of 33% in the overall CP population. The DR can be easily identified on midsagittal and coronal T1WI and T2WI as a hypointense canal-shaped signal of variable length. No similar duct-like structure has ever been observed in any other 3V tumor category. Therefore, the DR represents an invaluable sign for accurately diagnosing strictly 3V papillary CPs.

ACKNOWLEDGMENTS

The authors wish to especially thank Crystal Smith and Liliya Gusakova. Reference Librarians of the National Library of Medicine, National Institutes of Health (Bethesda, Maryland) for their kind assistance during the process of searching and retrieving articles and monographs used in this study. We are also grateful to Melissa Grafe, Librarian for Medical History Library, Yale University (New Haven, Connecticut) and to Lucretia MacLure, Jack Eckert, and the staff at the Francis A. Countway Library of Medicine at Harvard Medical School (Boston, Massachusetts) for their invaluable help in obtaining some of the original research material used for this study. Finally, we are grateful to George Hamilton for his critical review of the language and style of the manuscript.

Disclosure forms provided by the authors are available with the full text and PDF of this article at www.ajnr.org.

REFERENCES


10. Pascual JM, Prieto R, Castro-Dufourny I, et al. Topographic diagnosis of papillary craniopharyngiomas: the need for an accurate MRI-
Granulomatous hypophysitis (GH) is a rare, inflammatory condition of the pituitary gland characterized by the presence and formation of granulomas throughout or around the pituitary gland. It is most often associated with systemic diseases such as sarcoidosis or tuberculosis (secondary GH) and, less commonly, isolated to the gland (idiopathic GH). GH forms a subset of autoimmune hypophysitis (AH), which also includes lymphocytic hypophysitis (LH) and Langerhans cell histiocytosis in the differential.1,2

The imaging appearance of AH is nonspecific and overlaps with that of pituitary adenomas, with 1 prior study describing a grading scale to distinguish these entities.3 In terms of GH, there are scant case reports on the imaging findings, and they also overlap with those of pituitary adenomas.4-10 The purpose of this study was to test our observation that diffuse enhancement within the basisphenoid marrow below the sella can distinguish GH from a pituitary adenoma, a feature that is important diagnostically because medical and surgical management differs for these conditions.11,12

MATERIALS AND METHODS
We retrospectively reviewed an internal database for pathology-proved GH with preoperative contrast-enhanced MR imaging with a small FOV focused on the sella. T2-weighted, precontrast T1-weighted, and postcontrast T1-weighted images were reviewed for edema and enhancement of the basisphenoid bone marrow. Additionally, the patients’ electronic medical records were reviewed for clinical history, surgical pathology, and relevant laboratory results.

Our internal database was also reviewed for 100 consecutive pathology-proved pituitary adenomas with preoperative MR

Received March 25, 2022; accepted after revision June 28.
From the Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California.
Please address correspondence to Ian Mark, MD, Mayo Clinic, 200 1st Street SW, Rochester, MN 55905; e-mail: mark.ian@mayo.edu; @iantmark
http://dx.doi.org/10.3174/ajnr.A7618

imaging from January 2021 to January 2022. Images were primarily reviewed for edema and enhancement of the basisphenoid bone marrow. Additionally, the pneumatization pattern of the sphenoid sinus can limit bone marrow evaluation; therefore, the sphenoid sinus pneumatization was evaluated and graded as follows (Fig 1): type 1, conchal; type 2, presellar; type 3, sellar; and type 4, postellar.13 For the adenoma cases, we measured the maximum diameter and recorded their prolactin levels.

All cases were reviewed by a neuroradiology instructor (I.T.M.). Cases with equivocal findings were additionally reviewed by a neuroradiologist with 20 years of experience (C.M.G.). Basic statistical analysis was performed with Excel (Microsoft).

RESULTS

Patients with GH

Three cases of pathology-proved GH are presented below. Each patient had bone marrow enhancement of the basisphenoid below the sella.

Patient 1. A 51-year-old woman presented to an outside institution with headache, dizziness, hyponatremia (113 mEq/L), and emesis with 11 kg of unintentional weight loss (Fig 2). Her laboratory values were consistent with central hypothyroidism, and she was treated with levothyroxine. The contrast-enhanced MRI showed a 1.8-cm sellar mass with type 3 pneumatization of the sphenoid sinus and enhancing bone marrow edema of the basisphenoid. The diffuse enhancement spanned nearly the entire anterior-posterior and transverse dimensions of the bone marrow beneath the sella. She was thought to have a pituitary macroadenoma and underwent endoscopic transsphenoidal resection of the central pituitary gland. The pathology demonstrated GH. Staining for acid-fast Bacillus was negative. She did not have a history of systemic granulomatous disease, and her pituitary lesion was thought to represent primary, idiopathic GH.

Patient 2. A 30-year-old woman presented with right orbital headaches, polydipsia, and polyuria (Fig 3). She was found to have hyperprolactinemia (49.5 μg/L) and a 1.7-cm sellar mass with type 3 pneumatization of the sphenoid sinus and diffuse enhancing bone marrow of the basisphenoid below the sella on MRI, thought to be a pituitary adenoma. She underwent a pituitary biopsy, findings of which were consistent with GH. Following the biopsy, she was treated with dexamethasone and desmopressin. Follow-up MRI 6 months later showed a decrease in the size of the pituitary gland and resolved bone marrow enhancement of the basisphenoid. A cervical lymph node biopsy for work-up of sarcoidosis was negative. She did not have a diagnosis of a granulomatous systemic disease, and her pituitary lesion was thought to represent primary, idiopathic GH. At follow-up 1.5 years after biopsy, the patient did not have symptoms of hypopituitarism, and her diabetes insipidus had resolved.

Patient 3. A 34-year-old woman presented with 3 months of progressive headache, gastrointestinal upset, amenorrhea, fatigue, and blurry vision (Fig 4). She was found to have hyperprolactinemia (78.1 μg/L) and a 1.6-cm sellar mass with type 3 pneumatization of the sphenoid sinus and diffuse enhancing edema of the basisphenoid below the sella, thought to be a pituitary adenoma. She underwent an endoscopic transsphenoidal exploration with a biopsy that revealed granulomatous inflammation. After treatment with oral dexamethasone, a follow-up MRI 7 months later showed a marked decrease in the size of the pituitary gland with resolved enhancing edema of the basisphenoid. One month after her pituitary biopsy, she had a stomach biopsy that was positive for non-necrotizing granulomas, and her pituitary lesion was thought to represent secondary GH in the setting of sarcoidosis.

Pituitary Adenoma. Of the 100 patients with pathology-proved pituitary adenomas, 67 were women and 33 were men. The average age was 53.3 (SD, 17.3) years (range, 19–84 years). The basisphenoid pneumatization patterns were as follows: 15 (type 2), 40 (type 3), and 45 (type 4). None of the 100 patients had diffuse basisphenoid enhancement (Fig 5). One patient had focal enhancement of the basisphenoid (Fig 6) but did not have the diffuse enhancement seen in the 3 GH cases. The adenomas had an average maximum diameter of 2.6 cm (range, 0.4–4.4 cm). The average prolactin level was 103.4 μg/L (range, 0.3–1781.0 μg/L); however, when we excluded 3 outlier patients with markedly high prolactin levels (1189, 1750, and 1781 μg/L), the average was 54.9 μg/L.

DISCUSSION

Our study presents 3 cases of pituitary GH with diffuse basisphenoid bone marrow enhancement that was not found in any of our cases.
of pituitary adenoma. Differentiating pituitary adenoma and GH can have a large impact on patient care. Pituitary adenomas, as in all 100 of our cases, are frequently resected. GH, on the other hand, can be treated with steroids after diagnosis with biopsy and was not further explained. Bhansali et al described pituitary stalk thickening and loss of the posterior pituitary bright spot as clues to the diagnosis of GH, but again, these are nonspecific to this diagnosis.

We found that the diffuse enhancement of the basisphenoid below the sella can be used to distinguish GH from pituitary adenoma. GH can be seen primarily in the sella or found in association with systemic disease such as sarcoidosis and tuberculosis. Histologically, GH is an inflammatory process with granulomas and multinucleated giant cells. Therefore, it should not be surprising that the adjacent bone of the basisphenoid below the sella had enhancement in the 3 cases that we present. However, this has not been described with LH, which, along with GH, is considered a subtype of AH. The relationship between LH and GH is controversial, with some believing that they represent opposite ends of the spectrum, while others report that they are 2 separate diseases. Unlike LH, which has a greater affinity for women and typically involves the late pregnancy or early postpartum periods, GH does not preferentially affect women or have an association with pregnancy.

The literature contains several case reports of GH, but they largely describe nonspecific imaging findings and do not assist in differentiation from adenomas. In a systematic review, Hunn et al examined the MR imaging findings of 51 cases of GH. Their most frequent MR imaging finding was isointense T1 lesion signal in 29.4% of patients. The next most frequent finding was soft tissue hypointense bright spot (19.6%), followed by T2-hyperintense signal (15.7%).

Vasile et al presented a case of GH and summarized 7 cases from the literature with MR imaging findings that were nonspecific: T1 isointense to brain (4/7 cases), heterogeneous T2 signal (2/7 cases), and homogeneous enhancement (3/7 cases). This work did state that findings of inflammation including dural enhancement, sphenoid sinus mucosal thickening, and bone marrow abnormality could be seen; however, abnormal bone marrow...
Gutenberg et al\textsuperscript{3} proposed a scoring system to distinguish AH and pituitary adenoma on the basis of an evaluation of 19 clinical and imaging features. However, their study examined all patients with AH, combining a smaller number of patients with GH and a larger number of those with LH. The case-control study included only 46 biopsy-proved cases of GH of 402 patients (11.4%). The most useful clinical feature to distinguish AH and pituitary adenoma was pregnancy; however, this is a key feature that differentiates LH and GH. Unfortunately, enhancing edema of the basisphenoid was not studied. One of their MR imaging features highly indicative of AH was loss of the posterior pituitary bright spot; however, 30% of their large adenomas had the same finding. Similarly, Sacki et al\textsuperscript{16} reported that the posterior pituitary bright spot was nonvisible in 20% of large adenomas, which can also be seen in nonpathologic conditions such as dehydration.\textsuperscript{17}

A case report by Kartal et al\textsuperscript{18} described clival enhancement in a patient with lymphocytic hypophysitis. However, on their fat-saturated postcontrast figure, the enhancement was along the dorsal cortex of the clivus and could very well represent dural thickening and/or venous congestion. In fact, their images clearly demonstrated no basisphenoid bone marrow enhancement. Nakata et al\textsuperscript{19} described T2 parasellar dark signal in cases of LH, which we did not see in our cases of GH.

Our study has several limitations, the first being the small sample size. GH is a rare disease and does not necessitate a biopsy if there is known systemic disease; therefore, we were only able to present 3 pathology-proved cases. However, all cases had stark diffuse enhancement of the basisphenoid bone marrow below the sella, which is distinctly different from findings in pituitary adenomas. Additionally, the identification of enhancing bone marrow depends on having bone marrow to evaluate; therefore, type 4 pneumatization patterns are difficult to evaluate in the bone marrow and comprised 45% of our pituitary adenoma cases. Additionally, if the postcontrast images are not fat-saturated, evaluating true enhancement from the T1-hyperintense signal of fatty bone marrow would be extremely limited. While GH is a rare disease, the implication for patient treatment compared with pituitary adenoma suggests that preoperative pituitary MR imaging protocols should contain postcontrast images with fat saturation. While basisphenoid bone marrow enhancement is not necessarily specific to GH, we could not find studies describing this in other inflammatory pathologies (abscess, LH), and more important, we did not find it in any of our cases of pituitary adenoma.

We did not evaluate other pathologies such as Rathke cleft cysts, intrasellar craniopharyngioma, or metastases. Finally, cases of infection, including sphenoid sinusitis and skull base osteomyelitis, could lead to bone marrow edema; however, clinical history as well as the epicenter of bone marrow edema could help to differentiate these cases, because GH primarily involves the bone marrow directly beneath the sella.

FIG 5. MR images of 2 patients with large pituitary adenomas demonstrate the typical nonenhancing basisphenoid bone marrow. Precontrast (IA/2A) and fat-saturated postcontrast (IB/2B), sagittal T1-weighted images without basisphenoid bone marrow enhancement. Both patients have type 2 pneumatization of the sella.

FIG 6. A large pituitary adenoma on precontrast sagittal T1-weighted (A), postcontrast sagittal (B), and coronal (C) T1-weighted images shows focal bone marrow enhancement in the right anterior and lateral aspect of the basisphenoid. This is a distinct pattern from the diffuse enhancement in patients with GH.

CONCLUSIONS

We present 3 cases of GH with diffuse enhancement of the infrasellar basisphenoid bone marrow that was not seen in our review of 100 cases of pituitary adenomas. This imaging feature may be
valuable to suggest a diagnosis of GH and avoid resection of what would otherwise be mistaken for a pituitary adenoma.

Disclosure forms provided by the authors are available with the full text and PDF of this article at www.ajnr.org.

REFERENCES
Normal Enhancement within the Vestibular Aqueduct: An Anatomic Review with High-Resolution MRI

G. Liu, J.C. Benson, C.M. Carr, and J.I. Lane

ABSTRACT

BACKGROUND AND PURPOSE: The normal appearance of the vestibular aqueduct on postcontrast MR images has not been adequately described in the literature. This study set out to characterize the expected appearance of the vestibular aqueduct, with particular emphasis on the enhancement of the structure on both 3D FSE T1 and 3D-FLAIR sequences.

MATERIALS AND METHODS: All MR imaging examinations of the internal auditory canals performed between March 1, 2021, and May 20, 2021, were retrospectively reviewed. All studies included high-resolution (≤0.5-mm section thickness) pre- and postgadolinium 3D FSE T1 with fat-saturated and postgadolinium 3D-FLAIR sequences. Two neuroradiologists independently reviewed the MR images of the vestibular aqueduct for the presence or absence of enhancement on both T1 and FLAIR images and compared the relative intensity of enhancement between sequences. The presence or absence of an enlarged vestibular aqueduct was also noted.

RESULTS: Ninety-five patients made up the patient cohort, of whom 5 did not have postcontrast FLAIR images available (50 women [55.6%]). On both sides, enhancement was significantly more commonly seen on postgadolinium FLAIR (76/180, 42.2%) than on T1 fat-saturated images (41/190, 21.6%) (P < .001). The intensity of enhancement was significantly greater on postgadolinium FLAIR images than on T1 fat-saturated images (38.9% versus 3.7%, respectively; P < .001).

CONCLUSIONS: Enhancement within the vestibular aqueduct is an expected finding on MR imaging and is both more common and more intense on postgadolinium 3D-FLAIR than on T1 fat-saturated sequences. Such enhancement should not be confused with pathology on MR imaging unless other suspicious findings are present.

ABBREVIATIONS: FS = fat-saturation; IAC = internal auditory canal; postgad = postgadolinium; VA = vestibular aqueduct

The vestibular aqueduct (VA) is a J-shaped bony canal measuring approximately 5–17 mm in length. It extends from the medial side of the vestibule to the petrous portion of the temporal bone and contains the endolymphatic duct, which is lined with cuboidal or low-columnar epithelial cells. Along its course, the duct progressively narrows until it becomes the endolymphatic sac. The endolymphatic duct serves to connect the endolymphatic sac, inner ear vestibule, and cochlea. It functions as 1 of the 3 communication pathways between the intracranial space and inner ear and is thought to provide inner ear pressure equilibrium and fluid homeostasis. The endolymphatic duct also acts as an intracranial pressure buffer via the connection between the cochlea aqueduct and CSF. Accurate evaluation of the VA is of utmost importance because abnormalities of the aqueduct can be associated with pathologic conditions, most notably enlarged VA syndrome and endolymphatic sac tumors. The anatomy of the VA and its appearance on MR cisternogram sequences have been previously described. Multiple studies have demonstrated high sensitivity in diagnosing an enlarged VA on MR imaging. McKinney has reported that enhancement within the VA can be a normal finding in 20%–30% of asymptomatic patients on MR imaging. Little, however, is known about the expected appearance of the VA on postcontrast MR imaging T1 and FLAIR sequences. Thus, this study set out to characterize the expected appearance of the VA in a cohort of patients being evaluated for asymmetric sensorineural hearing loss, with particular emphasis on enhancement within the structure on both T1 and FLAIR sequences.

MATERIALS AND METHODS

Patient Selection

Institutional review board approval was obtained for this study. A retrospective review was completed of all internal auditory canal (IAC) protocol MR imaging examinations performed between
March 1, 2021, and May 20, 2021, in patients being evaluated for asymmetric sensorineural hearing loss. We included MRIs with findings that were considered normal on both the initial interpretation and our subsequent review as part of this study. Included patients had 3T MR examinations (Verio, Skyra, Prisma; Siemens) that included high-resolution (≤0.5-mm section thickness) pre- and postgadolinium (postgad) sequences completed for IAC protocol imaging with 3D sampling perfection with application-optimized contrasts by using different flip angle evolution (SPACE; Siemens) FSE T2, 3D SPACE FSE T1 pre- and postgad (with fat-saturation [FS]), and 3D SPACE FLAIR. As part of the standard IAC MR imaging protocol of our institution, pre- and postgad T1-FS images and postgad FLAIR images are routinely obtained.

**Imaging and Clinical Review**

Two neuroradiologists independently reviewed MR images of the VA for the following: 1) the presence or absence of T1 postcontrast enhancement, 2) the presence or absence of postgad FLAIR enhancement, 3) comparison of enhancement intensity between T1 postcontrast and postgad FLAIR (ie, whether enhancement was subjectively greater on T1-FS or FLAIR sequences), and 4) the presence or absence of VA enlargement. To ensure that we were observing real enhancement, we coregistered pre- and postcontrast T1-weight images. All discrepancies were resolved by consensus.

**Statistical Analysis**

The frequency of enhancement in T1 postcontrast and FLAIR postcontrast images was compared. Two group proportions were compared using 2 group binomial tests. Additionally, the intensity of enhancement of both sequences was compared. Agreement for the left and right sides for both MR imaging sequences was compared using the $\chi^2$ test. The $\alpha$ level of <.05 was used as the significance level. All the statistical analyses were performed by BlueSky Statistics (Commercial server edition, Version 7.40; https://www.blueskystatistics.com/category-s/118.htm).

**RESULTS**

Of the 100 patients who met the inclusion criteria for this study, 5 were excluded due to incomplete MR imaging sequences. Five patients did not have postgad FLAIR sequence performed but were included in the remainder of the study. Hence, 95 patients made up the patient cohort, allowing a total of 190 VAs for analysis on postgad T1-FS images and 180 VAs for analysis on postgad FLAIR images. Fifty (55.6%) of the included subjects were women. The average patient age was 58 years, ranging from 18 to 84 years of age.

Enhancement was observed in 76/180 (42.2%) VAs on postgad FLAIR images, and in 41/190 (21.6%) VAs on postgad T1-FS images. VA enhancement was observed in significantly greater frequency on postgad FLAIR than on T1-FS sequences ($P < .0001$). In patients who had enhancement on both sequences, the intensity of enhancement was subjectively greater on a larger proportion of postgad FLAIR than on T1-FS sequences (38.9% versus 3.7%, respectively; $P < .0001$). There was no significant difference in the incidence of VA enhancement between the left and right sides ($P < .0001$). Only 1 VA was noted to be enlarged, which did not demonstrate enhancement on either sequence.

**DISCUSSION**

This study sought to characterize the prevalence of enhancement within the VA in healthy patients on high-resolution MR imaging. Our findings indicate that VA enhancement is an expected finding and is both more commonly observed and subjectively intense on postcontrast 3D-FLAIR sequences than on T1-FS sequences, as seen in Figure 1. The observed enhancement was present in patients with a normal-appearing VA on MR imaging. Only 1 VA was found to be enlarged on MR imaging, which did not demonstrate enhancement. For example, Figure 2 demonstrates a case of nonenhancing VA. Thus, unless other suspicious findings are present to raise concern for a pathologic process such as associated osseous abnormalities, endolymphatic duct or sac enlargement, or VA enlargement, the results indicate that enhancement of the VA should not be confused with pathology on MR imaging. Like all anatomic descriptions in radiology, this finding should serve as a foundation for many types of imaging interpretations. For example, if an examination is performed to assess leptomeningeal disease, isolated enhancement within the vestibular aqueduct should not be considered pathologic because we have shown that it frequently occurs in healthy patients. Thus, these findings can be used

![FIG 1. An example of VA enhancement. The VA is visible on thin-section 3D SPACE FSE T2 image (A), which demonstrates a normal-caliber aqueduct. Prominent enhancement is seen on postgad FLAIR image (B), while less prominent enhancement is seen on postgad T1-FS image (C). The curved arrow points to the vestibular aqueduct.](image-url)
with T1-weighted imaging, such as identification of inflammatory FLAIR images to be better at detecting enhancement in comparison FLAIR imaging. Many studies have shown contrast-enhanced T1-weighted images will also be demonstrated on postcontrast 1348 Liu Sep 2022 www.ajnr.org pathologic abnormality. to prevent inaccurate interpretation of enhancement in the VA as a pathologic abnormality.

While CT is better at visualizing the osseous VA, multiple studies have demonstrated that CT is not necessary to exclude a pathologically enlarged VA. In 1 study, MR imaging had a 97% sensitivity in diagnosing an enlarged VA. Another study demonstrated that there is diagnostic agreement of 93% on CT and MR imaging if applying the Valvassori criterion, which determined that the VA is enlarged when measuring >1.5 mm at the mid-point. The advantages of using MR imaging include better visualization of the cochlear nerve and lack of radiation, especially valuable in the pediatric population to reduce exposure.

Although it is uncertain why enhancement within the VA was observed with such frequency, the most likely explanation is that the enhancement is related to normal vasculature within or immediately adjacent to the aqueduct. This hypothesis fits with what is known about the anatomy of the VA. An accessory canal, called the paravestibular canal, runs parallel to the VA, which usually contains 1 or 2 paravestibular veins. A micro-CT study by Nordström et al demonstrated the proximity of the VA to the vein of the VA. These form a rich vascular plexus containing the vein of the VA, which provides the main venous outflow of the vestibule, endolymphatic walls, and endolymphatic sac.

FLAIR is an inversion recovery sequence that is heavily T2-weighted with nullled CSF signals and a component of mild T1-weighted contrast. Therefore, any enhancement on postcontrast T1-weighted images will also be demonstrated on postcontrast FLAIR imaging. Many studies have shown contrast-enhanced FLAIR images to be better at detecting enhancement in comparison with T1-weighted imaging, such as identification of inflammatory leptomeningeal disease, disruption of blood-CSF barrier, infectious meningitis, and so forth. A probable explanation for this phenomenon may be that postcontrast FLAIR is more sensitive to the T1-shortening agent in comparison with T1-weighted imaging. Additionally, suppression of the CSF signal on FLAIR postcontrast imaging could demonstrate better contrast of enhancement. Thus, the observations of this study—that contrast was more readily seen on FLAIR than T1-FS—fit with the known sensitivity of the postgad FLAIR sequences to detect subtle enhancement.

To our knowledge, there have been only a few studies on enhancement within the VA on MR imaging in the past. A 2001 study by Naganawa et al using a mixed cohort of patients with hearing loss and Menière disease and age-matched controls found that enhancement of the endolymphatic sac was seen in similar frequency among patients with Menière disease and age-matched controls, though it was noted in higher frequency in patients with sudden hearing loss. A 2003 study by Sugiuira et al however, found that the frequency of endolymphatic sac enhancement was similar among patients with hearing loss and control subjects. Our study has a much larger sample size and hence more statistical power.

Our study has a few limitations. First, this was a single-institution study, which may limit the generalizability of our results, particularly because differences in MR imaging sequences between institutions may affect the observed findings. Second, this was a retrospective, observational study that cannot provide definite information on cause-and-effect relationships. Further studies will be needed to evaluate any relationships between VA enhancement and pathology.

CONCLUSIONS
Enhancement within the VA is frequently present on high-resolution MR imaging and should be considered a normal finding unless other suspicious findings are present. The observed enhancement is more common and more intense on FLAIR images than on T1-FS sequences.

Disclosure forms provided by the authors are available with the full text and PDF of this article at www.ajnr.org.

REFERENCES

FIG 2. An example of a nonenhancing VA. The VA is faintly visible on axial postgad FLAIR (A) image but does not demonstrate enhancement. The structure cannot convincingly be seen on postgad T1-FS image (B). The curved arrow points to the vestibular aqueduct.


ABSTRACT

PURPOSE: To determine the accuracy of MR imaging for diagnosis of meningitis in infants.

MATERIALS AND METHODS: Retrospective review of infants less than 1 year of age who underwent a brain MR imaging for meningitis from 2010–2018. Gold standard for diagnosis of bacterial meningitis was a positive bacterial CSF culture or a positive blood culture with an elevated CSF WBC count, and diagnosis of viral meningitis was a positive CSF PCR result and elevated CSF WBC count. Sensitivity, specificity, PPV, NPV, and accuracy for MR imaging diagnosis of meningitis were calculated.

RESULTS: Two hundred nine infants with mean age 80 days (range 0–347 days) were included. There were 178 true positives with the most common pathogens being: Group B Streptococcus (58), E. coli (50), Streptococcus pneumoniae (21), H. influenzae (4); Herpes simplex virus 1 or 2 (18); Enterovirus (4); and other (23). There were 31 true negatives. Range of sensitivity, specificity, PPV, NPV, and accuracy of MR imaging for detection of meningitis was 67.4–83.5%, 92.3–95.7%, 95.0–98.6%, 33.3–76.5%, and 71.3–86.5% respectively. MR imaging sensitivity decreased after 10 days from time of presentation while specificity remained stable. Among individual MR imaging findings, leptomeningeal enhancement was the most sensitive finding, while cerebritis, infarction, ventriculitis, abscess, and intraventricular purulent material were the most specific findings.

CONCLUSIONS: MR imaging of the brain demonstrates high specificity and moderate sensitivity for diagnosis among infants presenting with signs and symptoms of meningitis. The results reflect current standard of care for imaging of infants with meningitis however a selection bias for imaging of more severe meningitis may affect these results.

ABBREVIATIONS: NPV = negative predictive value; PCR = polymerase chain reaction; PPV = positive predictive value; WBC = white blood cell

Bacterial and viral CNS infections are common in infants and can present with various nonspecific signs and symptoms, including fever, hypothermia, irritability, poor feeding, bulging fontanelle, and seizures. Bacterial meningitis is an inflammation of the meninges affecting the pia and arachnoid and subarachnoid spaces in response to bacteria and/or bacterial products and is most common in the first year of life.1,2 In infants, bacteria and viruses can enter the body through the skin, mucosa, blood, and respiratory and gastrointestinal tracts. They most commonly enter the CNS by the hematogenous route and, less commonly, by direct spread from adjacent sites such as the sinuses or mastoids. In the modern era, the mortality from bacterial meningitis is approximately 10%, and survivors remain at high risk for neurologic sequelae.3,4 In neonates, the most common causes of meningitis in infants are Group B Streptococcus and Escherichia coli, while Streptococcus pneumoniae is the most common cause in infants.1,5 The most common causes of viral meningitis in neonates and infants are herpes simplex and Enterovirus; however, many viral infections remain undiagnosed due to limitations in laboratory testing.

The diagnosis of bacterial or viral meningitis relies on isolation in a culture or detection by molecular testing of the causative pathogen from the CSF. Patients with potential meningitis will often undergo an MR imaging of the brain to assess imaging findings supportive of a CNS infection and complications that can include abscess, empyema, arterial or venous infarction, and hydrocephalus/CSF circulation disorders. However, the exact diagnostic accuracy of MR imaging for the detection of meningitis in infants remains unknown. In addition, it is unknown which MR imaging findings are the most sensitive or specific for the diagnosis of meningitis and whether the length of time from presentation to MR imaging affects the diagnostic sensitivity of MR imaging.
Therefore, the purpose of this study was to determine the diagnostic accuracy of MR imaging for the diagnosis of meningitis among infants and determine which factors affect the diagnostic performance of MR imaging.

**MATERIALS AND METHODS**

Following institutional review board approval (Texas Children’s Hospital), a retrospective review was performed from 2010 to 2018 among infants younger than 1 year of age who presented with signs and symptoms of meningitis, including any combination of fever, seizure, lethargy, respiratory distress, decreased oral intake, or irritability. All patients had a lumbar puncture with CSF laboratory data, CSF culture, anaerobic and aerobic blood cultures, and an MR imaging of the brain performed without and with IV contrast within 30 days of presentation. The timing from when CSF was obtained with respect to administration of IV antibiotics and acyclovir was recorded as either before administration, <24 hours after administration, or >24 hours after administration. The age (including neonate age range defined as age <30 days) and prematurity (defined as <37 gestational weeks) of the patients were extracted from the electronic medical records. Because of the retrospective nature of this study, decision to perform an MR imaging was based on standard clinical care and at our institution this includes routine MR imaging for infants less than 6 weeks and after 6 weeks is based on physician judgment of severity or potential for complications of meningitis.

The criterion standard diagnosis of bacterial meningitis was determined by either a CSF culture positive for meningitis or a blood culture positive for meningitis combined with elevated CSF white blood cell (WBC) count (>20 WBC/µL for younger than 30 days of age, >9 WBC/µL for 30–90 days of age, and >6 WBC/µL for older than 90 days of age). The criterion standard diagnosis of viral meningitis was a viral polymerase chain reaction (PCR) from CSF with positive findings and an elevated CSF WBC count. Patients with true-negative findings had a normal CSF WBC count and a CSF culture and PCR testing with negative findings. A total of 42 patients with CSF WBC counts above the normal range but without a CSF culture, blood culture, or viral PCR positive for meningitis were excluded from analysis. CSF cultures with coagulase-negative staphylococci or other skin contaminants were excluded. Patients with no CSF sampling, immunodeficiency, malignancy, or presence of an intracranial shunt were also excluded.

MR imaging of the brain was performed in all patients on 1.5T and 3T MR imaging scanners using standard departmental protocols including precontrast axial and sagittal 2D T1-weighted TSE with 3- to 4-mm section thickness, axial 2D FLAIR with 3- to 4-mm section thickness, axial and coronal 2D T2-weighted TSE with 2.5- to 4-mm section thickness, axial gradient-echo or SWI with 2.5- to 4-mm section thickness, axial DWI/DTI with 2.5- to 4-mm section thickness, and postcontrast axial and coronal 2D T1-weighted imaging with 3- to 4-mm section thickness with the axial imaging performed immediately after intravenous contrast administration followed by the coronal imaging. The TE/TR times varied by scanner with T1W MRI TE/TR ranging from 10–12.5 ms/458–533 ms and T2W MRI TE/TR times ranging from 80–120 ms/3074–7000ms. Standard of care at our institution is to perform post contrast imaging in patients with suspected meningitis unless standard contraindications existed such as renal failure or contrast allergy.

Retrospective independent blinded reviews of initial brain MRIs performed without and with intravenous contrast were performed by 2 board-certified neuroradiologists (S.K., and M.K.) with, respectively, 10 and 13 years of experience in pediatric neuroradiology, for the presence of direct signs of meningitis, including leptomeningeal enhancement, ventriculitis, cerebritis, infarction, abscess/granuloma, and extra-axial (subarachnoid or subdural spaces) or intraventricular purulent material. Representative examples of these findings are shown in Fig 1. These findings are considered most typical for intracranial infection in patients presenting with signs and symptoms of meningitis. The neuroradiologists reviewed the MRIs of the brain with the clinical indication of possible meningitis but were blinded to the CSF analysis results and pathogen diagnosis.

Meningeal enhancement was defined as abnormal/increased contrast enhancement of the leptomeninges on postcontrast T1-weighted imaging. Ventriculitis was defined as contrast enhancement of the ependymal surface of the ventricles on postcontrast T1-weighted imaging. Cerebritis was defined as cortical contrast enhancement on postcontrast T1-weighted imaging with or without associated diffusion restriction. Granuloma was defined as a homogeneously enhancing parenchymal lesion on postcontrast T1-weighted imaging with extra-axial purulent material was defined as extra-axial (subarachnoid, subdural, or epidural space) diffusion restriction not caused by hemorrhage as indicated by a lack of susceptibility artifacts or T1-shortening. Intraventricular purulent material was defined as diffusion restriction within the ventricles not caused by hemorrhage as indicated by a lack of susceptibility artifacts or T1-shortening. Additional findings that are considered indirect signs or complications of meningitis were recorded, including hydrocephalus, dural sinus thrombosis, and hemorrhage.

For all patients in whom there was a discordant MR imaging finding, the reviewers reached a consensus on the finding, and this consensus was used as the final diagnosis. Interobserver agreement for individual MR imaging findings was calculated using the κ statistic. A κ value of 0.81–1.0 indicated excellent agreement; 0.61–0.80, good agreement; 0.41–0.60, moderate agreement; 0.21–0.40, fair agreement; and 0–0.20, slight agreement.

An MR imaging diagnosis positive for meningitis was defined as any combination of leptomeningeal enhancement, ventriculitis, extra-axial or intraventricular purulent material, or cerebritis. Subsequently, the sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and accuracy of an MR imaging diagnosis of meningitis was calculated for the initial MRIs of the brain performed within 1, 3, 7, 10, 14, 21, and 30 days of the initial presentation. Following these calculations, the timeframe of brain MRIs performed within 7 days of presentation (the timeframe that demonstrated the greatest accuracy) was chosen to subsequently determine the accuracy of indirect MR imaging findings, the effects of the timing of antibiotic and acyclovir administration,
prematurity, and age (neonate versus non-neonate age) on the diagnostic performance of MR imaging and to evaluate the diagnostic performance of individual MR imaging findings. Last, a Fisher exact test was used to compare direct MR imaging findings of meningitis found in bacterial-versus-viral meningitis. A \( P \) value < .05 was considered statistically significant.

RESULTs

Patient demographics are shown in Table 1. Two hundred nine infants with a mean age 80 days (range, 0–347 days) were included. The mean days from presentation to lumbar puncture were 0.9 (SD, 1.6) days. The mean difference between date of symptom onset and date of presentation was 0.6 days (range 0–3 days). There were a total of 178 cases of meningitis (true-positives). Bacterial meningitis pathogens included the following: Group B Streptococcus \((n = 58)\); Escherichia coli \((n = 50)\); Streptococcus pneumoniae \((n = 21)\); Haemophilus influenzae \((n = 4)\); Neisseria meningitides \((n = 3)\); Enterobacter \((n = 3)\); Enterococcus \((n = 3)\); Streptococcus bovis \((n = 2)\); Citrobacter \((n = 2)\); Salmonella \((n = 2)\); Streptococcus pyogenes \((n = 2)\); Streptococcus infantarius \((n = 1)\); Proteus mirabilis \((n = 1)\); Pseudomonas aeruginosa \((n = 1)\); Klebsiella \((n = 1)\); Acinetobacter \((n = 1)\); Serratia \((n = 1)\). Viral pathogens included herpes simplex 1 or 2 \((n = 18)\) and Enterovirus \((n = 4)\).

There was excellent interobserver agreement for all direct MR imaging findings of meningitis as follows: leptomeningeal enhancement, 0.85 (95% CI, 0.74–0.95); cerebritis, 0.90 (95% CI, 0.89–1.0); ventriculitis, 0.91 (95% CI, 0.80–1.0); abscess, 1.0 (95% CI, 1.0–1.0); infarction, 0.95 (95% CI, 0.89–1.0); extra-axial purulent material, 0.90 (95% CI, 0.81–0.99); and intraventricular purulent material, 0.96 (95% CI, 0.89–1.0).

The diagnostic performance of brain MRIs with respect to the time from presentation is shown in Table 2. Overall, brain MRIs demonstrated high specificity and moderate sensitivity. The range of diagnostic performance of MR imaging for the detection of meningitis was the following: sensitivity, 70.5%–83.5%;
specification, 92.9%–95.7%; PPV, 95.0%–98.6%; NPV, 33.3%–76.5%; and accuracy, 71.3%–86.5%. Although there was overlap of the 95% confidence intervals, there was a trend toward decreasing sensitivity but consistent specificity as the duration of time increased from clinical presentation to brain MR imaging as seen in Fig 2.

Because MRIs performed within 7 days showed the highest accuracy, this timeframe was chosen to evaluate additional factors. Diagnostic performance of individual MR imaging findings is shown in Table 3. Among individual MR imaging findings, leptomeningeal contrast enhancement was the most sensitive finding (73.3%), while cerebritis, infarction, ventriculitis, abscess, and intraventricular purulent material were the most specific findings (100%). For MRIs performed within 7 days of presentation, the sensitivity and specificity for patients receiving antibiotics before CSF (n = 39) versus after CSF (n = 70) were 86% (95% CI, 66%–95%) and 91% (95% CI, 57%–99%) versus 83% (95% CI, 70%–91%) and 92% (95% CI, 62%–100%). For MRIs performed within 7 days of presentation, the sensitivity and specificity for neonates (n = 37) versus non-neonates (n = 72) was 76% (95% CI, 56%–89%) and 88% (95% CI, 47%–99%) versus 88% (95% CI, 75%–94%) and 94% (95% CI, 68%–100%). For MRIs performed within 7 days of presentation, the sensitivity and specificity for preterm infants (n = 15) versus full-term infants (n = 94) was 81% (95% CI, 48%–97%) and 100% (95% CI, 40%–100%) versus 84% (95% CI, 73%–91%) and 90% (95% CI, 67%–98%). Last, for MRIs within 7 days of presentation, indirect findings and complications of meningitis including hydrocephalus, dural sinus thrombosis, and hemorrhage demonstrated a sensitivity and specificity of 78% and 62%, respectively, for the diagnosis of meningitis, indicating an expected reduced accuracy compared with direct MR imaging findings of meningitis.

**Table 2: MR imaging diagnosis of meningitis with respect to time**

<table>
<thead>
<tr>
<th>Time from Presentation to MR Imaging</th>
<th>No. of Patients</th>
<th>Sensitivity</th>
<th>Specificity</th>
<th>PPV</th>
<th>NPV</th>
<th>Accuracy</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 day</td>
<td>37</td>
<td>82.6% (61.2%–95.1%)</td>
<td>92.9% (66.1%–99.8%)</td>
<td>95.0% (74.0%–99.2%)</td>
<td>76.5% (56.9%–88.9%)</td>
<td>86.5% (71.2%–95.5%)</td>
</tr>
<tr>
<td>3 days</td>
<td>69</td>
<td>80.0% (66.3%–90.0%)</td>
<td>94.4% (72.7%–99.9%)</td>
<td>97.6% (85.6%–99.6%)</td>
<td>63.0% (49.1%–75.0%)</td>
<td>83.8% (72.9%–91.6%)</td>
</tr>
<tr>
<td>7 days</td>
<td>108</td>
<td>83.5% (73.9%–90.7%)</td>
<td>95.7% (78.1%–99.9%)</td>
<td>98.6% (91.2%–99.8%)</td>
<td>61.1% (49.0%–72.2%)</td>
<td>86.1% (78.1%–92.0%)</td>
</tr>
<tr>
<td>10 days</td>
<td>119</td>
<td>80.7% (71.2%–88.1%)</td>
<td>92.3% (74.9%–99.1%)</td>
<td>97.4% (90.8%–99.3%)</td>
<td>57.1% (46.5%–67.2%)</td>
<td>83.2% (75.2%–89.4%)</td>
</tr>
<tr>
<td>14 days</td>
<td>157</td>
<td>75.8% (67.4%–82.9%)</td>
<td>93.1% (77.2%–99.2%)</td>
<td>98.0% (92.7%–99.5%)</td>
<td>46.6% (38.7%–54.6%)</td>
<td>79.0% (71.8%–85.1%)</td>
</tr>
<tr>
<td>21 days</td>
<td>197</td>
<td>70.5% (62.9%–77.3%)</td>
<td>93.6% (78.6%–99.2%)</td>
<td>98.3% (93.9%–99.6%)</td>
<td>37.2% (31.5%–43.2%)</td>
<td>74.1% (67.4%–80.1%)</td>
</tr>
<tr>
<td>30 days</td>
<td>209</td>
<td>67.4% (60.0%–74.2%)</td>
<td>93.6% (75.6%–99.2%)</td>
<td>98.4% (94.0%–99.6%)</td>
<td>33.3% (28.4%–38.6%)</td>
<td>71.3% (64.7%–77.3%)</td>
</tr>
</tbody>
</table>

**Note:** True positives/true negatives for each time frame as follows: 1 day (19/13), 3 days (41/17), 7 days (71/22), 10 days (75/24), 14 days (97/27), 21 days (117/29), 30 days (178/29). Numbers in parentheses are 95% confidence intervals.

**FIG 2.** MR imaging diagnosis of meningitis relative to the time from presentation to MR imaging.
The diagnostic performance for the detection of bacterial and viral meningitis is shown in Table 4. Although there is overlap in the 95% confidence intervals between the groups, there was a trend toward higher sensitivity for the detection of bacterial meningitis compared with viral meningitis. Differences in the detection of individual direct MR imaging findings for patients with bacterial meningitis versus viral meningitis are as follows: leptomeningeal enhancement, 54% (84/156) versus 36% (8/22) \( (P = .17); \) extra-axial purulent material, 38% (60/156) versus 0% (0/22) \( (P < .0001); \) intraventricular purulent material, 15% (24/156) versus 0% (0/22) \( (P = .048); \) ventriculitis, 12% (19/156) versus 9% (2/22) \( (P = .10); \) infarction, 28% (43/156) versus 36% (8/22) \( (P = .45); \) cerebritis, 17% (26/156) versus 36% (8/22) \( (P = .13); \) and abscess, 1% (2/156) versus 0% (0/22) \( (P = 1.0). \)

**DISCUSSION**

In this study, we evaluated the accuracy of MR imaging for the detection of meningitis in infants and evaluated which factors may affect the accuracy of MR imaging. The results of this study demonstrate that MR imaging has a high specificity and PPV but moderate sensitivity for the diagnosis of meningitis in infants. MR imaging retains the high level of specificity, even with an increasing length of time from presentation. Conversely, the sensitivity of MR imaging appears to decrease with time after approximately 10 days. Prematurity, neonatal age, and administration of antibiotics or acyclovir before obtaining CSF do not appear to affect the accuracy of MR imaging; however, the sensitivity of MR imaging may be lower for viral meningitis compared with bacterial meningitis.

Although CSF laboratory and culture remain the criterion standard for diagnosis, these results provide useful clinical information and quantitative data for the long-held clinical notion regarding the utility of MR imaging for the diagnosis of meningitis. These results quantitatively demonstrate the percentage of false-negative MRIs in patients with CSF culture or PCR-confirmed meningitis, supporting the established practice of CSF analysis, culture, and PCR for diagnosis. The results are also useful for other frequent clinical scenarios in which the diagnosis of meningitis is uncertain. In some patients, CSF can be difficult to obtain at presentation, and in these patients, MR imaging could be performed to assess meningitis and provide information supportive of the diagnosis. Other patients may have a CSF culture with negative findings, a blood culture with positive findings, and a borderline or elevated CSF WBC count. In these patients, an MR imaging with positive findings would support the diagnosis of meningitis because the PPV is >95%, while an MR imaging with negative findings could be better understood as indeterminate because the NPV ranges from 33% to 77%. As both PPV and NPV are dependent on the prevalence of disease, a PPV in the setting of high prevalence generally has less utility but for serious infections from meningitis this would still retain its value. We chose to exclude patients with elevated CSF WBC count but negative culture and PCR results because additional factors including CSF glucose and protein values, and whether the infant was pretreated with antibiotics influences our physicians whether to continue to treat or not treat as meningitis. For this reason and our definition of gold standard diagnosis of meningitis, these patients were excluded.

We evaluated the various factors that may affect an MR imaging diagnosis of meningitis. The duration from presentation to MR imaging affects its accuracy. Sensitivity decreases with time while the specificity remains at a consistently high level. While it is unlikely that MR imaging would be used for diagnosing meningitis at 30 days from presentation, the results form a better understanding of the evolution of imaging findings, but further research is needed for better understanding the expected duration for which MR imaging findings persist. Other factors including antibiotic and acyclovir administration before obtaining CSF, prematurity, and neonatal age were evaluated but did not alter the sensitivity and specificity of MR imaging when performed with in 7 days of presentation. Last, we compared MR imaging findings in patients with bacterial and viral pathogens. As expected, extra-axial purulent material, intraventricular purulent material, and abscess were found only with bacterial meningitis and not in viral meningitis. Meanwhile, leptomeningeal enhancement, cerebritis, infarction, and ventriculitis were found with both bacterial and viral meningitis.
There are several limitations of this study. First, this was a single-center, retrospective study, so external validity may be limited. The inclusion criteria create a potential selection bias because patients with less severe disease may not be imaged but reflect the current clinical practice. Another potential limitation of this study is the subjectivity in the determination of individual MR imaging findings. This subjectivity was mitigated by independent imaging reviews by 2 experienced pediatric neuroradiologists, consensus diagnosis in discordance findings, and calculation of interobserver agreement. We observed excellent interobserver agreement for all MR imaging findings. Although some of the MR imaging findings could be seen in diseases other than meningitis such as leptomeningeal enhancement with malignancy, this study was performed among patients with signs and symptoms of meningitis, many of whom will present with fever. This clinical context is necessary, and extrapolation of these results to other clinical scenarios should be avoided.

Another potential limitation is the lack of a postcontrast FLAIR imaging of the brain. Postcontrast FLAIR may increase the sensitivity for the detection of leptomeningeal enhancement, which may improve the sensitivity of MR imaging. Because our institution does not routinely use postcontrast FLAIR imaging, these data were not available in all patients and, therefore, could not be included in this study. Further research assessing the accuracy of MR imaging, including the use of postcontrast FLAIR, would be valuable because this may further increase the sensitivity of MR imaging. Another limitation is the exclusion of patients with a CSF WBC count. These patients represent a substantial number of patients and are a challenge with regard to clinical decision-making about treatment. Because this study required a criterion standard for comparison with MR imaging, we did not evaluate the role of MR imaging in these patients. One could extrapolate, however, that given the high PPV of MR imaging, an MR imaging with positive findings in these patients could be considered evidence of meningitis. Similarly, we used CSF or blood culture and CSF PCR testing as criterion standards; however, these tests may have limitations in the detection of meningitis, and although this represents standard clinical care, it could impact our results. In particular, the detection of viral causes of meningitis is likely to be incomplete so that the accuracy of MR imaging should be reassessed if further advances in laboratory testing occur. Lastly, subgroup analysis for bacterial and viral pathogens was performed to establish an understanding of potential differences, however, the smaller numbers of patients with a viral pathogen is a limitation and future studies with larger numbers of infants with viral meningitis should be performed to better understand the accuracy of MR imaging.

CONCLUSIONS

MR imaging of the brain demonstrates high specificity and moderate sensitivity for diagnosis of meningitis in infants. The accuracy of MR imaging is greatest when performed within 7 days of the time of presentation, but the specificity remains for a much longer time period. Accuracy does not appear to be affected by pretreatment with antibiotics or acyclovir, prematurity, or neonatal age. Institutional selection bias for imaging may affect the results of the accuracy of MR imaging for diagnosis of meningitis.

Disclosure forms provided by the authors are available with the full text and PDF of this article at www.ajnr.org.

REFERENCES

MR Imaging Characteristics and ADC Histogram Metrics for Differentiating Molecular Subgroups of Pediatric Low-Grade Gliomas

S. Shrot, A. Kerpel, J. Belenky, M. Lurye, C. Hoffmann, and M. Yalon

ABSTRACT

BACKGROUND AND PURPOSE: BRAF and type 1 neurofibromatosis status are distinctive features in pediatric low-grade gliomas with prognostic and therapeutic implications. We hypothesized that DWI metrics obtained through volumetric ADC histogram analyses of pediatric low-grade gliomas at baseline would enable early detection of BRAF and type 1 neurofibromatosis status.

MATERIALS AND METHODS: We retrospectively evaluated 40 pediatric patients with histologically proved pilocytic astrocytoma (n = 33), ganglioglioma (n = 4), pleomorphic xanthoastrocytoma (n = 2), and diffuse astrocytoma grade 2 (n = 1). Apart from 1 patient with type 1 neurofibromatosis who had a biopsy, 11 patients with type 1 neurofibromatosis underwent conventional MR imaging to diagnose a low-grade tumor without a biopsy. BRAF molecular analysis was performed for patients without type 1 neurofibromatosis. Eleven patients presented with BRAF V600E-mutant, 20 had BRAF-KIAA rearrangement, and 8 had BRAF wild-type tumors. Imaging studies were reviewed for location, margins, hemorrhage or calcifications, cystic components, and contrast enhancement. Histogram analysis of tumoral diffusivity was performed.

RESULTS: Diffusion histogram metrics (mean, median, and 10th and 90th percentiles) but not kurtosis or skewness were different among pediatric low-grade glioma subgroups (P < .05). Diffusivity was lowest in BRAF V600E-mutant tumors (the 10th percentile reached an area under the curve of 0.9 on receiver operating characteristic analysis). There were significant differences between evaluated pediatric low-grade glioma margins and cystic components (P = .03 and P = .001, respectively). Well-defined margins were characteristic of BRAF-KIAA or wild-type BRAF rather than BRAF V600E-mutant or type 1 neurofibromatosis tumors. None of the type 1 neurofibromatosis tumors showed a cystic component.

CONCLUSIONS: Imaging features of pediatric low-grade gliomas, including quantitative diffusion metrics, may assist in predicting BRAF and type 1 neurofibromatosis status, suggesting a radiologic-genetic correlation, and might enable early genetic signature characterization.

ABBREVIATIONS: AUC = area under the curve; GG = ganglioglioma; MAPK = mitogen-activated protein kinase pathway; NFI = type 1 neurofibromatosis; pLGG = pediatric low-grade glioma; rADC = relative ADC; RAS = rat sarcoma virus; ROC = receiver operating characteristic

original research

Pediatric low-grade gliomas (pLGGs) are the most frequent brain tumors in children.1 pLGGs are defined as World Health Organization grade I or II malignancies and include a wide array of histologies, such as juvenile pilocytic astrocytoma, ganglioglioma (GG), dysembryoplastic neuroepithelial tumor, and pleomorphic xanthoastrocytoma.2 The components of treatment for pLGGs have historically been surgery, radiation, and multiagent chemotherapy. Surgical resection may be curative in the case of gross total resection. However, most children cannot undergo complete resection due to the location of the tumor. Ten-year progression-free survival drops significantly if a radiologically visible residual tumor is evident.3 In such patients, adjuvant focal radiation therapy was performed in the past. However, due to the long-term adverse effects of radiation, adjuvant chemotherapy has been the main treatment technique for patients with pLGG.

BRAF is a serine/threonine-protein kinase that has a key role in growth signal transduction. In the past decade, emerging molecular data have suggested that in pLGGs, there is near-universal up-regulation of the rat sarcoma virus (RAS)-mitogen-activated protein kinase pathway (MAPK),4 most commonly due to somatic alterations involving the BRAF proto-oncogene or germline type 1

Received February 28, 2022; accepted after revision June 28.

From the Section of Neuroradiology, Division of Diagnostic Imaging (S.S., A.K., J.B., C.H.) and Department of Pediatric Hemato-Oncology (M.L., M.Y.), Sheba Medical Center, Ramat-Gan, Israel; and Sackler School of Medicine (S.S., C.H., M.Y.), Tel Aviv University, Tel Aviv, Israel.

Please address correspondence to Shai Shrot, MD, Section of Neuroradiology, Division of Diagnostic Imaging, Sheba Medical Center, 2 Sheba Rd, Ramat Gan, 52621 Israel; e-mail: shai.shrot@sheba.health.gov.il

Indicates article with online supplemental data.
http://dx.doi.org/10.3748/ajnr.A7614

1356 Shrot Sep 2022 www.ajnr.org
neurofibromatosis (NF1) alterations. The 2 major BRAF gene alterations in pLGG are BRAF rearrangement (duplication of the BRAF oncogene, followed by its insertion into 1 of several fusion targets, most often the KIAA1549 gene) and BRAF V600E point mutation (V600E). These molecular alterations in the BRAF gene lead to constitutive activation of the kinase and downstream signaling pathways that drive uncontrolled cell proliferation and tumorigenesis.

NF1 is a common autosomal dominant disorder that results in the most frequent tumor predisposition syndrome. Neurofibromin, the protein product of the NF1 gene that is mutated in patients with NF1, has been shown to function as a tumor-suppressor gene, acting as a negative regulator of RAS. Loss of neurofibromin increases RAS activity and induces downstream activity of the MAPK pathway as well as the PI3K-Akt-mammalian target of rapamycin (mTOR) pathway. Approximately 15% of children with NF1 develop low-grade optic pathway gliomas. Therefore, optic pathway gliomas in these patients are primarily diagnosed via germline NF1 alteration and imaging rather than a biopsy.

Exploring the BRAF status of pLGGs improves risk-stratification and tailored targeted therapies in patients with residual disease in whom additional therapy is needed. Whereas patients with BRAF fusion and NF1 have a favorable outcome, those with the BRAF V600E mutation, particularly associated with cyclin-dependent kinase inhibitor 2A (CDKN2A) deletion, are at increased risk of progression with shorter progression-free survival rates and worse response to chemotherapy. Furthermore, molecularly targeted therapies have been shown to be effective in patients with residual pLGGs; for instance, type 1 BRAF inhibitors for BRAF V600E pLGG and mitogen-activated protein kinase inhibitors for pLGGs driven by NF1, BRAF-KIAA rearrangement, or BRAF V600E mutation. Most important, type 1 BRAF inhibitors have been shown to result in paradoxical activation and accelerating growth of pLGGs driven by the BRAF-KIAA fusion. Therefore, identifying the exact molecular alteration is crucial.

Radiogenomic techniques, which have emerged as valuable imaging tools to characterize brain tumors noninvasively, have a pivotal role in making treatment decisions in patients with pLGGs. Recently, a few studies have described imaging features of pLGGs in correlation with their BRAF status. Ramaglia et al. found lower ADC values in V600E-mutant pLGGs, though no morphologic imaging characteristics were found to have discriminatory power from wild-type BRAF. More advanced ADC metrics (such as histogram analysis) found to be of diagnostic value in pediatric tumors have not been evaluated in the genetic characterization of pLGG (BRAF or NF1 status). We hypothesized that ADC metrics obtained through volumetric ADC histogram analyses of pLGGs at baseline would enable early detection of BRAF and NF1 status.

**MATERIALS AND METHODS**

The institutional review board of the Sheba Medical Center approved this retrospective study.

**Study Design and Population**

Patients with pLGG, diagnosed and treated in our tertiary pediatric neuro-oncology clinics, were included. Inclusion criteria were the following: 1) available baseline presurgical MR imaging, and 2) biopsy and characteristics of BRAF status or a diagnosis of germ-line NF1. Exclusion criteria included a markedly degraded MR imaging study, pure optic nerve involvement, and spinal location.

**Brain MR Imaging**

MR imaging studies were performed in multiple centers on 1.5T or 3T magnets across various vendors. All patients had routine clinical MR imaging scans, including precontrast and postcontrast T1-weighted images, T2-FLAIR, and T2-weighted images. These sequences were performed with variable section thickness ranging from 1 to 5 mm. Heme-sensitive sequences, such as T2* gradient recalled-echo or SWI, were available in 33 patients. On each scanner, the DWI acquisition consisted of a diffusion-sensitized axial 2D spin-echo sequence with an EPI readout, with 2 b values of 0 and 1000 s/mm². Section thickness ranged from 3 to 4 mm, with interslice gaps of 0–1 mm.

**Image Analysis**

We analyzed the following tumoral morphologic imaging features: the presence of well-defined margins, a cystic component, contrast enhancement, and hemorrhagic components or calcifications, which were evaluated only in cases with available heme-sensitive MR imaging sequences (T2* or SWI) or CT scans. These were recorded as binary variables. For location, classification was according to the epicenter of the tumor (cerebral hemispheres, cerebellum, brainstem, or diencephalon). All images were assessed in consensus by 2 board-certified neuroradiologists (J.B. and S.S.) with 3 and 6 years of experience, respectively, blinded to the pathologic diagnosis.

**DWI Measurements**

Tumor segmentation was performed by a board-certified radiologist (A.K.) and was confirmed in consensus by a board-certified neuroradiologist with 6 years of neuroradiology experience (S.S.) using 3D Slicer (Version 4.11.2; http://www.slicer.org). Semiautomated tumor segmentation was performed on T2-FLAIR images in all respective MR imaging sections on noncystic, noncalcified, or hemorrhagic tumor areas using the level tracing effect tool. All ROIs were then copied to the automatically coregistered corresponding ADC maps via 3D Slicer. The transposed volumetric ROI was evaluated and manually corrected on the ADC maps, if necessary, by A.K. and S.S. in consensus. DWI metrics and histogram analysis of the selected volumetric whole-lesion ROIs were performed using the module SlicerRadiomics extension. For normalization of ADC values, a circular ROI was drawn on the right eye and left thalamus. Relative ADC (rADC) ratios were calculated by dividing each ADC metric of the lesion by the mean ADC value of the right eye and the normal-appearing thalamus. This step was performed to adjust ADC values across MR imaging vendors and magnetic field strengths.

**Statistical Analysis**

Descriptive statistics included mean and SD of continuous parameters; in the case of categoric factors, number and percentage distribution were used. The χ² test was used to analyze the differences in the categoric parameters and qualitative features among the various molecular tumor groups. DWI histogram analysis included
10th and 90th percentiles, mean, median, skewness, and kurtosis. The Kruskal-Wallis test with the post hoc Dunn-Bonferroni method was used to compare diffusivity metrics among genetic subgroups. *P* values have been adjusted by the Bonferroni correction for multiple comparisons. Receiver operating characteristic (ROC) curve analysis was performed, and the respective area under the curve (AUC) was calculated to assess the accuracy of ADC histogram features in differentiating various pLGG subgroups. The ROC curve plots the true-positive rate against the false-positive rate at various threshold settings. DeLong test was used for the comparison of various AUCs. A 2-tailed *P* < .05 was considered statistically significant. Analyses were performed with SPSS (Version 27.0, 2021; IBM).

**RESULTS**

**Study Population**
The study cohort (Fig 1) included 51 patients in whom histologically proved tumors included pilocytic astrocytoma (*n* = 33), GG (*n* = 4), pleomorphic xanthoastrocytoma (*n* = 2), and diffuse astrocytoma grade II (*n* = 1). Of patients with NF1, 11 underwent imaging with a diagnosis of a low-grade tumor without a biopsy. One patient with NF1 underwent a biopsy with a histology of GG. *BRAF* molecular analysis was performed for patients without NF1. Eleven patients presented with the *BRAF* V600E mutation; 20 patients had *BRAF*-KIAA rearrangement, and 8 had *BRAF* wild-type tumors. pLGG was diagnosed at a younger age in patients with *BRAF*-KIAA rearrangement and NF1 groups than in *BRAF* V600E-mutant or wild-type *BRAF* groups (*P* = .03). The demographic data are presented in Table 1.

**Morphologic MR Imaging Findings**
Ill-defined borders were more characteristic of *BRAF* V600E-mutant tumors rather than in *BRAF*-KIAA rearrangement or wild-type *BRAF* pLGGs. Examples of MR images of pLGGs are shown in Fig 2. Hemorrhagic components or calcifications were seen in wild-type *BRAF* tumors compared with *BRAF* alterations of NF1 tumors. Lack of a cystic component characterized NF1 tumors compared with *BRAF* alteration of wild-type *BRAF* tumors. No significant differences were found among study groups in terms of tumor location. A summary of the morphological imaging findings is presented in Table 2.

**Diffusion Metrics**
Significant differences were found in evaluated diffusion metrics between pLGG subgroups, except for kurtosis and skewness (Online Supplemental Data). These results were similar when ADC measurements were normalized to the thalamus or the eye globe. For most diffusivity metrics, rADC measurements were lower in *BRAF* V600E-mutant tumors than in the *BRAF*-KIAA rearrangement subgroup (representative metrics are presented in Fig 3). rADCmean and rADCmedian (relative to the thalamus) were significantly lower in NF1 tumors compared with *BRAF*-KIAA rearrangement or wild-type *BRAF* subgroups (*P* < .001). Differences in diffusion histogram metrics among pLGG subgroups were also significant when excluding NF1 tumors (Online Supplemental Data).

According to ROC curve analyses, the rADC10 values had the highest AUC values for differentiating *BRAF* V600E-mutant from the *BRAF*-KIAA rearrangement group (AUC = 0.895 and 0.905, relative to the thalamus or eye globe, respectively). rADC10 values also had high diagnostic performances for differentiating *BRAF* V600E-mutant from *BRAF*-KIAA rearrangement or wild-type *BRAF* subgroups (*P* < .001). However, the high performance of rADC10 did not reach statistical significance compared with other diffusivity metrics. For differentiating NF1 tumors from wild-type.
type or altered \textit{BRAF}, the performance of diffusivity metrics was relatively low, except for rADC$_\text{min}$ (AUC = 0.803 and 0.746, relative to the thalamus or eye globe, respectively). Overall, diagnostic performances were similar when comparing the normalization of ADC values with that of the thalamus or eye globe. In NF1 tumors, except for rADC$_\text{min}$, there was higher discriminative power for normalization to the globe over the thalamus ($P < .001$–.02), even though absolute AUC values were relatively low. The diagnostic performance of rADC$_\text{min}$, rADC$_{10}$, rADC$_{90}$, rADC$_\text{mean}$, and rADC$_\text{median}$ for differentiating various pLGG subgroups is summarized in the Online Supplemental Data.

**DISCUSSION**

In the past decade, there has been increasing evidence of the importance of \textit{BRAF} status, which has major therapeutic and prognostic implications in pLGGs, especially if these tumors are unresectable. Currently, most non-NF1 pLGGs undergo surgical biopsy for genetic analysis, even if curative resection is not possible. Our results suggest that in pLGGs, morphologic MR imaging features show significant differences according to \textit{BRAF} and NF1 status, which might improve the early prediction of the genetic alterations of pLGGs. Quantitative diffusion metrics from cumulative ADC histograms based on the T2-FLAIR imaging abnormalities were found to be promising for differentiating pLGG subgroups. However, other parameters of histogram distribution, particularly kurtosis and skewness, have limited diagnostic value.

The ill-defined border of the pLGG, radiographically suggesting infiltration, was found in our cohort to be more characteristic for \textit{BRAF} V600E-mutant pLGGs (10/11) compared with wild-type \textit{BRAF} (5/13) or \textit{BRAF-KIAA} rearrangement (11/20). Ho et al. have described peritumoral T2 abnormality, suggesting infiltration in half the \textit{BRAF} V600E-mutant pLGGs compared with a minority (~8%) of wild-type \textit{BRAF} tumors. Most interesting, such infiltration is a well-known feature of NF1 tumors, also found in our cohort (10/12). In our cohort, hemorrhagic components or calcifications were characteristic of wild-type \textit{BRAF} pLGG over other \textit{BRAF} alterations or NF1 tumors.

Nevertheless, there is usually an overlap of qualitative imaging characteristics, limiting their use in defining the pLGG subgroup signature. Studies describing quantitative imaging features differentiating pLGG molecular subgroups are even more sparse than

**FIG 2.** Representative T2-FLAIR images of pLGGs of various molecular subgroups. A, A 5-month-old boy with a diencephalic pLGG infiltrating the optic tracts (\textit{BRAF}-mutant). B, A 15-year-old boy with a well-defined diencephalic pLGG (\textit{BRAF-KIAA} rearrangement). C, A 20-year-old woman with well-defined diencephalic pLGG (wild-type \textit{BRAF}), associated with a large central hemorrhagic area. D, A 16-year-old boy with a typical diencephalic glioma infiltrating the optic tracts (NF1).

**Table 2: Morphologic MR imaging characteristics**

<table>
<thead>
<tr>
<th></th>
<th>\textit{BRAF} V600E-Mut ((n = 11))</th>
<th>\textit{BRAF-KIAA} rearrangement ((n = 20))</th>
<th>Wild-Type \textit{BRAF} ((n = 8))</th>
<th>NF1 ((n = 12))</th>
<th>(P) Value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Location (No.) (%)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cerebral hemisphere</td>
<td>3 (27.3%)</td>
<td>3 (15%)</td>
<td>1 (2.5%)</td>
<td>1 (8.3%)</td>
<td>.15</td>
</tr>
<tr>
<td>Cerebellum</td>
<td>1 (9.1%)</td>
<td>7 (35%)</td>
<td>5 (62.5%)</td>
<td>2 (16.7%)</td>
<td></td>
</tr>
<tr>
<td>Brainstem</td>
<td>2 (18.2%)</td>
<td>6 (30%)</td>
<td>0 (0%)</td>
<td>2 (16.7%)</td>
<td></td>
</tr>
<tr>
<td>Diencephalon</td>
<td>5 (45.5%)</td>
<td>4 (20%)</td>
<td>2 (25%)</td>
<td>7 (58.3%)</td>
<td></td>
</tr>
<tr>
<td><strong>Well-defined margins (yes/no)</strong></td>
<td>9.1% (1/10)</td>
<td>45.0% (9/11)</td>
<td>62.5% (5/3)</td>
<td>16.6% (2/10)</td>
<td>.03$^{ab,c}$</td>
</tr>
<tr>
<td>Hemorrhagic components or calcifications (yes/no)*</td>
<td>0% (0/8)</td>
<td>15.3% (2/13)</td>
<td>62.5% (5/3)</td>
<td>0% (0/6)</td>
<td>.005$^{bc,f}$</td>
</tr>
<tr>
<td>Cystic components (yes/no)</td>
<td>45.4% (5/6)</td>
<td>60% (12/20)</td>
<td>87.5% (7/3)</td>
<td>0% (0/12)</td>
<td>.004$^{cd,e}$</td>
</tr>
<tr>
<td>Contrast enhancement (yes/no)</td>
<td>81.8% (9/2)</td>
<td>85% (7/3)</td>
<td>100% (8/0)</td>
<td>50% (6/6)</td>
<td>.04$^{bc,d}$</td>
</tr>
</tbody>
</table>

Note: Mut indicates mutant. Each superscript letter represents a significant difference between 2 categories.

- $^{a}$ \textit{BRAF} V600E-mutant versus \textit{BRAF-KIAA} rearrangement.
- $^{b}$ \textit{BRAF} V600E-mutant versus \textit{BRAF} wild-type.
- $^{c}$ \textit{BRAF} wild-type versus NF1.
- $^{d}$ \textit{BRAF} V600E-mutant versus NF1.
- $^{e}$ \textit{BRAF-KIAA} rearrangement versus NF1.
- $^{f}$ \textit{BRAF} wild-type versus \textit{BRAF-KIAA} rearrangement.
- *Evaluated only when SWI/T2 or CT scans were available \((n = 35)\).
descriptive imaging studies. To our knowledge, there have been only a limited number of reports regarding genetic profiling of pLGG using DWI and no literature reports investigating the usefulness of the ADC histogram for such analysis. In our study, BRAF V600E-mutant pLGGs showed decreased diffusivity on various diffusion histogram metrics (ADC_{10}, ADC_{90}, mean and median ADC values) compared with BRAF-KIAA rearrangement pLGGs. Similar results were also reported by Ramaglia et al for BRAF V600E-mutant pLGG, compared with wild-type BRAF, though BRAF-KIAA rearrangement or NF1 pLGG were not included in their study.

In a small case series, Ishi et al described a lower T2 signal and a larger T2/contrast-enhanced T1 mismatch to be more suggestive of BRAF V600E-mutation in optic pathway gliomas. Recently, Wagner et al described using a machine learning scheme to differentiate pLGG genetics subgroups according to their T2-FLAIR features. Although machine learning–based approaches might detect differences in neuroimaging data that might not be identified with conventional approaches, such as multiple T2-FLAIR features, traditional statistical approaches, such as used in the current study, might improve our understanding of the different radiologic-pathologic correlations in various pLGGs. Although isocitrate dehydrogenase (IDH) mutations are rare among pLGGs, diffusion metrics were also found to assist in differentiating IDH status in adult LGGs. Most ADC percentiles were found to be lower in IDH-negative compared with IDH-mutated gliomas.

DWI reflects the free motion of water molecules in biologic tissue. Highly cellular tumors, ie, with a high nuclear-to-cytoplasmic ratio, typically show diffusion restriction with decreased ADC values. Ho et al have described a distinctive histologic pattern in BRAF V600E-mutant pLGG of a monophasic dense, compact architecture resembling the compact, fiber-rich regions previously described in pilocytic astrocytomas, which might explain the

**FIG 3.** Boxplots comparing rADC_{10} and rADC_{mean}, relative to the mean ADC values of the right thalamus (A and B, respectively) or the right eye globe (C and D, respectively). Group differences were significant (P < .001, Kruskal-Wallis test). Significant pair-wise differences are indicated in the figure (Dunn-Bonferroni post hoc analysis, Double asterisks indicate P < .005).
decreased diffusivity found in these tumors in our cohort compared with wild-type BRAF pLGG. For ADC measurements, most studies used ROI analysis to evaluate brain lesions. Such analysis is based on the representative part of the lesion.\textsuperscript{23,24} However, selecting a representative location is subjective and may be difficult, especially when the lesion is heterogeneous and includes atypical imaging features. ADC histogram analysis was found to be useful for grading gliomas and predicting the treatment response and progression-free survival rates in patients with high-grade gliomas.\textsuperscript{25–27} Given that histogram analysis includes an entire lesion, it may reveal the heterogeneity of lesions and thus ensure more accurate tissue characteristics.

NF1 is a tumor-predisposition genetic disorder, usually diagnosed using a clinical phenotype indicative of a germline NF1 mutation.\textsuperscript{9} The most common CNS tumors in NF1 are low-grade gliomas, with the optic pathway gloma being the hallmark lesion. Surgery is not the first treatment choice in NF1-associated gliomas, which are commonly nonresectable and have a relatively benign course. However, infiltrative optic pathway pLGG, typical of patients with NF1, might have a BRAF alteration rather than an NF1 mutation, a difference that has major clinical consequences.\textsuperscript{28} A biopsy is often performed in such cases, especially if NF1 cannot be diagnosed clinically or genetically. Our results might also assist in identifying the imaging signature of NF1 pLGG relative to other BRAF-altered gliomas.

The reproducibility of lesional ADC measurements over various field strengths, different vendors, and acquisition parameters is critical for the applicability of our results. Multiple in vivo studies have reported near-identical ADC measurements on 1.5T and 3T scanners.\textsuperscript{29,30} However, other phantoms and in vivo studies have demonstrated a significant ADC difference among different magnet fields.\textsuperscript{31,32} Therefore, SASA et al\textsuperscript{33} have suggested using rADC values because they might be more suitable than absolute ADC values for evaluating diffusion abnormalities acquired in different scanners and field strengths. ROIs drawn on the normal-appearing white matter\textsuperscript{33} or gray matter\textsuperscript{11} are commonly used for ADC normalization. We have calculated the rADC values normalized to the normal-appearing thalamus and the eye globe to minimize the differences among absolute ADC values across various platforms. Both references have shown similar reproducible and discriminative results among various pLGG subgroups. Such rADCs are robust across MR imaging vendors and platforms and may be considered reliable.\textsuperscript{11,34} The ADC histogram analysis technique used in the current study is a promising method that can be used on clinically acquired diffusion MR imaging data for subsequent analysis, allowing comparison at different institutions and use in multicenter clinical trials.

There are several limitations to our study. First, our study was a retrospective investigation of a relatively small patient cohort. More pLGGs will be required to strengthen the statistical power and generalize our results in future studies. Due to the small cohort, obtaining ADC thresholds from ROC-AUC, which can be used in clinical settings, is limited. Second, accurately defining the imaging borders of infiltrative lesions is suboptimal, with relatively high interobserver variability. Given the large volumetric data included in the histogram analysis of an entire lesion, the nonperfect delineation of the lesion boundaries is relatively acceptable compared with ROI analysis. Last, tumor delineation was performed on T2-FLAIR images, and coregistration of T2-FLAIR imaging with the ADC map was required in our study. Although the tumor was carefully delineated, there is still the possibility of misregistration and the inclusion of erroneous ADC values at the tumor boundaries.

In the current study, diffusion metrics have improved radiologic-genetic correlation in pLGGs. Such tumoral quantitative features have the potential for better characterizing tumor structure and evaluating early treatment-related changes. Diffusion metrics have been shown to correlate and even predict the response to radiation or biologic treatment in high-grade gliomas.\textsuperscript{35,36} Moreover, Poussaint et al\textsuperscript{57} described a significant correlation between diffusion metrics and survival in patients with diffuse intrinsic pontine gliomas. In the current study, due to the small number of patients and heterogeneity of treatment protocols, such correlation between diffusion metrics and response to treatment could not be assessed.

**CONCLUSIONS**

Our results suggest that ADC histogram analysis based on an entire pLGG could help to discriminate various pLGG genetic subgroups, thus expanding and refining the correlation between clinically acquired imaging, including DWI, and the pLGG genetic signature. Such radiologic-genetic correlation has a critical role in the early detection of molecular subgroups and early clinical stratification of children with pLGGs.

**Disclosure forms** provided by the authors are available with the full text and PDF of this article at www.ajnr.org.

**REFERENCES**


Noninvasive Follow-up Imaging of Ruptured Pediatric Brain AVMs Using Arterial Spin-Labeling


ABSTRACT

BACKGROUND AND PURPOSE: Brain AVMs represent the main etiology of pediatric intracranial hemorrhage. Noninvasive imaging techniques to monitor the treatment effect of brain AVMs remain an unmet need. In a large cohort of pediatric ruptured brain AVMs, we aimed to investigate the role of arterial spin-labeling for the longitudinal follow-up during treatment and after complete obliteration by analyzing CBF variations across treatment sessions.

MATERIALS AND METHODS: Consecutive patients with ruptured brain AVMs referred to a pediatric quaternary care center were prospectively included in a registry that was retrospectively queried for children treated between 2011 and 2019 with unimodal or multimodal treatment (surgery, radiosurgery, embolization). We included children who underwent an arterial spin-labeling sequence before and after treatment and a follow-up DSA. CBF variations were analyzed in univariable analyses.

RESULTS: Fifty-nine children with 105 distinct treatment sessions were included. The median CBF variation after treatment was $-43\text{mL} / 100\text{mg/min}$ (interquartile range, $-102$–$-5.5$), significantly lower after complete nidal surgical resection. Following radiosurgery, patients who were healed on the last DSA follow-up demonstrated a greater CBF decrease on intercurrent MR imaging, compared with patients with a persisting shunt at last follow-up (mean, $-62$ [SD, $61$] mL/100 mg/min versus $-17$ [SD, $40.1$] mL/100 mg/min; $P = 0.02$). In children with obliterated AVMs, recurrences occurred in 12% and resulted in a constant increase in CBF (mean, $+89$ [SD, $77$] mL/100 mg/min).

CONCLUSIONS: Our results contribute data on the role of noninvasive arterial spin-labeling monitoring of the response to treatment or follow-up after obliteration of pediatric AVMs. Future research may help to better delineate how arterial spin-labeling can assist in decisions regarding the optimal timing for DSA.

ABBREVIATIONS: ASL = arterial spin-labeling; EVT = endovascular treatment; IQR = interquartile range; SRS = stereotactic radiosurgery

Pediatric intracerebral hemorrhage accounts for half of strokes in children$^{1,2}$ and has severe long-term medical and psychosocial consequences.$^3$ In children, brain AVMs represent the main underlying risk factor for hemorrhage, being responsible for up to 80% of nontraumatic hemorrhages.$^1,2$ Treatment strategy includes surgical excision, serial endovascular treatment (EVT), and stereotactic radiosurgery (SRS), alone or in combination, according to the AVM size and location. After the initial work-up and treatment of a ruptured AVM, invasive DSA is the criterion standard to tailor the adequate subsequent therapeutic strategy$^5,6$ or to confirm the complete obliteration of the AVM. Nevertheless, repeat DSA exposes children to the long-term risks of ionizing radiation, injection of an exogenous contrast agent, multiple exposures to general anesthesia, and neurologic adverse events. Hence, in children with ruptured AVMs, evaluating noninvasive imaging techniques for the mid and long-term intermediate follow-up and treatment

Received February 2, 2022; accepted after revision June 28.

From the Department of Pediatric Radiology (J.F.H., G.B., F.G., L.G., N.B., V.D.R., O.N.), Pediatric Neurointensive Care Unit (P.M.), and Department of Pediatric Neurology (M.K.), Assistance Publique–Hôpitaux de Paris, Hôpital Universitaire, Necker Hospital–Sick Children, Paris, France; Department of Neuroradiology (J.F.H., G.B., B.K., O.N.), GHU Paris, Paris, France; L’Institut National de la Santé et de la Recherche Médicale, University Hospital Group Paris, ID66, IMA–BRAIN (J.F.H., G.B., B.K., O.N.), Université de Paris, Paris, France; Department of Pediatric Neurosurgery (S.B., S.S., T.B.), Institut Imagine, L’Institut National de la Santé et de la Recherche Médicale, Unité Mixte de Recherche 1363, Assistance Publique–Hôpitaux de Paris, Necker Hospital–Sick Children, Paris, France; Department of Neuroradiology (F.G.), University Hospital of Bordeaux, Bordeaux, France; INSERM U894, French Center for Pediatric Stroke (M.K., T.B., O.N.), L’Institut National de la Santé et de la Recherche Médicale, Paris, France; Departments of Neuroradiology (N.G.) and Radiology (V.V.), University Hospital of Timone Hospital, Assistance Publique–Hôpitaux of Marseille, Marseille, France; Université de Paris (N.B., V.D.R.), L’Institut National de la Santé et de la Recherche Médicale, ERL, Paris, France; and Institut Imagine (N.B., V.D.R.), Université de Paris, Unité Mixte de Recherche 163, Paris, France.

J.F. Hak and G. Boulouis contributed equally to this work.

J.F. Hak was supported by a grant provided by the Société Française de Radiologie, French Society of Radiology, together with the Collège des Enseignants en Radiologie de France, French Academic College of Radiology.

Please address correspondence to Jean-Francois Hak, MD, Department of Pediatric Radiology, AP-HP, University Hospital Necker-Enfants-Malades, 75015 Paris, France; e-mail: jean-francois.hak@gmail.com; @JFHak

http://dx.doi.org/10.3174/ajnr.A8261

planning is an important purpose. In this context, MR imaging possibly represents the best noninvasive technique, and advanced techniques such as arterial spin-labeling (ASL) sequences have shown their role in detecting CBF in patients with AVMs and are useful tools in adults for the follow-up of AVMs after embolization or SRS. Furthermore, accumulating evidence indicates that AVMs in children are more likely to re-appear after DSA-proved complete obliteration, reinforcing the need for prolonged follow-up and the drawbacks of invasive imaging in the setting of a healed shunt. A preliminary analysis from our group evaluated the CBF, computed using ASL after treatment in 21 patients (yet only including 9 patients who had undergone ASL both before and after therapeutic procedures), and demonstrated its potential role in the noninvasive follow-up of AVMs in patients under treatment or after treatment.

In a large cohort of children with an initially ruptured AVM, we aimed to investigate the role of ASL for the longitudinal follow-up of patients under treatment and after complete obliteration by analyzing CBF variations on pseudocontinuous ASL across treatment sessions.

MATERIALS AND METHODS

Study Design and Patient Selection

Consecutive patients referred to our institution, a pediatric quaternary care center and coordinating center for the French Pediatric Stroke Network, were prospectively enrolled in a registry initiated in 2008. The registry has been described elsewhere in detail. For the purpose of this analysis, the sample was restricted to children (1 month to 18 years of age) meeting the following criteria: 1) ruptured brain AVMs; 2) between January 2011 (date of ASL implementation at our site) and October 2019; 3) with unimodal or multimodal AVM treatment (surgery, SRS, embolization); and 4) an ASL sequence before and after treatment and intercurrent DSA, performed within 24 hours of the ASL sequence. Patients were excluded for the following reasons: 1) no ASL follow-up; 2) no DSA follow-up; 3) a ruptured AVM without treatment; and 4) lost to follow-up.

Imaging Acquisition

MR Imaging Procedure. MR imaging was performed for each patient with a Signa HDxt 1.5T system (GE Healthcare) and a 12-channel head-neck-spine coil. The MR imaging investigation included standard pulse sequences according to local AVM protocol: 3D T1WI, 4D-MRA, gadolinium-enhanced 3D T1WI, T2*WI, DWI, TOF-MRA of the circle of Willis, and unenhanced perfusion imaging with a 3D pseudocontinuous ASL sequence. Acquisition parameters for the ASL pulse sequence were unchanged since the beginning of the protocol: TR/TE, 4428/10.5 ms; postlabeling delay, 1025 ms; label duration, 1500 ms; 80 axial partitions; FOV, 240 × 240 × 4 mm; acquisition matrix, 8 spiral arms in each 3D partition with 512 points per arm; flip angle, 155°; acquisition time, 4 minutes 17 seconds.

Paired DSA and ASL. At our institution, follow-up DSA sessions were performed 3 years after SRS or after the last treatment to document AVM obliteration, and 5 years thereafter, and at 18 years of age, whichever comes last. DSA sessions were performed with the patient under general anesthesia in a dedicated neuroangiography suite. A brain MR imaging including an ASL sequence was performed systematically the day before DSA.

Imaging Analysis

DSA Analysis. Two readers (15 [O.N.] and 7 [G.B.] years of experience) evaluated DSA during a single joint reading session. A residual AVM was defined as the early opacification of a cerebral vein, visible in the vicinity of nidal location, during the arterial phase of angiographic runs.

MR Imaging and ASL Analysis. Image analysis was performed using a PACS, independently, by 2 readers (6 [J.F.H.] and 5 [B.K.] years of experience). Readers were blinded to clinical and follow-up data and reported patient and AVMs characteristics. The CBF map was automatically generated using the 3D-ASL application of the Advantage Windows Workstation Functool (GE Healthcare) postprocessing software. For qualitative analysis, the color scale was set to rainbow with the warmer color representing the highest CBF.

Criteria for the presence of an AVM on MR images were defined with the visualization of an early venous filling at the arterial phase (4D-MRA), enlarged and dilated serpiginous vessels (TOF-MRA, postgadolinium 3D-T1), and/or direct visualization of the fistulous point/nidus (TOF-MRA) and, for ASL, the presence of an intracranial venous hypersignal within the dural sinuses or cortical veins and a focal intravascular warm color (“hot spot”) on a CBF map.

The quantitative analysis of ASL was staged as follows:

1. Visual inspection of the ASL-derived CBF maps and identification of the most densely perfused areas of the lesion, if present.
2. 2D ROI placement using a calibrated round 20-mm ROI on the regional where the CBF was visually of the highest value corresponding to the AVM nidus or draining vein. Inside each ROI, the nidal CBF (CBF_nidus) mean values were automatically calculated by the software. We analyzed the mean values of the 2 readers for each variable. For each patient, the ROI was placed in the exact same hot spot localization as in the MRIs performed before and after each treatment.
3. The relative lesion CBF, corresponding to the ratio of CBF_nidus/CBF_cortex, was obtained by normalizing CBF to a 20-mm ROI in the contralateral normal-appearing cortical gray matter (CBF_cortex) in the cerebellum for posterior fossa AVMs and in the frontal and parietal lobes for supratentorial AVMs. Gray matter was chosen as a reference because it has a higher SNR.

If a difference of ≥ 10 mL/100 mg/min was realized between the 2 readers, a consensus was reached on CBF maps and other MR imaging sequences to best position the ROIs. In case of negative ASL findings following treatment, the nidal ROI was placed at the exact same localization as the presurgical ASL ROI after manual coregistration of MR imaging sequences.

Statistical Analysis

Baseline characteristics were explored using descriptive statistics as appropriate per variable makeup and are displayed as absolute number (percentage) or mean (SD) or median (interquartile...
RESULTS

Patients and AVM Characteristics
A total of 127 children were prospectively enrolled after 2011 in the database. After the application of study-specific inclusion and exclusion criteria, 59 patients were analyzed, and 68 patients were excluded. The flow chart in Fig 1 details patient selection. In included patients, AVMs were more frequently superficially located (57.4% versus 29.3%, P = .02). There was no difference between included and excluded patients in age at presentation (mean, 9.8 [SD, 3.7] versus 9.8 [SD, 3.8] years), clinical outcomes (P = .36), AVM location (supratentorial, 90% versus 83%, P = .12), and AVM grades (mean, 9.8 [SD, 3.7] versus 9.8 [SD, 3.8] years), clinical outcomes (P = .12). In

The 59 included patients benefited from 105 distinct treatment sessions with pre- and posttreatment MR imaging including ASL. The initial treatment was partial EVT, SRS, and partial and exhaustive microsurgery for, respectively, 38 (64.4%), 12 (20.3%), 3 (5.1%), and 6 (10.2%) children. Study sample baseline characteristics as well as treatments are detailed in the Table.

On baseline MR imaging performed before any treatment, findings of the visual inspection of the ASL-derived CBF map were considered positive in 56 patients (94.9%). The mean CBF

AVM Follow-up of Patients under Treatment
General Considerations. We observed high interreader agreement for CBF measurement, using the Fleiss κ analysis (κ = 0.92; 95% CI, 0.8–1.0; P < .0001). The median CBF variation after treatment was −43 mL/100 mg/min (IQR, −102–5.5 mL/100 mg/min). There was a higher decrease in CBF after exhaustive nidal microsurgery (n = 13; median, −98 mL/100 mg/min [IQR, −161 to −50]) than after EVT, SRS, or partial microsurgery (P = .002). There was no significant difference in CBF variations after EVT versus SRS, SRS versus partial microsurgery, or EVT versus partial microsurgery (all P > .05) (see Fig 2 for details). The median time interval between MR imaging examinations was 10 months (IQR, 4–20 months).

CBF Variation after SRS. Twenty-seven patients were treated with SRS, and an ASL sequence was performed before and after treatment at each SRS session. The median interval time delay between sessions of MR imaging was 26 months (IQR, 12–39.5 months). Among these patients, DSA-proved complete obliteration at last follow-up was found in 14 patients (51.9%), whereas 13 patients were still under surveillance. The mean variation in CBF values on interval MRIs was −62 (SD, 61) mL/100 mg/min in eventually healed patients, whereas it was −17 (SD, 40.1) mL/100 mg/min in patients with incomplete obliteration at last follow-up (P = .02). In 8 of the 27 patients treated with SRS, CBF did not decrease (Δ > 0), and only 2/8 (25%) of these patients’ AVMs were obliterated at the latest follow-up.

Patient characteristics

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>No. (%)</th>
<th>Median (IQR)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Primary symptom</td>
<td>Headaches</td>
<td>50 (84.7%)</td>
</tr>
<tr>
<td>Sex</td>
<td>Male</td>
<td>28 (47.5%)</td>
</tr>
<tr>
<td>Sex</td>
<td>Female</td>
<td>31 (52.5%)</td>
</tr>
<tr>
<td>Age (median)</td>
<td>10.1 (7.2–13.0)</td>
<td></td>
</tr>
<tr>
<td>Headaches</td>
<td>50 (84.7%)</td>
<td></td>
</tr>
<tr>
<td>Seizures</td>
<td>15 (25.4%)</td>
<td></td>
</tr>
<tr>
<td>Emesis</td>
<td>37 (62.7%)</td>
<td></td>
</tr>
<tr>
<td>Focal deficit</td>
<td>22 (37.3%)</td>
<td></td>
</tr>
<tr>
<td>GCS (median)</td>
<td>14 (3–15)</td>
<td></td>
</tr>
<tr>
<td>ICH characteristics</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Supratentorial location</td>
<td>41 (69.5%)</td>
<td></td>
</tr>
<tr>
<td>ICH volume (median)</td>
<td>10.9 (0.1–58)</td>
<td></td>
</tr>
<tr>
<td>ICH/TBV (median)</td>
<td>1.2 (0.8–5.6)</td>
<td></td>
</tr>
<tr>
<td>IVH</td>
<td>8 (13.6%)</td>
<td></td>
</tr>
<tr>
<td>Treatment characteristics</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total No. of treatments</td>
<td>105</td>
<td></td>
</tr>
<tr>
<td>Patients treated with unimodal treatment</td>
<td>38 (64.4%)</td>
<td></td>
</tr>
<tr>
<td>Patients treated with multimodal treatment</td>
<td>21 (35.6%)</td>
<td></td>
</tr>
<tr>
<td>No. of treatment sessions (median)</td>
<td>1 (1–6)</td>
<td></td>
</tr>
<tr>
<td>EVT</td>
<td>58 (55.2%)</td>
<td></td>
</tr>
<tr>
<td>EVT (No. of sessions) (median)</td>
<td>1.5 (1–5)</td>
<td></td>
</tr>
<tr>
<td>SRS</td>
<td>26 (24.8%)</td>
<td></td>
</tr>
<tr>
<td>Partial surgery</td>
<td>6 (5.7%)</td>
<td></td>
</tr>
<tr>
<td>Complete surgery</td>
<td>15 (14.3%)</td>
<td></td>
</tr>
<tr>
<td>AVM characteristics</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Brain AVM</td>
<td>59 (100%)</td>
<td></td>
</tr>
<tr>
<td>SM grade 1–2</td>
<td>38 (64.4%)</td>
<td></td>
</tr>
<tr>
<td>SM grade 3</td>
<td>14 (23.7%)</td>
<td></td>
</tr>
<tr>
<td>SM grade 4–5</td>
<td>7 (11.9%)</td>
<td></td>
</tr>
<tr>
<td>Supratentorial</td>
<td>49 (83%)</td>
<td></td>
</tr>
<tr>
<td>Deep</td>
<td>31 (52.5%)</td>
<td></td>
</tr>
<tr>
<td>Elloquent area</td>
<td>33 (55.9%)</td>
<td></td>
</tr>
<tr>
<td>Nidus size (median)</td>
<td>22 (9–60)</td>
<td></td>
</tr>
<tr>
<td>Compact nidus</td>
<td>38 (64.4%)</td>
<td></td>
</tr>
<tr>
<td>Aneurysm (arterial/venous)</td>
<td>25 (42.4%)</td>
<td></td>
</tr>
<tr>
<td>Any deep venous drainage</td>
<td>30 (50.8%)</td>
<td></td>
</tr>
</tbody>
</table>

Note:—GCS, indicates Glasgow Coma Scale; ICH, intracerebral hemorrhage; TBV, total brain volume; IVH, intraventricular hemorrhage; SM, Spetzler-Martin.

*Variables are displayed as No. (%) or median (25th to 75th quantiles).
After SRS, the mean CBF \( D \) for the healed children at 3 years versus the nonhealed at 3 years was, respectively, \(-68.3\) (SD, 61.0) \((n = 4)\) versus \(-14.5\) (SD, 17.7) \((n = 2)\) at 1 year after SRS \((n = 6)\), and, respectively, \(-105.8\) (SD, 66.3) versus 65.7 (SD, 150.3) at 2 years after SRS \((n = 19)\). Thus, 1 year after SRS, a decrease in CBF of \( > 50\) mL/100 mg/min was associated with a 3-fold increase in the rate of eventual obliteration after 3 years.

**Follow-up after Complete Obliteration.** Among 34 patients achieving DSA-proved complete obliteration during follow-up, 4 (11.8%) children presented with a DSA recurrence at a mean delay of 21.8 (SD, 22.2) months. At the time of recurrence, the CBF increased in all patients by a mean of 89 (SD, 77) mL/100 mg/min, corresponding to relative CBF lesion increases of a mean of 311% (SD, 147%). See Fig 3 for an example of recurrence after treatment.

**DISCUSSION**
We present robust data on the role of ASL in the noninvasive follow-up of ruptured pediatric AVMs during and after treatment. Our analysis notably shows that ASL-CBF increased in all patients with DSA recurrences, with direct clinical applications in children followed up after AVM obliteration. Furthermore, we showed that 1 year after SRS, a decrease in CBF of \( > 50\) mL/100 mg/min was associated with a 3-fold increase in the rate of eventual obliteration after 3 years. In our sample, patients with eventually healed AVMs after SRS had a mean CBF decrease of \(-62\) mL/100 mg/min when it was \(-17\) mL/100 mg/min in patients with incomplete obliteration at 3 years. These results add to the evidence of the role of noninvasive imaging in objectively delineating treatment effect in pediatric AVMs, provide additional evidence justifying intermediate MR imaging follow-up of children with obliterated AVMs, and pave the way for noninvasive biomarkers of anticipated treatment effect, especially after SRS. An additional supporting argument was the high interreader agreement for CBF measurement, suggesting the reproducibility of our findings, at least internally.

Several adult studies reported a role for ASL in the noninvasive follow-up of ruptured AVMs. Suazo et al\(^7\) reported a fair agreement between ASL and DSA for the assessment of shunt reduction achieved by embolization for 8 AVMs. Other studies focusing on SRS-treated AVMs reported a promising role for ASL: first, to show and quantify differences in AVM nidal flow ratios and the associated steal phenomena between treated and untreated groups;\(^16\) and second, to detect

---

**FIG 2.** Boxplots of ASL variations by treatment technique per time interval.

**FIG 3.** Example of a right occipital ruptured AVM confirmed with ASL (A) and DSA (B), completely treated with embolization 15 days after the initial diagnosis (C) and without a CBF increase, with ASL performed 4 months after the initial diagnosis (D). The 4-year ASL control revealed a focal ASL-derived CBF increase (E) suspicious for recurrence, confirmed with DSA (F).
incomplete-versus-complete AVM obliteration.8-11 Altogether, these results contribute to determining the important role of ASL in AVM follow-up for patients under treatment or after obliteration, to minimize the use of DSA in the vulnerable sample of children with ruptured AVMs.

Pediatric AVMs have been shown to be dynamic lesions with vascular changes and higher rates of recurrence after complete obliteration, compared with adults.12,13 In addition, the susceptibility effects of the liquid embolic agents on perfusion imaging may hinder the quantitative perfusion measurements,17 justifying the need for our analysis in the subgroup of ruptured pediatric AVMs. This analysis complements a preliminary work from our group,14 in which 3 ruptured pediatric AVMs followed up after embolization alone showed a reduction in both nidus size and ASL-derived CBF values as well as 5 ruptured pediatric AVMs followed up after SRS, in which a reduction in the nidus size was observed, despite persistent elevated CBF in nidus values.

Despite these prior data, noninvasive AVM follow-up is an unmet need. Studies have evaluated 4D-MRA for AVM follow-up, but there are many practical drawbacks to the use of IV contrast in pediatric patients, including the need for IV access; increased scan time; children’s fatigue, anxiety, and motion; and exposure to possible adverse effects of the contrast agent.18-23 Conversely, ASL sequences allow quantitative mapping of CBF, without contrast injection,34 and are known to be relevant in detecting the presence of arteriovenous shunts by demonstrating high signal in the nidus as well as arterialized venous structures.14,25-27

In line with previous studies,7-11,16,28 we showed that most patients had decreased CBF after treatment with SRS or embolization, yet some lesions demonstrated no CBF decrease despite interval treatment. This finding supports the concept of dynamic AVM lesions in children, considered as an evolving vasculopathy rather than a simple amorphous vascular connection, with interval increasing arterial feeding and/or shunt acceleration. It appears, therefore, that AVMs have a remodeling potential that explains the reported cases of spontaneous growth.29,30 as well as spontaneous regression.31-33 Therefore, pretreatment ASL allows a radiation- and injection-free tool for treatment planning.

As previously reported, the AVM recurrence rate is higher for pediatric AVMs than for those in adults.12,13 In our cohort, 4 (11.8%) children presented with an angiographic recurrence with a CBF increase in all patients, by a mean of 89 (SD, 77) mL/100 mg/min. To our knowledge, we report the first preliminary data on ASL-CBF increase for the diagnosis of recurrent AVMs. We acknowledge, nonetheless, that our sample provides a limited number of recurrent AVMs and that this finding should be further supported by a larger study.

Note that at our institution, a pediatric quaternary care center and coordinating center for the French Pediatric Stroke Network, a DSA is performed in the initial AVM imaging assessment for angioarchitectural characterization and appropriate treatment. Following treatment, DSAs are performed 3 years after SRS or after the last treatment to document AVM obliteration, 3 and 5 years thereafter, and at 18 years of age, whichever comes last. Accordingly, DSA is not replaced by ASL, but ASL should be considered as a tool to facilitate the timing of follow-up DSA studies, reduce the number of DSAs for each patient, and for the planning of additional AVM treatment.

Our study has several shortcomings, mostly inherent in its retrospective and noncontrolled design. Specifically, in our center, to optimize the SNR of the ASL sequence for AVMs detection,34 we used a postlabeling delay of 1025 ms, shorter than the value typically recommended (1500 ms).35 We chose this postlabeling because we have been using it since 2011, after local optimization with an excellent SNR across various cerebrovascular diseases. Second, this approach is very commonly used by experienced teams using ASL and has been validated extensively.36

We also acknowledge that some patients have been lost to imaging follow-up following SRS outside our center, introducing some degree of attrition bias. Finally, these results were obtained in a sample of ruptured brain AVMs and may not be transferable to children with initially unruptured lesions.

CONCLUSIONS

In children with ruptured AVMs, ASL allows detection of hemodynamic changes after treatment, noninvasively and without radiation exposure or contrast media administration. Our results contribute data on the role of noninvasive ASL monitoring of the response of pediatric AVMs to treatment or follow-up after obliteration. Future research may help better elucidate how ASL can assist in decisions regarding optimal timing for DSA.

Disclosure forms provided by the authors are available with the full text and PDF of this article at www.ajnr.org.

REFERENCES


Effect of Normal Breathing on the Movement of CSF in the Spinal Subarachnoid Space


ABSTRACT

BACKGROUND AND PURPOSE: Forced respirations reportedly have an effect on CSF movement in the spinal canal. We studied respiratory-related CSF motion during normal respiration.

MATERIALS AND METHODS: Six healthy subjects breathed at their normal rate with a visual guide to ensure an unchanging rhythm. Respiratory-gated phase-contrast MR flow images were acquired at 5 selected axial planes along the spine. At each spinal level, we computed the flow rate voxelwise in the spinal canal, together with the associated stroke volume. From these data, we computed the periodic volume changes of spinal segments. A phantom was used to quantify the effect of respiration-related magnetic susceptibility changes on the velocity data measured.

RESULTS: At each level, CSF moved cephalad during inhalation and caudad during expiration. While the general pattern of fluid movement was the same in the 6 subjects, the flow rates, stroke volumes, and spine segment volume changes varied among subjects. Peak flow rates ranged from 0.60 to 1.59 mL/s in the cervical region, 0.46 to 3.17 mL/s in the thoracic region, and 0.75 to 3.64 mL/s in the lumbar region. The differences in flow rates along the canal yielded cyclic volume variations of spine segments that were largest in the lumbar spine, ranging from 0.76 to 3.07 mL among subjects. In the phantom study, flow velocities oscillated periodically during the respiratory cycle by up to 0.02 cm/s or 0.5%.

CONCLUSIONS: Respiratory-gated measurements of the CSF motion in the spinal canal showed cyclic oscillatory movements of spinal fluid correlated to the breathing pattern.

ABBREVIATION: SSAS = spinal subarachnoid space

Respirations reportedly have an effect on CSF movement in the spinal subarachnoid space (SSAS), which is also known to undergo a cardiac-driven oscillatory motion1,4 associated with the periodic changes in intracranial pressure, superposed on a steady motion resulting from secretion of CSF by the choroid plexus in the ventricles on the one hand and steady-streaming effects appearing as small nonzero time averages of oscillatory components on the other hand. Whereas steady secretion by the choroid plexus results in slow cranio-caudal spinal fluid flow,5,6 commonly known as bulk flow, steady-streaming results in closed recirculating regions caused by the variation of anterior-posterior SSAS size along the spine7,8 or localized anatomic features such as nerve roots.10 Forced respirations have been shown to produce oscillatory motion of the CSF at a slower cycling rate than the cardiac cycle, both in the spine and the brain.11-26 Most previously published observations on spinal CSF flow during respiration have used real-time MR imaging, short acquisitions, and forced or deep breathing, coughing, or sniffing.11-24 In previous reports, the forced respiratory efforts produced both cranio-caudal and caudo-cranial CSF movements along the entire spinal canal and especially in the lower thoracic segment. In some experiments, forced inspiration and expiration apparently were the major factors in spinal fluid flow.14,16,20,21,24,25 The effect

http://dx.doi.org/10.3174/ajnr.A7603
of normal breathing on spinal CSF flow has recently been studied, but only at the foramen magnum, where it was found to play a lesser role compared with cardiac-driven motion.

A detailed analysis of CSF movement along the length of the spinal canal related to normal breathing has not, to our knowledge, been published. An improved quantitative knowledge of respiratory effects on CSF flow will enhance our understanding of CSF dynamics, which is key in the characterization of nutrient movement and waste product clearance in the subarachnoid spaces and the distribution of drugs injected intrathecally.

We planned a study to quantify respiratory-related CSF motion along the length of the spinal canal during breathing at a normal rate and depth. We developed a method of maintaining a constant respiratory rhythm during flow data acquisition and used a respiratory-gated MR imaging acquisition, which achieves greater temporal and spatial resolution than the real-time MR imaging acquisition used in previous studies. We acquired flow data at multiple spinal levels to characterize, as completely as possible, the effects of normal breathing on fluid movement along the length of the spinal canal.

MATERIALS AND METHODS

Subjects
Six subjects (2 women, 4 men; age range, 27–53 years; weight range, 50–82 kg; and height range, 160–175 cm) with good health, normal pulse and respiratory rates, no spinal disorders, and no contraindications to MR imaging were enrolled for MR imaging data collection at the Mind, Brain and Behavior Research Center of the University of Granada and analysis of CSF flow. The study was approved by the institutional review board of the Universidad de Granada, and written informed consent was obtained from each subject before MR imaging. The MR images obtained in the subjects were reviewed by a neuroradiologist to exclude spinal pathologies.

Study Design
Each subject was instructed to breath guided by a video showing a sine wave with a frequency at the subject’s previously determined normal breathing rate (15–18 breaths per minute in the 6 subjects). Subjects were fitted with a thoracic circumference monitoring belt and asked to inhale and exhale normally to match the chest diameter to the sine wave, achieving inspiration and expiration of equal duration. Each subject practiced breathing to the visual guide for a period of time before imaging. For imaging, conventional T1- and T2-weighted images of the entire spine were obtained in each subject, and flow measurements were acquired at 5 locations along the spinal canal: C2/C3, T2/T3, T6/T7, T10/T11, and L1/L2 (Fig 1).

MR Imaging Measurements
All imaging was performed on a 3T Magnetom Prisma Fit MR imaging scanner (Siemens) using a 64-channel head and neck coil and a 32-channel spine coil. High-resolution, whole-spine images were obtained using a 3-block sagittal 3D T2 SPACE sequence, and flow measurements were acquired with a 2D phase-contrast MR imaging sequence at 5 locations along the spinal canal: C2/C3, T2/T3, T6/T7, T10/T11, and L1/L2 (Fig 1B), with the following imaging parameters: TR = 1500 ms, TE = 231 ms, bandwidth = 504 Hz/pixel, 1.4 averages, in-plane resolution = 0.625 × 0.625 mm², 64 slices per block, section thickness = 0.8 mm. CSF flow-velocity data were acquired at the 5 selected spinal locations applying a 2D phase-contrast MR imaging sequence with section orientation perpendicular to the long axis of the spinal canal. The imaging parameters included the following: flip angle = 15°, FOV = 160 × 160 mm², matrix = 256 × 205, in-plane resolution = 0.625 × 0.78 reconstructed to 0.625 × 0.625 mm², section thickness = 10 mm. The velocity encoding was adjusted to the anticipated optimum for each subject and ranged from 3 to 15 cm/s, with TE and TR varying correspondingly between 7.71 and 9.98 and 71.22 and 89.42 ms, respectively. Between 40 and 55

![FIG 1. A, Schematic overview of the MR imaging setup. The subject, in a supine position, was instructed to breath guided by a video on an external display. Thoracic circumference respiratory bellows were used to monitor breathing. B, High-resolution, whole-spine images were obtained using a 3-block sagittal 3D T2 SPACE sequence, and flow measurements were acquired with a 2D phase-contrast MR imaging sequence at 5 locations along the spinal canal: C2/C3, T2/T3, T6/T7, T10/T11, and L1/L2. At each level, the ROIs corresponding to the SSAS were drawn manually (yellow shaded regions). Images shown correspond to subject 3.](https://www.ajnr.org/content/85/6/1370)
Changes Due to Respiration

Quantification of the Flow Rate and Spinal Canal Volume Changes Due to Respiration

An in-house-developed Matlab code (MathWorks) was used to postprocess the MR phase and magnitude measurements and to obtain the in-plane velocity distribution of velocity \( U \) in the SSAS at each spinal level (Fig 2A), the location of which has a distance \( x_i \) along the spinal canal to the foramen magnum (Fig 1B). At each level, the ROIs corresponding to the SSAS were drawn manually (Fig 1B). By numerically integrating the velocity over these ROIs, the volume flow rates across each location \( \langle Q(x, t) = \int_{ROI} U \text{d}A \rangle \) were obtained as a function of time \( t \) (Fig 2B). The results were filtered with a 5-point moving mean (Fig 2C). Stroke volume was calculated for each level by numerically integrating the flow rate over the respiratory cycle, \( V_i(x) = 0.5 \int_0^T |Q(x, t)| \text{d}t \) (Fig 2E). The instantaneous change in volume of each spine segment, with respect to the start of the inhalation cycle, was computed as the integral of the difference in flow rates across the spinal levels that delimitate the segment, \( \Delta V_{i \rightarrow i+1}(t) = \int_0^T (Q(x_i, t) - Q(x_{i+1}, t)) \text{d}t \) (Fig 2D). The net volume change over inhalation and exhalation (Fig 2E, -F) for each segment was calculated as \( \Delta V_{i \rightarrow i+1}(t_{1/2}) - \Delta V_{i \rightarrow i+1}(0) \) and \( \Delta V_{i \rightarrow i+1}(T) - \Delta V_{i \rightarrow i+1}(t_{1/2}) \), where \( t_{1/2} \) corresponds to the instant in time at the end of inhalation and the start of exhalation, defined as the point where \( Q(x, t) \) crosses zero, so that \( t_{1/2} \approx T/2 \).

Evaluation of Magnetic Susceptibility Artifacts in In Vivo Flow Measurements

A phantom was used to quantify the effect of magnetic susceptibility changes in the FOV induced by the thoracic motion on velocity data measured with phase-contrast MR imaging. The phantom contained a closed hydraulic circuit composed of a straight tube of constant diameter equal to 2.2 cm, a pump, and a mass flow meter. Tap water with a T1 of 2.7 seconds to simulate CSF, which has a T1 relaxation time of about 3 seconds, was pumped through the phantom at a constant flow rate. Respiratory-gated MR imaging flow measurements were obtained of the phantom with and without a subject lying supine on the phantom. Data were acquired at 2 locations, T6/T7 and L1/L2, with the same MR imaging parameters and protocols as used for imaging the subjects.

RESULTS

MR imaging showed no evidence of spinal pathology in the 6 subjects. All subjects breathed with a sinusoidal pattern closely approximating their normal respiratory volumes. Flow measurements were obtained from MR imaging measurements successfully in all subjects and selected spinal locations. Aliasing artifacts were encountered in 2 subjects for 2 spinal levels and were corrected accordingly. We first describe the results for subject 1 in detail (Fig 2) and then compare results in the 6 subjects (Fig 3).

FIG 2. Results for subject 1. A, Map of flow velocity in centimeters per second across each section at mid-inhalation (left column) and mid-expiration (right column). B, Plot of the flow rate in milliliters per second across each section through the respiratory cycle. C, Plot of temporally filtered flow rate through the respiratory cycle. D, Change in fluid volume through the respiratory cycle with respect to the start of inhalation for each spinal level. E, Amount of fluid moved between adjacent levels (stroke volume) for each section. F, Net volume increase or decrease at each level during inhalation. G, Net volume increase or decrease during expiration.
In subject 1, the respiratory-gated flow was caudocranial during inhalation and craniocaudal during exhalation at all spinal levels. Velocity fields (Fig 2A) taken mid-inhalation and mid-exhalation showed that CSF flow is uniformly distributed over the cross-sectional area of the SSAS, with peak velocities ranging from 5 to 8 cm/s. The corresponding volume flow rates $Q(x, t)$ (Fig 2B, -C) confirmed that the directionality of the flow was in phase with inhalation and exhalation and differed in phase by 180°. Flow volume rates between inspiration and expiration differed by <10%.

The largest volume of flow rate was observed at L1/L2 (2 mL/s). The concomitant stroke volume, $V_s$ (Fig 2E), which is a measure of the volume of CSF that passes through L1/L2 at this location, was 1.75 mL. Cranially from L1/L2, the stroke volume progressively decreased toward the foramen magnum (minimum, $V_s$ of 1 mL). Above the L1/L2 level, the stroke volumes were <0.5 mL. Caudally from L1/L2, the stroke volume diminished to zero. The largest variation of CSF volume was found in the stretch of canal between the L1/L2 level and the caudal end of the canal. The corresponding total accumulation and depletion of CSF between the start and end of inhalation (Fig 2E) and between the start and end of exhalation (Fig 2F) were equal.

The general trends described for subject 1 are evident in all subjects (Fig 3), though large subject-to-subject variations were found. During inspiration, caudocranial CSF flow was induced, and during exhalation, craniocaudal flow. The velocity fields during inhalation were found to be comparable in magnitude with those during exhalation at all spinal levels. Correspondingly, the volume of flow rates during inhalation (Fig 3C) were similar in magnitude to those during exhalation. The variation in stroke volume (red dots in Fig 3E, -G) generally was largest in the lower lumbar region and least in the cervical region, except in 1 subject (subject 4). Peak flow rates ranged from 0.60 to 1.59 mL/s in the cervical region, 0.46 mL/s to 3.17 mL/s in the thoracic region, and 0.75 mL/s to 3.64 mL/s in the lumbar region. Differences in flow rates are correlated to differences in stroke volume and, consequently, to the increase or decrease in CSF volume. The Table summarizes the minimum, mean, and maximum observed stroke volumes and volume changes along the spinal canal. The increase or decrease in CSF volume (Fig 3D) was largest in the lumbar region.

In the phantom study of respiratory-induced artifacts in flow measurements, flow velocities measured in the phantom under a supine subject breathing typically deviated periodically during the respiratory cycle by up to 0.02 cm/s for all flow velocities tested,
which ranged from 0 to 15 cm/s. The deviations did not exceed 0.5% of the mean velocities tested.

**DISCUSSION**

Respiratory-gated measurements of the CSF motion in the spinal canal during normal rates and volumes of respiration showed cyclic oscillatory movements of spinal fluid correlated to the breathing pattern. The stroke volume, an integral measure of how much fluid moves across a certain spinal section over the course of 1 respiratory period, was, on average, largest in the lower thoracic and upper lumbar spine, decreasing cranially up to 35% toward the foramen magnum and caudally toward the distal end, where it vanished. The concomitant net volume variation was found largest at the upper lumbar-sacral segment and considerably lower elsewhere. This finding indicates the volume variation of the subarachnoid space near the thoracolumbar junction through the respiratory cycle as the main effect of respiration. The minimum and maximum measured values of stroke volume and net volume change in the Table reveal large interindividual differences.

The results of this study agree qualitatively with those in previous studies\(^{12,16,17,20,21,24-26}\) in which spinal fluid was found to move cranially during inspiration and caudally during expiration. The effect of normal, sustained breathing was reported to induce peak velocities of approximately 1.3 cm/s at the foramen magnum,\(^{17,26}\) compared with 5 cm/s for subject 1 at C2/C3 in our results. Studies that reported the spatial distribution of respiratory-induced flow along the spinal canal mostly considered forced respiration\(^{12,16,20,21,24,25}\) or breathing maneuvers such as coughing or sniffing.\(^{24}\) In agreement with our findings, the largest respiration-induced flow rates occurred at the upper lumbar spinal level.\(^{20,21}\) Flow rates and associated stroke volumes greater than ours were measured, consistent with the use of more forceful respiratory efforts. For example, the mean stroke volumes corresponding to forced breathing\(^{20}\) compared with those of the present study under normal breathing are 2.4 versus 1.0 mL at C2/C3, 1.6 versus 1.1 mL at T6/T7, 6.7 versus 1.5 mL at T10/T11, and 2.0 versus 1.5 mL at L1/L2, respectively. The maximum associated net volume variation over inspiration or exhalation occurred in the caudal half of the spinal canal. For forced breathing,\(^{20}\) the maximum was found in the segment between T6 and T10 (mean, 5.1 mL), whereas for the present work, it occurred in the lumbar segment between L1/L2 and the sacral end (mean, 1.5 mL). Previous studies have hypothesized that the nonuniform compliance of the SSAS is coupled to the extraspinal paravertebral venous plexus.\(^{24,25}\) Furthermore, forced respiratory effort induced a nonzero net CSF flow.\(^{20,21}\) On the contrary, our data, acquired over multiple minutes of normal breathing, showed no net flow, consistent with conservation of total spinal CSF volume over the course of the experiment. We are not aware of any previously reported detailed CSF flow measurements at multiple spinal levels during normal respiration.

Respiratory-driven spinal CSF flow occurs in addition to that driven by the cardiac cycle.\(^{9,29-31}\) Induced by intracranial pressure fluctuations, the cardiac-driven flow presents a different spatial variation of flow rate and stroke volume along the spine (eg, Figs 2 and 3 in Sincomb et al\(^{31}\)) with maximum values in the upper cervical region, decreasing monotonically toward the closed caudal end. Given the large subject-to-subject variations in observed respiratory-driven flow, comparisons between cardiac- and respiratory-driven flow should be conducted on a subject-to-subject basis. As an example, subjects 1 and 2 in Sincomb et al,\(^{31}\) respectively, correspond to subjects 5 and 2 of the present study. For these subjects, the ratios between respiratory- and cardiac-driven peak flow rates were, respectively, 0.1 and 0.3 at C2/C3, 0.2 and 0.4 at T6/T7, and 0.7 and 1.3 at L1 and L2, where both peak values become comparable. Nevertheless, because the respiratory cycle is approximately 3.5 times longer, the associated stroke volumes become dominant in the lower spine. In particular, the ratios between the respiratory- and cardiac-driven stroke volumes for subjects 5 and 2 are respectively 0.8 and 1.2 at C2/C3, 1.1 and 1.6 at T6/T7, and 4.9 and 7.3 at L1/L2. Future work should confirm these trends.

Our study had a small number of subjects, with an age range of 26 years. The analysis should be extended in the future to a larger number of subjects with greater anatomic variations to investigate reproducibility and determine the origin of the large interindividual differences. The influence of subject posture, which has been conjectured to influence cardiac-driven steady-streaming CSF flow,\(^{9}\) was not studied here. Furthermore, the duration of inhalation and exhalation was equal, which might not be reflective of normal breathing. The study should be extended to further evaluate the effect of different respiration modes on the CSF motion. Finally, small experimental errors might be expected from the limited accuracy of phase-contrast MR measurements of slow flow and from the section orientation not being perfectly perpendicular to the axis of the spinal canal.

This study shows that respiration affects CSF flow, especially in the lower thoracic and lumbar spine. The total pulsating motion of the CSF in the SSAS is the sum of the cardiac- and respiratory-driven components. The cardiac-driven flow exhibits near-zero velocities in the lumbar region,\(^{9}\) much smaller than those associated with the respiratory-driven flow measured here, so that respiration is the main driving mechanism in the lumbar

---

**Table:**

<table>
<thead>
<tr>
<th>Section</th>
<th>Stroke Volume (mL)</th>
<th>Net Volume Increase during Expiration (mL)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Min</td>
<td>Mean</td>
</tr>
<tr>
<td>C2/C3</td>
<td>0.54</td>
<td>0.99</td>
</tr>
<tr>
<td>T2/T3</td>
<td>0.62</td>
<td>1.37</td>
</tr>
<tr>
<td>T6/T7</td>
<td>0.38</td>
<td>1.44</td>
</tr>
<tr>
<td>T10/T11</td>
<td>0.57</td>
<td>1.54</td>
</tr>
<tr>
<td>L1/L2</td>
<td>0.76</td>
<td>1.52</td>
</tr>
</tbody>
</table>

Note: Min indicates minimum; Max, maximum.
spine. Consequently, the respiratory cycle may be a factor in the movement of drugs and anesthetics administered intrathecally. Modeling of CSF movement and drug transport must take into consideration the effect of respiration.

**CONCLUSIONS**

Normal respiration in healthy subjects induces CSF motion in the spinal canal, which is directed caudocranially during inhalation and cranio-caudally during exhalation. Compared with cardiac-driven CSF flow, respiratory-driven flow dominates in the lumbar region. Respiration constitutes, therefore, an important driving mechanism of CSF. Patient-specific analyses of cardiac-driven and respiratory-driven CSF flow and anatomic measurements in combination with complementary mathematical models can help improve the effectiveness and predictability of intrathecal drug delivery treatments in the future.

Disclosure forms provided by the authors are available with the full text and PDF of this article at www.ajnr.org.

**REFERENCES**


Celebrating 35 Years of the AJNR

September 1987 edition

Transluminal Angioplasty of the Vertebral and Basilar Artery

Transluminal angioplasty of intracranial vessels for atherosclerotic stenosis is now being performed at several centers. We have now treated 14 cases of vertebral-artery stenosis and two cases of vertebral-artery occlusion by transluminal balloon angioplasty. Clinical presentation included cerebral vasospasm, encephalopathy, hemiparesis, and increasingly severe neurologic deficits. The procedure was performed by one of us (T.H.H.).

In one patient with bilateral vertebral-artery stenoses and severe cerebellar signs, transluminal angioplasty was performed bilaterally. Following the procedure, there was a transient improvement in the neurologic deficit. In two other patients with severe occlusion of the vertebral artery, transluminal angioplasty was performed, and the neurologic deficit was improved. In one patient with a bilateral vertebral-artery occlusion, the procedure was performed on one side with transient improvement in the neurologic deficit.

None of these studies include follow-up of transluminal angioplasty. Follow-up studies indicate that the procedure is effective for the treatment of atherosclerotic disease in the vertebral artery and basilar artery. The procedure is effective for the treatment of cerebrovascular disease, and it is effective for the treatment of cerebrovascular disease in patients with severe cerebellar and spinal cord signs.

Subjects and Methods

Subjects included 10 cases of vertebral-artery stenosis, 3 cases of vertebral-artery occlusion, and 1 case of posterior inferior cerebellar artery occlusion. Two cases of symmetrical vertebral-artery stenosis and two cases of single vertebral-artery occlusion were treated by angioplasty. The procedure was performed using standard techniques. All cases were treated with a 4- to 5-mm-diameter balloon.

Results

In the 10 cases of vertebral-artery stenosis, the improvement in neurologic deficit was transient. The improvement lasted for 1 to 3 days. In the 3 cases of vertebral-artery occlusion, the improvement in neurologic deficit was permanent. The improvement lasted for 3 to 6 months. In the case of posterior inferior cerebellar artery occlusion, the improvement in neurologic deficit was transient. The improvement lasted for 1 to 3 days.

Chiari II Malformation: MR Imaging

The purpose of this study was to evaluate the value of MR imaging in the diagnosis of the Chiari II malformation. Twenty-two patients with Chiari II malformation underwent MR imaging. The results were compared with the results of other diagnostic modalities. The MR images were obtained using a 1.5-T MR scanner. The MR images were obtained in the axial, coronal, and sagittal planes. The MR images were obtained with a gradient-echo sequence (TR = 400 ms, TE = 20 ms, flip angle = 30°).

The MR images were analyzed for the presence of cerebellar tonsillar herniation, Arnold-Chiari malformation, syringomyelia, and other abnormalities. The MR images were analyzed for the presence of cerebellar tonsillar herniation. The MR images were analyzed for the presence of Arnold-Chiari malformation. The MR images were analyzed for the presence of syringomyelia.

Results

In the 22 patients, cerebellar tonsillar herniation was present in 20 patients. Arnold-Chiari malformation was present in 18 patients. Syringomyelia was present in 16 patients. Other abnormalities were present in 14 patients.
Amyloid-Related Imaging Abnormalities with Emerging Alzheimer Disease Therapeutics: Detection and Reporting
Recommendations for Clinical Practice


ABSTRACT

SUMMARY: Monoclonal antibodies are emerging disease-modifying therapies for Alzheimer disease that require brain MR imaging for eligibility assessment as well as for monitoring for amyloid-related imaging abnormalities. Amyloid-related imaging abnormalities result from treatment-related loss of vascular integrity and may occur in 2 forms. Amyloid-related imaging abnormalities with edema or effusion are transient, treatment-induced edema or sulcal effusion, identified on T2* gradient recalled-echo. As monoclonal antibodies become more widely available, treatment screening and monitoring brain MR imaging examinations may greatly increase neuroradiology practice volumes. Radiologists must become familiar with the imaging appearance of amyloid-related imaging abnormalities, how to select an appropriate imaging protocol, and report findings in clinical practice. On the basis of clinical trial literature and expert experience from clinical trial imaging, we summarize imaging findings of amyloid-related imaging abnormalities, describe potential interpretation pitfalls, and provide recommendations for a standardized imaging protocol and an amyloid-related imaging abnormalities reporting template. Standardized imaging and reporting of these findings are important because an amyloid-related imaging abnormalities severity score, derived from the imaging findings, is used along with clinical status to determine patient management and eligibility for continued monoclonal antibody dosing.

ABBREVIATIONS: AJB = amyloid-betas; AD = Alzheimer disease; APP = amyloid precursor protein; ARIA = amyloid-related imaging abnormalities; ARIA-E = amyloid-related imaging abnormalities with edema or effusion; ARIA-H = amyloid-related imaging abnormalities with hemorrhage; CAA = cerebral amyloid angiopathy; CAA-RI = CAA-related inflammation; GRE = gradient recalled-echo; mAb = monoclonal antibody

As clinically defined, probable Alzheimer disease (AD) dementia is estimated to affect approximately 11% of Americans aged 65 years and older, and there is a large group of patients who may be potential candidates for emerging disease-modifying therapies. Recently, monoclonal antibodies against beta-amyloid have become available (in clinical trials and early clinical practice) for the treatment of AD. These therapies require frequent brain MR imaging examinations to detect contraindications to treatment and to monitor for subclinical or symptomatic adverse events associated with treatment, which are used to guide decisions on dose-adjustment or discontinuation. Neuroradiologists will play an important role in diagnostic evaluations, which will include MRIs and either lumbar punctures or amyloid PET scans, and monitoring adverse events associated with treatment along with longer-term structural and functional effects of therapy, analogous to safety monitoring for progressive multifocal leukoencephalopathy in patients undergoing treatment for multiple sclerosis. Given the large number of AD therapeutic candidates, implementation of treatment and monitoring may greatly increase neuroradiology practice volumes. Radiologists, both neuroradiologists and generalists in private practice and academic institutions, should, therefore, be familiar with the pathophysiology of AD relevant to anti-amyloid therapy and the mechanism and appearance of amyloid-related imaging abnormalities (ARIA) that may result from treatment. In addition, knowledge of the pitfalls in interpretation of these imaging abnormalities, selection of an appropriate imaging protocol, and standardization of imaging and reporting of these findings in clinical practice are important. Use of the recommended standardized imaging protocols and reporting templates will improve ARIA detection and timely communication of
findings to referring providers, ensuring optimal patient care and management.

Background: Amyloid Beta, ARIA, and Cerebral Amyloid Angiopathy

Neuropathology and Pathophysiology of Alzheimer Disease and Cerebral Amyloid Angiopathy. The major proteinopathy that forms amyloid plaques is amyloid-beta (Aβ), specifically the 42 amino acid peptide Aβ42. Amyloid plaques are one of the 2 defining pathologic features of AD, the other being neurofibrillary tangles.14 Aβ42 is derived from proteolytic metabolism of amyloid precursor protein (APP). APP may be cleaved by α-secretase in a nonamyloidogenic pathway or by β-secretase in an amyloidogenic pathway to form α- or β-C terminal fragments that are subsequently cleaved by γ-secretase to form P3 and Aβ peptides, respectively.6 Due to differential cleavage sites, Aβ exists in many isoforms, but the 2 most relevant for this discussion are Aβ42 and Aβ40. Soluble Aβ monomers may undergo clearance via enzymatic degradation, transport across the blood-brain barrier, or efflux out of the brain via perivascular drainage pathways, which include periarterial as well as perivenous or recently detailed lymphatic drainage pathways.7,8 Soluble Aβ monomers may also aggregate into a range of successively larger protein complexes, oligomers, protofibrils, and mature fibrils, that can subsequently deposit in the brain as amyloid plaques (predominantly Aβ42) or in the vessel wall (predominantly Aβ40) and result in AD pathology and cerebral amyloid angiopathy (CAA), respectively.9 Accumulation of Aβ in vessel walls may result from and further contribute to impaired Aβ clearance and loss of vascular integrity. Aβ is, therefore, central to the development of both AD and CAA, which often co-occur.10

Rationale for Beta-Amyloid Removal as Treatment for Alzheimer Disease. Aβ removal for treatment of AD is based on the amyloid cascade hypothesis.11 This model proposes that amyloid plaque deposition facilitates downstream pathophysiologic events including tau phosphorylation, neurofibrillary tangle formation, microglial activation, and eventually neurodegeneration and progressive cognitive decline.5,12,13 In addition, rare familial (and often young-onset) cases of AD are caused by mutations in genes with central roles in amyloid biology (presenilin 1 and 2, PSEN1 and PSEN2, and APP), further pointing to a central early role of amyloid accumulation in the disease.14 Although tau aggregation has been shown to be more closely related to neuronal loss and cognitive decline both spatially and temporally, it is thought that amyloid plaque deposition is the key initiating step in AD pathophysiology.15-17 Halting β-amyloid formation or facilitating its removal is therefore expected to decrease or halt downstream pathophysiologic processes, tau phosphorylation, tau deposition, neurodegeneration, and cognitive decline. Recent clinical trials of anti-amyloid therapies have indeed demonstrated that removal of amyloid plaques from the brain can result in short-term improvement in downstream biomarkers of tauopathy and neurodegeneration, though longer-term consequences on disease biomarkers and clinical course are not fully understood.18,19

Treatment Strategies and Origin of the Term ARIA. Therapeutic approaches for reducing amyloid in the brain have included inhibitors of amyloid aggregation, inhibitors of β-secretase, inhibitors of γ-secretase, and immunotherapy to remove amyloid from the brain, with immunotherapy being the most extensively employed mode of action in clinical trials.20 Active and passive immunotherapy approaches have been investigated, though the use of active immunotherapy has been limited due to adverse reactions including meningoencephalitis.21 Clinical trials using passive immunotherapy, exogenously administered monoclonal antibodies (mAb) against Aβ, have been ongoing for approximately 2 decades. Bapineuzumab was the first mAb to enter clinical trials. It binds the N-terminus of Aβ and clears both soluble and fibrillar Aβ. In early studies of bapineuzumab, monitoring MR imaging brain examinations showed edema and microhemorrhages in 3/10 participants.22,23 The Alzheimer’s Association Research Roundtable convened a workgroup in 2010 to provide information and recommendations regarding the imaging abnormalities encountered in the anti-amyloid trials. This workgroup termed these amyloid-related imaging abnormalities as ARIA with ARIA-E for edema or effusion and ARIA-H for microhemorrhages and hemosiderosis.24

Multiple monoclonal antibodies with variable targets and incidence of ARIA have since been developed and tested in clinical trials (Table 1).18,19,25-32 Aducanumab recently received accelerated approval by the FDA for potential clinical use in mild, symptomatic AD, based on reduction in amyloid plaque.7 Other agents (donanemab, lecanemab, gantenerumab) are currently in late-phase clinical trials and will undergo similar FDA reviews.18,19,31 The Centers for Medicare and Medicaid Services currently proposes coverage for FDA-approved anti-amyloid mAbs in Centers for Medicare and Medicaid Services–approved randomized control trials. To date, uncertainties remain on several fronts including the presence and extent of insurance coverage, the results of an anticipated Phase IV confirmatory study required by the FDA, multiple stakeholder preparedness across a wide range of clinical practices, and other factors.

ARIA Mechanism. Amyloid deposition in vessel walls (CAA) may result in loss of vascular integrity and reduced perivascular clearance and may be related to spontaneously occurring microhemorrhages.33 When anti-amyloid monoclonal antibody therapy is initiated, antibody-mediated breakdown of amyloid plaque and mobilization of parenchymal and vascular Aβ increase the load of perivascular drainage.2 The overload of perivascular drainage pathways may transiently increase amyloid deposition in the arterial wall. At the same time, antibody-mediated inflammation and breakdown of amyloid also occur in the vessel wall. These processes cause further loss of vascular integrity and blood-brain barrier breakdown.24 As a result, proteinaceous fluid and/or red blood cells leak into the parenchyma and/or leptomeningeal space and result in edema/effusion (ARIA-E) or microhemorrhages/superficial siderosis (ARIA-H).

ARIA versus CAA-Related Inflammation. The further loss of vascular integrity and blood-brain barrier breakdown with immunotherapy against Aβ may be thought of as transient exacerbation
<table>
<thead>
<tr>
<th>Monoclonal Antibody</th>
<th>Aβ Binding Site</th>
<th>Amyloid Target</th>
<th>Completed Phase III Trials</th>
<th>Main Results</th>
<th>ARIA-E Incidence(^a)</th>
<th>ARIA-H Incidence(^a)</th>
<th>Active Phase III Trials</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aducanumab</td>
<td>N-terminus conformational epitope</td>
<td>Aβ oligomers, fibrils, and plaques</td>
<td>EMERGE ENGAGE</td>
<td>Reduced decline in cognitive end points Increase in CSF Aβ42 Decrease in amyloid PET SUVR and CSF p-tau</td>
<td>35.2% 20.3% NC 43.0% C</td>
<td>mH 19.1% 12.4% NC 22.7% C SS 14.7% 6.2% NC 19.1% C</td>
<td>EMBARK TRAILBLAZER ALZ-4</td>
</tr>
<tr>
<td>Bapineuzemab</td>
<td>N-terminus</td>
<td>Aβ monomers, oligomers, and fibrils</td>
<td>NCT00574132 NCT00575055</td>
<td>No effect on cognitive end points Decrease in amyloid PET SUVR and CSF p-tau in APOE ε4 carriers</td>
<td>4.2% NC 15.3% C</td>
<td>– –</td>
<td>– –</td>
</tr>
<tr>
<td>Crenezumab</td>
<td>Aβ peptides</td>
<td>Aβ oligomers, fibrils, and plaques</td>
<td>CREAD CREAD 2</td>
<td>No effect on cognitive end points, amyloid PET or CSF p-tau Increase in CSF Aβ42</td>
<td>0% 4.9%</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Donanemab</td>
<td>Pyroglutamate form of Aβ</td>
<td>Aβ plaques</td>
<td>TRAILBLAZER-ALZ-2</td>
<td>Reduced decline cognitive end points Decrease in amyloid PET SUVR</td>
<td>27.5% 11.4% NC 44.0% C</td>
<td>30.5%</td>
<td>TRAILBLAZER-ALZ-3 TRAILBLAZER-ALZ-4</td>
</tr>
<tr>
<td>Ponezumab</td>
<td>C-terminus</td>
<td>Soluble Aβ1-40</td>
<td>–</td>
<td>No effect on cognitive end points, CSF Aβ42 or amyloid PET</td>
<td>0.7% 16.4%</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Gantenerumab</td>
<td>N-terminus and central amino acids</td>
<td>Aβ oligomers, fibrils, and plaques</td>
<td>SCarlet RoAD Marguerite RoAD</td>
<td>No effect on cognitive end points or CSF Aβ42 Decrease in amyloid PET SUVR and CSF p-tau</td>
<td>13.5% 11.0% NC 11.0% NC 15.0% C</td>
<td>16.2% 11.0% NC 11.0% NC 19.4% C</td>
<td>GRADUATE 1 GRADUATE 2</td>
</tr>
<tr>
<td>Lecanemab</td>
<td>Aβ protofibril</td>
<td>Aβ protofibrils</td>
<td>Reduceda decline in cognitive end points Increase in CSF Aβ42 Decrease in amyloid PET SUVR and CSF p-tau</td>
<td></td>
<td>9.9% 8.0% NC 14.3% C</td>
<td>10.7% 4.6% NC 13.1% C</td>
<td>CLARITY AD AHEAD 3-45</td>
</tr>
<tr>
<td>Solanezumab</td>
<td>Mid-domain</td>
<td>Aβ monomers</td>
<td>EXPEDITION 1 EXPEDITION 2 EXPEDITION 3 EXPEDITION PRO</td>
<td>No effect on cognitive end points, amyloid PET SUVR, or CSF p-tau Increase in CSF Aβ42</td>
<td>0.9% 4.9%</td>
<td>9.9%</td>
<td>A4 DIAN-TU</td>
</tr>
</tbody>
</table>

**Note:** mH indicates microhemorrhage; SS, siderosis; NC, APOE ε4 noncarrier; C, APOE ε4 carrier; SUVR, standardized uptake value ratio; –, none or not reported.

\(^a\)ARIA incidence reported for the highest dose in studies with variable dosing arms. ARIA incidence reported for all participants and separately for APOE ε4 noncarriers and carriers when data are available.
of the effects of CAA, similar to CAA-related inflammation (CAA-RI). CAA-RI is a spontaneously occurring inflammatory condition that responds to steroid treatment or immunosuppression, whereas ARIA occurs secondary to monoclonal antibody therapy and generally resolves spontaneously on interruption or discontinuation of therapy. The presence of spontaneously occurring CSF autoantibodies against Aβ in patients with CAA-RI suggests that CAA and CAA-RI are a natural model for ARIA. Aβ and ARIA have similar imaging findings of sulcal effusion and edema involving the white and gray matter as well as microhemorrhages and siderosis and are best differentiated by whether or not the patient is undergoing anti-amyloid therapy.

ARIA Risk Factors. Risk factors for ARIA are drug exposure, APOE-e4 allele carrihership, and pretreatment microhemorrhages. Regarding drug exposure, the risk of ARIA was found to be greater at higher drug doses and earlier in the treatment course. It is noted that the risk for developing ARIA is reduced if patients are started at a low drug dose and progressively titrated over time to the higher final optimal treatment dose. In theory, this titration phase allows time for the cerebral vasculature to undergo the transient process of loss of structural integrity, due to amyloid removal, over a more prolonged period, thus allowing reconstitution of vascular integrity by the time the patient is titrated to higher treatment doses. As such, dose titration or dose escalation strategies have become commonplace in anti-amyloid mAb treatment studies. For example, in Phase III trials of aducanumab, the rates of ARIA were reduced with dose titration compared with nontitration. Additionally, most ARIA developed within the first 8 doses of the final target dose, during this transient phase of presumed loss of vessel wall integrity. APOE-e4 allele carrihership remains the greatest risk factor for the development of ARIA, second only to drug dose, and is likely related to higher load of vascular amyloid and poorer vascular integrity pretreatment. In a Phase III trial of gantenerumab, ARIA-E occurred in 10.7% of homozygous APOE-e4 carriers, 5.4% of heterozygous carriers, and 1.8% of noncarriers. Similarly, ARIA-H occurred in 32.0% of homozygous carriers compared with 19.8% in heterozygous carriers and 12.3% in noncarriers. The presence of pretreatment hemosiderin products most consistent with CAA, lobar microhemorrhages and superficial siderosis, is a serious imaging risk factor predictive of ARIA with the use of anti-amyloid mAb therapies, particularly in APOE-e4 carriers. Due to the increased risk of adverse events in homozygous APOE-e4 carriers, APOE-e4 testing could be considered before drug initiation and could be used to help determine the frequency of safety monitoring examinations in future, updated treatment guidelines.

Additionally, in clinical trials, the incidence of ARIA has varied with the Aβ binding site and targeted Aβ structure (Table 1). ARIA incidence was higher with mAbs that bind the N- versus C-terminus and target aggregated-versus-soluble forms of Aβ.

Conversely, risk factors for CAA are AD pathology and genetic factors that promote AD pathology, namely APOE-e4, Down syndrome, PSEN1, PSEN2, and APP mutations. Note, vessel-related risk factors for ARIA relate to amyloid deposition and as with CAA are not related to common vascular risk factors such as hypertension, hyperlipidemia, diabetes mellitus, or the severity of atherosclerosis.

ARIA-E Imaging Appearance. The E in ARIA-E stands for edema, effusion, and exudate. A leak of proteinaceous fluid into the parenchyma results in edema, with the imaging appearance similar to that of vasogenic edema and best visualized on a T2-FLAIR sequence (Figs 1 and 2). T2-hyperintense signal occurs in the white matter, gray matter, or both. There may be associated local mass effect and gyral swelling. Findings may be differentiated from cytotoxic edema by absent diffusion restriction; intense diffusion restriction associated with an acute infarct is not a characteristic of ARIA. When the leak occurs in the leptomeningeal space, the result is a sulcal effusion or exudate, only appreciated on T2-FLAIR sequences due to T1-shortening related to proteinaceous content (Fig 3). ARIA-E may present as either parenchymal edema or sulcal effusion, or both may occur together; sulcal effusion was the most common manifestation of ARIA-E in some mAb trial analyses, and parenchymal edema, in others. ARIA-E most commonly affects the occipital lobes followed by the parietal, frontal, and temporal lobes and, least frequently, the cerebellum. The intensity and size of the signal abnormality are variable, from subtle small, 1- to 2-cm zones of cortico-subcortical abnormality to multifocal-to-near hemispheric signal T2-hyperintense signal alterations. These regions of signal abnormality generally have ill-defined margins, though they may infrequently
have circumscribed margins and mimic a neoplastic lesion (Fig 4).

Both the edema and effusion/exudate of ARIA-E are transient and typically resolve over time upon interruption or discontinuation of anti-amyloid therapy (and have even been observed to resolve under continued dosing).44

Interpretation Pitfalls. Imaging experience in clinical trials has provided insight into potential interpretation pitfalls in the assessment of ARIA-E. Any condition that results in T2-FLAIR hyperintensity, such as incomplete water suppression, susceptibility artifact, etc, may serve as an ARIA-E mimic (Fig 5). Shading artifacts and scanner or sequence variability may make identification and interpretation of ARIA-E-versus-artifacts difficult. Shading artifacts may occur when prescan normalization is inadvertently turned off or the patient is not centered in the receive coil, resulting in artfactually bright regions. When this occurs focally on the T2-FLAIR sequence, the artifacts may simulate ARIA-E, particularly when occurring in the occipital lobes where ARIA-E is most common. The occipital white matter signal may also vary with MR imaging scan vendor or field strength.45 If a patient is imaged on different scanners, it may be difficult to distinguish true ARIA-E versus technical variation (Fig 5). Similarly, white matter signal may differ with scan technique, such as the use of 3D-versus-2D FLAIR.46 CSF suppression may be suboptimal, and CSF may remain very high in signal in the presence of large susceptibility or due to inflow phenomena.47

Other entities may simulate ARIA. Posterior reversible encephalopathy syndrome may similarly have T2-hyperintense signal involving the white and gray matter, co-occurring hemorrhage, and a predilection for the occipital lobes, though often with a more near-symmetric parasagittal distribution.48 A subacute infarct that no longer demonstrates diffusion restriction may be difficult to differentiate from the parenchymal edema of ARIA-E in the absence of prior imaging from the acute stage or a history of focal neurologic deficit. Incomplete water suppression on FLAIR, oxygen supplementation, subarachnoid hemorrhage, and other entities that cause FLAIR hyperintense sulcal signal may mimic ARIA-E sulcal effusion.49 Although these entities have overlapping radiographic features, when clinical history is available, they may be differentiated from ARIA by the absence of prior anti-amyloid therapy and, in some cases, the presence of clinical symptoms.

Comparison with the baseline, pretreatment T2-FLAIR study is important in ARIA-E detection. ARIA-E that is subtle or that occurs in the setting of extensive small-vessel disease, particularly in a peripheral pattern, may only be appreciated when a careful comparison is made with the baseline T2-FLAIR study. In other cases, the normal compact configuration of sulci with faint cortical/leptomeningeal hyperintensity may mimic an area of ARIA-E, when this is simply normal anatomy confirmed as present at the baseline scan. Subtraction imaging may help detect subtle ARIA-E cases.50

Hyperintense signal on DWI (lower left) is confirmed to be T2 shine-through on the ADC map (lower right), differentiating ARIA-E from acute ischemia or other cause of cytotoxic edema. Images courtesy of Biogen and the Dominantly Inherited Alzheimer Network.
Spontaneous Edema/Effusion versus Treatment-Emergent ARIA-E.

ARIA-E is not uncommon in clinical trials of mAbs. For example, this was identified in 17% of participants in the bapineuzumab treatment arm and 35% of the aducanumab treatment arm, with incidence varying with treatment and patient-related factors described above. On the other hand, spontaneous, transient edema is rare and was reported in 0.05% of baseline examinations for early anti-amyloid trials and 3% of the aducanumab placebo arm.

Clinical Consequences. On the basis of available clinical trial data and experience, ARIA-E is most frequently detected on routine, protocol-specified, surveillance MRIs in patients who are clinically asymptomatic. When ARIA-E is symptomatic, the symptoms are most commonly nonlocalizing, such as headache or confusion, but can additionally include visual disturbances, visuospatial impairment, or praxis difficulties in view of the relative predilection for posterior involvement of ARIA-E. Like the imaging findings, the clinical symptoms are generally expected to resolve over time with treatment pause or withdrawal. In the rare event of symptomatic ARIA-E or in cases with asymptomatic radiographically severe ARIA-E, treatment with intravenous methylprednisolone and possibly other therapies (eg, antihypertensives, anti-seizure medications) may be indicated on the basis of anecdotal reports.

ARIA-H

Imaging Appearance. ARIA-H, hemorrhage, includes microhemorrhages and superficial siderosis. When a leakage of heme products occurs in the parenchyma, microhemorrhages develop. Microhemorrhages are punctate, rounded, and markedly hypointense foci in the brain parenchyma on T2* sequences, measuring <10 mm in diameter (Fig 6). A leak of heme products into the leptomeningeal or subpial space results in superficial siderosis, which manifests as curvilinear hypointensity along the brain surface (Fig 7). Lobar macrohemorrhage (focus of hemorrhage identifiable on T1- or T2-weighted imaging, and usually >10 mm in diameter on gradient recalled-echo [GRE]) rarely occurs with anti-amyloid agents, and when it does, it may be the result of an underlying disease process such as CAA.

ARIA-H is detected on heme-sensitive sequences, ie, T2* GRE and SWI. SWI achieves increased sensitivity for microhemorrhage detection by generating both magnitude and phase images and multiplying the magnitude image by the phase image. Sensitivity to the detection of ARIA-H is also increased by higher field strength, longer TEs, and lower readout bandwidth. Improved spatial resolution on SWI sequences compared with 2D GRE decreases partial volume effects, which may obscure microhemorrhages, but

FIG 3. ARIA-E, sulcal effusion. Axial T2-FLAIR images from 4 separate patients at pretreatment baseline (left) and on a monitoring examination following initiation of anti-amyloid monoclonal antibody therapy (postdosing, right). A, Compared with the baseline examination, new sulcal T2-FLAIR hyperintense signal in the right temporal-occipital lobe measuring <5 cm in transverse dimensions (mild ARIA-E, red circle). B, Postdosing, new T2-FLAIR sulcal effusion involving the right posterior temporal and parietal lobes measuring 5–10 cm (moderate ARIA-E). C, Subtle multifocal, bi-occipital, sulcal effusion on the postdosing examination, each region measuring <5 cm (moderate ARIA-E, red arrows). A single region of ARIA-E measuring <5 cm would be classified as mild, but >1 cm yields a classification of moderate. Multiplicity of ARIA-E involvement yields a classification of moderate, as long as each region is <10 cm in diameter. Identification of these subtle abnormalities requires careful comparison with prior monitoring and/or baseline examination. D, Postdosing, extensive T2-FLAIR sulcal effusion involving the bilateral temporal and occipital lobes measuring ≥10 cm in extent (severe ARIA-E). Images courtesy of Biogen and the Dominantly Inherited Alzheimer Network.
also results in a reduction in the SNR. The imaging sequence, sequence parameters, scanner, and field strength all affect the sensitivity for detection of microhemorrhages. As discussed below, counting the number of microhemorrhages is a key component of ARIA assessment; therefore, a standardized imaging protocol is needed.

Interpretation Pitfalls. There are both patient-related and acquisition-related interpretation pitfalls or difficulties with ARIA-H and, in particular, microhemorrhage detection (Fig 8). Blurring due to patient motion may impair detection of small microhemorrhages. Areas of prominent air-tissue susceptibility effects may induce punctate artifacts that look similar to microhemorrhages, especially near the frontal sinuses, mastoid air cells, and skull base. Susceptibility-related signal loss from physiologic mineralization in the basal ganglia may be misinterpreted as microhemorrhages and should not be incorporated into the overall microhemorrhage count. Bulk susceptibility effects that produce signal loss may preclude evaluation of the inferior temporal and anterior frontal lobes. Partial volume effects may cause a small microhemorrhage to be poorly seen or to have a variable appearance on serial examinations. Thick-section acquisitions may also make it difficult to distinguish a microhemorrhage from a vessel flow void. A flow void should be able to be tracked across multiple contiguous slices, though a vessel image in profile may mimic microhemorrhage on a single section. T2-weighted images can be useful for comparisons, as flow voids in vessels do not have a blooming effect. Reader biases may also affect interpretation, as readers have been found to undercall possible microhemorrhages in a patient without other microhemorrhages and to overcall in patients with many.

Microhemorrhages: Spontaneous versus Treatment-Emergent versus Cerebrovascular Disease. The treatment-emergent microhemorrhages of ARIA-H have a peripheral (lobar) predilection and most commonly occur in the cortex and gray-white matter junction as well as the cerebellum, similar to where ARIA-E may occur. These microhemorrhages have the same morphologic appearance and distribution as those that occur spontaneously and characterize and define CAA. Importantly, these areas of hemosiderin deposition typically occur in different brain areas from those related to vascular risk factors, namely hypertension, which most commonly occur in the deep white matter, deep gray matter, and brainstem. In the current clinical trials and the aducanumab FDA label ARIA severity grading, all microhemorrhages, regardless of location and suspected etiology, were included in the count used to determine eligibility and continuation of anti-amyloid therapy. Of note, although discrete microhemorrhages in the deep gray structures are included in the ARIA assessment, ill-defined susceptibility in the basal ganglia related to senescent change or mineralization (Fig 8) is not. In future clinical trials and clinical practice, we recommend that the inclusion of microhemorrhages in the deep gray matter and brainstem in the count used to determine treatment eligibility be reassessed, as these are most likely secondary to vascular risk factors and not related to amyloidosis. The differentiation of microhemorrhages most likely secondary to vascular risk factors from those related to amyloidosis and an increased risk of adverse events with mAbs may be particularly important as mAb use expands to clinical practice and inclusion of patient populations with higher prevalence of vascular risk factors than clinical trial populations.

Spontaneous microhemorrhages are relatively common in elderly persons, with a prevalence of up to 15%–30% in memory clinic and AD cohorts and a similar prevalence in baseline MR

![FIG 4. Atypical ARIA-E, parenchymal edema. Axial T2-FLAIR images from 3 separate patients at pretreatment baseline (left) and on a monitoring examination following initiation of anti-amyloid monoclonal antibody therapy (postdosing, right). A, Adjacent slices on postdosing T2-FLAIR show development of multiple nodular areas of ARIA-E (red arrows). This nodular presentation is less commonly encountered in contrast to the typical ARIA-E, which has an amorphous parenchymal pattern as expected for vasogenic edema. In this case, although each area of ARIA-E is small (<5 cm), the multiplicity of lesions yields a classification of moderate ARIA-E. B, Atypical ARIA-E as a rounded focus of T2-FLAIR hyperintense signal in the left parietal white matter (left, red arrow) that may be mistaken for neoplastic process and differentiated by the time course of appearance coinciding with monoclonal antibody dosing and subsequent resolution. C, Atypical ARIA-E in the cerebellar vermis. Postdosing, new T2-FLAIR hyperintense signal in the cerebellar vermis (red arrow), a less common location for ARIA-E relative to the cerebral hemispheres. Although ARIA-E has a slight predilection for the parieto-occipital lobes, similar to posterior reversible encephalopathy, any part of the brain may be affected. Images courtesy of Biogen and the Dominantly Inherited Alzheimer Network.](image-url)
The prevalence of spontaneous superficial siderosis is considerably lower (prevalence 0.4% versus 12.8% for superficial siderosis versus lobar microhemorrhages in the Framingham and Rotterdam cohorts), though it may be as high as 5% in AD cohorts. The incidence of mAb treatment-related microhemorrhages, ARIA-H, has been variable in clinical trials, for example 4.9% in a trial of solanezumab and 30.5% for donanemab. The abnormality resolved (not shown). ARIA-H or ARIA-E independently is likely due to the timing of leakage events. Imaging appearance depends on the composition of the leakage products. It is thought that proteinaceous fluid also leaks any time there is leakage of red blood cells or that ARIA-E occurs, to some extent, with any ARIA-H. However, isolated ARIA-H may be detected as ARIA-E is transient and resolves over the course of weeks to months, while the hemosiderin deposition of ARIA-H typically does not resolve.

As discussed above, both ARIA-E and H share a common mechanism relating to increased vascular permeability, but MR imaging appearance depends on the composition of the leakage products. It is thought that proteinaceous fluid also leaks any time there is leakage of red blood cells or that ARIA-E occurs, to some extent, with any ARIA-H. However, isolated ARIA-H may be detected as ARIA-E is transient and resolves over the course of weeks to months, while the hemosiderin deposition of ARIA-H typically does not resolve. In the authors' experience, the detection of isolated ARIA-H should prompt the imager to pay particular attention to the T2-FLAIR sequence in this area for subtle ARIA-E; treatment-emergent ARIA-H will often be the harbinger of subtle ARIA-E, which will only be appreciated with directed focus to this area. Note, although microhemorrhages are thought to not resolve, when incident ARIA-H is detected in the acute phase, these fresh blood-degeneration products may become less apparent on subsequent imaging, due to some degree of resorption.

In contrast, ARIA-E may occur without ARIA-H if not enough red blood cells have leaked into the extracellular or subarachnoid space or if not enough time has passed to allow heme product degradation to affect T2* signal. In summary, the recognition of ARIA-H or ARIA-E independently is likely due to the timing of imaging relative to the time of the vascular leak.

**ARIA Imaging in Clinical Trials**

Clinical Trial Imaging Protocols. Standardization of imaging protocols is employed in clinical imaging trials to obtain consistent
FIG 6. ARIA-H, microhemorrhage. Baseline and postdosing GRE (left, A–C) and T2-FLAIR (right, A–C) for 3 patients. A, Postdosing, few (<5) new peripheral left frontal microhemorrhages (mild ARIA-H, red circle) that occur with new patchy T2-FLAIR hyperintense signal in that region (mild ARIA-E, red circle). B, Postdosing, 5 treatment-emergent microhemorrhages (moderate ARIA, red circle) that occurred with regional mild ARIA-E edema (red circle). C, Postdosing, ≥10 new microhemorrhages (severe ARIA-H, red circle). Associated extensive right cerebral hemisphere T2-FLAIR hyperintense signal involving the cortex and subcortical white matter with mass effect and midline shift (severe ARIA-E). D, At least 12 treatment-emergent cerebral microhemorrhages (severe ARIA-H, red arrows) without ARIA-E. In comparison with case C, these microhemorrhages are scattered, rather than clustered. Regional distribution of microhemorrhages may vary, and both cases C and D are severe ARIA-H and would prompt discontinuation of anti-amyloid therapy per current guidelines. Images courtesy of Biogen and the Dominantly Inherited Alzheimer Network.
Criteria are monitoring examinations. In clinical trials, common exclusion and provide baseline for comparison on the subsequent safety-association with increased risk of adverse treatment events imaging is required to evaluate for pre-existing hemosiderin deposits.

Before therapy initiation, brain MR imaging is required to evaluate for pre-existing hemosiderin deposition associated with increased risk of adverse treatment events and provide baseline for comparison on the subsequent safety-monitoring examinations. In clinical trials, common exclusion criteria are ≥5 microhemorrhages or any superficial siderosis on the baseline MR imaging. The recent FDA guidance for clinical use of aducanumab lists exclusion criteria as ≥10 microhemorrhages, any superficial siderosis, or parenchymal hemorrhages measuring >1 cm in the prior year. The baseline imaging should be performed using the same MR imaging protocol as used for the subsequent safety-monitoring examinations.

ARIA Severity Grading on Monitoring Examinations. Different ARIA grading schemes have been suggested. However, a specific scheme was included in the recent FDA guidance for clinical use of aducanumab. Given the FDA endorsement, this scheme is likely to become a default standard at least as a starting point. In this framework, ARIA-E, ARIA-H microhemorrhage, and ARIA-H superficial siderosis are each categorized by radiographic severity (Table 2 and Figs 2, 3, 6, and 7). ARIA-E scoring was defined as mild: 1 site of sulcal or cortical/subcortical T2-FLAIR hyperintense signal measuring <5 cm; moderate: 1 site measuring 5–10 cm or >1 site each measuring <10 cm; and severe: 1 or more sites measuring >10 cm.

To assess ARIA-E extent, a measure is made along the single greatest dimension of the lesion. This measurement should encompass both parenchymal and sulcal T2-FLAIR hyperintensities as well as any related gyral swelling and sulcal effacement. Measuring in the plane of acquisition should be relevant in most situations. For lesions that have a greater through-plane extent, i.e., craniocaudal extent, one may determine lesion size by reformatting data into another plane or estimating extent on the basis of the number of slices on which the abnormality is identified. Each lesion, which is separate and distinct (e.g., separated by normal brain tissue, sulci, and gyri), should be measured separately. In other words, reporting the number of sites involved does not need to account for anatomic locations but should only rely on the presence or absence of physically separated lesions. If the lesion spans multiple contiguous brain lobes, it should still be counted as a single location. If there are lesions in both hemispheres, they should be reported as separate locations, as measurements would not cross the midline.

Microhemorrhages were scored using the cumulative number of treatment-emergent microhemorrhages: mild: ≤ 4; moderate: 5–9; and severe: ≥ 10 new microhemorrhages since the baseline examination. Superficial siderosis was scored as cumulative regions of treatment-emergent regions of siderosis: mild: 1; moderate: 2; severe: > 2 new areas of superficial siderosis since the baseline, pretreatment examination. As the presence of any siderosis should exclude a patient from treatment, cumulative treatment-emergent regions of siderosis should correspond with total regions of siderosis present. On the other hand, a patient may have up to 4 or 9 microhemorrhages before treatment, depending on the exclusion criteria implemented, and these would not be included in the count for ARIA-H severity grading. As with ARIA-E, the number of involved regions of superficial siderosis is important, and each involved site, region, or area is similarly defined as a physically separate region of contiguous sulcal signal abnormality.

Clinical Management Based on ARIA Findings. In deciding to continue with treatment dose and dose escalations, 2 metrics were employed in the clinical trials and are described in the aducanumab FDA label (Fig 10). The patient had to be asymptomatic, and the following imaging criteria had to be met to continue with dosing. For asymptomatic patients, dosing was continued with mild ARIA-E and/or mild ARIA-H, but dosing was suspended in patients with moderate ARIA-E and/or moderate ARIA-H. Once dosing was suspended due to imaging findings, serial imaging was performed monthly, and dosing was resumed following the resolution of ARIA-E and stabilization of ARIA-H. If ARIA was associated with the symptoms, dosing resumed only after both the resolution of clinical symptoms and the resolution of ARIA-E and stabilization of ARIA-H. Dosing was permanently discontinued in participants with severe ARIA-H (≥10 treatment-emergent microhemorrhages or >2 areas of treatment-emergent superficial siderosis) or a macrohemorrhage (>10 mm in diameter). Real-world clinical practice guidelines may require adjustments to these protocols on the basis of further experience and depending on the extent to which the
Considerations for Neurology Practice

Developments in anti-amyloid mAbs for AD herald a potential shift in management of an exceptionally common and devastating disease. These new anti-amyloid agents are the first potentially disease-modifying agents for AD. In contrast, current mainstays of therapy for AD are not disease-modifying but, instead, are simply symptomatic and supportive in nature, predominantly related to lifestyle and environmental modifications and use of pharmacotherapies (eg, cholinesterase inhibitors), which target symptoms but do not alter the disease itself (which continues to progress). As a result, current neurology practice operations and infrastructure may need to rapidly evolve to accommodate emerging therapeutics that have very different profiles (relating to adverse effects, financial and nonfinancial costs, test and visit types, and frequencies for treatment initiation and monitoring) from existing options.

Several points of interface between neurology and radiology are relevant in this space. There is broad agreement among cognitive/behavioral neurology subspecialists that appropriate application of anti-amyloid therapies would, at minimum, require biomarker evidence that AD is the etiology for a patient’s cognitive impairment.62,63 As a result, sites may need to plan for increased volumes of lumbar punctures (for CSF biomarker studies) and/or amyloid PET scans as part of initial evaluations. This context could impact logistics and personnel (to ensure appropriate expertise) around fluoroscopically guided lumbar punctures and PET tracer and scanner access. Multidisciplinary input from experts at local sites could also help to inform appropriate candidacy.

In addition, given the need for regular monitoring for ARIA, practices will also benefit from anticipating an increase in MR imaging examinations to prevent delays for patients receiving treatment, including patients in whom symptoms potentially necessitate more urgent evaluation. As part of this, clinical practices will need to decide on the most appropriate timeline for scheduled safety MR imaging scans, with expert recommendations currently favoring more frequent scanning (particularly early in the course of treatment) in line with protocols from existing Phase III trials. Currently, in most clinical trials, anti-amyloid dosing occurs on a monthly basis. MR imaging is performed at baseline, and at weeks 14 and 22 as the patients are being titrated to the maximal drug...
dose. Subsequently, monitoring MR images are taken a month after receiving the maximal maintenance dose and every 3 months thereafter while patients are on this maintenance dose.

In rare cases in which hospitalization for ARIA may be required, access and education will be crucial, particularly given the subtleties of ARIA detection and distinctions with management (principally related to drug discontinuation and therapeutic steroids) in comparison with other mimics.

More broadly, it is crucial to remember that the collective clinical experience with anti-amyloid mAbs is in its relative infancy and thus far is mostly restricted to clinical trial populations, which may not fully reflect real world practice within the broader population having symptomatic AD. In addition, there are ongoing trials testing an anti-amyloid mAb in asymptomatic individuals with intermediate (A3 trial) and elevated (A45 trial) brain amyloid loads, and results from these trials may further influence the timing and target population for therapy. As such, neurology and radiology providers will benefit from being collaborative and nimble over the coming period.

**ARIA Imaging in Clinical Practice**

**Role of the Radiologist in Clinical Management.** Detailed description and quantification of ARIA findings will be used in guiding patient therapeutic dosing, and changes over time must be accurately assessed. To obtain accurate longitudinal assessment of findings, standardized methods are needed for image acquisition and reporting. The minimum sequences and reporting guidelines should be standardized within an institution or practice and ideally across institutions. To promote such efforts, recommendations for an imaging protocol and reporting template are provided below.

**Recommendations for Clinical Imaging Protocol**

**Minimal Required Sequences.** The minimal recommended sequences for ARIA ascertainment are T2-FLAIR, T2* GRE, and DWI.
T2-FLAIR imaging is necessary for detection of ARIA-E. In clinical trials, 2D axial T2-FLAIR imaging was performed. Over the past decade, 3D FLAIR imaging has become more widely employed and has some advantages relative to 2D FLAIR, including improved CSF suppression and increased sensitivity for parenchymal edema.\textsuperscript{47,65} Therefore, 3D FLAIR may be preferred if it can be performed routinely with high quality and in a standardized fashion. However, if that is not feasible in your practice at the current time, 2D FLAIR should be performed. In summary, T2 FLAIR imaging is required for ARIA-E detection and should be performed using whichever technique is reliable, reproducible, and works for your practice.

T2* sequences are required for ARIA-H assessment, and in clinical trials, the GRE sequence was used. SWI may provide improved sensitivity for microhemorrhage detection\textsuperscript{52} but is less widely available and has more variability among MR image vendors compared with the GRE sequence. Also, current rules for dose-adjustment are based on 2D-GRE data. In other words, the increased sensitivity of SWI in the detection of microhemorrhages may cause a patient to enter the category of dose suspension due to too many microhemorrhages detected, whereas on the basis of the GRE scan, the lower microhemorrhage count would allow for continued treatment. Therefore, 2D axial GRE is recommended for ARIA-H assessment in clinical practice and should use parameters similar to those employed in clinical trials (non-EPI technique: 3T TE, \~20 ms; maximum section thickness, 4 mm; acquisition time, \~4–5 minutes).

Whenever a new signal abnormality is noted on a monitoring MR imaging study, the DWI sequence plays an important role in helping to differentiate ARIA-E from acute/subacute infarct. As such, it is recommended that a standard clinical axial 2D trace DWI sequence be included as routine protocol.

Standardized versions of these 3 sequences are required at the enrollment (pretreatment screening/baseline) examination and each treatment monitoring examination. In regard to ARIA-E, the increased sensitivity of SWI in the detection of microhemorrhages may cause a patient to enter the category of dose suspension due to too many microhemorrhages detected, whereas on the basis of the GRE scan, the lower microhemorrhage count would allow for continued treatment. Therefore, 2D axial GRE is recommended for ARIA-H assessment in clinical practice and should use parameters similar to those employed in clinical trials (non-EPI technique: 3T TE, \~20 ms; maximum section thickness, 4 mm; acquisition time, \~4–5 minutes).

### Table 3: Recommended imaging sequences for baseline imaging and ARIA monitoring examinations based on clinical trial experience and current guidelines\textsuperscript{*}

<table>
<thead>
<tr>
<th>Field strength</th>
<th>Minimal</th>
<th>Recommended</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>ARIA-E detection</td>
<td>2D-FLAIR</td>
<td>2D- or 3D-FLAIR</td>
<td>Either 2D or 3D is acceptable, whichever can be performed with consistent quality and optimal CSF suppression</td>
</tr>
<tr>
<td>ARIA-H detection</td>
<td>T2*-GRE</td>
<td>T2*-GRE (±SWI)</td>
<td>Recommendations for enrollment and dose suspension are based on T2*-GRE detection of blood products; SWI may also be performed for confirmation and may be of value to gather data going forward</td>
</tr>
<tr>
<td>Infarct assessment</td>
<td>DWI</td>
<td>DWI</td>
<td>DWI required to differentiate ARIA from acute/subacute infarct and identification of incidental infarcts</td>
</tr>
</tbody>
</table>

\textsuperscript{*} Additional optional sequences may be added per individual site preference.

---

**FIG 10.** Patient management based on ARIA severity and clinical symptoms. ARIA-H management rules are the same for each severity of microhemorrhages and superficial siderosis. C (green) indicates continue dosing at current dose and schedule; S (yellow), suspend dosing; resume dosing at same dose once ARIA-E resolved or ARIA-H stable and clinical symptoms resolve; D (red), discontinue dosing; Serious (other), medical event unrelated to anti-amyloid therapy.
Considerations for Additional Optional Sequences, Enrollment, and Monitoring Protocols. Additional sequences may be performed at individual sites on the basis of their standard protocols and procedures, interests, and available scan time, and these additional sequences could be tailored to separate enrollment and monitoring protocols. For example, in many practices, MPRAGE and volumetric analyses are performed on all MR imaging scans for the evaluation of dementia, and the enrollment MR imaging scan would fall under this category. However, such volumetric assessment is not needed for safety monitoring during treatment. Therefore, the MPRAGE sequence could be included in a dedicated enrollment protocol. T2 TSE/FSE may be included to help resolve ambiguous T2*-findings, such as differentiating a microhemorrhage from a vessel flow void. SWI could be added (but not replace GRE) to either the enrollment or monitoring protocols if there is interest in more sensitive microhemorrhage detection or academic comparison with GRE. Postcontrast imaging is not recommended unless there is a diagnostic dilemma or incidental finding requiring further evaluation.

Importance of Consistent Serial Imaging: Field Strength and Vendor. In addition to a standardized imaging protocol, patients would also ideally be imaged on the same field strength and vendor on sequential visits due to scanner-related differences (see “ARIA-E” “Interpretation Pitfalls”). As with recent clinical trials, we recommend that imaging be performed at 3T rather than 1.5T due to improved SNR with higher field strengths, which may allow improved detection of small microhemorrhages and subtle ARIA-H. However, if 3T imaging is not available or the patient is not a candidate for 3T imaging (eg, devices), imaging may be performed on 1.5T. Whichever field strength and vendor is used for imaging a patient, effort should be made to be consistent from scan to scan whenever possible. Patients may be encouraged to visit a consistent imaging facility for their monitoring scans. Within an institution, AD therapeutic imaging could be triaged to a certain group of scanners as scheduling allows.

Need for Routine MR Imaging: Consideration for AD Therapeutic Enrollment. Patient factors that would preclude routine MR imaging should be considered at the time of enrollment. Patients with MR imaging—unsafe devices or other MR imaging contraindication (eg, metallic foreign body in the eye) would not be able to be imaged. Patients with MR imaging—conditional devices requiring scanning at specific institutions and imaging slots for which scanning may be monitored by an MR imaging physicist may be ineligible. Additionally, patients with claustrophobia, unable to undergo MR imaging without anesthesia, may be considered ineligible for treatment.

Online Resources. If in the future, vendor-specific protocols are made available for ARIA monitoring, these will be posted on the American Society of Neuroradiology website. As additional mAbs obtain FDA approval and guidelines are modified, the recommended imaging sequences and protocols may evolve.

Recommendations for Reporting/Communication

Clinical History. Relevant clinical history should be available at the time of image review and include the drug the patient is receiving, drug dose, duration of treatment, date of last dose, and whether the patient has experienced previous episodes of ARIA.

Reporting of Baseline/Enrollment MR Imaging Examination. The number and location of existing microhemorrhages and superficial siderosis must be tabulated on the baseline examination. In line with exclusion criteria, microhemorrhage number should be summarized as 0–4, 5–9, and ≥10 and superficial siderosis as present or absent. Any significant incidental and acute findings, such as acute or chronic infarctions, also should be documented in the report narrative.

Reporting of Monitoring MR Imaging Examinations. The radiology report must include the patient to be given an ARIA severity score for each ARIA-E, ARIA-H microhemorrhage, and ARIA-H superficial siderosis, which will be used along with the clinical symptom score to determine continued dosing. The quantitative nature of the ARIA severity scoring lends itself to a templated report including the following sections. ARIA-E must be noted as absent or present. If present, the location and maximal transverse diameter of each noncontiguous, involved site must be reported. When following a patient with ARIA-E at the prior time point, one must describe interval change and resolution. For microhemorrhages, the number and location of prior and new microhemorrhages must be reported, and the number of cumulative treatment-emergent microhemorrhages may be reported in relevant categories of 0–4, 5–9, and ≥10. The description of superficial siderosis should include the number and location of each prior and new noncontiguous site. Incidental and acute findings such as acute or interval (nonacute) infarct should be included in the report narrative.

Considerations for ARIA Reporting. As the presence of ARIA-E and siderosis, the number of microhemorrhages, and changes over time directly determine patient management, radiologists must carefully consider their level of diagnostic uncertainty and level of sensitivity versus specificity for ARIA detection. In clinical trial interpretations, the practice at some central reading sites is that each finding is marked as possible or definite and only definite findings are counted toward ARIA severity scoring and exclusion or dosing-discontinuation criteria. Possible findings may include a subtle abnormality (small, faint possible microhemorrhage or subtle increased extent of occipital white matter hyperintensity) or be related to image acquisition (motion-degraded examination, poor CSF suppression, or change in imaging technique). While only definite findings are counted toward ARIA severity scoring, participants may be asked to return for repeat imaging in the case of possible ARIA-E, as its presence would affect continued drug dosing. Although exact cut-points for microhemorrhages are used

standardized imaging will allow the detection of subtle T2-FLAIR changes by comparison with baseline. In regard to ARIA-H, baseline imaging is essential for patient selection to exclude those patients with pre-existing siderosis or too many microhemorrhages, for whom there is a higher rate of adverse events. As such, baseline imaging is critical to ensure proper patient selection, image interpretation, and patient management.

Within an institution, AD therapeutic imaging could be triaged to various centers and imaging slots for which scan-
in severity scoring, the presence of a possible microhemorrhage is less likely to affect the treatment course.

In clinical ARIA reporting, we recommend that only definite microhemorrhages be included in the quantitative ARIA template; possible microhemorrhages should be described in the report narrative as a pointer to direct the next radiologist interpreting a scan for this patient. For ARIA-E, we recommend both definite and possible ARIA-E (parenchymal edema or effusion) be included in the templated report. Finally, we recommend including whether the image quality is adequate for ARIA assessment or inadequate, such as due to motion or poor CSF suppression, requiring the patient to return for repeat imaging.

**Recommended Reporting Template.** A recommended reporting template is posted on the American Society of Neuroradiology website at https://www.asnr.org/alzheimers-webinar-series/. As with the imaging protocol, the recommended reporting template may evolve and will be updated as guidelines are modified on the basis of growing experience in clinical trials and clinical practice.

**Communication with Referring Physicians.** Use of the recommended ARIA reporting template will allow clear communication of relevant ARIA findings that will, in part, determine eligibility for treatment and further drug dosing. All ARIA reports should be generated in a timely manner, as each dosing session is typically preceded by imaging and dose administration is dependent on a satisfactory radiographic report. Findings of severe ARIA should be communicated in an urgent manner as they may affect dosing and patient management.

**CONCLUSIONS**

The emerging monoclonal antibody therapies for AD require both baseline pretreatment brain MR imaging as well as frequent monitoring MR imaging examinations for the detection of potential subclinical adverse events that may require dose adjustment. As these therapies begin to be implemented in clinical practice, treatment enrollment and monitoring brain MR imaging examinations may greatly increase neuroradiology practice volumes and will introduce a new imaging entity, ARIA, requiring awareness by all radiologists. ARIA-E is transient, treatment-induced edema or sulcal effusion, identified on T2-FLAIR that must be differentiated from an acute infarct or other entities causing hyperintense T2 signal. ARIA-H is treatment-induced microhemorrhages or superficial siderosis identified on T2* GRE, qualitatively similar to spontaneous hemosiderin deposition in CAA. Use of the recommended standardized imaging protocols and reporting templates will improve ARIA detection and timely communication of findings to referring providers, ensuring optimal patient care and management.

**ACKNOWLEDGMENTS**

We thank Biogen and the Dominantly Inherited Alzheimer Network for images and the American Society of Neuroradiology for support in development of this manuscript.

**REFERENCES**

22. Salloway S, Sperling R, Gilman S, et al; Bapineuzumab 201 Clinical
28. Salloway S, Sperling R, Fox NC, et al; Bapineuzumab 301 and 302


Regarding “Brain Perfusion Alterations on 3D Pseudocontinuous Arterial Spin-Labeling MR Imaging in Patients with Autoimmune Encephalitis: A Case Series and Literature Review”

We read with interest the article by Li et al, “Brain Perfusion Alterations on 3D Pseudocontinuous Arterial Spin-Labeling MR Imaging in Patients with Autoimmune Encephalitis: A Case Series and Literature Review,” recently published in the American Journal of Neuroradiology. In this retrospective case series, the authors found that all patients with autoimmune encephalitis (AE) had increased CBF in the inflammatory area. Indeed, arterial spin-labeling (ASL) is critical in the diagnosis of AE and may serve as early evidence preceding conventional abnormal findings on MR imaging and laboratory diagnosis. Sachs et al found cerebral hyperperfusion in anti-N-methyl-D-aspartate (NMDAR) encephalitis. Vallabhaneni et al demonstrated increased CBF and CBV in the left parieto-occipital gray matter on CT perfusion. Sarria-Estrada et al revealed ASL hyperperfusion overlapping the involved lesions, but they also found increased perfusion and increased metabolism on [18F] FDG-PET/CT and SPECT in paraneoplastic autoimmune encephalitis.

As mentioned above, we have also encountered several cases of AE with hypoperfusion or without any visible changes on ASL perfusion in clinical practice. We retrospectively reviewed image data from 30 consecutive patients with AE in the most recent 2 years including major constituents of AE-covered anti-NMDAR (11 patients), anti-leucine-rich glioma inactivated-1 (5 patients), anti-G-protein coupled receptor for gamma-aminobutyric acid receptor (4 patients), anti-myelin oligodendrocyte glycoprotein antibody associated encephalitis (3 patients), anti-contactin-associated protein-like 2 antibody-associated disease (3 patients), Hashimoto encephalopathy (2 patients), anti-glutamic acid decarboxylase-65 AE (1 patient), and anti-CV2 AE (1 patient). All MR imaging of our patients was also performed on a 3T MR imaging scanner (Discovery 750; GE Healthcare) with a 3D ASL sequence. Seven patients had visible infected lesions with increased perfusion on ASL, 5 patients showed asymmetric changes across brain regions without intracranial lesions on T2 FLAIR, and 2 patients presented with decreased perfusion with visible infected focus, while the rest of the patients presented with normal perfusion without intracranial lesions.

Comparing the findings of Li et al, we wondered why our hospitalized patients with AE failed to show a high proportion of hyperperfusion changes on ASL. We reviewed the published CBF studies evaluated using 3D ASL perfusion imaging in patients with AE and found that brain MR imaging revealed no morphologic abnormalities in patients with anti-NMDAR AE, but 3D ASL perfusion imaging showed reduced CBF in the special brain regions, including the left frontal and temporal regions and the right cerebellum. Li et al also found hyperintensities in the bilateral hippocampus on MR imaging for patients with anti-LGI 1 AE, but no abnormal perfusion/metabolism on ASL and [18F] FDG-PET/CT.

Different from the higher CBF in patients with herpes simplex encephalitis at the acute stage, AE is one of the emergent causes of subacute changes caused by antibodies. CSF analysis and MR imaging could reveal inflammatory changes. However, less than half of the cases of AE showed any abnormal findings on brain MR imaging, which is also consistent with our findings. ASL hyperperfusion of the affected brain regions in AE may be due to either a seizure-related outcome or active inflammation of the brain involved. Kumar et al found MR imaging changes (9 patients included) in Rasmussen encephalitis on conventional MR imaging (without atrophy), corresponding to regional hyperperfusion in 7 patients on ASL, and they also found ASL hypoperfusion in 2 patients, who had respective volume loss on MR imaging. Most cogently, 5 patients showed a concordance between ASL hyperperfusion and the clinical ictal onset zone.

Another very interesting finding was that several cases with ASL hyperperfusion were concordant with the interictal epileptiform discharges (7 patients) and the electroencephalogram ictal onset zone (6 patients). This finding can be confirmed in the other studies as well. Despite normal MR imaging findings, reversible mixed perfusion on iodine 123 (123I-IMP) SPECT was found in patients with anti-alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor encephalitis and anti-gamma-aminobutyric acid. 

http://dx.doi.org/10.3174/ajnr.A7563
acid B (GABAB) receptor encephalitis, in which the first SPECT revealed hypoperfusion of the limbic system and cerebellum. These areas often contain high levels of GABAB receptors. Meanwhile, hyperperfusion in the motor strip and left temporal lobe was consistent with some of the patients’ symptoms, like seizures. In view of our cases, some patients with hyperperfusion may be in status epilepticus or an acute stage of the disease, while normal perfusion or hypoperfusion may be due to their invisible abnormal findings on brain MR imaging or subclinical and chronic phases. Of course, susceptibility artifacts are unavoidable and should be excluded in cases with misrepresentation of brain MR imaging. Our findings need to be confirmed by a larger sample size and electrophysiology in the future.

In conclusion, 3D pseudocontinuous arterial spin-labeling may have added value in the early diagnosis and assessment of the therapeutic effects in AE. ASL not only presented hyperperfusion changes, but also showed no perfusion changes or hypoperfusion at different stages of the disease.

Disclosure forms provided by the authors are available with the full text and PDF of this article at www.ajnr.org.

REFERENCES

X. Zhang
D. Zheng
Q. Huang
Department of Radiology
Nanjing Brain Hospital, Nanjing Medical University
Jiangning District, Nanjing, China
We appreciate the comments by Dr Zhang and colleagues on “Brain Perfusion Alterations on 3D Pseudocontinuous Arterial Spin-Labeling MR Imaging in Patients with Autoimmune Encephalitis: A Case Series and Literature Review” and thank the Editor for giving us the opportunity to reply to the comments. The application of arterial spin-labeling (ASL) for the assessment of autoimmune encephalitis (AE), a heterogeneous group of newly identified disorders, has seldom been described previously, and we agree that AE may have different abnormal perfusion patterns on 3D pseudocontinuous arterial spin-labeling (pCASL).

First, the authors mentioned the proportion of hyperperfusion alterations on ASL in their hospitalized patients with AE, which may be related to the types of AE included. AE subtypes that predominantly involve the white matter are less likely to cause hyperperfusion compared with autoimmune limbic encephalitis. In our study, the cases mainly included autoimmune limbic encephalitis and anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis, not, as the author mentioned in the letter, AE subtypes that predominantly involve the white matter, such as anti-myelin oligodendrocyte glycoprotein antibody-associated encephalitis and Hashimoto encephalopathy, and usually present with a clinical profile and MR imaging features clearly different from those of autoimmune limbic encephalitis.

Second, 2 main abnormal metabolic patterns (mixed hyper-/hypometabolic and neurodegenerative-like) on PET/CT have been reported, and different “paradigms” of encephalitis (mainly limbic versus NMDAR) may have different PET/CT findings. Studies have shown that metabolic patterns on PET/CT, to a certain extent, are associated with different autoantibody subtypes, implying that different pathophysiologic mechanisms may exist. We admit that the brain perfusion alterations may be associated with different autoantibody subtypes, which is an impetus for further studies revealing the correlation between perfusion and metabolism in AE subtypes.

Third, perfusion alterations for AE are also linked to the staging of disease, which usually presents with hyperperfusion during the acute and subacute periods and hypoperfusion in the chronic phase, though the division of the staging is controversial in clinical practice. Meanwhile, treatment may also affect the perfusion changes.

Finally, the authors mentioned the mechanisms leading to the perfusion alteration for AE. The exact pathophysiologic mechanism remains to be elucidated, and possible reasons include an inflammatory process due to an antigen-antibody-mediated immune response and the loss of vascular autoregulatory mechanisms due to autonomic instability, and so forth. In addition, many subtypes of AE are frequently accompanied by seizures, which can also affect CBF. In our study, the patients who had clinical seizures were imaged during the interictal phase, but this effect cannot be completely excluded theoretically.

In summary, we admit that the sample size was small and the type of patients with AE was limited in our study. However, we believe that 3D pCASL may have added value in the early diagnosis and assessment of therapeutic effects in AE. Because perfusion alterations may be associated with multiple factors, such as autoantibody subtypes, the staging of disease, and whether the disease is accompanied by seizures, large cohort and longitudinal studies are needed to elucidate the contribution of 3D pCASL in the scenarios discussed above.

REFERENCES

R. Li
Department of Medical Imaging
Tianjin Huahnu Hospital
Tianjin, China
Department of Radiology
The First Medical Center of PLA General Hospital
Beijing, China
L. Ma
Department of Radiology
The First Medical Center of PLA General Hospital
Beijing, China

http://dx.doi.org/10.3174/ajnr.A7621